0001048477-19-000017.txt : 20191104 0001048477-19-000017.hdr.sgml : 20191104 20191104073619 ACCESSION NUMBER: 0001048477-19-000017 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 191188257 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 10-Q/A 1 bmrn-30sep19x10qxa.htm 10-Q/A Document
P5YP1YP5YP1YP1YP1YAmendment to revise drafting error on Form 10Q for period ended September 30, 2019true--12-31Q3201900010484770.0010.0015000000005000000001782529541796043811782529541796043810.0150.005990.0150.00599the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility)032640000002019-12-312019-10-312020-09-302019-10-312020-09-302019-11-302019-10-312019-10-312022-09-302022-09-302019-11-302019-10-312019-10-312019-10-312019-07-312019-10-312019-10-312019-12-312019-10-312019-11-302019-10-31P3YP3Y0.3840.3740.3680.3710.0280.0300.0230.022P5Y8M12DP4Y7M6DP5Y9M18DP4Y7M6D0 0001048477 2019-01-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-01-01 2019-09-30 0001048477 2019-10-18 0001048477 2018-12-31 0001048477 2019-09-30 0001048477 2018-01-01 2018-09-30 0001048477 2019-07-01 2019-09-30 0001048477 2018-07-01 2018-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-01-01 2019-09-30 0001048477 us-gaap:ProductMember 2018-01-01 2018-09-30 0001048477 us-gaap:ProductMember 2018-07-01 2018-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember 2019-01-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2018-07-01 2018-09-30 0001048477 us-gaap:ProductMember 2019-07-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2018-01-01 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001048477 2018-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001048477 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-09-30 0001048477 2017-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001048477 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2019-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001048477 us-gaap:CommonStockMember 2019-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-07-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2017-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 0001048477 us-gaap:RetainedEarningsMember 2018-01-01 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-06-30 0001048477 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-06-30 0001048477 2018-06-30 0001048477 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2017-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001048477 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2019-09-30 0001048477 srt:MaximumMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember 2019-01-01 2019-09-30 0001048477 2019-04-01 2019-06-30 0001048477 srt:RestatementAdjustmentMember 2019-06-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2019-09-30 0001048477 us-gaap:ConstructionInProgressMember 2018-12-31 0001048477 us-gaap:LandMember 2018-12-31 0001048477 us-gaap:EquipmentMember 2019-09-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001048477 us-gaap:ComputerEquipmentMember 2019-09-30 0001048477 us-gaap:LandImprovementsMember 2018-12-31 0001048477 us-gaap:LandMember 2019-09-30 0001048477 us-gaap:ConstructionInProgressMember 2019-09-30 0001048477 us-gaap:LandImprovementsMember 2019-09-30 0001048477 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2019-09-30 0001048477 us-gaap:ComputerEquipmentMember 2018-12-31 0001048477 us-gaap:EquipmentMember 2018-12-31 0001048477 us-gaap:FurnitureAndFixturesMember 2019-09-30 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:ContingentPaymentMember 2018-12-31 0001048477 bmrn:ContingentPaymentMember 2019-09-30 0001048477 bmrn:ContingentPaymentMember 2019-01-01 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-07-01 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:COP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-09-30 0001048477 currency:RUB us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 currency:AUD us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:CAD us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:COP us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:NOK us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0001048477 currency:NOK srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:CAD srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:NOK srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:AUD srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:AUD srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:CAD srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:RUB srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:RUB srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 2018-01-01 2018-12-31 0001048477 us-gaap:OperatingExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:OperatingExpenseMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2019-09-30 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2018-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2018-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2019-09-30 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2019-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001048477 us-gaap:ConvertibleDebtMember 2018-07-01 2018-09-30 0001048477 us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-12-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-06-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member 2017-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001048477 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomersMember 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomersMember 2018-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFiveMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFourMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFiveMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFourMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductSixMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductTwoMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductThreeMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFiveMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductFourMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductFourMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFiveMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductTwoMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSevenMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductTwoMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductTwoMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2019-01-01 2019-09-30 0001048477 country:US 2019-07-01 2019-09-30 0001048477 srt:EuropeMember 2019-01-01 2019-09-30 0001048477 srt:LatinAmericaMember 2019-07-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2018-01-01 2018-09-30 0001048477 country:US 2019-01-01 2019-09-30 0001048477 srt:EuropeMember 2019-07-01 2019-09-30 0001048477 srt:LatinAmericaMember 2018-01-01 2018-09-30 0001048477 srt:LatinAmericaMember 2019-01-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2019-01-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2019-07-01 2019-09-30 0001048477 srt:LatinAmericaMember 2018-07-01 2018-09-30 0001048477 srt:EuropeMember 2018-01-01 2018-09-30 0001048477 country:US 2018-07-01 2018-09-30 0001048477 country:US 2018-01-01 2018-09-30 0001048477 srt:EuropeMember 2018-07-01 2018-09-30 0001048477 bmrn:RestOfWorldMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-01-01 2019-09-30 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-07-01 2019-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-31 0001048477 bmrn:TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-08-01 2019-08-31 0001048477 bmrn:TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-08-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001048477 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001048477 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001048477 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001048477 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-06-01 2019-06-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-06-01 2019-06-30 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-07-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2018-01-01 2018-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2018-07-01 2018-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-01-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2018-01-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001048477 us-gaap:StockCompensationPlanMember 2018-01-01 2018-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2018-07-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-09-30 0001048477 bmrn:ClinicalAndPostMarketingServicesMember 2019-09-30 0001048477 bmrn:ThirdPartyMember bmrn:CompletedProjectMember 2019-01-01 2019-09-30 0001048477 bmrn:ThirdPartyMember 2019-01-01 2019-09-30 iso4217:NOK iso4217:RUB iso4217:EUR iso4217:COP iso4217:BRL iso4217:USD iso4217:GBP xbrli:shares xbrli:pure bmrn:Derivative iso4217:AUD iso4217:CAD iso4217:USD xbrli:shares bmrn:Segment

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
______________________________________
Form 10-Q/A 
(Amendment No. 1)
______________________________________
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
Or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                      .
Commission File Number: 000-26727
______________________________________ 
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)  
______________________________________
Delaware
68-0397820
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
 
 
 
770 Lindaro Street
San Rafael
California
94901
(Address of principal executive offices)
(Zip Code)
 
(415) 506-6700
(Registrant’s telephone number including area code)
______________________________________

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.001
 
BMRN
 
The NASDAQ Global Select Market
______________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large Accelerated Filer
 
☒
 
Accelerated Filer
 
☐
 
 
 
 
Non-accelerated Filer
 
☐
 
Smaller Reporting Company
 
☐
Emerging Growth Company
 
☐
 
 
 
 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  ☐    No  ☒
Applicable only to corporate issuers:
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 179,625,303 shares of common stock, par value $0.001, outstanding as of October 18, 2019.
 


Explanatory Note

The purpose of this Amendment No. 1 (this Amendment) to the Quarterly Report on Form 10-Q filed on October 29, 2019 (the Original Filing) is to revise the update regarding the valoctocogene roxaparvovec program found under “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Business Developments-Continued Emphasis on Research and Development” to correct a drafting error. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment also contains new certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Except as described above, no changes have been made to the Original Filing, and this Amendment does not modify, amend, or update in any way, any of the financial or other information contained in the Original Filing. This Amendment does not reflect events that may have occurred subsequent to the filing date of the Original Filing.





BIOMARIN PHARMACEUTICAL INC.
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2

Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to “BioMarin,” the “Company,” “we,” “us,” and “our” refer to BioMarin Pharmaceutical Inc. and, where appropriate, its wholly owned subsidiaries.
BioMarin®, Brineura®, Firdapse®, Kuvan®, Naglazyme®, Palynziq® and Vimizim® are our registered trademarks. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this report are the property of their respective owners.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under securities laws. Many of these statements can be identified by the use of terminology such as “believes,” “expects,” “intends,” “anticipates,” “plans,” “may,” “will,” “could,” would,” “projects,” “continues,” “estimates,” “potential,” “opportunity” or the negative versions of these terms and other similar expressions. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “Risk Factors,” in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as information provided elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (the SEC) on February 28, 2019. You should carefully consider that information before you make an investment decision.
You should not place undue reliance on these types of forward-looking statements, which speak only as of the date that they were made. These forward-looking statements are based on the beliefs and assumptions of the Company’s management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, the Company does not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events.
The discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q.

3

PART I. FINANCIAL INFORMATION
Item 1.    Financial Statements
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30, 2019 and December 31, 2018
(In thousands, except share amounts)
 
September 30,
2019
 
December 31, 2018 (1)
ASSETS
(unaudited)
 
 

Current assets:
 
 
 
Cash and cash equivalents
$
423,220

 
$
493,982

Short-term investments
297,572

 
590,326

Accounts receivable, net
402,970

 
342,633

Inventory
609,049

 
530,871

Other current assets
126,548

 
98,403

Total current assets
1,859,359

 
2,056,215

Noncurrent assets:
 
 
 
Long-term investments
431,804

 
235,864

Property, plant and equipment, net
969,300

 
948,682

Intangible assets, net
462,849

 
491,808

Goodwill
197,039

 
197,039

Deferred tax assets
525,131

 
460,952

Other assets
112,646

 
36,568

Total assets
$
4,558,128

 
$
4,427,128

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable and accrued liabilities
$
483,745

 
$
437,290

Short-term contingent consideration
10,000

 
85,951

Total current liabilities
493,745

 
523,241

 
 
 
 
Noncurrent liabilities:
 
 
 
Long-term convertible debt, net
843,616

 
830,417

Long-term contingent consideration
48,930

 
46,883

Other long-term liabilities
97,432

 
58,647

Total liabilities
1,483,723

 
1,459,188

Stockholders’ equity:
 
 
 
Common stock, $0.001 par value: 500,000,000 shares authorized; 179,604,381 and 178,252,954 shares issued and outstanding, respectively.
180

 
178

Additional paid-in capital
4,782,916

 
4,669,926

Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)
(9,961
)
 
(13,301
)
Accumulated other comprehensive income
37,003

 
5,271

Accumulated deficit
(1,735,733
)
 
(1,694,134
)
Total stockholders’ equity
3,074,405

 
2,967,940

Total liabilities and stockholders’ equity
$
4,558,128

 
$
4,427,128

(1)
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

4

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Three and Nine Months Ended September 30, 2019 and 2018
(In thousands, except per share amounts)
(unaudited)
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
REVENUES:
 
 
 
 
 
 
 
Net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205

Royalty and other revenues
10,197

 
5,386

 
25,147

 
14,793

Total revenues
461,097

 
391,706

 
1,249,605

 
1,137,998

OPERATING EXPENSES:
 
 
 
 
 
 
 
Cost of sales
96,949

 
78,893

 
263,567

 
240,245

Research and development
172,963

 
161,408

 
542,195

 
520,938

Selling, general and administrative
170,112

 
148,566

 
493,024

 
440,182

Intangible asset amortization and contingent consideration
17,063

 
18,580

 
57,114

 
42,009

Gain on sale of intangible assets
—

 
—

 
(15,000
)
 
(20,000
)
Total operating expenses
457,087

 
407,447

 
1,340,900

 
1,223,374

INCOME (LOSS) FROM OPERATIONS
4,010

 
(15,741
)
 
(91,295
)
 
(85,376
)
 
 
 
 
 
 
 
 
Equity in the loss of BioMarin/Genzyme LLC
(551
)
 
(468
)
 
(780
)
 
(507
)
Interest income
5,340

 
6,338

 
17,537

 
17,141

Interest expense
(2,937
)
 
(12,131
)
 
(16,530
)
 
(35,918
)
Other income, net
3,960

 
2,589

 
6,038

 
5,266

INCOME (LOSS) BEFORE INCOME TAXES
9,822

 
(19,413
)
 
(85,030
)
 
(99,394
)
Benefit from income taxes
(45,214
)
 
(6,793
)
 
(46,158
)
 
(25,833
)
NET INCOME (LOSS)
$
55,036

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
NET INCOME (LOSS) PER SHARE, BASIC
$
0.31

 
$
(0.07
)
 
$
(0.22
)
 
$
(0.42
)
NET INCOME (LOSS) PER SHARE, DILUTED
$
0.30

 
$
(0.07
)
 
$
(0.22
)
 
$
(0.42
)
Weighted average common shares outstanding, basic
179,289

 
177,481

 
178,873

 
176,767

Weighted average common shares outstanding, diluted
185,924

 
177,481

 
178,873

 
176,767

 
 
 
 
 
 
 
 
COMPREHENSIVE INCOME (LOSS)
$
74,600

 
$
(13,651
)
 
$
(7,140
)
 
$
(52,174
)
 
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

5

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
Three and Nine Months Ended September 30, 2019 and 2018
(In thousands)
(unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Shares of Common Stock
 
 
 
 
 
 
 
Beginning balance at June 30, 2019 and 2018 and December 31, 2018 and December 31, 2017, respectively (1)
179,433

 
177,508

 
178,253

 
175,844

Issuances under equity incentive plans
171

 
395

 
1,351

 
2,059

Ending balance
179,604

 
177,903

 
179,604

 
177,903

 
 
 
 
 
 
 
 
Beginning balance of stockholders' equity at June 30, 2019 and 2018 and December 31, 2018 and December 31, 2017, respectively (1)
$
2,960,954

 
$
2,885,104

 
$
2,967,940

 
$
2,808,663

Common stock:
 
 
 
 
 
 
 
Beginning balance (1)
179

 
178

 
178

 
176

Issuances under equity incentive plans, net of tax
1

 
—

 
2

 
2

Ending balance
180

 
178

 
180

 
178

Additional paid-in capital:
 
 
 
 
 
 
 
Beginning balance (1)
4,744,316

 
4,577,300

 
4,669,926

 
4,483,220

Issuances under equity incentive plans, net of tax
(1,294
)
 
5,151

 
(19,183
)
 
21,461

Stock-based compensation
40,144

 
38,366

 
122,212

 
116,136

Common stock held by the NQDC
(250
)
 
—

 
(692
)
 
 
Accounting impact of NQDC Plan change (See Note 9)
—

 
—

 
10,653

 
—

Ending balance
4,782,916

 
4,620,817

 
4,782,916

 
4,620,817

Company common stock held by the NQDC:
 
 
 
 
 
 
 
Beginning balance (1)
(10,211
)
 
(13,390
)
 
(13,301
)
 
(14,224
)
Common stock held by the NQDC
250

 
(25
)
 
692

 
809

Accounting impact of NQDC Plan change (See Note 9)
—

 
—

 
2,648

 
—

Ending balance
(9,961
)
 
(13,415
)
 
(9,961
)
 
(13,415
)
Accumulated other comprehensive income (loss):
 
 
 
 
 
 
 
Beginning balance (1)
17,439

 
(1,129
)
 
5,271

 
(22,961
)
Impact of changes in accounting principle
—

 
—

 
—

 
(586
)
Other comprehensive income (loss)
19,564

 
(1,031
)
 
31,732

 
21,387

Ending balance
37,003

 
(2,160
)
 
37,003

 
(2,160
)
Accumulated Deficit:
 
 
 
 
 
 
 
Beginning balance (1)
(1,790,769
)
 
(1,677,855
)
 
(1,694,134
)
 
(1,637,548
)
Impact of changes in accounting principles
—

 
—

 
(2,727
)
 
20,634

Net income (loss)
55,036

 
(12,620
)
 
(38,872
)
 
(73,561
)
Ending balance
(1,735,733
)
 
(1,690,475
)
 
(1,735,733
)
 
(1,690,475
)
Total stockholders' equity, ending balances at September 30, 2019 and September 30, 2018, respectively
$
3,074,405

 
$
2,914,945

 
$
3,074,405

 
$
2,914,945

(1)
The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 

6

BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended September 30, 2019 and 2018
(In thousands)
(unaudited)
 
Nine Months Ended September 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net loss
$
(38,872
)
 
$
(73,561
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
79,510

 
70,955

Non-cash interest expense
9,395

 
26,099

(Accretion of discount) Amortization of premium on investments
(1,897
)
 
769

Stock-based compensation
121,763

 
112,261

Gain on sale of intangible assets
(15,000
)
 
(20,000
)
Deferred income taxes
(59,780
)
 
(32,735
)
Unrealized foreign exchange (gain) loss
784

 
(11,997
)
Non-cash changes in the fair value of contingent consideration
5,646

 
12,836

Other
(18
)
 
(459
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(61,803
)
 
(95,884
)
Inventory
(52,571
)
 
(10,232
)
Other current assets
(13,259
)
 
4,276

Other assets
(7,112
)
 
(3,148
)
Accounts payable and accrued liabilities
21,747

 
(12,090
)
Other long-term liabilities
2,386

 
3,744

Net cash used in operating activities
(9,081
)
 
(29,166
)
CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property, plant and equipment
(94,241
)
 
(102,541
)
Maturities and sales of investments
635,678

 
857,063

Purchases of available-for-sale securities
(528,497
)
 
(439,198
)
Proceeds from sale of intangible assets
15,000

 
20,000

Purchase of intangible assets
(8,323
)
 
—

Other
(1,747
)
 
(10
)
Net cash provided by investing activities
17,870

 
335,314

CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Proceeds from exercises of awards under equity incentive plans
21,768

 
55,643

Taxes paid related to net share settlement of equity awards
(40,951
)
 
(34,180
)
Payment of contingent acquisition consideration
(57,508
)
 
(43,108
)
Other
(2,025
)
 
—

Net cash used in financing activities
(78,716
)
 
(21,645
)
Effect of exchange rate changes on cash
(835
)
 
(347
)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
(70,762
)
 
284,156

Cash and cash equivalents:
 
 
 
Beginning of period
$
493,982

 
$
598,028

End of period
$
423,220

 
$
882,184

SUPPLEMENTAL CASH FLOW DISCLOSURES:
 
 
 
Cash paid for income taxes
$
6,088

 
$
15,791

Cash paid for interest
5,777

 
7,521

SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Decrease in accounts payable and accrued liabilities related to fixed assets
$
(5,801
)
 
$
(7,678
)
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

7
BIOMARIN PHARMACEUTICAL INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)


(1) NATURE OF OPERATIONS
BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.

(2) BASIS OF PRESENTATION
The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other period.
On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, Leases (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.
As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of $55.9 million and lease liabilities of $59.0 million as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  
On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.

8
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)


(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Except as detailed below, there have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2019, as compared to the significant accounting policies disclosed in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Leases
The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis. 
Derivatives and Hedging Activities
The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in Accumulated Other Comprehensive Income (AOCI) and amounts deferred in AOCI will be reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in Operating Expenses in the Consolidated Statements of Comprehensive Income (Loss).

(4) RECENT ACCOUNTING PRONOUNCEMENTS
Except as described in Note 2 – Basis of Presentation and below, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the nine months ended September 30, 2019, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, that the Company believes are of significance or potential significance to the Company.
Accounting Pronouncements Not Yet Adopted
Effective January 1, 2020, the Company will adopt ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach, with certain exceptions allowed. The standard amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The Company is evaluating the impact of the adoption of ASU 2016-13 on its Condensed Consolidated Financial Statements.


9
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

(5) FINANCIAL INSTRUMENTS
All marketable securities were classified as available-for-sale at September 30, 2019 and December 31, 2018.
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of September 30, 2019 and December 31, 2018, respectively:
As of September 30, 2019
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
294,543

 
$
—

 
$
—

 
$
294,543

 
$
294,543

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
128,678

 
—

 
—

 
128,678

 
128,678

 
—

 
—

Corporate debt securities
519,693

 
3,713

 
(67
)
 
523,339

 
—

 
206,782

 
316,557

U.S. government agency securities
204,371

 
1,073

 
(97
)
 
205,347

 
—

 
90,790

 
114,557

Foreign and other
549

 
142

 
(1
)
 
690

 
—

 
—

 
690

Subtotal
853,291

 
4,928

 
(165
)
 
858,054

 
128,678

 
297,572

 
431,804

Total
$
1,147,834

 
$
4,928

 
$
(165
)
 
$
1,152,596

 
$
423,220

 
$
297,572

 
$
431,804

As of December 31, 2018
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
228,809

 
$
—

 
$
—

 
$
228,809

 
$
228,809

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
205,736

 
—

 
—

 
205,736

 
205,736

 
—

 
—

Corporate debt securities
564,852

 
214

 
(2,288
)
 
562,778

 
2,000

 
376,545

 
184,233

Commercial paper
77,702

 
—

 
—

 
77,702

 
21,964

 
55,738

 
—

U.S. government agency securities
240,436

 
144

 
(697
)
 
239,883

 
31,474

 
156,967

 
51,442

Foreign and other
5,126

 
139

 
(1
)
 
5,264

 
3,999

 
1,076

 
189

Subtotal
1,093,852

 
497

 
(2,986
)
 
1,091,363

 
265,173

 
590,326

 
235,864

Total
$
1,322,661

 
$
497

 
$
(2,986
)
 
$
1,320,172

 
$
493,982

 
$
590,326

 
$
235,864

(1)    The Company’s short-term marketable securities mature in one year or less.
(2)    The Company’s long-term marketable securities mature between one and five years.
As of September 30, 2019, the Company’s investments in an unrealized loss position were not significant, and since the Company has the ability and intent to hold all investments that have been in a continuous loss position until maturity or recovery, no other-than-temporary impairment was deemed to have occurred.


10
BIOMARIN PHARMACEUTICAL INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

(6) INTANGIBLE ASSETS
Intangible assets consisted of the following:
 
September 30,
2019
 
December 31,
2018
Intangible assets:
 
 
 
Finite-lived intangible assets
$
642,677

 
$
307,995

Indefinite-lived intangible assets
—

 
326,359

Gross intangible assets:
642,677

 
634,354

Less: Accumulated amortization
(179,828
)
 
(142,546
)
Net carrying value
$
462,849

 
$
491,808


During the second quarter of 2019, $326.4 million of indefinite-lived intangible assets were reclassified to definite-lived as the underlying in-process research and development (IPR&D) was placed into service upon receiving European regulatory approval for Palynziq. The Company will straight-line the amortization expense for the underlying IPR&D over its estimated useful life through August 2028.
During the second quarter of 2019, the Company recorded a $15.0 million gain on sale of intangible assets in the Condensed Consolidated Statements of Comprehensive Income (Loss) due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.

(7) PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, net consisted of the following: 
 
September 30,
2019
 
December 31,
2018
Building and improvements
$
709,990

 
$
694,447

Manufacturing and laboratory equipment
365,348

 
345,947

Computer hardware and software
165,235

 
157,787

Leasehold improvements
52,379

 
41,188

Furniture and equipment
37,603

 
33,234

Land improvements
7,239

 
6,551

Land
83,094

 
77,993

Construction-in-progress
84,021

 
64,170

 
1,504,909

 
1,421,317

Accumulated depreciation
(535,609
)
 
(472,635
)
Total property, plant and equipment, net
$
969,300

 
$
948,682


The construction-in-progress balance primarily included costs related to significant in-process projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.
Depreciation expense for the three and nine months ended September 30, 2019 was $24.2 million and $67.2 million, respectively, of which $9.8 million and $24.9 million, respectively, was capitalized into inventory. Depreciation expense for the three and nine months ended September 30, 2018 was $26.6 million and $66.7 million, respectively, of which $8.1 million and $18.6 million, respectively, was capitalized into inventory.


11
BIOMARIN PHARMACEUTICAL INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

(8) SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventory consisted of the following:
 
September 30,
2019
 
December 31,
2018
Raw materials
$
68,391

 
$
74,616

Work-in-process
321,073

 
231,064

Finished goods
219,585

 
225,191

Total inventory
$
609,049

 
$
530,871


Inventory as of September 30, 2019, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $7.1 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. The Company believes that all material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale have been significantly reduced. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If regulatory approval is not obtained, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed.
Accounts Payable and Accrued Liabilities consisted of the following:
 
September 30, 2019
 
December 31, 2018
Accounts payable and accrued operating expenses
$
226,769

 
$
207,620

Accrued compensation expense
132,049

 
149,937

Accrued rebates payable
55,957

 
43,116

Accrued royalties payable
27,881

 
19,977

Value added taxes payable
7,556

 
7,785

Forward foreign currency exchange contracts
8,731

 
4,178

Lease liability
10,225

 
—

Other
14,577

 
4,677

Total accounts payable and accrued liabilities
$
483,745

 
$
437,290



    

(9) FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2019 and December 31, 2018. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2019.

12
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

 
Fair Value Measurements at September 30, 2019
 
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
NQDC Plan assets
 
$
1,135

 
$
—

 
$
1,135

Other assets:
 
 
 
 
 
 
NQDC Plan assets
 
15,039

 
—

 
15,039

Restricted investments (1)
 
3,157

 
—

 
3,157

Total other assets
 
18,196

 
—

 
18,196

Total assets
 
$
19,331

 
$
—

 
$
19,331

Liabilities:
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
$
1,135

 
$
—

 
$
1,135

Contingent consideration
 
—

 
10,000

 
10,000

Total current liabilities
 
1,135

 
10,000

 
11,135

Other long-term liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
15,039

 
—

 
15,039

Contingent consideration
 
—

 
48,930

 
48,930

Total other long-term liabilities
 
15,039

 
48,930

 
63,969

Total liabilities
 
$
16,174

 
$
58,930

 
$
75,104



13
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

 
Fair Value Measurements at December 31, 2018
 
Quoted Price in
Active Markets
For Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
 
NQDC Plan assets
$
—

 
$
370

 
$
—

 
$
370

Restricted investments (1)
—

 
9,581

 
—

 
9,581

Total other current assets
—

 
9,951

 
—

 
9,951

Other assets:
 
 
 
 
 
 
 
NQDC Plan assets
—

 
12,828

 
—

 
12,828

Restricted investments (1)
—

 
2,450

 
—

 
2,450

Strategic investments (3)
942

 
—

 
—

 
942

Total other assets
942

 
15,278

 
—

 
16,220

Total assets
$
942

 
$
25,229

 
$
—

 
$
26,171

Liabilities:
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
$
55

 
$
370

 
$
—

 
$
425

Contingent consideration
—

 
—

 
85,951

 
85,951

Total current liabilities
55

 
370

 
85,951

 
86,376

Other long-term liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
17,598

 
12,828

 
—

 
30,426

Contingent consideration
—

 
—

 
46,883

 
46,883

Total other long-term liabilities
17,598

 
12,828

 
46,883

 
77,309

Total liabilities
$
17,653

 
$
13,198

 
$
132,834

 
$
163,685

(1)
The restricted investments at September 30, 2019 and December 31, 2018 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
(2)
The Company’s NQDC Plan was amended during the second quarter of 2019, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC Plan. The obligation was previously classified as a liability recorded at fair value and has been reclassified into equity and recorded at the shares' respective grant date fair values at June 30, 2019. The change to the NQDC Plan related to the prohibition of participants to diversify investments for deferrals of Company stock contributed into other types of investments. The NQDC Plan liabilities classified as Level 2 represent investments held in plan assets excluding shares of the Company's common stock.
(3)
The Company had investments in marketable equity securities measured using quoted prices in an active market that were considered strategic investments and were included in Other Assets on the Company's Condensed Consolidated Balance Sheets. During the second quarter of 2019, the Company realized an immaterial gain upon the sale of the shares.
There were no transfers between levels during the three and nine months ended September 30, 2019.

14
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

The following table represents a roll-forward of contingent consideration.
Contingent consideration at December 31, 2018
$
132,834

Changes in fair value of other contingent consideration
19,916

Milestone payments to Ares Trading S.A. (Merck Serono)
(83,472
)
Milestone payments to former LEAD Therapeutics, Inc. shareholders
(5,987
)
Realized gain on settlement of contingent consideration
(1,928
)
Foreign exchange remeasurement of Euro denominated contingent consideration
(2,433
)
Contingent consideration at September 30, 2019
$
58,930


 

(10) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted product revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also uses forward contracts for economic hedging purposes which are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from net product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, derivatives that hedge cash flows must be highly effective at offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The following table summarizes the Company’s derivatives designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Australian Dollars – Sell
 
6

 
2.8

 
Oct 2019 - Dec 2019
Canadian Dollars – Sell
 
24

 
28.1

 
Oct 2019 - Sept 2020
Colombian Pesos – Sell
 
12

 
89,400.0

 
Oct 2019 - Sept 2020
Euros – Purchase
 
150

 
189.4

 
Oct 2019 - Sept 2022
Euros – Sell
 
453

 
624.2

 
Oct 2019 - Sept 2022
Norwegian Krone – Sell
 
3

 
11.7

 
Oct 2019 - Dec 2019
Total
 
648

 
 
 
 

The following table summarizes the Company’s derivatives not designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Colombian Pesos – Sell
 
2

 
96,000.0

 
Oct 2019 - Nov 2019
Euros – Purchase
 
2

 
44.1

 
Oct 2019 - Nov 2019
Great British Pounds - Purchase
 
1

 
4.9

 
Oct 2019
Great British Pounds - Sell
 
1

 
2.0

 
Oct 2019
Rubles – Sell
 
2

 
1,420.0

 
Oct 2019 - Nov 2019
Total
 
8

 
 
 
 


15
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet Location
September 30, 2019
 
December 31, 2018
Derivatives designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
29,900

 
$
12,686

Other assets
22,892

 
10,324

Subtotal
$
52,792

 
$
23,010

 
 
 
 
Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
7,875

 
$
4,036

Other long-term liabilities
7,641

 
3,653

Subtotal
$
15,516

 
$
7,689

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
71

 
$
168

Other assets
—

 
—

Subtotal
$
71

 
$
168

Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
858

 
$
142

Other long-term liabilities
—

 
—

Subtotal
$
858

 
$
142

 
 
 
 
Total Derivatives Assets
$
52,863

 
$
23,178

Total Derivatives Liabilities
$
16,374

 
$
7,831

(1)  
For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Financial Statements for the period presented.
 
Three Months Ended
 
Nine Months Ended
Derivatives Designated as Cash Flow Hedging Instruments
September 30, 2019
 
September 30, 2019
Amount of Gain (Loss) Recognized in Other Comprehensive Income
$
23,973

 
$
35,431

 
Three Months Ended
 
Nine Months Ended
 
September 30, 2019
 
September 30, 2019
Derivatives Designated as Cash Flow Hedging Instruments
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
 
 
 
 
 
Net product revenues as reported
$
450,900

 
$
6,196

 
$
1,224,458

 
$
11,171

Operating expenses as reported
$
457,087

 
$
(1,388
)
 
$
1,340,900

 
$
(1,885
)
 
 
 
 
 
 
 
 
Derivatives Not Designated as Hedging Instruments
 
 
Gains (Losses) Recognized in Earnings
 
 
 
Gains (Losses) Recognized in Earnings
Operating Expenses
 
 
$
(1,286
)
 
 
 
$
(5,182
)


16
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

As of September 30, 2019, the Company expects to reclassify unrealized gains of $19.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next 12 months.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.

(11) LEASES
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2019: 
Lease Classification
 
Classification
 
September 30,
2019
Assets:
 
 
 
 
Operating
 
Other Assets
 
$
51,284

Financing
 
Other Assets
 
10,346

Total ROU assets
 
 
 
$
61,630

Liabilities:
 
 
 
 
Current:
 
 
 
 
Operating
 
Accounts payable and accrued liabilities
 
$
7,273

Financing
 
Accounts payable and accrued liabilities
 
2,952

Noncurrent:
 
 
 
 
Operating
 
Other long-term liabilities
 
45,499

Financing
 
Other long-term liabilities
 
9,544

Total lease liabilities
 
 
 
$
65,268


Maturities of lease liabilities as of September 30, 2019 by fiscal year were as follows: 
Maturity of Lease Liabilities
 
Operating
 
Financing
 
Total
Remainder of 2019
 
$
3,115

 
$
3,204

 
$
6,319

2020
 
9,925

 
3,464

 
13,389

2021
 
8,721

 
2,865

 
11,586

2022
 
8,406

 
2,258

 
10,664

2023
 
7,504

 
1,748

 
9,252

Thereafter
 
27,464

 
—

 
27,464

Total lease payments
 
65,135

 
13,539

 
78,674

Less: Interest
 
(12,363
)
 
(1,043
)
 
(13,406
)
Present value of lease liabilities
 
$
52,772

 
$
12,496

 
$
65,268



Lease Cost
 
Classification
 
Three Months Ended
September 30, 2019
 
Nine Months Ended
September 30, 2019
Operating (1)
 
Operating Expenses
 
$
3,535

 
$
9,946

Financing:
 
 
 
 
 
 
Amortization
 
Operating Expenses
 
600

 
1,811

Interest expense
 
Operating Expenses
 
142

 
455

Total lease costs
 
 
 
$
4,277

 
$
12,212

 
(1)
Includes short-term leases and variable lease costs, both of which were not material.

17
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Other Information
 
September 30,
2019
Weighted average remaining lease term (in years):
 
 
Operating leases
 
8.0

Financing leases
 
4.2

 
 
 
Weighted average discount rate:
 
 
Operating leases
 
5.2
%
Financing leases
 
5.4
%
 
As of September 30, 2019, no operating leases are expected to commence in the remainder of 2019.
Supplemental Cash Flow Information
 
Nine Months Ended
September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
 
 
Cash used in operating activities:
 
 
Operating leases
 
$
5,918

Financing leases
 
$
454

Cash used in financing activities:
 
 
Financing leases
 
$
2,027

ROU assets obtained in exchange for lease obligations:
 
 
Operating leases
 
$
9,268

Financing leases
 
$
72

 
Lease Commitments as of December 31, 2018
Minimum lease payments for future years as of December 31, 2018 were as follows: 
2019
$
12,976

2020
12,549

2021
11,198

2022
10,574

2023
9,993

Thereafter
27,701

Total
$
84,991

 
Rent expense for the year ended December 31, 2018 was $12.2 million. Total deferred rent accruals at December 31, 2018 were $2.1 million, of which $0.5 million was short-term.


18
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

(12) DEBT
Convertible Notes
As of September 30, 2019, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $870.0 million (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
 
September 30,
2019
 
December 31,
2018
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993

 
374,993

Unamortized discount
(15,780
)
 
(26,581
)
Unamortized deferred offering costs
(1,359
)
 
(2,334
)
Convertible Notes due in 2020, net
357,854

 
346,078

 
 
 
 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000

 
495,000

Unamortized discount
(6,887
)
 
(7,946
)
Unamortized deferred offering costs
(2,351
)
 
(2,715
)
Convertible Notes due in 2024, net
485,762

 
484,339

 
 
 
 
Total convertible debt, net
$
843,616

 
$
830,417

 
 
 
 
Fair value of fixed rate convertible debt
 
 
 
Convertible Notes due in October 2020 (1)
384,713

 
419,722

Convertible Notes due in August 2024 (1)
490,297

 
491,626

Total fair value of fixed rate convertible debt
$
875,010

 
$
911,348

 
(1)
The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Interest expense on the Company’s convertible debt consisted of the following: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Coupon interest expense
$
2,271

 
$
3,331

 
$
6,681

 
$
9,819

Amortization of debt issuance costs
508

 
1,008

 
1,522

 
3,018

Accretion of discount on convertible notes
4,005

 
7,792

 
11,860

 
23,081

Total interest expense on convertible debt
$
6,784

 
$
12,131

 
$
20,063

 
$
35,918

 
See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 for additional information related to the Company’s convertible debt.

19
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable, except that if at least $100.0 million aggregate principal amount of the 2020 Notes remain outstanding on August 1, 2020 and certain other conditions have not been met, the Company may be required to repay all amounts borrowed under the 2018 Credit Facility on August 1, 2020. The Company incurred approximately $1.0 million of issuance costs, which will be amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2019, and December 31, 2018, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility. As of September 30, 2019, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants.

(13) ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2019 and 2018. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification
 
2019
 
2018
 
2019
 
2018
 
Gains (losses) on cash flow hedges:
 
 
 
 
 
 
 
 
 
Forward contracts
$
6,196

 
$
5,025

 
$
11,171

 
$
(6,683
)
 
Net product revenues
Forward contracts
(1,388
)
 
498

 
(1,885
)
 
3,762

 
Operating expenses
Total gain (loss) on cash flow hedges
$
4,808

 
$
5,523

 
$
9,286

 
$
(2,921
)
 
 

The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2019
$
14,181

 
$
3,271

 
$
(13
)
 
$
17,439

Other comprehensive income (loss) before
     reclassifications
23,973

 
522

 
(3
)
 
24,492

Less: net gain (loss) reclassified from AOCI
4,808

 
—

 
—

 
4,808

Tax effect
—

 
(120
)
 
—

 
(120
)
Net current-period other comprehensive income (loss)
19,165

 
402

 
(3
)
 
19,564

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003



20
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

 
Nine Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2018
$
7,201

 
$
(1,917
)
 
$
(13
)
 
$
5,271

Other comprehensive income (loss) before
     reclassifications
35,431

 
7,256

 
(3
)
 
42,684

Less: gain (loss) reclassified from AOCI
9,286

 
—

 
—

 
9,286

Tax effect
—

 
(1,666
)
 
—

 
(1,666
)
Net current-period other comprehensive income (loss)
26,145

 
5,590

 
(3
)
 
31,732

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003


 
Three Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2018
$
2,568

 
$
(3,686
)
 
$
(11
)
 
$
(1,129
)
Other comprehensive income (loss) before
     reclassifications
3,355

 
1,475

 
—

 
4,830

Less: gain (loss) reclassified from AOCI
5,523

 
—

 
—

 
5,523

Tax effect
—

 
(338
)
 
—

 
(338
)
Net current-period other comprehensive income (loss)
(2,168
)
 
1,137

 
—

 
(1,031
)
AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)



 
Nine Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2017
$
(20,232
)
 
$
(2,722
)
 
$
(7
)
 
$
(22,961
)
Impact of change in accounting principle
—

 
(586
)
 
—

 
(586
)
AOCI balance at January 1, 2018
$
(20,232
)
 
$
(3,308
)
 
$
(7
)
 
$
(23,547
)
Other comprehensive income (loss) before
     reclassifications
17,711

 
985

 
(4
)
 
18,692

Less: gain (loss) reclassified from AOCI
(2,921
)
 
—

 
—

 
(2,921
)
Tax effect
—

 
(226
)
 
—

 
(226
)
Net current-period other comprehensive income (loss)
20,632

 
759

 
(4
)
 
21,387

AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)


(14) REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product

21
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues by geographic region:
 
 
 
 
 
 
 
United States
$
201,874

 
$
174,722

 
$
562,217

 
$
528,082

Europe
125,485

 
111,069

 
369,585

 
323,940

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
49,939

 
30,515

 
153,671

 
134,021

Total revenues
$
461,097

 
$
391,706

 
$
1,249,605

 
$
1,137,998



The following table disaggregates Net Product Revenues by product. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net product revenues by product:
 
 
 
 
 
 
 
Aldurazyme
$
22,852

 
$
27,593

 
$
73,945

 
$
117,652

Brineura
19,840

 
9,936

 
46,815

 
27,743

Firdapse
5,668

 
4,977

 
16,262

 
15,080

Kuvan
120,524

 
113,254

 
340,771

 
321,414

Naglazyme
94,408

 
103,089

 
279,462

 
269,171

Palynziq
24,142

 
4,129

 
55,250

 
4,129

Vimizim
163,466

 
123,342

 
411,953

 
368,016

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205


The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
United States
$
175,127

 
$
146,742

 
$
480,330

 
$
409,294

Europe
121,363

 
107,851

 
358,041

 
315,270

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
47,759

 
28,734

 
148,010

 
129,034

Total net product revenues marketed by the Company
428,048

 
358,727

 
1,150,513

 
1,005,553

Aldurazyme net product revenues marketed by Genzyme
22,852

 
27,593

 
73,945

 
117,652

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205

 

22
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Customer A
16
%
 
16
%
 
17
%
 
17
%
Customer B
13
%
 
12
%
 
12
%
 
12
%
Customer C
10
%
 
10
%
 
11
%
 
10
%
Customer D
5
%
 
7
%
 
6
%
 
11
%
Customer E
12
%
 
—
%
 
6
%
 
—
%
Customer F
—
%
 
13
%
 
—
%
 
6
%
Total
56
%
 
58
%
 
52
%
 
56
%
 
On a consolidated basis, three customers accounted for 23%, 14% and 12% of the September 30, 2019 accounts receivable balance, respectively, compared to December 31, 2018, when two customers accounted for 30% and 16% of the accounts receivable balance, respectively. As of September 30, 2019, and December 31, 2018, the accounts receivable balance for Genzyme included $67.7 million and $73.9 million, respectively, of unbilled accounts receivable, which become payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires immediate payment in certain circumstances.
The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for the Company’s products. The Company has not historically experienced a significant level of uncollected receivables and has received continued payments from its more aged accounts in these countries. The Company believes that the allowances for doubtful accounts related to these countries, if any, is adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries.

(15) STOCK-BASED COMPENSATION
Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Cost of sales
$
4,093

 
$
3,974

 
$
12,629

 
$
10,360

Research and development
14,261

 
14,257

 
43,037

 
43,099

Selling, general and administrative
20,819

 
18,815

 
66,097

 
58,802

Total stock-based compensation expense
$
39,173

 
$
37,046

 
$
121,763

 
$
112,261


Stock-based compensation of $5.1 million and $13.2 million was capitalized into inventory for the three and nine months ended September 30, 2019, respectively, compared to $5.3 million and $14.3 million for the three and nine months ended September 30, 2018, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.
Equity Awards with Service-Based Vesting Conditions
During the nine months ended September 30, 2019, the Company granted 1,844,308 RSUs with service-based vesting conditions with a weighted-average fair value of $91.23 per share. 
The Company did not grant any options to purchase shares of common stock during the three months ended September 30, 2019. During the nine months ended September 30, 2019, the Company granted 610,250 options to purchase shares of common stock with a weighted-average fair value of $36.84 per share.

23
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
N/A
 
36.8%
 
37.1 – 37.4%
 
36.8 – 38.4%
Dividend yield
N/A
 
0.0%
 
0.0%
 
0.0%
Expected life (in years)
N/A
 
5.7
 
4.6 – 5.8
 
4.6 – 5.7
Risk-free interest rate
N/A
 
2.8%
 
2.2 – 3.0%
 
2.3 – 2.8%
 
The Company did not issue any new stock purchase rights under the Employee Stock Purchase Plan during the three months ended September 30, 2019. The Company issued 107,473 new stock purchase rights under the Employee Stock Purchase Plan during the nine months ended September 30, 2019.
Restricted Stock Unit Awards with Performance Conditions
In August 2019, the Compensation Committee of the Board of Directors (Board) approved the grant of 44,260 RSUs with performance-based vesting conditions and a grant date fair value of $81.00 per RSU. This award is contingent upon obtaining regulatory approval for valoctocogene roxaparvovec by January 2022 and the awarded RSUs, if any, vest ratably from the time regulatory approval is obtained through January 2022. The Company evaluated the current timeline and plans for submitting the regulatory applications and determined that for accounting purposes attainment of the performance measure is not probable as of September 30, 2019 as the regulatory approval is outside of the Company's control. Therefore, the Company did not record any expense associated with these awards.
In March 2019, the Compensation Committee and Board approved the grant of 99,010 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $94.53 per RSU. This award is contingent upon the achievement of a 2019 revenue target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the 2019 revenue target in the context of its current 2019 revenue forecast, and related confidence level in the forecast, and determined that attainment of the revenue target was probable for accounting purposes commencing in the first quarter of 2019. The number of shares that may be earned range between 0% and 200% of the base RSUs, depending on the percentage of 2019 “managed revenues” (defined as the Company’s net product revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates) achieved against the target managed revenues, with a threshold achievement level of 75% of target and a ceiling achievement level of 125% of target.
Restricted Stock Unit Awards with Market Conditions
In March 2019, the Compensation Committee and Board approved the grant of 99,010 RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs, vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between 0% and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the 50th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of $143.92 per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.


24
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)


(16) INCOME TAXES
The Company utilizes an estimated annual effective tax rate for calculating a tax provision under ASC 740-270. That rate is applied to year-to-date ordinary income or loss in order to compute the year-to-date income tax provision. For the three months ended September 30, 2019, the Company recognized a net tax benefit of $45.2 million primarily attributed to the quarter fluctuations in the mix and timing of our profits and losses on a territorial basis when applying the estimated annual effective tax rate to the year-to-date earnings.
The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s Dutch subsidiary had a full valuation allowance against a deferred tax asset of $29.6 million at December 31, 2018. Historical earnings, future taxable income and ongoing prudent and feasible tax planning strategies have been considered in assessing the need for the valuation allowance; and based on projected income and other key operating factors, the Company concluded in the second quarter of 2019 that it is more likely than not that the benefit of these deferred tax assets would be realized. As a result, the amount of the valuation allowance related to the deferred tax assets that are expected to be realized was reversed in the second quarter of 2019, resulting in a net tax benefit of $27.1 million recognized during the nine months ended September 30, 2019.

(17) NET INCOME (LOSS) PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, common stock held by the Company's NQDC Plan and contingent issuances of common stock related to convertible debt.
The following table sets forth the computation of basic and diluted earnings per common share (in thousands of common shares):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net Income (Loss), basic
$
55,036

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Add: Interest on 2024 notes
937

 
—

 
—

 
—

Net Income (Loss), diluted
$
55,973

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Denominator:
 
 
 
 
 
 
 
Weighted-average common shares outstanding, basic
179,289

 
177,481

 
178,873

 
176,767

Effect of dilutive securities:
 
 
 
 
 
 
 
Options to purchase common stock
1,560

 
—

 
—

 
—

Common stock issuable under the 2024 notes
3,970

 
—

 
—

 
—

Unvested RSUs
669

 
—

 
—

 
—

Common stock potentially issuable for ESPP purchases
231

 
—

 
—

 
—

Common shares held by the NQDC
205

 
—

 
—

 
—

Weighted-average common shares outstanding, diluted
185,924

 
177,481

 
178,873

 
176,767

Net Income (Loss) per common share, basic
0.31

 
(0.07
)
 
(0.22
)
 
(0.42
)
Net Income (Loss) per common share, diluted
0.30

 
(0.07
)
 
(0.22
)
 
(0.42
)

In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive using the if-converted or treasury stock method (in thousands of common shares):

25
BIOMARIN PHARMACEUTICAL INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)

 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Options to purchase common stock
5,829

 
7,517

 
7,388

 
7,517

Common stock issuable under the 2018 Notes
—

 
3,983

 
—

 
3,983

Common stock issuable under the 2020 Notes
3,983

 
3,983

 
3,983

 
3,983

Common stock issuable under the 2024 Notes
—

 
3,970

 
3,970

 
3,970

Unvested RSUs
3,360

 
3,411

 
4,029

 
3,411

Common stock potentially issuable for ESPP purchases
222

 
407

 
453

 
407

Common stock held by the NQDC
—

 
208

 
205

 
208

Total number of potentially issuable shares
13,394

 
23,479

 
20,028

 
23,479

The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net loss per share as of September 30, 2019 as the Company’s closing stock price on September 30, 2019 did not exceed the conversion price of $94.15 per share. Although the Company’s stock price on September 28, 2018 (the last trading day before September 30, 2018) exceeded the conversion price, the potential effect of the capped call transactions and potential shares issuable under the Company’s 0.75% senior subordinated convertible notes due in 2018 and the 2020 Notes were excluded from the calculation of diluted loss per share in the three and nine months ended September 30, 2018 as they were anti-dilutive using the if-converted method. There is no similar capped call transaction associated with the 2024 Notes. See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 for additional information related to the Company’s convertible debt and capped call transaction.

(18) COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.
Contingent Payments
As of September 30, 2019, the Company was subject to contingent payments totaling approximately $376.9 million upon achievement of certain development and regulatory activities and commercial sales and licensing milestones if they occur before certain dates in the future. Of this amount, $65.5 million relates to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and $239.7 million relates to programs that are no longer being developed.
As of September 30, 2019, the Company recorded a total of $69.1 million of contingent liabilities, of which $20.2 million was short-term. See Note 9 to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients and certain other inventory-related items. As of September 30, 2019, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $131.6 million.


26

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties described in “Risk Factors” in Part II, Item 1A in this Quarterly Report on Form 10-Q. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled “Forward-Looking Statements” that appears at the beginning of this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments.

Overview
We are a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products.
Our portfolio consists of several commercial products and multiple clinical and preclinical product candidates. A summary of our major commercial products, including key metrics, as of September 30, 2019, is provided below:
Major Commercial Products
 
Indication
 
U.S. Orphan Drug Exclusivity
Expiration (1)
 
U.S. Biologic
Exclusivity
Expiration (2)
 
EU Orphan Drug Exclusivity
Expiration (1)
Aldurazyme (laronidase)
 
 MPS I (3)
 
Expired
 
Expired
 
Expired
Brineura (cerliponase alfa)
 
 CLN2 (4)
 
2024
 
2029
 
2027
Kuvan (sapropterin dihydrochloride)
 
 PKU (5)
 
Expired
 
Not Applicable (5)
 
2020 (5)
Naglazyme (galsulfase)
 
 MPS VI (6)
 
 Expired
 
 Expired
 
 Expired
Palynziq (pegvaliase-pqpz)
 
 PKU (7)
 
2025
 
2030
 
2029
Vimizim (elosulfase alpha)
 
 MPS IVA (8)
 
2021
 
2026
 
2024
(1)
See “Government Regulation—Orphan Drug Designation” in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019 (our “Annual Report”) for further discussion
(2)
See “Government Regulation— Healthcare Reform” in Part I, Item 1 of our Annual Report for further discussion
(3)
For the treatment of Mucopolysaccharidosis I (MPS I)
(4)
For the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
(5)
For the treatment of phenylketonuria (PKU). Kuvan, a small molecule therapy, has been granted orphan drug status in the European Union (EU), which together with pediatric exclusivity, confers 12 years of market exclusivity in the EU that expires in 2020.
(6)
For the treatment of Mucopolysaccharidosis VI (MPS VI)
(7)
For the treatment of PKU in adult patients. Palynziq was approved by the U.S. Food and Drug Administration (FDA) in May 2018 and by the European Commission in May 2019.  
(8)
For the treatment of Mucopolysaccharidosis IV Type A (MPS IVA)
A summary of our ongoing major development programs, including key metrics as of September 30, 2019, is provided below:
Major Product Candidates
in Development
 
Target
Indication
 
U.S. Orphan
Designation
 
EU Orphan
Designation
 
Stage
Valoctocogene roxaparvovec
 
Hemophilia A (1)
 
 Yes
 
 Yes
 
 Clinical Phase 3
Vosoritide
 
 Achondroplasia
 
 Yes
 
 Yes
 
 Clinical Phase 3
BMN 307
 
 PKU
 
 Not applicable
 
 Not applicable
 
 Preclinical
(1)
Hemophilia A is also called factor VIII deficiency or classic hemophilia

27
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

Business Developments
We continued to grow our commercial business and advance our product candidate pipeline over the course of 2019. We believe that the combination of our internal research programs, acquisitions and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Below is a summary of key business developments during the nine months ended September 30, 2019:
Product Approval
•
Palynziq – In May 2019, the European Commission granted marketing authorization for Palynziq at doses of up to 60 mg once daily, to reduce blood Phe concentrations in patients with PKU aged 16 and older, who have inadequate blood Phe control (blood Phe levels greater than 600 micromol/L) despite prior management with available treatment options. EU commercial sales commenced in the third quarter of 2019 and we anticipate meaningful revenue contributions from this region in 2020.
Continued Emphasis on Research and Development
•
BMN 307 - In September 2019, we submitted a clinical trial application with the Medicines and Healthcare Products Regulatory Agency in the United Kingdom for BMN 307, a gene therapy product candidate for the treatment of PKU. Product to support clinical evaluation is being produced at our gene therapy manufacturing facility, where valoctocogene roxaparvovec is currently made, using a commercial-scale manufacturing process to facilitate rapid clinical development.
•
Valoctocogene roxaparvovec – In July 2019, we announced our plan to submit marketing applications in both the U.S. and Europe in the fourth quarter of 2019 for valoctocogene roxaparvovec based on recent meetings with the FDA and the European Medicines Agency (EMA). These submissions will be based on the updated three-year Phase 1/2 data and the recently completed Phase 3 interim analysis of patients treated with valoctocogene roxaparvovec.
In August 2019 we announced the discontinuation of the valoctocogene roxaparvovec study with the 4e13 vg/kg dose given the overwhelming preference by patients to be treated with the 6e13 vg/kg dose. Enrollment continues in the GENEr8-1 Phase 3 open-label study and the 52-week results are anticipated at the end of 2020. Although the trial is open-label, we have instituted a data access plan designed to significantly mirror a blinded trial, such that only a very limited group of medical personnel who are assisting with monitoring and managing the trial have access to any portion of the ongoing results, and then only to the extent necessary to perform the monitoring and management.
•
BMN 290 - In August 2019 we announced plans to cease the development of BMN 290 program for the treatment of Friedreich’s Ataxia program based on progress of other portfolio assets that have demonstrated stronger product profiles.
•
Vosoritide – In June 2019, the New England Journal of Medicine published the 42-month results from our Phase 2 study with vosoritide in children ages 5 to 14. We expect top line results from the ongoing fully-enrolled global, Phase 3 study by year-end. The vosoritide development program includes four distinct areas of focus to support global approval, including a large contemporaneous natural history study, which is underway.
•
Brineura – In February 2019, we announced that twenty-three patients in the ongoing open-label extension study treated with Brineura continued to show a reduced rate of decline compared to a natural history cohort of CLN2 disease for three years as measured by the CLN2 Clinical Rating Scale.
Financial Highlights
Key components of our results of operations include the following:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues
$
461.1

 
$
391.7

 
$
1,249.6

 
$
1,138.0

Cost of sales
97.0

 
78.9

 
263.6

 
240.2

Research and development (R&D) expense
173.0

 
161.4

 
542.2

 
520.9

Selling, general and administrative (SG&A) expense
170.1

 
148.6

 
493.0

 
440.2

Intangible asset amortization and contingent consideration
17.0

 
18.6

 
57.1

 
42.0

Gain on sale of intangible assets
—

 
—

 
(15.0
)
 
(20.0
)
Net Income/(Loss)
55.0

 
(12.6
)
 
(38.9
)
 
(73.6
)

28
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

We recognized Net Income for the three months ended September 30, 2019 as compared to a Net Loss for the three months ended September 30, 2018, primarily due to the following:
•
increased gross profit driven by increased sales revenue from products we market;
•
increased tax benefit primarily attributed to quarterly fluctuations in the mix and timing of our profits and losses on a territorial basis. See Benefits from Income Taxes below for additional discussion; partially offset by
•
increased sales and marketing expense primarily attributed to pre-commercial activities related to valoctocogene roxaparvovec and commercial activities in support of the EU commercial launch and continued U.S. expansion of Palynziq;
•
increased general and administrative expense primarily attributed to personnel-related costs resulting from increased headcount to support our growth and consulting and professional services expenses; and
•
increased R&D expense primarily attributed to pre-clinical activities related to BMN 307 and clinical activities related to our vosoritide and valoctocogene roxaparvovec development program partially offset by decreased R&D expense related to Palynziq for which we began capitalizing manufacturing costs upon FDA approval in May 2018, and a decrease in tralesinidase alfa clinical manufacturing costs.
The decrease in Net Loss for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018 was primarily attributed to the following:
•
increased gross profit driven by increased sales revenue from products we market;
•
increased tax benefit primarily attributed to quarterly fluctuations in the mix and timing of our profits and losses on a territorial basis and reversals of certain Dutch tax reserves that were no longer required; partially offset by
•
increased sales and marketing expense primarily in support of the EU commercial launch and continued U.S. expansion of Palynziq and valoctocogene roxaparvovec pre-commercialization activities;
•
increased R&D expense primarily attributed to preclinical and manufacturing activities related to our PKU gene therapy development program and clinical activities related to our valoctocogene roxaparvovec development program partially offset by decreased R&D expense related to Palynziq for which we began capitalizing manufacturing costs upon FDA approval in May 2018, and a decrease in tralesinidase alfa clinical manufacturing costs; and
•
increased intangible asset amortization related to the Palynziq in-process research and development assets that were placed into service following EU approval in May 2019.
See “Results of Operations” below for additional information related to the Net Income/(Loss) fluctuations presented above.
Our cash, cash equivalents and investments totaled approximately $1.2 billion as of September 30, 2019, compared to $1.3 billion as of December 31, 2018. We have historically financed our operations primarily through our cash flows from operating activities and the issuance of common stock and convertible debt. We will be highly dependent on our net product revenues to supplement our current liquidity and fund our operations for the foreseeable future. We may in the future elect to supplement this with further debt or equity offerings or commercial borrowing. Further, depending on market conditions, our financial position and performance and other factors, we may in the future choose to use a portion of our cash, cash equivalents or investments to repurchase our convertible debt or other securities. See “Financial Position, Liquidity and Capital Resources” below for a further discussion of our liquidity and capital resources.
Critical Accounting Policies, Estimates and Judgments
In preparing our Condensed Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions.
There have been no significant changes to our critical accounting policies, estimates and judgments during the nine months ended September 30, 2019, compared to the critical accounting policies, estimates and judgments disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2018.

29

Recent Accounting Pronouncements
See Note 4 to our accompanying Condensed Consolidated Financial Statements for a description of recent accounting pronouncements and our expectation of their impact on our results of operations and financial condition.
Results of Operations
Revenues
Net Product Revenues consisted of the following:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Aldurazyme
$
22.8

 
$
27.6

 
$
(4.8
)
 
$
73.9

 
$
117.7

 
$
(43.8
)
Brineura
19.8

 
9.9

 
9.9

 
46.8

 
27.7

 
19.1

Firdapse
5.7

 
5.0

 
0.7

 
16.3

 
15.1

 
1.2

Kuvan
120.6

 
113.3

 
7.3

 
340.8

 
321.4

 
19.4

Naglazyme
94.4

 
103.1

 
(8.7
)
 
279.5

 
269.2

 
10.3

Palynziq
24.1

 
4.1

 
20.0

 
55.2

 
4.1

 
51.1

Vimizim
163.5

 
123.3

 
40.2

 
412.0

 
368.0

 
44.0

Total net product revenues
$
450.9

 
$
386.3

 
$
64.6

 
$
1,224.5

 
$
1,123.2

 
$
101.3

Net Product Revenues include revenues generated from our approved products. In the U.S., our commercial products, except for Palynziq and Aldurazyme, are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. Palynziq is distributed in the U.S. through certain certified specialty pharmacies under the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program, and Aldurazyme is marketed world-wide by Sanofi Genzyme (Genzyme). Outside the U.S., our commercial products are sold to authorized distributors or directly to government purchasers or hospitals, which act as the end-users. In certain countries, such as in Latin America, governments place large periodic orders for Naglazyme and Vimizim. The timing of these large government orders can be inconsistent and can create significant quarter to quarter variation in our revenues.
The increase in Net Product Revenues for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018 was primarily attributed to the following:
•
Vimizim: the increase was primarily attributed to increased sales volume due to government ordering patterns in the Middle East and Latin America;
•
Palynziq: the increase was attributed to a combination of revenue from more patients achieving maintenance dosing and new patients initiating therapy in the U.S. as the product launched in the third quarter of 2018;
•
Brineura: the increase was primarily attributed to growth in the number of patients in all regions; and
•
Kuvan: the increase was primarily attributed to increased sales volume driven by an increase in the number of patients in the U.S market; partially offset by
•
Naglazyme: the decrease was primarily attributed to decreased sales volume driven by government ordering patterns from certain Latin American and European countries; and
•
Aldurazyme: the decrease was primarily attributed to decreased sales volume due to the timing of customer acceptance for product shipped to Genzyme.  
The increase in Net Product Revenues for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018 was primarily attributed to the following:
•
Palynziq: the increase was attributed to a combination of revenue from more patients achieving maintenance dosing and new patients initiating therapy in the U.S. as the product launched in the third quarter of 2018;
•
Vimizim: the increase was primarily attributed to increased sales volume due to government ordering patterns in the Middle East and Latin America;
•
Kuvan: the increase was primarily attributed to increased sales volume driven by an increase in the number of patients in Europe and North America;
•
Brineura: the increase was primarily attributed to an increase in the number of patients in Europe;

30
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

•
Naglazyme: the increase was primarily attributed to increased sales volume driven by government ordering patterns from certain Latin American and European countries; partially offset by
•
Aldurazyme: the decrease was primarily attributed to decreased sales volume due to the timing of customer acceptance for product shipped to Genzyme.  
We face exposure to movements in foreign currency exchange rates, primarily the Euro. We use foreign currency exchange contracts to hedge a percentage of our foreign currency exposure.
The following table shows our Net Product Revenues denominated in U.S. Dollar (USD) and foreign currencies (as-converted to USD):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Sales denominated in USD
$
284.6

 
$
243.3

 
$
41.3

 
$
738.6

 
$
698.6

 
$
40.0

Sales denominated in foreign currencies
166.3

 
143.0

 
23.3

 
485.9

 
424.6

 
61.3

Total Net Product Revenues
$
450.9

 
$
386.3

 
$
64.6

 
$
1,224.5

 
$
1,123.2

 
$
101.3

The net impact of foreign currency exchange rates on product sales denominated in currencies other than USD during the three months ended September 30, 2019 was negative by $6.9 million, compared to a negative impact of $10.2 million for the three months ended September 30, 2018. The foreign exchange impacts for the three months ended September 30, 2019 and 2018, were driven by fluctuations in the Euro and Brazilian Real. The net impact of foreign currency exchange rates on product sales denominated in currencies other than USD during the nine months ended September 30, 2019 was negative by $18.6 million, compared to a positive impact of $1.7 million for the nine months ended September 30, 2018, both of which were driven primarily by the fluctuations in the Euro, partially offset by the Brazilian Real.
Cost of Sales
Cost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and internal and external final formulation and packaging costs. Cost of Sales also includes royalties payable to third parties based on sales of our products.
The following table summarizes our Cost of Sales and product gross margin:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Total Net Product Revenues
$
450.9

 
$
386.3

 
$
64.6

 
$
1,224.5

 
$
1,123.2

 
$
101.3

Cost of Sales
97.0

 
78.9

 
18.1

 
263.6

 
240.2

 
23.4

Product gross margin
79
%
 
80
%
 
(1
)%
 
79
%
 
79
%
 
—
%
Our Cost of Sales increased for the three and nine months ended September 30, 2019 compared to the same periods in 2018 due to increased sales volumes. Product gross profits for the three months ended September 30, 2019 compared to the same period in 2018 were lower due primarily to lower unit prices for products sold. Product gross profits for the nine months ended September 30, 2019 compared to the same periods in 2018 remained flat.
Research and Development
R&D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our approved products. R&D expense primarily includes preclinical and clinical studies, personnel and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, facilities and regulatory costs.
We manage our R&D expense by identifying the R&D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.
We continuously evaluate the recoverability of costs associated with pre-launch or pre-qualification manufacturing activities, and if it is determined that recoverability is highly likely and therefore future revenues are expected, the costs

31
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

subsequently incurred related to pre-launch or pre-qualification manufacturing activities for purposes of commercial sales will likely be capitalized. When regulatory approval and the likelihood of future revenues for a product candidate are less certain, the related manufacturing costs are expensed as R&D expenses. Starting in the second quarter of 2019, we have capitalized $7.1 million of manufacturing related costs for the commercial production of valoctocogene roxaparvovec through September 30, 2019 as we believe those costs are likely to be recoverable. See Note 8 to our accompanying Condensed Consolidated Financial Statements for additional information regarding our inventory.
R&D expense consisted of the following:
 
Three Months Ended June 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Valoctocogene roxaparvovec
$
40.9

 
$
35.7

 
$
5.2

 
$
144.8

 
$
107.9

 
$
36.9

Vosoritide
25.3

 
19.4

 
5.9

 
85.4

 
59.8

 
25.6

PKU gene therapy (BMN 307)
31.9

 
5.3

 
26.6

 
73.1

 
10.6

 
62.5

Palynziq
17.3

 
20.3

 
(3.0
)
 
57.3

 
77.2

 
(19.9
)
Brineura
9.2

 
10.7

 
(1.5
)
 
30.4

 
34.9

 
(4.5
)
Tralesinidase alfa
6.8

 
14.3

 
(7.5
)
 
22.6

 
68.6

 
(46.0
)
Other approved products
14.1

 
16.1

 
(2.0
)
 
48.1

 
51.7

 
(3.6
)
Early stage programs
21.1

 
16.7

 
4.4

 
57.9

 
49.3

 
8.6

Other
6.4

 
22.9

 
(16.5
)
 
22.6

 
60.9

 
(38.3
)
Total
$
173.0

 
$
161.4

 
$
11.6

 
$
542.2

 
$
520.9

 
$
21.3

The increase in R&D expense for the three and nine months ended September 30, 2019 as compared to 2018 was primarily attributed to the following:
•
an increase in preclinical and manufacturing activities related to our BMN 307 development program, including clinical manufacturing costs;
•
an increase in clinical activity related to our late-stage product candidates valoctocogene roxaparvovec and vosoritide; partially offset by
•
a decrease in other R&D expenses related to development activities that are not allocated to programs; and
•
a decrease in tralesinidase alfa clinical manufacturing costs.
For the remainder of 2019, we expect our R&D spending to remain flat compared to 2018 levels primarily due to lower development costs related to valoctocogene roxaparvovec and a reduction in costs following the out license of the tralesinidase alfa to a third party in October 2019, offset by increased costs related to BMN 307 and other programs progressing in their development. We expect to continue incurring R&D expense for the foreseeable future due to long-term clinical activities related to post-approval regulatory commitments for our approved products.
Selling, General and Administrative
Sales and Marketing (S&M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and administrative (G&A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.

32
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

Selling, General and Administrative (SG&A) expense consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Selling & Marketing expense
$
93.5

 
$
81.2

 
$
12.3

 
$
264.7

 
$
238.4

 
$
26.3

General & Administrative expense
76.6

 
67.4

 
9.2

 
228.3

 
201.8

 
26.5

Total SG&A expense
$
170.1

 
$
148.6

 
$
21.5

 
$
493.0

 
$
440.2

 
$
52.8

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Selling & Marketing expense by product
2019
 
2018
 
Change
 
2019
 
2018
 
Change
PKU Products
$
32.8

 
$
31.7

 
$
1.1

 
$
97.3

 
$
88.2

 
$
9.1

MPS Products
28.5

 
26.5

 
2.0

 
85.2

 
86.3

 
(1.1
)
Brineura
11.3

 
10.7

 
0.6

 
31.0

 
31.8

 
(0.8
)
Valoctocogene roxaparvovec
12.6

 
4.7

 
7.9

 
28.7

 
12.0

 
16.7

Other
8.3

 
7.6

 
0.7

 
22.5

 
20.1

 
2.4

Total Selling & Marketing expense
$
93.5

 
$
81.2

 
$
12.3

 
$
264.7

 
$
238.4

 
$
26.3

The increase in SG&A expense for the three and nine months ended September 30, 2019 as compared to the same periods in 2018 was primarily attributed to the following:
•
an increase in S&M expense related to pre-commercialization activities related to valoctocogene roxaparvovec and commercialization activities in support of the continued U.S. expansion and EU commercial launches of Palynziq; partially offset by
•
a decrease in commercial activities related to our other approved products as resources were reallocated to supporting the launch of Palynziq; and
•
increased G&A expense primarily attributed to increased personnel-related costs resulting from increased headcount to support our growth and other administrative-related costs.
We expect SG&A expense to increase in future periods as a result of the continued commercial launch of Palynziq, pre-commercialization efforts related to valoctocogene roxaparvovec, and the continued international expansion of Vimizim.
Intangible Asset Amortization, Contingent Consideration and Gain on Sale of Intangible Assets
Changes during the periods presented for Intangible Asset Amortization and Contingent Consideration include:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Changes in the fair value of contingent consideration
$
0.8

 
$
11.0

 
$
(10.2
)
 
$
19.9

 
$
19.3

 
$
0.6

Amortization of intangible assets
16.3

 
7.6

 
8.7

 
37.2

 
22.7

 
14.5

Total intangible asset amortization and contingent consideration
$
17.1

 
$
18.6

 
$
(1.5
)
 
$
57.1

 
$
42.0

 
$
15.1

 
 
 
 
 
 
 
 
 
 
 
 
Gain on sale of intangible assets
$
—

 
$
—

 
$
—

 
$
(15.0
)
 
$
(20.0
)
 
$
5.0

Fair value of contingent consideration – the changes in the fair value of the contingent consideration for the three and nine months ended September 30, 2019 were attributable to changes in the estimated probability of achieving development milestones, which was primarily related to the continued progress of the Palynziq program that achieved EU marketing approval in May 2019.
Amortization of intangible assets – the increase in the three and nine months ended September 30, 2019 was primarily due to the Palynziq acquired in-process research and development assets that were placed into service following EU marketing approval in May 2019.
Gain on Sale of Intangible Assets – we recognized a gain of $15.0 million in the nine months ended September 30, 2019 due to a third party’s achievement of a milestone during the second quarter of 2019, related to a previously sold intangible asset. See Note 6 to the accompanying Condensed Consolidated Financial Statements for additional information.

33
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

Interest Income
We invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk. The change during the periods presented for interest income was as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Interest income
$
5.3

 
$
6.3

 
$
(1.0
)
 
$
17.5

 
$
17.1

 
$
0.4

The decrease in interest income for the three months ended September 30, 2019 compared to 2018 was primarily due to a lower investment balance compared to the prior period. The increase in interest income for the nine months ended September 30, 2019 compared to 2018 was primarily due to a higher average interest rate on investments.
Interest Expense
We incur interest expense on our convertible debt. Interest expense for the periods presented consisted of the following:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
Change
 
2019
 
2018
 
Change
Total interest expense
$
2.9

 
$
12.1

 
$
(9.2
)
 
$
16.5

 
$
35.9

 
$
(19.4
)
The decrease in interest expense on convertible debt for the three and nine months ended September 30, 2019 compared to 2018 was primarily due to the maturity of our 0.75% senior subordinated convertible notes that matured on October 15, 2018.
See Note 12 to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 for additional information related to our convertible debt.  
Benefit from Income Taxes
For the three and nine months ended September 30, 2019, we recognized an income tax benefit of $45.2 million and $46.2 million, respectively, compared to the three and nine months ended September 30, 2018 when we recognized an income tax benefit of $6.8 million and $25.8 million, respectively. U.S. and foreign tax expense was computed using a forecasted annual effective tax rate for the three and nine months ended September 30, 2019 and 2018. The Tax Cuts and Jobs Act of 2017 (the 2017 Tax Act), which became effective on January 1, 2018, resulted in significant changes to the U.S. corporate income tax system including a federal statutory rate reduction from 35% to 21% and the elimination or reduction of certain domestic deductions and credits. The 2017 Tax Act changed U.S. international taxation from a worldwide basis to a modified territorial system that includes base erosion prevention measures on foreign earnings. This will result in our foreign subsidiaries being subject to U.S. taxation.
The large benefit recognized during the three months ended September 30, 2019 is primarily attributed to the quarter fluctuations in the mix and timing of our profits and losses on a territorial basis when using an estimated annual effective tax rate under ASC 740-270 applied to year-to-date earnings. The income tax benefit for the three and nine months ended September 30, 2019 also consisted of state, federal and foreign current tax expense offset by deferred tax benefits from federal orphan drug and R&D credits, the tax benefit related to stock option exercises during the period and a valuation allowance release of $27.1 million in the second quarter of 2019 on foreign net operating loss carryforwards that resulted in a net income tax benefit in the nine month period. The income tax benefit for the three and nine months ended September 30, 2018 also consisted of deferred tax benefits from federal orphan drug and R&D credits and the tax benefit related to stock option exercises during that period and was partially offset by state, federal and foreign current income tax expense, which resulted in a net income tax benefit. We recorded a tax benefit of $4.6 million associated with a measurement-period adjustment in the nine months ending September 30, 2018 related to the remeasurement of deferred taxes as a result of the 2017 Tax Act.
See Note 14 to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 for additional discussion of our income taxes.

Financial Position, Liquidity and Capital Resources
As of September 30, 2019, we had approximately $1.2 billion in cash, cash equivalents and investments. We expect to fund our operations with our net product revenues from our commercial products, cash, cash equivalents and investments, supplemented as may become necessary by proceeds from equity or debt financings and loans, or collaborative agreements with corporate partners. We may require additional financing to fund the repayment of our convertible debt, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The timing and mix of our funding options could change depending on many factors, including how much we elect to spend on our development programs,

34
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

potential licenses and acquisitions of complementary technologies, products and companies or if we elect to settle all or a portion of our convertible debt in cash.
In managing our liquidity needs in the U.S., we do not rely on unrepatriated earnings as a source of funds and we have not provided for U.S. federal or state income taxes on these undistributed foreign earnings. We do not record U.S. tax expense on the undistributed earnings of our controlled foreign subsidiaries as these earnings are intended to be indefinitely reinvested offshore. As of September 30, 2019, $206.0 million of our $1.2 billion balance of cash, cash equivalents, and investments was held in foreign subsidiaries, a significant portion of which is required to fund the liquidity needs of these foreign subsidiaries. For additional discussion regarding income taxes, see Note 14 to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.
We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. We will continue to monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.
Our liquidity and capital resources as of September 30, 2019 and December 31, 2018 were as follows:
 
September 30, 2019
 
December 31, 2018
 
Change
Cash and cash equivalents
$
423.2

 
$
494.0

 
$
(70.8
)
Short-term investments
297.6

 
590.3

 
(292.7
)
Long-term investments
431.8

 
235.9

 
195.9

Cash, cash equivalents and investments
$
1,152.6

 
$
1,320.2

 
$
(167.6
)
 
 
 
 
 
 
Convertible debt
$
843.6

 
$
830.4

 
$
13.2

Our cash flows for the nine months ended September 30, 2019 and 2018 are summarized as follows:
 
2019
 
2018
 
Change
Cash and cash equivalents at the beginning of the period
$
494.0

 
$
598.0

 
$
(104.0
)
Net cash used in operating activities
(9.1
)
 
(29.2
)
 
20.1

Net cash provided by investing activities
17.9

 
335.3

 
(317.4
)
Net cash used in financing activities
(78.7
)
 
(21.6
)
 
(57.1
)
Foreign exchange impact
(0.8
)
 
(0.3
)
 
(0.5
)
Cash and cash equivalents at the end of the period
$
423.2

 
$
882.2

 
$
(459.0
)
Short-term and long-term investments
729.4

 
766.1

 
(36.7
)
Cash, cash equivalents and investments
$
1,152.6

 
$
1,648.3

 
$
(495.7
)
Cash Used in Operating Activities
Cash used in operating activities decreased by $20.1 million to $9.1 million in the nine months ended September 30, 2019, compared to $29.2 million in the nine months ended September 30, 2018. The decrease is primarily attributed to the timing of cash receipts from customers, payments to vendors and higher inventory levels.
Cash Provided by Investing Activities
Net cash provided by investing activities decreased by $317.4 million to $17.9 million in the nine months ended September 30, 2019, compared to $335.3 million during the nine months ended September 30, 2018. The decrease in net cash provided by investing activities during the nine months ended September 30, 2019 was primarily attributable to the lower net maturities of available-for-sale debt securities.  
Cash Used in Financing Activities
Net cash used in financing activities increased by $57.1 million to $78.7 million used in the nine months ended September 30, 2019, compared to $21.6 million during the nine months ended September 30, 2018. The increase in net cash used in financing activities for the nine months ended September 30, 2019 was primarily attributed to a $33.9 million decrease in proceeds from the exercise of awards under the incentive plans, a $14.4 million increase in payments of contingent consideration and an increase of $6.8 million in cash paid for taxes related to the net settlement of equity awards.  
Other Information

35
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

Our $870.0 million (undiscounted) of total convertible debt as of September 30, 2019 will impact our liquidity due to the semi-annual cash interest payments. As of September 30, 2019, our indebtedness consisted primarily of the 1.50% senior subordinated convertible notes due in 2020 (the 2020 Notes) and our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes and, together with the 2020 Notes, the Notes), which, if not converted, will be required to be repaid in cash at maturity in 2020 and 2024, respectively. We will need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.
In the event the conditional conversion feature of the 2020 Notes is triggered, holders of the 2020 Notes will be entitled to convert the 2020 Notes at any time during specified periods at their option. In addition, the 2020 Notes will be freely convertible on or after July 15, 2020. We intend to use the remaining balance of the net proceeds we received from the issuance of the 2024 Notes to repay, repurchase or settle in cash some or all of the 2020 Notes. We may elect to settle conversions of the 2020 Notes in cash, in whole or in part, which could further affect our liquidity. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon such events, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all. Even if holders of the 2020 Notes do not elect to convert their 2020 Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of such Notes as a current liability rather than long-term liability (for example, when there are 12 months or less remaining until maturity), which would result in a material reduction of our net working capital.
In October 2018, we entered into an unsecured revolving credit facility of $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is also intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at our option, at a rate equal to either (a) the LIBOR rate, or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Our obligations under the Credit Facility are guaranteed by our direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon our net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable, except that if at least $100.0 million aggregate principal amount of the 2020 Notes remain outstanding on August 1, 2020 and certain other conditions have not been met, we may be required to repay all amounts borrowed under the 2018 Credit Facility on August 1, 2020. The 2018 Credit Facility contains financial covenants requiring us to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2019, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility.
For additional discussion about our debt, see Note 12 included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Funding Commitments
We cannot estimate with certainty the cost to complete any of our product development programs. Additionally, we cannot precisely estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see “Risk Factors” included in Part II, Item 1A of this Quarterly Report on Form 10-Q, for a discussion of the reasons we are unable to estimate such information, and in particular the following risk factors:
•
If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase;
•
If we are unable to successfully develop and maintain manufacturing processes for our products to produce sufficient quantities at acceptable costs, we may be unable to meet demand for our products and lose potential revenue, have reduced margins or be forced to terminate a program;
•
If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected; and
•
If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.

36
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

Our investment in our product development programs and continued development of our existing commercial products has a major impact on our operating performance. The R&D expenses of our major development programs from inception to September 30, 2019 were as follows:
 
Since Program Inception
 
Palynziq
$
675.0

Valoctocogene roxaparvovec
545.8

Vosoritide
404.4

Brineura
317.5

PKU gene therapy
91.2

Other approved products
1,098.5

We may need or elect to increase our spending above our current long-term plans to be able to achieve our long-term goals. This may increase our capital requirements, including: costs associated with the commercialization of our products; additional clinical trials; investments in the manufacturing of our commercial products; preclinical studies and clinical trials for our other product candidates; potential licenses and other acquisitions of complementary technologies, products and companies; and general corporate purposes.
Our future capital requirements will depend on many factors, including, but not limited to:
•
our ability to successfully market and sell our products;
•
the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities;
•
the progress and success of our preclinical studies and clinical trials (including the manufacture of materials for use in such studies and trials);
•
the timing, number, size and scope of our preclinical studies and clinical trials;
•
the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities; and
•
the progress of research programs carried out by us.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our consolidated financial position or results of operations.

Contractual and Commercial Obligations
We have contractual and commercial obligations under our convertible debt, leases and other obligations related to R&D activities, purchase commitments, licenses and sales royalties with annual minimums.
Our contractual obligations as of September 30, 2019 are presented in the table below.
 
Payments Due Within
 
Remainder of 2019
 
2020 - 2021
 
2022 - 2024
 
Thereafter
 
Total
2020 Notes and related interest
$
2.8

 
$
380.6

 
$
—

 
$
—

 
$
383.4

2024 Notes and related interest
—

 
5.9

 
503.9

 
—

 
509.8

Leases
6.3

 
25.0

 
25.7

 
21.7

 
78.7

R&D and purchase commitments
107.2

 
24.4

 
—

 
—

 
131.6

Total
$
116.3

 
$
435.9

 
$
529.6

 
$
21.7

 
$
1,103.5

We are also subject to contingent payments related to certain development and regulatory activities and commercial sales and licensing milestones totaling approximately $376.9 million as of September 30, 2019, which are due upon achievement

37
Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued)
(In millions, except as otherwise disclosed)

of certain development and commercial milestones and if they occur before certain dates in the future. Of this amount, $65.5 million relates to remaining amounts due to a third party from whom we acquired certain rights and other assets with respect to Kuvan and Palynziq in 2016, and $239.7 million relates to programs that are no longer being developed.
As of September 30, 2019, we recorded $69.1 million of total contingent liabilities on our Condensed Consolidated Balance Sheets, of which $20.2 million was short-term.
See Note 18 to our accompanying Condensed Consolidated Financial Statements for additional discussion on our commitments.



38

Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Our market risks during the nine months ended September 30, 2019 have not materially changed from those discussed in Part II, Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2018.

Item 4.
Controls and Procedures
(a) Controls and Procedures
An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this report.
Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2019.
In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management must apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure controls system are met.
(b) Change in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We are utilizing the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control.

39

PART II. OTHER INFORMATION
Item 1.
Legal Proceedings.
None.
Item 1A.
Risk Factors
An investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.
We have marked with an asterisk (*) those risk factors below that include a substantive change from or update to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 28, 2019.
Risks Related to Our Business
*If we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenue from the sale of these product candidates, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will increase.
We must obtain and maintain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain Food and Drug Administration (FDA) approval for each product candidate that we intend to commercialize, and in Europe we must obtain approval from the European Medicines Agency (EMA). The FDA and EMA approval processes are typically lengthy and expensive, and approval is never certain. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory agency will mean that other agencies will also approve the same product candidate. Similarly, regulatory authorities may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.
We have had fewer interactions with regulatory authorities outside the U.S. and the EU as compared to our interactions with the FDA and EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EMA approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EMA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA or EMA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA or EMA approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file we may not receive necessary approvals to commercialize our product candidates in any market.
Although the FDA and the EMA have programs to facilitate accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. In addition, the FDA, the EMA and other international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory agencies may not agree that we have demonstrated the requisite level of product safety and efficacy to grant approval and may require additional data. If we fail to obtain regulatory approval for our product candidates, we will be unable to market and sell those product candidates. Because of the risks and uncertainties in pharmaceutical development, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. We also rely on independent third-party contract research organizations (CROs) to file some of our foreign marketing applications and important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.
In addition, some of our product candidates are intended to be used in combination with a delivery device, such as an injector or other delivery system. Medical products containing a combination of new drugs, biological products or medical devices may be regulated as “combination products” in the U.S. A combination product generally is defined as a product consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). Each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. Our product candidates intended for use with such devices, or expanded indications that we may seek for our products used with such devices, may not be approved or may be

40

substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug or biologic product and device is sought under a single application, the increased complexity of the review process may delay approval. The FDA review process and criteria are not well-established areas, which could also lead to delays in the approval process. In addition, because these delivery devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.
From time to time during the regulatory approval process for our products and product candidates, we engage in discussions with the FDA and comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory agencies globally, but we do not always follow such guidance. This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. For example, although we designed our Phase 3 study of vosoritide in a manner that we believe can demonstrate efficacy and safety of the product candidate for the target patient population, the FDA may ultimately disagree. Moreover, sometimes different regulatory agencies provide different or conflicting advice. While we attempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other non-U.S. regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.
*Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenue from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.
Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim have received regulatory approval to be commercially marketed and sold in the U.S., the EU and certain other countries, Palynziq has received regulatory approval to be commercially marketed in the U.S. and the EU and Firdapse has received regulatory approval to be commercially marketed in the EU. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EMA and other comparable international regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current good manufacturing practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.
An example of the ongoing regulatory requirements our products are subject to is the Palynziq Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., Palynziq is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:
•
prescribers must be certified by enrolling in the REMS program and completing training;
•
prescribers must prescribe auto-injectable epinephrine with Palynziq;
•
pharmacies must be certified with the REMS program and must dispense Palynziq only to patients who are authorized to receive it;
•
patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with Palynziq; and
•
patients must have auto-injectable epinephrine available at all times while taking Palynziq.
Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of Palynziq. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the Palynziq REMS program, or whether the FDA will permit modifications to the Palynziq REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute Palynziq in the U.S., impair the safety profile of Palynziq, disrupt continuity of care for Palynziq patients and/or negatively affect sales of Palynziq.
Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product's approved labeling. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that

41

is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved.
In addition, the FDA often requires post-marketing testing and surveillance to monitor the effects of products. The FDA, the EMA and other comparable international regulatory agencies may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient.
Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:
•
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
•
restrictions on product manufacturing processes;
•
restrictions on the marketing of a product;
•
restrictions on product distribution;
•
requirements to conduct post-marketing clinical trials;
•
untitled or warning letters or other adverse publicity;
•
withdrawal of the products from the market;
•
refusal to approve pending applications or supplements to approved applications that we submit;
•
recall of products;
•
refusal to permit the import or export of our products;
•
product seizure;
•
fines, restitution or disgorgement of profits or revenue;
•
injunctions; or
•
imposition of civil or criminal penalties.
If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EMA or any other comparable international regulatory agency withdraws its approval of a product, we will be unable to generate revenue from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.
If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.
As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. In the EU, orphan drug designation is available if a sponsor can establish: that the medicine is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, which is equivalent to around 250,000 people or fewer or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the medicinal product in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity (extendable to twelve years for medicines that have complied with an agreed pediatric investigation plan pursuant to Regulation 1901/2006) is available. Orphan drug marketing exclusivity may be lost in the EU if a manufacturer is unable to supply sufficient quantities and marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this medicinal product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug exclusivity for our products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.
Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which

42

means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor product’s orphan drug exclusivity period expires. Moreover, with respect to biologics and gene therapy, it is uncertain how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidates’ orphan drug exclusivities. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.
We may face competition from biosimilars approved through an abbreviated regulatory pathway.
Our Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act (the FDC Act) and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and approval by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated approval of biological products that are demonstrated to be “biosimilar” or “interchangeable” with an FDA-approved biological product. A similar abridged marketing authorization process is available to biosimilar products in the EU. In order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of exclusivity for reference products. In Europe, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or MAAs in Europe, as well as products in development that may be approved under those regimes in the future, could be reference products for biosimilar marketing applications.
*To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution since the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.
As part of the drug development process we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early stage product candidates, we may need to perform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial will be favorable. From time to time, we have and may in the future publish or report preliminary, initial or interim data from our clinical trials, such as the data we have announced from the GENEr-8-1 study for valoctocogene roxaparvovec. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.
Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions

43

where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.
Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:
•
slow or insufficient patient enrollment;
•
slow recruitment of, and completion of necessary institutional approvals at, clinical sites;
•
budgetary constraints or prohibitively high clinical trial costs;
•
longer treatment time required to demonstrate efficacy;
•
lack of sufficient supplies of the product candidate;
•
adverse medical events or side effects in treated patients, including immune reactions;
•
lack of effectiveness of the product candidate being tested;
•
availability of competitive therapies to treat the same indication as our product candidates;
•
regulatory requests for additional clinical trials or preclinical studies;
•
deviations in standards for Good Clinical Practice (GCP); and
•
disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services reportable to the FDA or other regulatory authority. If the FDA or other regulatory authority concludes that a financial relationship between us and a principal investigator has created a conflict of interest, the FDA or other regulatory authority may question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.
*Our valoctocogene roxaparvovec program is based on a gene therapy approach, which, as a novel technology, presents additional treatment, regulatory, manufacturing, and commercial risks in relation to our other, more traditional drug development programs.
In addition to the risks set forth in this Risk Factors section associated with developing and commercializing more traditional pharmaceutical drugs, there are additional, unique risks associated with gene therapy products like our product candidate valoctocogene roxaparvovec (formerly referred to as BMN 270). The goal of gene therapy is to be able to correct an inborn genetic defect through one-time administration of therapeutic genetic material containing non-defective gene copies. The gene copies are designed to reside permanently in a patient, allowing the patient to produce an essential protein or ribonucleic acid (RNA) molecule that a healthy person would normally produce. There is a risk, however, that the new gene copies will produce too little or too much of the desired protein or RNA. Although a one-time administration of a gene therapy product like our product candidate valoctocogene roxaparvovec is intended to correct an inborn genetic defect for the entire lifetime of a patient, there is a risk that the therapeutic effect will not be durable and production of the desired protein or RNA will decrease over time or cease entirely. Because the treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential overproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Furthermore, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed.
We may experience development problems related to our gene therapy program that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials and the FDA has approved several cell-based gene therapy treatments to date, the FDA has only approved a very small number of vector-based gene therapy products thus far. Moreover, there are very few approved gene therapy products outside the U.S. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for valoctocogene roxaparvovec in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. Regulatory review agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our treatment candidate or lead to significant post-approval studies, limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring valoctocogene roxaparvovec to market could have a negative effect on our business and financial condition. Even if we do obtain regulatory approval, ethical, social and legal concerns about gene therapy arising in the future could result in additional regulations restricting or prohibiting sale of our product.
We plan to submit a BLA for valoctocogene roxaparvovec to the FDA in the fourth quarter of 2019. If original FDA approval for valoctocogene roxaparvovec is granted via the accelerated approval pathway, we may be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of the FDA’s marketing approval for valoctocogene roxaparvovec, which could have a negative effect on our business and financial condition.
Even if we obtain and maintain regulatory approval for valoctocogene roxaparvovec, we may experience delays, and increased costs, in developing, optimizing and operating a sustainable, reproducible and large-scale manufacturing process.

44

Gene therapy products are novel, complex and difficult to manufacture, and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the valoctocogene roxaparvovec manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies or commercializing valoctocogene roxaparvovec in a timely, or on a profitable, basis, if at all.
Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we also face uncertainty with respect to the pricing, coverage and reimbursement of valoctocogene roxaparvovec, if approved. In order to recover our research and development costs and commercialize this one-time treatment on a profitable basis, we expect the cost of a single administration of valoctocogene roxaparvovec to be substantial. Therefore, we expect that coverage and reimbursement by governments and other third-party payers will be essential for the vast majority of patients to be able to afford valoctocogene roxaparvovec. Accordingly, sales of valoctocogene roxaparvovec, if approved, will depend substantially, both domestically and internationally, on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of valoctocogene roxaparvovec.
We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. Even if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product candidate in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Even if valoctocogene roxaparvovec displays a favorable efficacy and safety profile in clinical trials and is ultimately approved, market acceptance of valoctocogene roxaparvovec will not be fully known until after it is launched. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the development and commercialization of, and demand for, valoctocogene roxaparvovec.
*We have implemented a data access plan for valoctocogene roxaparvovec, which restricts our management’s review of emerging data from these trials.  Without access to ongoing data, management does not have the ability to adjust the trials based on such emerging data, which could adversely impact the ultimate outcome of these trials.
In order to preserve the scientific integrity of the valoctocogene roxaparvovec trials and to allow us to only report on data at intervals that we believe will be meaningful to investors, we have implemented a data access plan related to the ongoing open label trials, which is designed to significantly mirror blinded trials.  Pursuant to this plan, the ongoing emerging data are generally not collected by us, with the exception that certain specific data points are collected and reviewed by a small group of medical personnel monitoring and managing the trial, and then, only to the extent necessary to allow them to perform their monitoring responsibilities.  As we disclose and publicly discuss prior data from these trials, such discussions do not incorporate any of the currently emerging data that are being collected and reviewed by personnel monitoring the trial and, accordingly, this prior data may differ significantly from more recent data that are only available to such personnel.  Further, since our management does not have access to any of the ongoing data and does not have the ability to adjust the trials based on such emerging data, the data access plan could adversely impact the ultimate outcome of the trials.
If we continue to incur operating losses and experience net cash outflows for a period longer than anticipated, we may be unable to continue our operations at planned levels and be forced to reduce our operations.
Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for each year since our inception, with the exception of 2008 and 2010. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we fail to become profitable and cash flow positive or are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.
*If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.
As of September 30, 2019, we had cash, cash equivalents and investments totaling $1.2 billion and long-term debt obligations of $870.0 million (undiscounted), which consisted of our 1.50% senior subordinated convertible notes due in 2020 (the 2020 Notes) and our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes and, together with the 2020 Notes, the Notes), which, if not converted, will be required to be repaid in cash at maturity in 2020 and 2024, respectively. We will

45

need cash not only to pay the ongoing interest due on the Notes during their term, but also to repay the principal amount of the Notes if not converted.
In January 2016 we terminated our License and Commercialization Agreement with Ares Trading, S.A. (Merck Serono). Pursuant to the Termination and Transition Agreement related to Kuvan and the Termination Agreement related to Palynziq, we are obligated to make certain payments to Merck Serono if sales and development milestones are achieved. The remaining milestone payments that may become payable include up to a maximum of €60 million, in cash, if future sales milestones are met with respect to Kuvan and Palynziq.
We may require additional financing to fund the repayment of our Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.
We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:
•
our ability to successfully market and sell our products;
•
the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);
•
the timing, number, size and scope of our preclinical studies and clinical trials;
•
the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;
•
the progress of research programs carried out by us;
•
our possible achievement of development and commercial milestones under agreements with third parties, such as the Kuvan and Palynziq milestones under the termination agreements with Merck Serono;
•
any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;
•
Sanofi Genzyme’s (Genzyme) ability to continue to successfully commercialize Aldurazyme; and
•
whether our convertible debt is converted to common stock in the future.
Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:
•
additional licenses and collaborative agreements;
•
additional contracts for product manufacturing; and
•
additional financing facilities or arrangements.
We will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.
*We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.
As of September 30, 2019, we had $870.0 million (undiscounted) principal amount of indebtedness, including $375.0 million (undiscounted) principal amount of indebtedness under the 2020 Notes and $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes. In October 2018, we also entered into an unsecured credit agreement (the 2018 Credit Facility) with Bank of America, N.A., as the administrative agent, swingline lender and a lender, Citibank N.A. as letter of credit issuer and each of Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citibank, N.A. and Wells Fargo Securities, LLC as joint lead arrangers and joint bookrunners, providing up to $200.0 million in revolving loan commitments and terminated the credit facility that we entered into in November 2016, which had provided for up to $100.0 million in revolving loans (the 2016 Credit Facility). The 2018 Credit Facility replaced the 2016 Credit Facility. Our indebtedness may:
•
limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;
•
limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;
•
require us to use a substantial portion of our cash flow from operations to make debt service payments;

46

•
limit our flexibility to plan for, or react to, changes in our business and industry;
•
place us at a competitive disadvantage compared to our less leveraged competitors; and
•
increase our vulnerability to the impact of adverse economic and industry conditions.
In addition, the 2018 Credit Facility contains, and any future indebtedness that we may incur may contain, financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full. If we default under the 2018 Credit Facility, the outstanding borrowings thereunder could become immediately due and payable, the 2018 Credit Facility lenders could refuse to permit additional borrowings under the facility, or it could lead to defaults under agreements governing our current or future indebtedness, including the indentures governing our Notes. If we default under any of the Notes, such Notes could become immediately due and payable and it could lead to defaults under the other Notes and/or the 2018 Credit Facility.
In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.
Our outstanding indebtedness consists primarily of the 2020 Notes and 2024 Notes, which, if not converted, will be required to be repaid in cash at maturity in 2020 and 2024, respectively. In addition, in the event the conditional conversion feature of the 2020 Notes is triggered, holders of the 2020 Notes will be entitled to convert the 2020 Notes at any time during specified periods at their option, and the 2020 Notes will be freely convertible on or after July 15, 2020. We may elect to settle conversions of the 2020 Notes in cash, in whole or in part, which could further affect our liquidity. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon such events, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.
We could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2020 Notes as a current rather than long-term liability (for example, if there are 12 months or less remaining until maturity), which would result in a material reduction of our net working capital. While we could seek to obtain third-party financing to pay for any amounts due in cash upon such events, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all. Furthermore, if we are required to share settle any conversions of Notes, due to lack of requisite liquidity or otherwise, we may cease to be eligible to account for the Notes using the treasury stock method, which may adversely impact our diluted earnings per share. In addition, we also may borrow up to $200.0 million in revolving loans under the 2018 Credit Facility, which would be required to be repaid in cash at maturity on October 19, 2021, except that if at least $100.0 million aggregate principal amount of the 2020 Notes remains outstanding on August 1, 2020 and certain other conditions have not been met, we may be required to repay all amounts borrowed under the 2018 Credit Facility on August 1, 2020.
If we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.
Before we can begin commercial manufacture of our products, regulatory authorities must approve marketing applications that identify manufacturing facilities operated by us or our contract manufacturers that have passed regulatory inspection and manufacturing processes that are acceptable to the regulatory authorities. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced inspection by the FDA and international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facility in the U.S. has been approved by the FDA for the manufacture of Palynziq, and it has been approved by the FDA, the European Commission (EC), and health agencies in other countries for the manufacture of Aldurazyme, Brineura, Naglazyme and Vimizim. Our manufacturing facility in Shanbally, Cork, Ireland has been approved by the FDA, the EC, and health agencies in other countries for the manufacture of Vimizim, and it has been approved by the FDA and the EMA as a formulated bulk drug substance manufacturing and quality control facility for Brineura. In addition, our third-party manufacturers’ facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.
Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal or international regulatory inspection.
If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.
If we are unable to successfully develop and maintain manufacturing processes for our products to produce sufficient quantities at acceptable costs, we may be unable to meet demand for our products and lose potential revenue, have reduced margins or be forced to terminate a program.

47

Due to the complexity of manufacturing our products, we may not be able to manufacture products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins.
The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.
Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.
Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs, including Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim, have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.
We have entered into contractual relationships with third-party manufacturers to produce active ingredients in Firdapse, Kuvan and Palynziq. If those manufacturers are unwilling or unable to fulfill their contractual obligations, we may be unable to meet demand for Firdapse, Kuvan and Palynziq, or sell these products at all, we may lose potential revenue, and we may be forced to terminate a program. We have contracts for the production of final product for Firdapse, Kuvan and Palynziq. We also currently rely on third parties for portions of the manufacture of Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.
In addition, our manufacturing processes subject us to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.
Supply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.
We depend on single-source suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:
•
timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;
•
labor interruptions;
•
changes in our sources for manufacturing;
•
the timing and delivery of shipments;
•
our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; and
•
conditions affecting the cost and availability of raw materials.
If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.
Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.

48

With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.
Because the target patient populations for our products are small, we must achieve significant market share and maintain high per-patient prices for our products to achieve profitability.
All of our products target diseases with small patient populations. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve profitability. For Brineura, Naglazyme and Vimizim in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.
If we fail to obtain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.
The course of treatment for patients using our products is expensive. We expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenue and gross margins will be adversely affected.
Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.
Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.
Reimbursement in the EU and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.
For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margins may be adversely affected.
A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenue in these countries.
We make a significant portion of our international sales of Naglazyme and Vimizim through special access or “named patient” programs, which do not require full product approval, and we expect a significant portion of our international sales of Brineura will also be through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained for each patient. The approval normally requires an application or a lawsuit accompanied by evidence of medical need. Generally, the approvals for each patient must be renewed from time to time.
These programs are not well defined in some countries and are subject to changes in requirements and funding levels. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the

49

programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.
Without the special access programs, we would need to seek full product approval to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek and maintain a full product approval, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.
If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected.
Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely) or commercialize their products before we do. If we do not compete successfully, our revenue would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.
Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenue and results of operations.
We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has recently come under increased scrutiny and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.
International operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected.
We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenue and results of operations.
*Government healthcare reform could increase our costs and adversely affect our revenue and results of operations.
Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the PPACA, as well as recent efforts by the U.S. Presidential administration to repeal or replace certain aspects of the PPACA, and we expect there will be additional challenges and amendments to the PPACA in the future. Since January 2017, the U.S. President has signed two Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed legislation repealing the PPACA in its entirety, it has enacted laws that modify certain provisions of the PPACA such as removing penalties, starting January 1, 2019, for not complying with the PPACA’s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. Additionally, on December 14, 2018, a Texas U.S. District Court Judge ruled

50

that the PPACA is unconstitutional in its entirety because the individual mandate was repealed by Congress as part of the Tax Cuts & Jobs Act. While the Texas U.S. District Court Judge, as well as the current U.S. Presidential administration and the Centers for Medicare and Medicaid Services (CMS), have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the PPACA will impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.
We anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Recently there has been heightened governmental scrutiny in countries worldwide over the manner in which manufacturers set prices for their marketed products.
In the U.S., there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Moreover, the U.S. Presidential administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. Although a number of these, and other potential measures may require authorization to become effective, Congress and the U.S. Presidential administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
Likewise, in many EU countries, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our products and any approved product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU countries and other foreign countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. Moreover, in order to obtain reimbursement for our products in some countries, we may be required to conduct clinical trials that compare the cost-effectiveness of our products to other available therapies.
Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
For more information regarding government healthcare reform, see “Government Regulation - Health Reform” in Part I, Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.
Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.
*If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations.
We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase,

51

order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers.
Federal and state false claims laws, including the civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
In addition, recent healthcare reform legislation has strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and foreign laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the United States, California recently enacted the California Consumer Privacy Act (CCPA), which takes effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.
The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EU Member State implementing legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to legal challenges and uncertainty about compliance with EU data protection laws remains.
Potential pecuniary fines for noncompliant companies may be up to the greater of €20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with the new EU data protection rules.
Substantial new provisions affecting compliance have also been adopted in the U.S. and certain foreign countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians and teaching hospitals, as well as investment and ownership interests held by physicians and their immediate family members during the preceding calendar year. Effective January 1, 2022, manufacturers will also be required to report on payments or transfers of value to physician assistants, nurse practitioners or clinical nurse specialists, certified registered nurse anesthetists, and certified nurse-midwives. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program

52

Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many foreign countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted legislation creates reporting obligations on payments, gifts and benefits made to these professionals; however, implementing regulations enacting such laws are still pending and subject to varying interpretations by courts and government agencies. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.
Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement agencies in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.
*We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenue and results of operations.
A significant portion of the sales of Aldurazyme, Brineura, Kuvan, Naglazyme and Vimizim, and all of the sales of Firdapse are generated from countries other than the U.S. Similarly, we expect a significant portion of the sales of Palynziq to be generated from countries other than the U.S. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:
•
the increased complexity and costs inherent in managing international operations;
•
diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;
•
political and economic instability;
•
diminished protection of intellectual property in some countries outside of the U.S.;
•
trade protection measures and import or export licensing requirements;
•
difficulty in staffing and managing international operations;
•
differing labor regulations and business practices;
•
potentially negative consequences from changes in or interpretations of tax laws;
•
changes in international medical reimbursement policies and programs;
•
financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by foreign governments;
•
regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ and service providers’ activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); and
•
rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.
Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations.
As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenue and profitability.
*The United Kingdom’s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business, which could adversely affect our revenue and results of operations.
    
In June 2016, a majority of the eligible members of the electorate in the United Kingdom voted to withdraw from the EU in a national referendum (Brexit). On March 29, 2017, the United Kingdom’s Prime Minister formally delivered the notice of withdrawal. The withdrawal of the United Kingdom from the EU will take effect on the earlier of the effective date of the withdrawal agreement or January 31, 2020, unless the United Kingdom opts to remain in the EU or the deadline is extended by the EU. It appears likely that this withdrawal will continue to involve lengthy negotiations between the United Kingdom and EU Member States to determine the future terms of the United Kingdom’s relationship with the EU and the wider EEA, and it is possible that these negotiations will fail, leading to a "no-deal" Brexit. The U.K. government is currently exploring ways to end the uncertainty over Brexit, including the possibility of a general election in the short-term.

53

These developments, or the perception that any of them could occur, have had and may continue to have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to global financial and banking markets, as well as on regulatory processes in Europe and the EEA. As a result of this uncertainty, global financial markets could experience significant volatility, which could adversely affect the market price of our shares. Asset valuations, currency exchange rates and credit ratings may also be subject to increased market volatility. Lack of clarity about future United Kingdom laws and regulations as the United Kingdom determines which EU rules and regulations to replace or replicate in the event of a withdrawal, including financial laws and regulations, tax and free trade agreements, intellectual property rights, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws, could decrease foreign direct investment in all markets, increase costs, depress economic activity and restrict access to capital.
If the United Kingdom and the EU are unable to negotiate acceptable withdrawal terms or if other EU countries pursue withdrawal, barrier-free access between the United Kingdom and other EU or EEA countries could be diminished or eliminated, which could make our doing business in the EU more difficult. As a result of Brexit, we may face disruptions in our supply chain, inventory management, manufacturing process and product distribution network, which could adversely affect our business and results of operations. Moreover, Brexit may also lead to new regulatory costs and challenges that could have a material adverse effect on our operations. The EMA has issued guidance to marketing authorization holders of centrally authorized medicinal products regarding certain requirements that need to be considered as part of Brexit, such as the requirement for the marketing authorization holder of a product centrally approved by the EC to be established in the EU, and the requirement for some activities relating to centrally approved products, such as batch release and pharmacovigilance, be performed in the EU. Furthermore, there are few indications of the effect Brexit will have on the pathway to obtaining marketing approval for any of our product candidates in the United Kingdom.
If we fail to comply with U.S. export control and economic sanctions, our business, financial condition and operating results may be adversely affected.
Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or in our decreased ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges, fines, which may be imposed on us and responsible employees or officers and, in extreme cases, the incarceration of responsible employees or officers.
We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, be renewed in the future or that we will remain in compliance. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.
We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the United States, the U.K. Bribery Act and other similar laws in other countries in which we do business. We operate in a number of countries that are recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to foreign officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered foreign officials for purposes of applicable anti-corruption laws.
Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of

54

any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.
Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products
Changes in funding for the FDA, the EMA and other government agencies or government shutdowns could hinder the ability of such agencies to hire and retain key leadership and other personnel or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
Changes in funding levels of government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA to timely review and approve INDs or marketing authorizations for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.
Government shutdowns could also impact the ability of government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory agencies, such as the FDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Our international operations pose currency risks, which may adversely affect our operating results and net income.
A significant and growing portion of our revenues and earnings, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the United Kingdom Pound, the Canadian Dollar and several other currencies, changes in those currencies relative to the U.S. Dollar will impact our revenues and expenses. If the U.S. Dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the U.S. Dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease,
having a positive impact on earnings. In addition, because our financial statements are reported in U.S. Dollars, changes in currency exchange rates between the U.S. Dollar and other currencies have had, and will continue to have, an impact on our results of operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.
We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.
If we are unable to protect our intellectual property, we may not be able to compete effectively.
Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.
The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of Aldurazyme, Naglazyme and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in Kuvan) and 3,4-DAP (the active ingredient in Firdapse) have also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.
We own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:

55

•
With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.
•
Patents have limited duration and expire. For example, our patents related to Aldurazyme expire in November 2019 and in 2020.
•
Competitors may interfere with our patent process in a variety of ways. Competitors may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, a competitor could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent.
•
Generic manufacturers may use litigation and regulatory means to obtain approval for generic versions of our products notwithstanding our filed patents or patent applications.
•
Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs.
•
Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.
•
The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a “first-to-invent” system to a “first-to-file” system, and the implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.
It is also unclear whether our trade secrets are adequately protected. Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.
Under policies recently adopted in the EU, clinical trial data submitted to the EMA in MAAs that were traditionally regarded as confidential commercial information are now subject to public disclosure. Subject to our ability to review and redact a narrow sub-set of confidential commercial information, the new EU policies will result in the EMA’s public disclosure of certain of our clinical study reports, clinical trial data summaries and clinical overviews for recently completed and future MAA submissions. The move toward public disclosure of development data could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, and enabling competitors to use our data to gain approvals for their own products.
If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenue and financial results generally.
Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.
Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, such as valoctocogene roxaparvovec, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or that we will not infringe intellectual property rights of competitors granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. If someone else claims we infringe its intellectual property, we would face a number of issues, including the following:
•
Defending a lawsuit takes significant executive resources and can be very expensive.
•
If a court decides that our product infringes a competitor’s intellectual property, we may have to pay substantial damages.
•
With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.
•
We may need to redesign our product so it does not infringe the intellectual property rights of others.

56

•
Redesigning our product so it does not infringe the intellectual property rights of competitors may not be possible or could require substantial funds and time.
We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations.
If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.
If our Manufacturing, Marketing and Sales Agreement with Genzyme were terminated, we could be prevented from continuing to commercialize Aldurazyme or our ability to successfully commercialize Aldurazyme would be delayed or diminished.
Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Genzyme and us related to Aldurazyme for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.
If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to Aldurazyme and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating party’s interest in Aldurazyme and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to Aldurazyme will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to Aldurazyme is to be sold to the highest bidder, with the proceeds to be split between Genzyme and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.
If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to Aldurazyme exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offeree’s interest in Aldurazyme and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating party’s interest in Aldurazyme and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to Aldurazyme. The Amended and Restated Collaboration Agreement between us and Genzyme will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.
If we were obligated or given the option to buy out Genzyme’s interest in Aldurazyme and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to Aldurazyme, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Genzyme’s interest, we may be held in breach of the agreement and may lose any claim to the rights to Aldurazyme and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing Aldurazyme. If this happened, not only would our product revenues decrease, but our share price would also decline.
If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.
Our future growth and development depend in part on our ability to successfully develop new products from our research and development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals, are inherently uncertain and may not result in the commercialization of any products.
Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as Aldurazyme, Firdapse, Kuvan and Naglazyme. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find

57

a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which may target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.
Universities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.
If generic manufacturers are successful in their use of litigation or regulatory means to obtain approval for generic versions of Kuvan, our revenue and results of operations would be adversely affected.
The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, permits the FDA to approve abbreviated new drug applications (ANDAs) for generic versions of branded drugs. We refer to this process as the ANDA process. The ANDA process permits competitor companies to obtain marketing approval for a drug with the same active ingredient as a branded drug, but does not generally require the conduct and submission of clinical efficacy studies for the generic product. In place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product is bioequivalent to the branded product.
Pursuant to the Hatch-Waxman Act, companies were permitted to file ANDA applications for proposed generic versions of Kuvan at any time after December 2011. We own several patents that cover Kuvan, and we have listed those patents in conjunction with that product in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). The Hatch-Waxman Act requires an ANDA applicant seeking FDA approval of its proposed generic product prior to the expiration of our Orange Book-listed patents to certify that the applicant believes that our patents are invalid or will not be infringed by the manufacture, use or sale of the drug for which the application has been submitted (a paragraph IV certification) and notify us of such certification (a paragraph IV notice). Upon receipt of a paragraph IV notice, the Hatch-Waxman Act allows us, with proper basis, to bring an action for patent infringement against the ANDA filer, asking that the proposed generic product not be approved until after our patents expire. If we commence a lawsuit within 45 days from receipt of the paragraph IV notice, the Hatch-Waxman Act provides a 30-month stay, during which time the FDA cannot finally approve the generic’s application. If the litigation is resolved in favor of the ANDA applicant during the 30-month stay period, the stay is lifted and the FDA may approve the ANDA if it is otherwise ready for approval. The discovery, trial and appeals process in such a lawsuit is costly, time consuming, and may result in generic competition if the ANDA applicant prevails.
We received separate paragraph IV notice letters in 2016, 2015 and 2014 from Dr. Reddy’s Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd. (collectively, DRL) and Par Pharmaceutical, Inc. (Par) notifying us that each of DRL and Par had filed ANDAs seeking approval of proposed generic versions of Kuvan (sapropterin dihydrochloride) 100 mg oral powder and Kuvan 100 mg oral tablets prior to the expiration of our Kuvan-related patents listed in the Orange Book. We filed lawsuits alleging patent infringement against DRL and Par, and in 2017, 2016 and 2015 we entered into separate settlement agreements with DRL (the DRL Settlement Agreement) and Par (the Par Settlement Agreement) that resolved the patent litigation in the U.S. Under the terms of the DRL Settlement Agreement, we granted DRL a non-exclusive license to our Kuvan-related patents to allow DRL to market a generic version of sapropterin dihydrochloride in 100 mg oral tablets and oral powder in 100 mg and 500 mg packet formulations in the U.S. for the indications approved for Kuvan beginning on October 1, 2020, or earlier under certain circumstances. Under the Par Settlement Agreement, we granted Par a non-exclusive license to our Kuvan-related patents to allow Par to market a generic version of sapropterin dihydrochloride in 100 mg oral tablets and oral powder in 100 mg and 500 mg packet formulations in the U.S. for the indications approved for Kuvan beginning on: April 1, 2021 if Par is not entitled to the statutory 180-day first filer exclusivity period; October 1, 2020 if Par is entitled to the statutory 180-day first filer exclusivity period; or earlier under certain circumstances.
We expect generic versions of Kuvan to first become available in the U.S. in the fourth quarter of 2020. The DRL Settlement Agreement and the Par Settlement Agreement, as well as any future ANDA or related legal proceeding, could have an adverse impact on our stock price, and litigation to enforce our patents has, and is likely to continue to, cost a substantial amount and require significant management attention. If the patents covering Kuvan and its use are not upheld in litigation, or if any ANDA filer we bring suit against is found to not infringe our asserted patents, the resulting generic competition following the expiration of regulatory exclusivity would have a material adverse effect on our revenue and results of operations. Moreover, generic competition from DRL and Par following the settlements described above could have a material adverse effect on our revenue and results of operations.
We also face potential generic competition for Kuvan in certain foreign countries, and there is a process equivalent to the ANDA process under Article 10 of Directive 2001/83/EC in the EU. Our ability to successfully market and sell Kuvan in many countries in which we operate is based upon patent rights or certain regulatory forms of exclusivity, or both. The scope of our patent rights and regulatory exclusivity for Kuvan vary from country to country and are dependent on the availability of meaningful legal remedies in each country. If our patent rights and regulatory exclusivity for Kuvan are successfully challenged, expire, or otherwise terminate in a particular country, the resulting generic competition could have a material adverse effect on our revenue and results of operations.

58

If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline.
We depend upon our key personnel and our ability to attract and retain employees.
Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of any member of our senior management or the inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results.
Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officers’ ability to compete with us after their employment is terminated. The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. Due to this intense competition, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. If we are unsuccessful in our recruitment and retention efforts, our business may be harmed.
Our success depends on our ability to manage our growth.
Product candidates that we are currently developing or may license or acquire in the future may be intended for patient populations that are significantly larger than any of the patient populations we currently target. In order to continue development and marketing of these products, if approved, we will need to significantly expand our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory and corruption risks and our management may be unable to manage successfully future market opportunities or our relationships with customers and other third parties.
Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.
Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as Aldurazyme, Naglazyme, and Vimizim in MPS diseases, could be greatly reduced. Moreover, if we obtain regulatory approval for valoctocogene roxaparvovec, the commercial success of valoctocogene roxaparvovec will still depend, in part, on the acceptance of physicians, patients and healthcare payers of gene therapy products in general, and our product candidate in particular, as medically necessary, cost-effective and safe. Changes in treatment method can be caused by the introduction of other companies’ products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.
If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.
We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercialization of our product programs.

59

We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
We rely significantly on our information technology and manufacturing infrastructure to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively. Our ability to manage and maintain our operations, inventory and internal reports, to manufacture and ship our products to customers and timely invoice them depends significantly on our enterprise resource planning, production management and other information systems. Cybersecurity incidents and attacks in particular are evolving and include, but are not limited to, malicious software, attempts to gain unauthorized access to data, business email compromise and other cyber attacks or cyber incidents that could lead to disruptions in or unavailability of systems, misappropriation of confidential or otherwise protected information, corruption or loss of data, data security breaches and other harm to our business or competitive position. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access of these systems, may affect our ability to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations. Moreover, if such an incident or computer security breach were to result in damage or unauthorized access to, or loss, corruption or unauthorized disclosure of, personally identifiable information, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media or individuals pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, if applicable. It could also cause a loss in the confidence of our customers, employees, and partners and other third parties with respect to our business. A breach in security, unauthorized access resulting in misappropriation, theft, or sabotage with respect to our proprietary, personal and confidential information, including research or clinical data and information about patients, employees, contractors and others, could require significant capital investments to remediate and could adversely affect our business, financial condition and results of operations. We would also be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims or litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.
If a natural disaster or terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.
We currently manufacture Aldurazyme, Brineura, Naglazyme, Palynziq and a portion of Vimizim in a manufacturing facility located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair our ability to manufacture Aldurazyme, Brineura, Naglazyme and Vimizim or our third-party manufacturers’ ability to manufacture Firdapse and Kuvan.
Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for Aldurazyme, Naglazyme and Palynziq and is one of two manufacturing facilities for Brineura and Vimizim. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support valoctocogene roxaparvovec clinical development activities and the anticipated commercial demand for valoctocogene roxaparvovec, if approved. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, power loss and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely, impaired, and our commercialization efforts and revenue could be seriously impaired. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.
The impact of the recently passed U.S. comprehensive tax reform bill on us is uncertain and could have a material adverse effect on our business and financial condition.
On December 22, 2017, the U.S. President signed into law new legislation, known as the Tax Cuts & Jobs Act, which significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, creation of a base erosion and anti-abuse tax and modification or repeal of many business deductions and credits (including reduction of tax credits under the Orphan Drug Act). Many aspects of the new federal tax law are unclear and may not be clarified for some time. Notwithstanding the reduction in the corporate income tax rate, it is possible that the Tax Cuts & Jobs Act, or regulations or interpretations under it, could adversely affect our business and financial condition, and such effect could be material. In addition, it is uncertain if and to what extent various U.S. states will conform to the newly enacted federal tax law.  
Our business is affected by macroeconomic conditions.

60

Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. For instance, if inflation or other factors were to significantly increase our business costs, it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counter parties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.
We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenue would be adversely affected.
Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.
Risks Related to Ownership of Our Securities
Our stock price may be volatile, and an investment in our stock could suffer a decline in value.
Our valuation and stock price have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock will fluctuate due to factors including: 
•
product sales and profitability of our products;
•
manufacturing, supply or distribution of our product candidates and commercial products;
•
progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;
•
results of clinical trials, announcements of technological innovations or new products by us or our competitors;
•
generic competition to Kuvan tablets and powder relating to our settlements with DRL and Par or potential generic competition from future competitors;
•
government regulatory action affecting our product candidates, our products or our competitors’ product candidates and products in both the U.S. and non-U.S. countries;
•
developments or disputes concerning patent or proprietary rights;
•
general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;
•
economic conditions in the U.S. or abroad;
•
negative publicity about us or the pharmaceutical industry;
•
changes in the structure of healthcare payment systems;
•
cybersecurity incidents experienced by us or others in our industry;
•
broad market fluctuations in the U.S., the EU or in other parts of the world;
•
actual or anticipated fluctuations in our operating results, including due to timing of large orders for our products, in particular in Latin America, where governments place large periodic orders for Naglazyme and Vimizim;
•
changes in company assessments or financial estimates by securities analysts;
•
acquisitions of products, businesses, or other assets; and
•
sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.
In the past, following periods of large price declines in the public market price of a company’s securities, securities class action litigation has often been initiated against that company. Litigation of this type could result in substantial costs and diversion of management’s attention and resources, which would hurt our business. Any adverse determination in litigation could also subject us to significant liabilities. In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.
Conversion of the Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress the price of our common stock.
The conversion of some or all of the Notes will dilute the ownership interests of existing stockholders to the extent we deliver shares upon conversion of any of the Notes. The Notes may in the future become convertible at the option of their holders prior to their scheduled terms under certain circumstances. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the

61

Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.
The capped call transactions may affect the value of the Notes and our common stock.
In connection with the issuance of the 2020 Notes, we entered into capped call transactions with respect to 50% of the principal amount of the 2020 Notes with certain hedge counterparties. The capped call transactions will cover, subject to customary anti-dilution adjustments, the aggregate number of shares of common stock underlying 50% of the principal amount of the 2020 Notes and are expected generally to reduce potential dilution to the common stock upon conversion of the 2020 Notes in excess of the principal amount of such converted 2020 Notes. In connection with establishing their initial hedges of the capped call transactions, the hedge counterparties (or their affiliates) entered into various derivative transactions with respect to the common stock concurrently with, and/or purchased the common stock shortly after, the pricing of the 2020 Notes. The hedge counterparties (or their affiliates) are likely to modify their hedge positions by entering into or unwinding various derivative transactions with respect to the common stock and/or by purchasing or selling the common stock or other securities of ours in secondary market transactions prior to the maturity of the 2020 Notes (and are likely to do so during the settlement averaging period under the capped call transactions, which precedes the maturity date of the 2020 Notes, and on or around any earlier conversion date related to a conversion of the 2020 Notes).
The effect, if any, of any of these transactions and activities on the market price of our common stock or the 2020 Notes will depend in part on market conditions and cannot be ascertained at this time, but any of these activities could adversely affect the value of our common stock, which could affect the value of the 2020 Notes and the value of our common stock, if any, that 2020 Note holders receive upon any conversion of the 2020 Notes.
Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.
We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholders’ meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.
The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take us over.
The terms of the Notes require us to repurchase the Notes in the event of a fundamental change. A takeover of us would trigger options by the respective holders of the applicable Notes to require us to repurchase such Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the Notes.
*Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for the adjudication of certain disputes, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for:
•
any derivative action or proceeding brought on our behalf;
•
any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of BioMarin to us or our stockholders;
•
any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; and
•
any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.
This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction, and further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of

62

and consented to the provisions of such provision, including consent to the personal jurisdiction of the Court of Chancery of the State of Delaware related to any action covered by such provision.
This exclusive-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3.
Defaults Upon Senior Securities.
None.
Item 4.
Mine Safety Disclosures
Not applicable.
Item 5.
Other Information.
None.

63

Item 6.
Exhibits.
Exhibit Number
Description
 
 
2.1
 
 
2.2
 
 
2.3
 
 
2.4
 
 
3.1
 
 
3.2
 
 
 
 
 
 
 
 
 
 
101.INS
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
101.SCH
Inline XBRL Taxonomy Extension Schema Document
 
 
101.CAL
Inline XBRL Taxonomy Extension Calculation Document
 
 
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase
 
 
101.LAB
Inline XBRL Taxonomy Extension Labels Linkbase Document

64

 
 
101.PRE
Inline XBRL Taxonomy Extension Presentation Link Document
 
 
104
XBRL tags for the cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, are embedded within the Inline XBRL document.
*    Filed herewith
+
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any of the Registrant’s filings under the Securities Act of 1933, as amended, irrespective of any general incorporation language contained in any such filing.
Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018, (ii) Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2019 and 2018, (iii) Condensed Consolidated Statement of Stockholders’ Equity for the three and nine months ended September 30, 2019 and 2018, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018, and (v) Notes to Condensed Consolidated Financial Statements.

65

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
BIOMARIN PHARMACEUTICAL INC.
 
 
 
 
Dated: November 4, 2019
 
By
 
/S/ DANIEL SPIEGELMAN
 
 
 
 
Daniel Spiegelman,
Executive Vice President and Chief Financial Officer
(On behalf of the registrant and as principal financial officer)

66
 EX-10.1 2 exhibit101-30sep19x10q.htm EXHIBIT 10.1 Exhibit
Exhibit 10.1
BioMarin Pharmaceutical Inc.
Summary of Independent Director Compensation
Effective as of September 19, 2019, the Board of Directors (the “Board”) of BioMarin Pharmaceutical Inc. (the “Company”) approved revised compensation for the independent directors of the Company. All independent directors are entitled to receive a combination of annual cash retainers and restricted stock unit (“RSU”) grants as summarized below as compensation for their service on the Company’s Board and Board committees.
Cash Compensation
The following table is a summary of the annual cash compensation payable to independent directors. Each applicable line item is an additional element of compensation.
Director Position
Annual Cash
Compensation
 
All Independent Directors
 
$
65,000
 
Additional Elements of Compensation:
 
 
 
 
Independent Chair of the Board (if applicable)
 
$
65,000
 
Lead Independent Director (if applicable)
 
$
65,000
 
Audit Committee Member
 
$
13,500
 
Audit Committee Chair (premium in addition to committee membership retainer)
 
$
13,000
 
Compensation Committee Member
 
$
10,000
 
Compensation Committee Chair (premium in addition to committee membership retainer)
 
$
10,000
 
Corporate Governance and Nominating Committee Member
 
$
8,750
 
Corporate Governance and Nominating Committee Chair (premium in addition to committee membership retainer)
 
$
10,000
 
Science and Technology Committee Member
 
$
10,000
 
Science and Technology Committee Chair (premium in addition to committee membership retainer)
 
$
10,000
 
Equity Compensation
Annual Award
On the date of our annual meeting of stockholders for a given year, each reelected director receives an RSU grant valued at $400,000, based on the Black-Scholes model valuation using a three-month trailing average closing price of our common stock. The shares of common stock subject to the Annual Award vest in full on the one-year anniversary of the grant date, subject to each respective director providing service to the Company through such vesting date.
New Independent Directors
Upon election or appointment, a new independent director will receive an RSU grant on the same terms as the Annual Award, pro-rated for amount and vesting to the nearest quarter for the time such new director will serve prior to the Company’s next Annual Meeting of Stockholders.

EX-31.1 3 exhibit311-30sep19x10q.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jean-Jacques Bienaimé, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q/A of BioMarin Pharmaceutical Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 4, 2019
/s/ JEAN-JACQUES BIENAIMÉ
Jean-Jacques Bienaimé
Chief Executive Officer


 EX-31.2 4 exhibit312-30sep19x10q.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Daniel Spiegelman, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q/A of BioMarin Pharmaceutical Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 4, 2019
/s/ DANIEL SPIEGELMAN
 
Daniel Spiegelman
Executive Vice President and Chief Financial Officer
 


 EX-32.1 5 exhibit321-30sep19x10q.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
We, Jean-Jacques Bienaimé and Daniel Spiegelman, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.’s Quarterly Report on Form 10-Q/A for the period ended September 30, 2019, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q/A fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc.
/s/ JEAN-JACQUES BIENAIMÉ
 
Jean-Jacques Bienaimé
Chief Executive Officer
 
November 4, 2019
 /s/ DANIEL SPIEGELMAN
 
Daniel Spiegelman
Executive Vice President and Chief Financial Officer
 
November 4, 2019
This certification accompanies the Quarterly Report on Form 10-Q/A to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q/A), irrespective of any general incorporation language contained in such filing.



 EX-101.DEF 6 bmrn-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 7 bmrn-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 8 bmrn-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2129100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) link:presentationLink link:calculationLink link:definitionLink 2429403 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2147100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2447401 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Debt - Summary of Convertible Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2428404 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2145100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2445401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2427408 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2427404 - Disclosure - Leases - Schedule of Lease Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 2427403 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2427403 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2427407 - Disclosure - Leases - Schedule of Minimum Lease Payments for Future Years (Detail) link:presentationLink link:calculationLink link:definitionLink 2427405 - Disclosure - Leases - Schedule of Other Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2427406 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2146100 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2446404 - Disclosure - Net Loss Per Common Share - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2446402 - Disclosure - NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2446403 - Disclosure - Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 2346301 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property Plant and Equipment - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2135100 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 2435402 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2435404 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 2435405 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) link:presentationLink link:calculationLink link:definitionLink 2435403 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) link:presentationLink link:calculationLink link:definitionLink 2335301 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2435406 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2440403 - Disclosure - Stock Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Stock-Based Compensation - Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2440404 - Disclosure - Stock-Based Compensation - Stock Option Valuation Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 bmrn-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 10 bmrn-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Non-cash interest expense Amortization of Debt Issuance Costs and Discounts (Accretion of discount) Amortization of premium on investments Accretion (Amortization) of Discounts and Premiums, Investments Stock-based compensation Share-based Payment Arrangement, Noncash Expense Gain on sale of intangible assets Gain (Loss) on Disposition of Intangible Assets Deferred income taxes Deferred Income Tax Expense (Benefit) Unrealized foreign exchange (gain) loss Foreign Currency Transaction Gain (Loss), Unrealized Non-cash changes in the fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Purchases of available-for-sale securities Payments to Acquire Debt Securities, Available-for-sale Proceeds from sale of intangible assets Proceeds from Sale of Intangible Assets Purchase of intangible assets Payments to Acquire Intangible Assets Other Payments for (Proceeds from) Other Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercises of awards under equity incentive plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-based Payment Arrangement Payment of contingent acquisition consideration Payment for Contingent Consideration Liability, Financing Activities Other Proceeds from (Payments for) Other Financing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Beginning of period Cash and Cash Equivalents, at Carrying Value End of period SUPPLEMENTAL CASH FLOW DISCLOSURES: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Decrease in accounts payable and accrued liabilities related to fixed assets Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period. Organization, Consolidation and Presentation of Financial Statements [Abstract] Inventory, Current [Table] Inventory, Current [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Pre-Launch Valoctocogene Roxaparvovec Pre-Launch Valoctocogene Roxaparvovec [Member] Pre-Launch Valoctocogene Roxaparvovec [Member] Inventory [Line Items] Inventory [Line Items] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventory Inventory, Net Share-based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative [Table] Derivative [Table] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Level 2: Fair Value, Inputs, Level 2 [Member] Hedging Designation Hedging Designation [Axis] Hedging Designation Hedging Designation [Domain] Derivatives Designated As Hedging Instruments Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other current assets Other Current Assets [Member] Other assets Other Noncurrent Assets [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Derivative [Line Items] Derivative [Line Items] Derivative Asset, Fair Value Derivative Asset, Fair Value, Gross Asset Derivative Liability, Fair Value Derivative Liability, Fair Value, Gross Liability Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Investments, Debt and Equity Securities [Abstract] Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block] Schedule of cash, cash equivalents and available-for-sale securities. Equity [Abstract] Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Domain] Amount Reclassified from AOCI Gain (Loss) Reclassification out of Accumulated Other Comprehensive Income [Member] Equity Components Equity Components [Axis] Equity Component Equity Component [Domain] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Product and Service Product and Service [Axis] Product and Service Product and Service [Domain] Net product revenues Product [Member] Derivative Instrument Derivative Instrument [Axis] Derivative Contract Derivative Contract [Domain] Forward contracts Foreign Exchange Forward [Member] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Net product revenues Revenue from Contract with Customer, Excluding Assessed Tax Operating expenses Operating Expenses Total gain (loss) on cash flow hedges Operating Income (Loss) SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Currency Currency [Axis] All Currencies All Currencies [Domain] Australian Dollars Australia, Dollars Canadian Dollars Canada, Dollars Colombian Pesos Colombia, Pesos Euros Euro Member Countries, Euro Norwegian Krone Norway, Krone Foreign exchange contracts Foreign Exchange Contract [Member] Range Statistical Measurement [Axis] Range Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Position Position [Axis] Position Position [Domain] Sell Short [Member] Purchase Long [Member] Number of Contracts Number of Foreign Currency Derivatives Held Aggregate Notional Amount in Foreign Currency Derivative, Notional Amount Maturity Maturity of Foreign Currency Derivatives Concentration Risk And Geographic Information [Abstract] Concentration risk and geographic information. Concentration Risk And Geographic Information [Table] Concentration Risk And Geographic Information [Table] Concentration risk and geographic information. Concentration Risk Type Concentration Risk Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Credit Concentration Risk Credit Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Net Product Revenue Revenue Benchmark [Member] Accounts Receivable Accounts Receivable [Member] Customer Customer [Axis] Customer Customer [Domain] Customer One Customer One [Member] Customer 1 Customer Two Customer Two [Member] Customer 2 Customer Three Customer Three [Member] Customer 3 Customers Customers [Member] Customers. Concentration Risk And Geographic Information [Line Items] Concentration Risk And Geographic Information [Line Items] Concentration risk and geographic information. Number of operating business segment Number of Operating Segments Concentration risk, percentage Concentration Risk, Percentage Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Leases [Abstract] Maturity of Lease Liabilities Maturity Of Lease Liabilities [Abstract] Maturity of lease liabilities. Operating Lessee, Operating Lease, Liability, Payment, Due [Abstract] Remainder of 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability Financing Finance Lease, Liability, Payment, Due [Abstract] Remainder of 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payment, Due Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability Total Operating And Finance Lease Liabilities Payments Due [Abstract] Operating and finance lease liabilities payments due. Remainder of 2019 Operating And Finance Lease Liability Payments Remainder Of Fiscal Year Operating and finance lease liability payments remainder of fiscal year. 2020 Operating And Finance Lease Liability Payments Due Year Two Operating and finance lease liability payments due year two. 2021 Operating And Finance Lease Liability Payments Due Year Three Operating and finance lease liability payments due year three. 2022 Operating And Finance Lease Liability Payments Due Year Four Operating and finance lease liability payments due year four. 2023 Operating And Finance Lease Liability Payments Due Year Five Operating and finance lease liability payments due year five. Thereafter Operating And Finance Lease Liability Payments Due After Year Five Operating and finance lease liability payments due after year five. Total lease payments Operating And Finance Lease Liability Payments Due Operating and finance lease liability payments due. Less: Interest Operating And Finance Lease Liability Undiscounted Excess Amount Operating and finance lease liability undiscounted excess amount. Present value of lease liabilities Operating And Finance Lease Liability Operating and finance lease liability. Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of Stock Option Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Concentration Risk And Segment Reporting Disclosure [Text Block] Concentration risk and segment reporting disclosure. 2019 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Great British Pounds United Kingdom, Pounds Rubles Russia, Rubles ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Accounts payable and accrued operating expenses Accounts Payable and Other Accrued Liabilities, Current Accrued compensation expense Employee-related Liabilities, Current Accrued rebates payable Accrued Marketing Costs, Current Accrued royalties payable Accrued Royalties, Current Value added taxes payable Sales and Excise Tax Payable, Current Forward foreign currency exchange contracts Derivative Liability, Current Lease liability Accrued Lease Liabilities Current Accrued lease liabilities current. Other Other Accounts Payable and Accrued Liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Operating Expenses Operating Expense [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Lease Cost Lease, Cost [Abstract] Operating Operating Lease, Cost Amortization Finance Lease, Right-of-Use Asset, Amortization Interest expense Finance Lease, Interest Expense Total lease costs Lease, Cost Accounting Policies [Abstract] NATURE OF OPERATIONS Nature of Operations [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type Award Type [Axis] Equity Award Award Type [Domain] Restricted Stock With Service Based Vesting Conditions Restricted Stock With Service Based Vesting Conditions [Member] Restricted stock with service based vesting conditions. Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member] Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member] Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member] March 2019 Base Restricted Stock Unit Awards with Performance Conditions Two Thousand Nineteen Base Restricted Stock Unit Awards With Performance Conditions [Member] Two thousand nineteen base restricted stock unit awards with performance conditions. March 2019 Base Restricted Stock Unit Awards with Market Conditions Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions [Member] Two thousand nineteen base restricted stock unit awards with market conditions. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation expense capitalized to inventory Share-based Payment Arrangement, Amount Capitalized Shares, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Weighted-average fair value per share granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Shares, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted-average fair value per RSU granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Shares issued under Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Granted restricted stock units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Award vesting service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Annual percentage of shares earned, performance metric Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage Percentage of annual threshold target Fair Value Inputs, Annual Revenue Multiple Threshold Target, Percentage Fair Value Inputs, Annual Revenue Multiple Threshold Target, Percentage Percentage of annual ceiling achievement Fair Value Inputs, Annual Revenue Multiple Ceiling Achievement, Percentage Fair Value Inputs, Annual Revenue Multiple Ceiling Achievement, Percentage Base percentage of annual target ceiling Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage Percentage of Annual TSR multiplier on absolute basis Annual Shareholder Return Multiplier On Absolute Basis, Percentage Annual Shareholder Return Multiplier On Absolute Basis, Percentage Other Information Other Information Lease Liability [Abstract] Other information lease liability. Weighted average remaining lease term (in years): Weighted Average Remaining Lease Term [Abstract] Weighted average remaining lease term abstract. Operating leases Operating Lease, Weighted Average Remaining Lease Term Financing leases Finance Lease, Weighted Average Remaining Lease Term Weighted average discount rate: Weighted Average Discount Rate [Abstract] Weighted average discount rate abstract. Operating leases Operating Lease, Weighted Average Discount Rate, Percent Financing leases Finance Lease, Weighted Average Discount Rate, Percent Additional leases not yet commenced (undiscounted): Lessee, Operating Lease, Not yet Commenced, Description [Abstract] Operating lease liability to commence in the remainder of 2019 Lessee, Operating Lease, Lease Not yet Commenced, Liability Lessee, Operating Lease, Lease Not yet Commenced, Liability BASIS OF PRESENTATION Basis of Accounting [Text Block] FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Short-term investments Debt Securities, Available-for-sale, Current Accounts receivable, net Inventory Other current assets Other Assets, Current Total current assets Assets, Current Noncurrent assets: Assets, Noncurrent [Abstract] Long-term investments Debt Securities, Available-for-sale, Noncurrent Property, plant and equipment, net Property, Plant and Equipment, Net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Goodwill Deferred tax assets Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable and accrued liabilities Short-term contingent consideration Business Combination, Contingent Consideration, Liability, Current Total current liabilities Liabilities, Current Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Long-term convertible debt, net Convertible Debt, Noncurrent Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value: 500,000,000 shares authorized; 179,604,381 and 178,252,954 shares issued and outstanding, respectively. Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) Common Stock Issued, Employee Stock Trust Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Schedule of ROU Assets and Lease Liabilities Schedule Of Lessee Lease Assets And Liabilities Table [Text Block] Schedule of Lessee lease assets and liabilities. Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Maturities of Finance Lease Liabilities Finance Lease, Liability, Maturity [Table Text Block] Schedule of Lease Cost Lease, Cost [Table Text Block] Schedule of Other Information Lessee Operating And Finance Leases Other Information Table [Text Block] Lessee operating and finance leases other information. Schedule of Minimum Lease Payments for Future Years Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Income Tax Disclosure [Abstract] Valuation allowance against a deferred tax asset Deferred Tax Assets, Valuation Allowance Net tax expense (benefit) Debt Disclosure [Abstract] DEBT Long-term Debt [Text Block] Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument, Name [Domain] The 2018 Credit Facility Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member] Senior unsecured revolving two thousand eighteen credit facility. Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] LIBOR Rate London Interbank Offered Rate (LIBOR) [Member] Base Rate Base Rate [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Carrying value of equity component Long-term Debt, Gross Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Interest rate on deemed loan description Debt Instrument, Interest Rate Terms Debt instrument interest rate percentage Debt Instrument, Basis Spread on Variable Rate Percentage of commitment fees payable on undrawn amount Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Maturity date of convertible debt Debt Instrument, Maturity Date To repay early, minimum required amount outstanding with certain other conditions have not been met To Repay Early Minimum Required Amount Outstanding With Certain Other Conditions Have Not Been Met To repay early minimum required amount outstanding with certain other conditions have not been met. Maturity date of credit facility, if certain other conditions have not been met Maturity Date Of Credit Facility If Certain Other Conditions Have Not Been Met Maturity date of credit facility if certain other conditions have not been met. Debt issuance costs Debt Issuance Costs, Gross Outstanding amount Long-term Line of Credit Schedule of Property Plant and Equipment Net Property, Plant and Equipment [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class Liability Class [Axis] Fair Value by Liability Class Fair Value by Liability Class [Domain] Contingent Payment Contingent Payment [Member] Contingent Payment Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Contingent consideration at December 31, 2018 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Changes in fair value of other contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Milestone payments to Ares Trading S.A. (Merck Serono) Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Ares Trading S.A. Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Ares Trading S.A. Milestone payments to former LEAD Therapeutics, Inc. shareholders Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Shareholders Fair value measurement with unobservable inputs reconciliations recurring basis milestone payments to shareholders. Realized gain on settlement of contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Realized Gain on Settlement of Contingent Consideration Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Realized Gain on Settlement of Contingent Consideration Foreign exchange remeasurement of Euro denominated contingent consideration Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement. Contingent consideration at September 30, 2019 Other- than- temporary impairment Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Contingent Consideration by Type Contingent Consideration by Type [Axis] Contingent Consideration Type Contingent Consideration Type [Domain] Completed Programs Completed Project [Member] Completed Project. Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Third Party Third Party [Member] Third party. Other Commitments Other Commitments [Axis] Other Commitments Other Commitments [Domain] Clinical and Post Marketing Services Clinical And Post Marketing Services [Member] Clinical and post marketing services. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones. Contingent liabilities Contingent Liability Accrual Sales And Licensing Milestones Contingent Liability Accrual Sales And Licensing Milestones Contingent liabilities short-term Contingent Liability Accrual Sales And Licensing Milestones, Current Contingent Liability Accrual Sales And Licensing Milestones, Current Purchase commitments and other minimum contractual obligations Purchase Commitment, Remaining Minimum Amount Committed Rent expense Operating Leases, Rent Expense, Net Deferred rent accruals Deferred Rent Receivables, Net Deferred rent accruals, current Deferred Rent Asset, Net, Current Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Common stock issuable under the 2024 Notes Convertible Senior Notes Due Two Thousand Twenty Four [Member] Options to purchase common stock Share-based Payment Arrangement, Option [Member] Unvested restricted stock units Restricted Stock [Member] Common stock potentially issuable for ESPP purchases Common Stock Issuable To Employee Stock Purchase Plan [Member] Common stock issuable for employee Stock Purchase Plan [Member] Common stock held by the NQDC Share-based Payment Arrangement [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net Income (Loss), basic Net Income (Loss) Available to Common Stockholders, Basic Add: Interest on 2024 notes Interest on Convertible Debt, Net of Tax Net Income (Loss), diluted Net Income (Loss) Available to Common Stockholders, Diluted Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted average number of shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Effect of dilutive securities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Weighted-average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Net Income (Loss) per common share, basic (in dollars per share) Earnings Per Share, Basic Net Income (Loss) per common share, diluted (in dollars per share) Earnings Per Share, Diluted Options to purchase common stock Common stock issuable under the 2018 Notes Convertible Senior Notes Due Two Thousand Eighteen [Member] Convertible senior notes due two thousand eighteen. Common stock issuable under the 2020 Notes Convertible Senior Notes Due Twenty Twenty [Member] Convertible senior notes due twenty twenty. Unvested RSUs Total number of potentially issuable shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Convertible Debt Convertible Debt [Table Text Block] Summary of Interest Expense on Debt Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Company Stock Held By NQDC Deferred Compensation, Share-based Payments [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Issuances under equity incentive plans (in shares) Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares Stock issued during period value new issues net excess tax benefit tax deficiency, shares. Ending balance (in shares) Beginning Balance Issuances under equity incentive plans, net of tax Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Stock issued during period value new issues net excess tax benefit tax deficiency. Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Common stock held by the NQDC Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Accounting impact of NQDC Plan change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change Impact of changes in accounting principle Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Net income (loss) Ending Balance Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Operating Expense Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Amount of Gain (Loss) Recognized in Other Comprehensive Income Gain (Loss) on Derivative Instruments, Net, Pretax Operating expenses as reported Costs and Expenses Cash Flow Hedging Gains (Losses) Reclassified into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Gains (Losses) Recognized in Earnings Derivative, Gain (Loss) on Derivative, Net Cost of sales Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Total stock-based compensation expense Share-based Payment Arrangement, Expense Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type Property, Plant and Equipment, Type [Domain] Building and improvements Building and Building Improvements [Member] Manufacturing and laboratory equipment Equipment [Member] Computer hardware and software Computer Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Furniture and equipment Furniture and Fixtures [Member] Land improvements Land Improvements [Member] Land Land [Member] Construction-in-progress Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, plant and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total property, plant and equipment, net SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Derivatives and Hedging Activities Derivatives, Policy [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Domain] Marketed by Company Sales Channel, Directly to Consumer [Member] Marketed by Genzyme Sales Channel, Through Intermediary [Member] Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim Products Excluding Product One [Member] Products excluding product one. Aldurazyme Product One [Member] Product 1 [Member] Total net product revenues Geographical Geographical [Axis] Geographical Geographical [Domain] United States UNITED STATES Europe Europe [Member] Latin America Latin America [Member] Rest of world Rest Of World [Member] Rest of world. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Total revenues Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule of cash, cash equivalents and available-for-sale securities. Level 1: Fair Value, Inputs, Level 1 [Member] Investment Type Investment Type [Axis] Investments Investments [Domain] Cash Cash [Member] Money market instruments Money Market Funds [Member] Corporate debt securities Corporate Debt Securities [Member] Commercial paper Commercial Paper [Member] U.S. government agency securities US Government Agencies Debt Securities [Member] Foreign and other Foreign Government And Other Debt Securities [Member] Foreign government and other debt securities. Schedule of Available-for-sale Securities [Line Items] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items] Schedule of cash, cash equivalents and available-for-sale securities. Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Cash Cash Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Aggregate Fair Value Debt Securities, Available-for-sale Cash and Cash Equivalents Short-term Marketable Securities Long-term Marketable Securities Long term marketable securities maturity period Long Term Marketable Securities Maturity Period Long-term marketable securities maturity period. Short term marketable securities maturity period Short Term Marketable Securities Maturity Period Short-term marketable securities maturity period. Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Amendment Description Amendment Description Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Supplemental Cash Flow Information Supplemental Cash Flow Lease Information [Abstract] Supplemental cash flow lease information. Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in measurement of lease liabilities abstract. Cash used in operating activities: Cash Flow, Operating Activities, Lessee [Abstract] Operating leases Operating Lease, Payments Financing leases Finance Lease, Interest Payment on Liability Cash used in financing activities: Cash Flow, Financing Activities, Lessee [Abstract] Financing leases Finance Lease, Principal Payments ROU assets obtained in exchange for lease obligations: Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract] Right of use assets obtained in exchange for lease obligations abstract. Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Financing leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Unrealized Gains (Losses) on Cash Flow Hedges Unrealized Gains (Losses) on Available for-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Other Accumulated Gain Loss From Other [Member] Accumulated gain (loss) from other. Total Adjustments for New Accounting Pronouncements Adjustments for New Accounting Pronouncements [Axis] Type of Adoption Type of Adoption [Domain] ASU 2018-02 Accounting Standards Update 2018-02 [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Impact of change in accounting principle Beginning Balance Stockholders Equity Adjusted Balance Stockholders equity, adjusted balance. Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Less: gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Tax effect Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Net current-period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Brineura Product Six [Member] Product six. Firdapse Product Five [Member] Product 5 [Member] Kuvan Product Three [Member] Product 3 [Member] Naglazyme Product Two [Member] Product 2 [Member] Palynziq Product Seven [Member] Product 7 [Member] Vimizim Product Four [Member] Product 4 [Member] INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] NET LOSS PER COMMON SHARE Earnings Per Share [Text Block] Earnings Per Share [Table] Earnings Per Share [Table] Earnings per share. Convertible Notes due 2020 Convertible Notes due 2018 Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings per share line Items. Debt instrument, convertible, conversion price, per share (in dollars per share) Debt Instrument, Convertible, Conversion Price Debt instrument, interest rate, stated percentage, per annum Debt Instrument, Interest Rate, Stated Percentage Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency Measurement Frequency [Axis] Fair Value, Measurement Frequency Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Asset Class Asset Class [Axis] Asset Class Asset Class [Domain] NQDC Plan assets Nonqualified Deferred Compensation Plan Assets [Member] Nonqualified deferred compensation plan assets. Restricted Investments Restricted Investments [Member] Restricted investments. Strategic Investments Strategic Investments [Member] Strategic investments. Quoted Price in Active Markets For Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] NQDC Plan liability Nonqualified Deferred Compensation Plan Liability [Member] Nonqualified deferred compensation plan liability. Contingent consideration Contingent Consideration [Member] Contingent consideration. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets remeasured Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Liabilities remeasured Fair value of other current assets Other Assets Current Fair Value Disclosure Other assets current fair value disclosure. Fair value of other non-current assets Other Assets Noncurrent Fair Value Disclosure Other assets noncurrent fair value disclosure. Fair value of financial assets, Total Assets, Fair Value Disclosure Fair value of other current liabilities Other Liabilities Current Fair Value Disclosure Other liabilities current fair value disclosure. Fair value of other non-current liabilities Other Liabilities Noncurrent Fair Value Disclosure Other liabilities noncurrent fair value disclosure. Fair value of financial liabilities, Total Financial and Nonfinancial Liabilities, Fair Value Disclosure LEASES Lessee Operating And Financing Leases Disclosure [Text Block] Lessee operating and financing leases disclosure. COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Summary of Derivatives Designated as Hedging Instruments Outstanding Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Fair Value Carrying Amount of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] INCOME TAXES Income Tax Disclosure [Text Block] Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] 1.50% Senior Subordinated Convertible Notes Due in October 2020 One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member] One point five zero percent senior subordinated convertible notes due in October twenty twenty. 0.599% Senior Subordinated Convertible Notes Due in August 2024 Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member] Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four. Convertible notes stated rate Convertible Notes Convertible debt, unamortized discount Debt Instrument, Unamortized Discount Convertible debt, Unamortized deferred offering costs Deferred Offering Costs Convertible Notes, net of unamortized discount and deferred offering costs Total convertible debt, net Convertible Debt Total fair value of fixed rate convertible debt Convertible Debt, Fair Value Disclosures New Accounting Pronouncements and Changes in Accounting Principles [Abstract] RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Lease Classification Assets and Liabilities, Lessee [Abstract] Assets: Lease Right Of Use Assets [Abstract] Lease right of use assets. Operating Operating Lease, Right-of-Use Asset Financing Finance Lease, Right-of-Use Asset Total ROU assets Operating And Finance Lease Right Of Use Asset Operating and finance lease right of use asset. Liabilities: Lease Liabilities [Abstract] Lease liabilities. Operating, Current Operating Lease, Liability, Current Financing, Current Finance Lease, Liability, Current Operating, Noncurrent Operating Lease, Liability, Noncurrent Financing, Noncurrent Finance Lease, Liability, Noncurrent Total lease liabilities Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Restatement Adjustment Restatement Adjustment [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Gain on sale of intangible assets Intangible assets: Intangible Assets, Net (Excluding Goodwill) [Abstract] Finite-lived intangible assets Finite-Lived Intangible Assets, Gross Indefinite-lived intangible assets Indefinite-lived Intangible Assets (Excluding Goodwill) Gross intangible assets: Intangible Assets, Gross (Excluding Goodwill) Less: Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Net carrying value Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Schedule of Net Product Revenues by Product Revenue from External Customers by Products and Services [Table Text Block] Schedule of Total Net Product Revenues Based on Patient Location Disaggregation of Revenue [Table Text Block] Schedule of Net Product Revenue Concentrations Attributed to Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Depreciation expense Depreciation Depreciation capitalized into inventory Depreciation Expense Capitalized Into Inventory Depreciation expense capitalized into inventory during the reporting period. Concentration Risk [Table] Concentration Risk [Table] Customer Concentration Risk Customer Concentration Risk [Member] Customer A Customer B Customer C Customer D Customer Four [Member] Customer 4 Customer E Customer Five [Member] Customer Five [Member] Customer F Customer Six [Member] Customer Six [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. ASC Topic 842 Accounting Standards Update 2016-02 [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Lease ROU assets Lease liabilities Income Statement [Abstract] Royalty and other revenues Royalty And Other [Member] Royalty and other. REVENUES: Revenues [Abstract] OPERATING EXPENSES: Costs and Expenses [Abstract] Cost of sales Cost of Revenue Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Intangible asset amortization and contingent consideration Intangible Asset Amortization And Contingent Consideration The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period. Total operating expenses INCOME (LOSS) FROM OPERATIONS Equity in the loss of BioMarin/Genzyme LLC Income (Loss) from Equity Method Investments Interest income Investment Income, Interest Interest expense Interest Expense Other income, net Other Operating Income (Expense), Net INCOME (LOSS) BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Benefit from income taxes Income Tax Expense (Benefit) NET INCOME (LOSS) NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) Weighted average common shares outstanding, basic (in shares) Weighted average common shares outstanding, diluted (in shares) COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule Of Interest Expenses [Table] Schedule Of Interest Expenses [Table] Schedule of interest expenses table. Long-term Debt, Type Long-term Debt, Type [Axis] Long-term Debt, Type Long-term Debt, Type [Domain] Convertible Senior Notes Convertible Debt [Member] Schedule Of Interest Expenses [Line Items] Schedule Of Interest Expenses [Line Items] Schedule of interest expenses. Coupon interest expense Interest Expense, Debt, Excluding Amortization Amortization of debt issuance costs Amortization of Debt Issuance Costs Accretion of discount on convertible notes Accretion Of Debt Discount Accretion of debt discount. Total interest expense on convertible debt Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Fair Value of Financial Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months XML 11 R70.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 39,173 $ 37,046 $ 121,763 $ 112,261
Cost of sales        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 4,093 3,974 12,629 10,360
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 14,261 14,257 43,037 43,099
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 20,819 $ 18,815 $ 66,097 $ 58,802
XML 12 R74.htm IDEA: XBRL DOCUMENT v3.19.3
NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Numerator:        
Net Income (Loss), basic $ 55,036 $ (12,620) $ (38,872) $ (73,561)
Net Income (Loss), diluted $ 55,973 $ (12,620) $ (38,872) $ (73,561)
Denominator:        
Weighted average number of shares outstanding, basic 179,289 177,481 178,873 176,767
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Weighted-average common shares outstanding, diluted 185,924 177,481 178,873 176,767
Net Income (Loss) per common share, basic (in dollars per share) $ 0.31 $ (0.07) $ (0.22) $ (0.42)
Net Income (Loss) per common share, diluted (in dollars per share) $ 0.30 $ (0.07) $ (0.22) $ (0.42)
Common stock issuable under the 2024 Notes        
Numerator:        
Add: Interest on 2024 notes $ 937 $ 0 $ 0 $ 0
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 3,970 0 0 0
Options to purchase common stock        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 1,560 0 0 0
Unvested restricted stock units        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 669 0 0 0
Common stock potentially issuable for ESPP purchases        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 231 0 0 0
Common stock held by the NQDC        
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]        
Effect of dilutive securities 205 0 0 0
XML 14 R57.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of Supplemental Cash Flow Information (Detail)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Cash used in operating activities:  
Operating leases $ 5,918
Financing leases 454
Cash used in financing activities:  
Financing leases 2,027
ROU assets obtained in exchange for lease obligations:  
Operating leases 9,268
Financing leases $ 72
XML 15 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of ROU Assets and Lease Liabilities (Detail)
$ in Thousands
Sep. 30, 2019
USD ($)
Assets:  
Operating $ 51,284
Financing 10,346
Total ROU assets 61,630
Liabilities:  
Operating, Current 7,273
Financing, Current 2,952
Operating, Noncurrent 45,499
Financing, Noncurrent 9,544
Total lease liabilities $ 65,268
XML 16 R32.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES (Tables)
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Schedule of ROU Assets and Lease Liabilities
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2019: 
Lease Classification
 
Classification
 
September 30,
2019
Assets:
 
 
 
 
Operating
 
Other Assets
 
$
51,284

Financing
 
Other Assets
 
10,346

Total ROU assets
 
 
 
$
61,630

Liabilities:
 
 
 
 
Current:
 
 
 
 
Operating
 
Accounts payable and accrued liabilities
 
$
7,273

Financing
 
Accounts payable and accrued liabilities
 
2,952

Noncurrent:
 
 
 
 
Operating
 
Other long-term liabilities
 
45,499

Financing
 
Other long-term liabilities
 
9,544

Total lease liabilities
 
 
 
$
65,268
Schedule of Maturities of Operating Lease Liabilities
Maturities of lease liabilities as of September 30, 2019 by fiscal year were as follows: 
Maturity of Lease Liabilities
 
Operating
 
Financing
 
Total
Remainder of 2019
 
$
3,115

 
$
3,204

 
$
6,319

2020
 
9,925

 
3,464

 
13,389

2021
 
8,721

 
2,865

 
11,586

2022
 
8,406

 
2,258

 
10,664

2023
 
7,504

 
1,748

 
9,252

Thereafter
 
27,464

 
—

 
27,464

Total lease payments
 
65,135

 
13,539

 
78,674

Less: Interest
 
(12,363
)
 
(1,043
)
 
(13,406
)
Present value of lease liabilities
 
$
52,772

 
$
12,496

 
$
65,268
Schedule of Maturities of Finance Lease Liabilities
Maturities of lease liabilities as of September 30, 2019 by fiscal year were as follows: 
Maturity of Lease Liabilities
 
Operating
 
Financing
 
Total
Remainder of 2019
 
$
3,115

 
$
3,204

 
$
6,319

2020
 
9,925

 
3,464

 
13,389

2021
 
8,721

 
2,865

 
11,586

2022
 
8,406

 
2,258

 
10,664

2023
 
7,504

 
1,748

 
9,252

Thereafter
 
27,464

 
—

 
27,464

Total lease payments
 
65,135

 
13,539

 
78,674

Less: Interest
 
(12,363
)
 
(1,043
)
 
(13,406
)
Present value of lease liabilities
 
$
52,772

 
$
12,496

 
$
65,268
Schedule of Lease Cost
Supplemental Cash Flow Information
 
Nine Months Ended
September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
 
 
Cash used in operating activities:
 
 
Operating leases
 
$
5,918

Financing leases
 
$
454

Cash used in financing activities:
 
 
Financing leases
 
$
2,027

ROU assets obtained in exchange for lease obligations:
 
 
Operating leases
 
$
9,268

Financing leases
 
$
72

Lease Cost
 
Classification
 
Three Months Ended
September 30, 2019
 
Nine Months Ended
September 30, 2019
Operating (1)
 
Operating Expenses
 
$
3,535

 
$
9,946

Financing:
 
 
 
 
 
 
Amortization
 
Operating Expenses
 
600

 
1,811

Interest expense
 
Operating Expenses
 
142

 
455

Total lease costs
 
 
 
$
4,277

 
$
12,212

 
(1)
Includes short-term leases and variable lease costs, both of which were not material.
Schedule of Other Information
Other Information
 
September 30,
2019
Weighted average remaining lease term (in years):
 
 
Operating leases
 
8.0

Financing leases
 
4.2

 
 
 
Weighted average discount rate:
 
 
Operating leases
 
5.2
%
Financing leases
 
5.4
%
Schedule of Minimum Lease Payments for Future Years
Minimum lease payments for future years as of December 31, 2018 were as follows: 
2019
$
12,976

2020
12,549

2021
11,198

2022
10,574

2023
9,993

Thereafter
27,701

Total
$
84,991
XML 17 R36.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Cost of sales
$
4,093

 
$
3,974

 
$
12,629

 
$
10,360

Research and development
14,261

 
14,257

 
43,037

 
43,099

Selling, general and administrative
20,819

 
18,815

 
66,097

 
58,802

Total stock-based compensation expense
$
39,173

 
$
37,046

 
$
121,763

 
$
112,261
Schedule of Stock Option Valuation Assumptions
The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
N/A
 
36.8%
 
37.1 – 37.4%
 
36.8 – 38.4%
Dividend yield
N/A
 
0.0%
 
0.0%
 
0.0%
Expected life (in years)
N/A
 
5.7
 
4.6 – 5.8
 
4.6 – 5.7
Risk-free interest rate
N/A
 
2.8%
 
2.2 – 3.0%
 
2.3 – 2.8%
XML 18 R15.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2019 and December 31, 2018. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2019.
 
Fair Value Measurements at September 30, 2019
 
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
NQDC Plan assets
 
$
1,135

 
$
—

 
$
1,135

Other assets:
 
 
 
 
 
 
NQDC Plan assets
 
15,039

 
—

 
15,039

Restricted investments (1)
 
3,157

 
—

 
3,157

Total other assets
 
18,196

 
—

 
18,196

Total assets
 
$
19,331

 
$
—

 
$
19,331

Liabilities:
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
$
1,135

 
$
—

 
$
1,135

Contingent consideration
 
—

 
10,000

 
10,000

Total current liabilities
 
1,135

 
10,000

 
11,135

Other long-term liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
15,039

 
—

 
15,039

Contingent consideration
 
—

 
48,930

 
48,930

Total other long-term liabilities
 
15,039

 
48,930

 
63,969

Total liabilities
 
$
16,174

 
$
58,930

 
$
75,104


 
Fair Value Measurements at December 31, 2018
 
Quoted Price in
Active Markets
For Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
 
NQDC Plan assets
$
—

 
$
370

 
$
—

 
$
370

Restricted investments (1)
—

 
9,581

 
—

 
9,581

Total other current assets
—

 
9,951

 
—

 
9,951

Other assets:
 
 
 
 
 
 
 
NQDC Plan assets
—

 
12,828

 
—

 
12,828

Restricted investments (1)
—

 
2,450

 
—

 
2,450

Strategic investments (3)
942

 
—

 
—

 
942

Total other assets
942

 
15,278

 
—

 
16,220

Total assets
$
942

 
$
25,229

 
$
—

 
$
26,171

Liabilities:
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
$
55

 
$
370

 
$
—

 
$
425

Contingent consideration
—

 
—

 
85,951

 
85,951

Total current liabilities
55

 
370

 
85,951

 
86,376

Other long-term liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
17,598

 
12,828

 
—

 
30,426

Contingent consideration
—

 
—

 
46,883

 
46,883

Total other long-term liabilities
17,598

 
12,828

 
46,883

 
77,309

Total liabilities
$
17,653

 
$
13,198

 
$
132,834

 
$
163,685

(1)
The restricted investments at September 30, 2019 and December 31, 2018 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
(2)
The Company’s NQDC Plan was amended during the second quarter of 2019, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC Plan. The obligation was previously classified as a liability recorded at fair value and has been reclassified into equity and recorded at the shares' respective grant date fair values at June 30, 2019. The change to the NQDC Plan related to the prohibition of participants to diversify investments for deferrals of Company stock contributed into other types of investments. The NQDC Plan liabilities classified as Level 2 represent investments held in plan assets excluding shares of the Company's common stock.
(3)
The Company had investments in marketable equity securities measured using quoted prices in an active market that were considered strategic investments and were included in Other Assets on the Company's Condensed Consolidated Balance Sheets. During the second quarter of 2019, the Company realized an immaterial gain upon the sale of the shares.
There were no transfers between levels during the three and nine months ended September 30, 2019.
The following table represents a roll-forward of contingent consideration.
Contingent consideration at December 31, 2018
$
132,834

Changes in fair value of other contingent consideration
19,916

Milestone payments to Ares Trading S.A. (Merck Serono)
(83,472
)
Milestone payments to former LEAD Therapeutics, Inc. shareholders
(5,987
)
Realized gain on settlement of contingent consideration
(1,928
)
Foreign exchange remeasurement of Euro denominated contingent consideration
(2,433
)
Contingent consideration at September 30, 2019
$
58,930
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.19.3
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other period.
On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, Leases (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.
As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of $55.9 million and lease liabilities of $59.0 million as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  
On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.19.3
FINANCIAL INSTRUMENTS
 9 Months Ended
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTS
All marketable securities were classified as available-for-sale at September 30, 2019 and December 31, 2018.
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of September 30, 2019 and December 31, 2018, respectively:
As of September 30, 2019
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
294,543

 
$
—

 
$
—

 
$
294,543

 
$
294,543

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
128,678

 
—

 
—

 
128,678

 
128,678

 
—

 
—

Corporate debt securities
519,693

 
3,713

 
(67
)
 
523,339

 
—

 
206,782

 
316,557

U.S. government agency securities
204,371

 
1,073

 
(97
)
 
205,347

 
—

 
90,790

 
114,557

Foreign and other
549

 
142

 
(1
)
 
690

 
—

 
—

 
690

Subtotal
853,291

 
4,928

 
(165
)
 
858,054

 
128,678

 
297,572

 
431,804

Total
$
1,147,834

 
$
4,928

 
$
(165
)
 
$
1,152,596

 
$
423,220

 
$
297,572

 
$
431,804

As of December 31, 2018
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
228,809

 
$
—

 
$
—

 
$
228,809

 
$
228,809

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
205,736

 
—

 
—

 
205,736

 
205,736

 
—

 
—

Corporate debt securities
564,852

 
214

 
(2,288
)
 
562,778

 
2,000

 
376,545

 
184,233

Commercial paper
77,702

 
—

 
—

 
77,702

 
21,964

 
55,738

 
—

U.S. government agency securities
240,436

 
144

 
(697
)
 
239,883

 
31,474

 
156,967

 
51,442

Foreign and other
5,126

 
139

 
(1
)
 
5,264

 
3,999

 
1,076

 
189

Subtotal
1,093,852

 
497

 
(2,986
)
 
1,091,363

 
265,173

 
590,326

 
235,864

Total
$
1,322,661

 
$
497

 
$
(2,986
)
 
$
1,320,172

 
$
493,982

 
$
590,326

 
$
235,864

(1)    The Company’s short-term marketable securities mature in one year or less.
(2)    The Company’s long-term marketable securities mature between one and five years.
As of September 30, 2019, the Company’s investments in an unrealized loss position were not significant, and since the Company has the ability and intent to hold all investments that have been in a continuous loss position until maturity or recovery, no other-than-temporary impairment was deemed to have occurred.
XML 21 R19.htm IDEA: XBRL DOCUMENT v3.19.3
ACCUMULATED OTHER COMPREHENSIVE INCOME
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2019 and 2018. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification
 
2019
 
2018
 
2019
 
2018
 
Gains (losses) on cash flow hedges:
 
 
 
 
 
 
 
 
 
Forward contracts
$
6,196

 
$
5,025

 
$
11,171

 
$
(6,683
)
 
Net product revenues
Forward contracts
(1,388
)
 
498

 
(1,885
)
 
3,762

 
Operating expenses
Total gain (loss) on cash flow hedges
$
4,808

 
$
5,523

 
$
9,286

 
$
(2,921
)
 
 

The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2019
$
14,181

 
$
3,271

 
$
(13
)
 
$
17,439

Other comprehensive income (loss) before
     reclassifications
23,973

 
522

 
(3
)
 
24,492

Less: net gain (loss) reclassified from AOCI
4,808

 
—

 
—

 
4,808

Tax effect
—

 
(120
)
 
—

 
(120
)
Net current-period other comprehensive income (loss)
19,165

 
402

 
(3
)
 
19,564

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003


 
Nine Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2018
$
7,201

 
$
(1,917
)
 
$
(13
)
 
$
5,271

Other comprehensive income (loss) before
     reclassifications
35,431

 
7,256

 
(3
)
 
42,684

Less: gain (loss) reclassified from AOCI
9,286

 
—

 
—

 
9,286

Tax effect
—

 
(1,666
)
 
—

 
(1,666
)
Net current-period other comprehensive income (loss)
26,145

 
5,590

 
(3
)
 
31,732

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003


 
Three Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2018
$
2,568

 
$
(3,686
)
 
$
(11
)
 
$
(1,129
)
Other comprehensive income (loss) before
     reclassifications
3,355

 
1,475

 
—

 
4,830

Less: gain (loss) reclassified from AOCI
5,523

 
—

 
—

 
5,523

Tax effect
—

 
(338
)
 
—

 
(338
)
Net current-period other comprehensive income (loss)
(2,168
)
 
1,137

 
—

 
(1,031
)
AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)



 
Nine Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2017
$
(20,232
)
 
$
(2,722
)
 
$
(7
)
 
$
(22,961
)
Impact of change in accounting principle
—

 
(586
)
 
—

 
(586
)
AOCI balance at January 1, 2018
$
(20,232
)
 
$
(3,308
)
 
$
(7
)
 
$
(23,547
)
Other comprehensive income (loss) before
     reclassifications
17,711

 
985

 
(4
)
 
18,692

Less: gain (loss) reclassified from AOCI
(2,921
)
 
—

 
—

 
(2,921
)
Tax effect
—

 
(226
)
 
—

 
(226
)
Net current-period other comprehensive income (loss)
20,632

 
759

 
(4
)
 
21,387

AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
REVENUES:        
Total revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
OPERATING EXPENSES:        
Cost of sales 96,949 78,893 263,567 240,245
Research and development 172,963 161,408 542,195 520,938
Selling, general and administrative 170,112 148,566 493,024 440,182
Intangible asset amortization and contingent consideration 17,063 18,580 57,114 42,009
Gain on sale of intangible assets 0 0 (15,000) (20,000)
Total operating expenses 457,087 407,447 1,340,900 1,223,374
INCOME (LOSS) FROM OPERATIONS 4,010 (15,741) (91,295) (85,376)
Equity in the loss of BioMarin/Genzyme LLC (551) (468) (780) (507)
Interest income 5,340 6,338 17,537 17,141
Interest expense (2,937) (12,131) (16,530) (35,918)
Other income, net 3,960 2,589 6,038 5,266
INCOME (LOSS) BEFORE INCOME TAXES 9,822 (19,413) (85,030) (99,394)
Benefit from income taxes (45,214) (6,793) (46,158) (25,833)
NET INCOME (LOSS) $ 55,036 $ (12,620) $ (38,872) $ (73,561)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) $ 0.31 $ (0.07) $ (0.22) $ (0.42)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) $ 0.30 $ (0.07) $ (0.22) $ (0.42)
Weighted average common shares outstanding, basic (in shares) 179,289 177,481 178,873 176,767
Weighted average common shares outstanding, diluted (in shares) 185,924 177,481 178,873 176,767
COMPREHENSIVE INCOME (LOSS) $ 74,600 $ (13,651) $ (7,140) $ (52,174)
Net product revenues        
REVENUES:        
Total revenues 450,900 386,320 1,224,458 1,123,205
Royalty and other revenues        
REVENUES:        
Total revenues $ 10,197 $ 5,386 $ 25,147 $ 14,793
XML 23 R27.htm IDEA: XBRL DOCUMENT v3.19.3
INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
 
September 30,
2019
 
December 31,
2018
Intangible assets:
 
 
 
Finite-lived intangible assets
$
642,677

 
$
307,995

Indefinite-lived intangible assets
—

 
326,359

Gross intangible assets:
642,677

 
634,354

Less: Accumulated amortization
(179,828
)
 
(142,546
)
Net carrying value
$
462,849

 
$
491,808
XML 24 R23.htm IDEA: XBRL DOCUMENT v3.19.3
NET LOSS PER COMMON SHARE
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
NET LOSS PER COMMON SHARE NET INCOME (LOSS) PER COMMON SHARE
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, common stock held by the Company's NQDC Plan and contingent issuances of common stock related to convertible debt.
The following table sets forth the computation of basic and diluted earnings per common share (in thousands of common shares):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net Income (Loss), basic
$
55,036

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Add: Interest on 2024 notes
937

 
—

 
—

 
—

Net Income (Loss), diluted
$
55,973

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Denominator:
 
 
 
 
 
 
 
Weighted-average common shares outstanding, basic
179,289

 
177,481

 
178,873

 
176,767

Effect of dilutive securities:
 
 
 
 
 
 
 
Options to purchase common stock
1,560

 
—

 
—

 
—

Common stock issuable under the 2024 notes
3,970

 
—

 
—

 
—

Unvested RSUs
669

 
—

 
—

 
—

Common stock potentially issuable for ESPP purchases
231

 
—

 
—

 
—

Common shares held by the NQDC
205

 
—

 
—

 
—

Weighted-average common shares outstanding, diluted
185,924

 
177,481

 
178,873

 
176,767

Net Income (Loss) per common share, basic
0.31

 
(0.07
)
 
(0.22
)
 
(0.42
)
Net Income (Loss) per common share, diluted
0.30

 
(0.07
)
 
(0.22
)
 
(0.42
)

In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive using the if-converted or treasury stock method (in thousands of common shares):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Options to purchase common stock
5,829

 
7,517

 
7,388

 
7,517

Common stock issuable under the 2018 Notes
—

 
3,983

 
—

 
3,983

Common stock issuable under the 2020 Notes
3,983

 
3,983

 
3,983

 
3,983

Common stock issuable under the 2024 Notes
—

 
3,970

 
3,970

 
3,970

Unvested RSUs
3,360

 
3,411

 
4,029

 
3,411

Common stock potentially issuable for ESPP purchases
222

 
407

 
453

 
407

Common stock held by the NQDC
—

 
208

 
205

 
208

Total number of potentially issuable shares
13,394

 
23,479

 
20,028

 
23,479

The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net loss per share as of September 30, 2019 as the Company’s closing stock price on September 30, 2019 did not exceed the conversion price of $94.15 per share. Although the Company’s stock price on September 28, 2018 (the last trading day before September 30, 2018) exceeded the conversion price, the potential effect of the capped call transactions and potential shares issuable under the Company’s 0.75% senior subordinated convertible notes due in 2018 and the 2020 Notes were excluded from the calculation of diluted loss per share in the three and nine months ended September 30, 2018 as they were anti-dilutive using the if-converted method. There is no similar capped call transaction associated with the 2024 Notes. See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 for additional information related to the Company’s convertible debt and capped call transaction.
XML 25 R65.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
USD ($)
Segment
Dec. 31, 2018
USD ($)
Concentration Risk And Geographic Information [Line Items]    
Number of operating business segment | Segment 1  
Accounts receivable, net $ 402,970 $ 342,633 [1]
Customers    
Concentration Risk And Geographic Information [Line Items]    
Accounts receivable, net $ 67,700 $ 73,900
Credit Concentration Risk | Accounts Receivable | Customer One    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 23.00% 30.00%
Credit Concentration Risk | Accounts Receivable | Customer Two    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 14.00% 16.00%
Credit Concentration Risk | Accounts Receivable | Customer Three    
Concentration Risk And Geographic Information [Line Items]    
Concentration risk, percentage 12.00%  
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 26 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Summary of Convertible Debt (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]    
Convertible Notes $ 870,000  
Convertible Notes, net of unamortized discount and deferred offering costs 843,616 $ 830,417 [1]
Total convertible debt, net 843,616 830,417
Total fair value of fixed rate convertible debt $ 875,010 $ 911,348
1.50% Senior Subordinated Convertible Notes Due in October 2020    
Debt Instrument [Line Items]    
Convertible notes stated rate 1.50% 1.50%
Convertible Notes $ 374,993 $ 374,993
Convertible debt, unamortized discount (15,780) (26,581)
Convertible debt, Unamortized deferred offering costs (1,359) (2,334)
Convertible Notes, net of unamortized discount and deferred offering costs 357,854 346,078
Total fair value of fixed rate convertible debt $ 384,713 $ 419,722
0.599% Senior Subordinated Convertible Notes Due in August 2024    
Debt Instrument [Line Items]    
Convertible notes stated rate 0.599% 0.599%
Convertible Notes $ 495,000 $ 495,000
Convertible debt, unamortized discount (6,887) (7,946)
Convertible debt, Unamortized deferred offering costs (2,351) (2,715)
Convertible Notes, net of unamortized discount and deferred offering costs 485,762 484,339
Total fair value of fixed rate convertible debt $ 490,297 $ 491,626
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 28 R69.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) - Customer Concentration Risk - Net Product Revenue
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Concentration Risk [Line Items]        
Concentration risk, percentage 56.00% 58.00% 52.00% 56.00%
Customer A        
Concentration Risk [Line Items]        
Concentration risk, percentage 16.00% 16.00% 17.00% 17.00%
Customer B        
Concentration Risk [Line Items]        
Concentration risk, percentage 13.00% 12.00% 12.00% 12.00%
Customer C        
Concentration Risk [Line Items]        
Concentration risk, percentage 10.00% 10.00% 11.00% 10.00%
Customer D        
Concentration Risk [Line Items]        
Concentration risk, percentage 5.00% 7.00% 6.00% 11.00%
Customer E        
Concentration Risk [Line Items]        
Concentration risk, percentage 12.00% 0.00% 6.00% 0.00%
Customer F        
Concentration Risk [Line Items]        
Concentration risk, percentage 0.00% 13.00% 0.00% 6.00%
XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 1,504,909 $ 1,421,317
Accumulated depreciation (535,609) (472,635)
Total property, plant and equipment, net 969,300 948,682 [1]
Building and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 709,990 694,447
Manufacturing and laboratory equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 365,348 345,947
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 165,235 157,787
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 52,379 41,188
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 37,603 33,234
Land improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 7,239 6,551
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 83,094 77,993
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 84,021 $ 64,170
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 31 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets remeasured $ 0  
Liabilities remeasured 0  
Fair Value, Measurements, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   $ 9,951,000
Fair value of other non-current assets 18,196,000 16,220,000
Fair value of financial assets, Total 19,331,000 26,171,000
Fair value of other current liabilities 11,135,000 86,376,000
Fair value of other non-current liabilities 63,969,000 77,309,000
Fair value of financial liabilities, Total 75,104,000 163,685,000
Fair Value, Measurements, Recurring | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 1,135,000 425,000
Fair value of other non-current liabilities 15,039,000 30,426,000
Fair Value, Measurements, Recurring | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 10,000,000 85,951,000
Fair value of other non-current liabilities 48,930,000 46,883,000
Fair Value, Measurements, Recurring | Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   0
Fair value of other non-current assets   942,000
Fair value of financial assets, Total   942,000
Fair value of other current liabilities   55,000
Fair value of other non-current liabilities   17,598,000
Fair value of financial liabilities, Total   17,653,000
Fair Value, Measurements, Recurring | Quoted Price in Active Markets For Identical Assets (Level 1) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities   55,000
Fair value of other non-current liabilities   17,598,000
Fair Value, Measurements, Recurring | Quoted Price in Active Markets For Identical Assets (Level 1) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities   0
Fair value of other non-current liabilities   0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   9,951,000
Fair value of other non-current assets 18,196,000 15,278,000
Fair value of financial assets, Total 19,331,000 25,229,000
Fair value of other current liabilities 1,135,000 370,000
Fair value of other non-current liabilities 15,039,000 12,828,000
Fair value of financial liabilities, Total 16,174,000 13,198,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 1,135,000 370,000
Fair value of other non-current liabilities 15,039,000 12,828,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 0 0
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   0
Fair value of other non-current assets 0 0
Fair value of financial assets, Total 0 0
Fair value of other current liabilities 10,000,000 85,951,000
Fair value of other non-current liabilities 48,930,000 46,883,000
Fair value of financial liabilities, Total 58,930,000 132,834,000
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | NQDC Plan liability    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 0 0
Fair value of other non-current liabilities 0 0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current liabilities 10,000,000 85,951,000
Fair value of other non-current liabilities 48,930,000 46,883,000
Fair Value, Measurements, Recurring | NQDC Plan assets    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 1,135,000 370,000
Fair value of other non-current assets 15,039,000 12,828,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   0
Fair value of other non-current assets   0
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 1,135,000 370,000
Fair value of other non-current assets 15,039,000 12,828,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets 0 0
Fair value of other non-current assets 0 0
Fair Value, Measurements, Recurring | Restricted Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   9,581,000
Fair value of other non-current assets 3,157,000 2,450,000
Fair Value, Measurements, Recurring | Restricted Investments | Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   0
Fair value of other non-current assets   0
Fair Value, Measurements, Recurring | Restricted Investments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   9,581,000
Fair value of other non-current assets 3,157,000 2,450,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other current assets   0
Fair value of other non-current assets $ 0 0
Fair Value, Measurements, Recurring | Strategic Investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets   942,000
Fair Value, Measurements, Recurring | Strategic Investments | Quoted Price in Active Markets For Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets   942,000
Fair Value, Measurements, Recurring | Strategic Investments | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets   0
Fair Value, Measurements, Recurring | Strategic Investments | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of other non-current assets   $ 0
XML 32 R26.htm IDEA: XBRL DOCUMENT v3.19.3
FINANCIAL INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of September 30, 2019 and December 31, 2018, respectively:
As of September 30, 2019
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
294,543

 
$
—

 
$
—

 
$
294,543

 
$
294,543

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
128,678

 
—

 
—

 
128,678

 
128,678

 
—

 
—

Corporate debt securities
519,693

 
3,713

 
(67
)
 
523,339

 
—

 
206,782

 
316,557

U.S. government agency securities
204,371

 
1,073

 
(97
)
 
205,347

 
—

 
90,790

 
114,557

Foreign and other
549

 
142

 
(1
)
 
690

 
—

 
—

 
690

Subtotal
853,291

 
4,928

 
(165
)
 
858,054

 
128,678

 
297,572

 
431,804

Total
$
1,147,834

 
$
4,928

 
$
(165
)
 
$
1,152,596

 
$
423,220

 
$
297,572

 
$
431,804

As of December 31, 2018
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Aggregate Fair Value
 
Cash and Cash Equivalents
 
Short-term
Marketable
Securities (1)
 
Long-term
Marketable
Securities (2)
Level 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash
$
228,809

 
$
—

 
$
—

 
$
228,809

 
$
228,809

 
$
—

 
$
—

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level 2:
 
 
 
 
 
 
 
 
 
 
 
 
 
Money market instruments
205,736

 
—

 
—

 
205,736

 
205,736

 
—

 
—

Corporate debt securities
564,852

 
214

 
(2,288
)
 
562,778

 
2,000

 
376,545

 
184,233

Commercial paper
77,702

 
—

 
—

 
77,702

 
21,964

 
55,738

 
—

U.S. government agency securities
240,436

 
144

 
(697
)
 
239,883

 
31,474

 
156,967

 
51,442

Foreign and other
5,126

 
139

 
(1
)
 
5,264

 
3,999

 
1,076

 
189

Subtotal
1,093,852

 
497

 
(2,986
)
 
1,091,363

 
265,173

 
590,326

 
235,864

Total
$
1,322,661

 
$
497

 
$
(2,986
)
 
$
1,320,172

 
$
493,982

 
$
590,326

 
$
235,864

(1)    The Company’s short-term marketable securities mature in one year or less.
(2)    The Company’s long-term marketable securities mature between one and five years.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company utilizes an estimated annual effective tax rate for calculating a tax provision under ASC 740-270. That rate is applied to year-to-date ordinary income or loss in order to compute the year-to-date income tax provision. For the three months ended September 30, 2019, the Company recognized a net tax benefit of $45.2 million primarily attributed to the quarter fluctuations in the mix and timing of our profits and losses on a territorial basis when applying the estimated annual effective tax rate to the year-to-date earnings.
The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s Dutch subsidiary had a full valuation allowance against a deferred tax asset of $29.6 million at December 31, 2018. Historical earnings, future taxable income and ongoing prudent and feasible tax planning strategies have been considered in assessing the need for the valuation allowance; and based on projected income and other key operating factors, the Company concluded in the second quarter of 2019 that it is more likely than not that the benefit of these deferred tax assets would be realized. As a result, the amount of the valuation allowance related to the deferred tax assets that are expected to be realized was reversed in the second quarter of 2019, resulting in a net tax benefit of $27.1 million recognized during the nine months ended September 30, 2019.
XML 34 R68.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]        
Net product revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
United States        
Disaggregation of Revenue [Line Items]        
Net product revenues 201,874 174,722 562,217 528,082
Europe        
Disaggregation of Revenue [Line Items]        
Net product revenues 125,485 111,069 369,585 323,940
Latin America        
Disaggregation of Revenue [Line Items]        
Net product revenues 83,799 75,400 164,132 151,955
Rest of world        
Disaggregation of Revenue [Line Items]        
Net product revenues 49,939 30,515 153,671 134,021
Aldurazyme        
Disaggregation of Revenue [Line Items]        
Net product revenues 22,852 27,593 73,945 117,652
Total net product revenues        
Disaggregation of Revenue [Line Items]        
Net product revenues 450,900 386,320 1,224,458 1,123,205
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim        
Disaggregation of Revenue [Line Items]        
Net product revenues 428,048 358,727 1,150,513 1,005,553
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim | United States        
Disaggregation of Revenue [Line Items]        
Net product revenues 175,127 146,742 480,330 409,294
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim | Europe        
Disaggregation of Revenue [Line Items]        
Net product revenues 121,363 107,851 358,041 315,270
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim | Latin America        
Disaggregation of Revenue [Line Items]        
Net product revenues 83,799 75,400 164,132 151,955
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim | Rest of world        
Disaggregation of Revenue [Line Items]        
Net product revenues 47,759 28,734 148,010 129,034
Marketed by Genzyme | Aldurazyme        
Disaggregation of Revenue [Line Items]        
Net product revenues $ 22,852 $ 27,593 $ 73,945 $ 117,652
XML 35 R64.htm IDEA: XBRL DOCUMENT v3.19.3
Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 01, 2018
Dec. 31, 2017
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Beginning Balance [1] $ 2,960,954 $ 2,885,104 $ 2,967,940 [2] $ 2,808,663    
Beginning Balance       (23,547)    
Other comprehensive income (loss) before reclassifications 24,492 4,830 42,684 18,692    
Less: gain (loss) reclassified from AOCI 4,808 5,523 9,286 (2,921)    
Tax effect (120) (338) (1,666) (226)    
Net current-period other comprehensive income (loss) 19,564 (1,031) 31,732 21,387    
Ending Balance 3,074,405 2,914,945 3,074,405 2,914,945    
ASU 2018-02            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Impact of change in accounting principle           $ (586)
Unrealized Gains (Losses) on Cash Flow Hedges            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Beginning Balance 14,181 2,568 7,201 (20,232)    
Beginning Balance       (20,232)    
Other comprehensive income (loss) before reclassifications 23,973 3,355 35,431 17,711    
Less: gain (loss) reclassified from AOCI 4,808 5,523 9,286 (2,921)    
Tax effect 0 0 0 0    
Net current-period other comprehensive income (loss) 19,165 (2,168) 26,145 20,632    
Ending Balance 33,346 400 33,346 400    
Unrealized Gains (Losses) on Cash Flow Hedges | ASU 2018-02            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Impact of change in accounting principle           0
Unrealized Gains (Losses) on Available for-Sale Debt Securities            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Beginning Balance 3,271 (3,686) (1,917) (2,722)    
Beginning Balance       (3,308)    
Other comprehensive income (loss) before reclassifications 522 1,475 7,256 985    
Less: gain (loss) reclassified from AOCI 0 0 0 0    
Tax effect (120) (338) (1,666) (226)    
Net current-period other comprehensive income (loss) 402 1,137 5,590 759    
Ending Balance 3,673 (2,549) 3,673 (2,549)    
Unrealized Gains (Losses) on Available for-Sale Debt Securities | ASU 2018-02            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Impact of change in accounting principle           (586)
Other            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Beginning Balance (13) (11) (13) (7)    
Beginning Balance       (7)    
Other comprehensive income (loss) before reclassifications (3) 0 (3) (4)    
Less: gain (loss) reclassified from AOCI 0 0 0 0    
Tax effect 0 0 0 0    
Net current-period other comprehensive income (loss) (3) 0 (3) (4)    
Ending Balance (16) (11) (16) (11)    
Other | ASU 2018-02            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Impact of change in accounting principle           $ 0
Total            
AOCI Attributable to Parent, Net of Tax [Roll Forward]            
Beginning Balance [1] 17,439 (1,129) 5,271 (22,961)    
Impact of change in accounting principle         $ (586)  
Ending Balance $ 37,003 $ (2,160) $ 37,003 $ (2,160)    
[1]
The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
[2]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 36 R60.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended
Oct. 31, 2018
Sep. 30, 2019
Dec. 31, 2018
Debt Instrument [Line Items]      
Carrying value of equity component   $ 870,000,000.0  
The 2018 Credit Facility      
Debt Instrument [Line Items]      
Maximum borrowing capacity $ 200,000,000.0    
Maturity date of convertible debt Oct. 19, 2021    
To repay early, minimum required amount outstanding with certain other conditions have not been met $ 100,000,000.0    
Maturity date of credit facility, if certain other conditions have not been met Aug. 01, 2020    
Debt issuance costs $ 1,000,000.0    
Outstanding amount   $ 0 $ 0
The 2018 Credit Facility | LIBOR Rate      
Debt Instrument [Line Items]      
Interest rate on deemed loan description   the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility)  
The 2018 Credit Facility | Minimum      
Debt Instrument [Line Items]      
Percentage of commitment fees payable on undrawn amount 0.15%    
The 2018 Credit Facility | Minimum | LIBOR Rate      
Debt Instrument [Line Items]      
Debt instrument interest rate percentage 1.00%    
The 2018 Credit Facility | Minimum | Base Rate      
Debt Instrument [Line Items]      
Debt instrument interest rate percentage 0.00%    
The 2018 Credit Facility | Maximum      
Debt Instrument [Line Items]      
Percentage of commitment fees payable on undrawn amount 0.35%    
The 2018 Credit Facility | Maximum | LIBOR Rate      
Debt Instrument [Line Items]      
Debt instrument interest rate percentage 1.95%    
The 2018 Credit Facility | Maximum | Base Rate      
Debt Instrument [Line Items]      
Debt instrument interest rate percentage 0.95%    
XML 37 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Property Plant and Equipment - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 24.2 $ 26.6 $ 67.2 $ 66.7
Depreciation capitalized into inventory $ 9.8 $ 8.1 $ 24.9 $ 18.6
XML 38 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) - Contingent Payment
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Contingent consideration at December 31, 2018 $ 132,834
Changes in fair value of other contingent consideration 19,916
Milestone payments to Ares Trading S.A. (Merck Serono) (83,472)
Milestone payments to former LEAD Therapeutics, Inc. shareholders (5,987)
Realized gain on settlement of contingent consideration (1,928)
Foreign exchange remeasurement of Euro denominated contingent consideration (2,433)
Contingent consideration at September 30, 2019 $ 58,930
XML 39 R71.htm IDEA: XBRL DOCUMENT v3.19.3
Stock Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense capitalized to inventory       $ 5.1 $ 5.3 $ 13.2 $ 14.3
Shares issued under Employee Stock Purchase Plan (in shares)       0   107,473  
Restricted Stock With Service Based Vesting Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares, granted (in shares)           1,844,308  
Weighted-average fair value per share granted (in dollars per share)           $ 91.23  
Shares, granted (in shares)       0   610,250  
Weighted-average fair value per RSU granted (in dollars per share)           $ 36.84  
Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share) $ 81.00            
Granted restricted stock units 44,260            
March 2019 Base Restricted Stock Unit Awards with Performance Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share)     $ 94.53        
Granted restricted stock units     99,010        
Award vesting service period   3 years          
Percentage of annual threshold target     75.00%        
Percentage of annual ceiling achievement     125.00%        
March 2019 Base Restricted Stock Unit Awards with Performance Conditions | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Annual percentage of shares earned, performance metric     0.00%        
March 2019 Base Restricted Stock Unit Awards with Performance Conditions | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Annual percentage of shares earned, performance metric     200.00%        
March 2019 Base Restricted Stock Unit Awards with Market Conditions              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average fair value per RSU granted (in dollars per share)     $ 143.92        
Granted restricted stock units     99,010        
Award vesting service period   3 years          
Base percentage of annual target ceiling     100.00%        
March 2019 Base Restricted Stock Unit Awards with Market Conditions | Minimum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Annual percentage of shares earned, performance metric     0.00%        
Percentage of Annual TSR multiplier on absolute basis     50.00%        
March 2019 Base Restricted Stock Unit Awards with Market Conditions | Maximum              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Annual percentage of shares earned, performance metric     200.00%        
XML 40 R75.htm IDEA: XBRL DOCUMENT v3.19.3
Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 13,394 23,479 20,028 23,479
Options to purchase common stock        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 5,829 7,517 7,388 7,517
Common stock issuable under the 2018 Notes        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 3,983 0 3,983
Common stock issuable under the 2020 Notes        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 3,983 3,983 3,983 3,983
Common stock issuable under the 2024 Notes        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 3,970 3,970 3,970
Unvested RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 3,360 3,411 4,029 3,411
Common stock potentially issuable for ESPP purchases        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 222 407 453 407
Common stock held by the NQDC        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Total number of potentially issuable shares (in shares) 0 208 205 208
XML 41 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of Other Information (Detail)
Sep. 30, 2019
USD ($)
Weighted average remaining lease term (in years):  
Operating leases 8 years
Financing leases 4 years 2 months 12 days
Weighted average discount rate:  
Operating leases 5.20%
Financing leases 5.40%
Additional leases not yet commenced (undiscounted):  
Operating lease liability to commence in the remainder of 2019 $ 0
XML 42 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Instruments and Hedging Strategies - Additional Information (Detail)
$ in Millions
 9 Months Ended
Sep. 30, 2019
USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions $ 19.2
XML 43 bmrn-30sep19x10qxa_htm.xml IDEA: XBRL DOCUMENT 0001048477 2019-01-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-01-01 2019-09-30 0001048477 2019-10-18 0001048477 2018-12-31 0001048477 2019-09-30 0001048477 2018-01-01 2018-09-30 0001048477 2019-07-01 2019-09-30 0001048477 2018-07-01 2018-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-01-01 2019-09-30 0001048477 us-gaap:ProductMember 2018-01-01 2018-09-30 0001048477 us-gaap:ProductMember 2018-07-01 2018-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember 2019-01-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2018-07-01 2018-09-30 0001048477 us-gaap:ProductMember 2019-07-01 2019-09-30 0001048477 bmrn:RoyaltyAndOtherMember 2018-01-01 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001048477 2018-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001048477 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-09-30 0001048477 2017-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001048477 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-01-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2019-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001048477 us-gaap:CommonStockMember 2019-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-07-01 2019-09-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001048477 us-gaap:CommonStockMember 2017-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001048477 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:RetainedEarningsMember 2019-01-01 0001048477 us-gaap:RetainedEarningsMember 2018-01-01 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2018-06-30 0001048477 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001048477 us-gaap:CommonStockMember 2018-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-06-30 0001048477 2018-06-30 0001048477 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001048477 us-gaap:RetainedEarningsMember 2017-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2017-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001048477 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ForeignGovernmentAndOtherDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:CashMember 2019-09-30 0001048477 srt:MaximumMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember 2018-01-01 2018-12-31 0001048477 srt:MinimumMember 2019-01-01 2019-09-30 0001048477 2019-04-01 2019-06-30 0001048477 srt:RestatementAdjustmentMember 2019-06-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2019-09-30 0001048477 us-gaap:ConstructionInProgressMember 2018-12-31 0001048477 us-gaap:LandMember 2018-12-31 0001048477 us-gaap:EquipmentMember 2019-09-30 0001048477 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001048477 us-gaap:ComputerEquipmentMember 2019-09-30 0001048477 us-gaap:LandImprovementsMember 2018-12-31 0001048477 us-gaap:LandMember 2019-09-30 0001048477 us-gaap:ConstructionInProgressMember 2019-09-30 0001048477 us-gaap:LandImprovementsMember 2019-09-30 0001048477 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001048477 us-gaap:LeaseholdImprovementsMember 2019-09-30 0001048477 us-gaap:ComputerEquipmentMember 2018-12-31 0001048477 us-gaap:EquipmentMember 2018-12-31 0001048477 us-gaap:FurnitureAndFixturesMember 2019-09-30 0001048477 bmrn:PreLaunchValoctocogeneRoxaparvovecMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel1Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:StrategicInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001048477 bmrn:ContingentPaymentMember 2018-12-31 0001048477 bmrn:ContingentPaymentMember 2019-09-30 0001048477 bmrn:ContingentPaymentMember 2019-01-01 2019-09-30 0001048477 us-gaap:FairValueInputsLevel1Member 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-07-01 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2018-12-31 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:COP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-09-30 0001048477 us-gaap:NondesignatedMember 2019-09-30 0001048477 currency:RUB us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-09-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0001048477 currency:AUD us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:CAD us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:COP us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 currency:NOK us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-09-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2019-07-01 2019-09-30 0001048477 currency:NOK srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:CAD srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:NOK srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:AUD srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:AUD srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:CAD srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:RUB srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:RUB srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:GBP us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 currency:EUR srt:MaximumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2019-01-01 2019-09-30 0001048477 currency:COP srt:MinimumMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2019-01-01 2019-09-30 0001048477 2018-01-01 2018-12-31 0001048477 us-gaap:OperatingExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:OperatingExpenseMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-31 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:BaseRateMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 srt:MinimumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2019-09-30 0001048477 srt:MaximumMember bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-10-01 2018-10-31 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2018-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2018-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2019-09-30 0001048477 bmrn:OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember 2019-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-07-01 2019-09-30 0001048477 us-gaap:ConvertibleDebtMember 2018-07-01 2018-09-30 0001048477 us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001048477 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember 2018-12-31 0001048477 bmrn:SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-07-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0001048477 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-07-01 2018-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-06-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-09-30 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-06-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member 2017-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-09-30 0001048477 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001048477 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2018-12-31 0001048477 bmrn:AccumulatedGainLossFromOtherMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomersMember 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001048477 bmrn:CustomersMember 2018-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFiveMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFourMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFiveMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFourMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductSixMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductTwoMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductThreeMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductFiveMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductFourMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductFourMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductFiveMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductTwoMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductSevenMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSevenMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductTwoMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductTwoMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductThreeMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductSixMember 2019-01-01 2019-09-30 0001048477 country:US 2019-07-01 2019-09-30 0001048477 srt:EuropeMember 2019-01-01 2019-09-30 0001048477 srt:LatinAmericaMember 2019-07-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2018-01-01 2018-09-30 0001048477 country:US 2019-01-01 2019-09-30 0001048477 srt:EuropeMember 2019-07-01 2019-09-30 0001048477 srt:LatinAmericaMember 2018-01-01 2018-09-30 0001048477 srt:LatinAmericaMember 2019-01-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2019-01-01 2019-09-30 0001048477 bmrn:RestOfWorldMember 2019-07-01 2019-09-30 0001048477 srt:LatinAmericaMember 2018-07-01 2018-09-30 0001048477 srt:EuropeMember 2018-01-01 2018-09-30 0001048477 country:US 2018-07-01 2018-09-30 0001048477 country:US 2018-01-01 2018-09-30 0001048477 srt:EuropeMember 2018-07-01 2018-09-30 0001048477 bmrn:RestOfWorldMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2019-01-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2019-07-01 2019-09-30 0001048477 bmrn:ProductsExcludingProductOneMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2018-01-01 2018-09-30 0001048477 bmrn:ProductsExcludingProductOneMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2018-07-01 2018-09-30 0001048477 bmrn:ProductOneMember us-gaap:SalesChannelThroughIntermediaryMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerSixMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFiveMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-09-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2018-09-30 0001048477 bmrn:CustomerFourMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-01-01 2019-09-30 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:RestrictedStockWithServiceBasedVestingConditionsMember 2019-07-01 2019-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 srt:MinimumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-03-01 2019-03-31 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-31 0001048477 bmrn:TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-08-01 2019-08-31 0001048477 bmrn:TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-08-31 0001048477 srt:MaximumMember bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-03-01 2019-03-31 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001048477 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001048477 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001048477 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001048477 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember 2019-06-01 2019-06-30 0001048477 bmrn:TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember 2019-06-01 2019-06-30 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-07-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2018-01-01 2018-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2018-07-01 2018-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2019-01-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2018-01-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001048477 us-gaap:RestrictedStockMember 2019-07-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandTwentyFourMember 2019-01-01 2019-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001048477 us-gaap:StockCompensationPlanMember 2018-01-01 2018-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2018-07-01 2018-09-30 0001048477 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001048477 bmrn:CommonStockIssuableToEmployeeStockPurchasePlanMember 2019-07-01 2019-09-30 0001048477 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001048477 us-gaap:StockCompensationPlanMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2019-01-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2018-07-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-01-01 2018-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-07-01 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwentyTwentyMember 2019-09-30 0001048477 bmrn:ConvertibleSeniorNotesDueTwoThousandEighteenMember 2018-09-30 0001048477 bmrn:ClinicalAndPostMarketingServicesMember 2019-09-30 0001048477 bmrn:ThirdPartyMember bmrn:CompletedProjectMember 2019-01-01 2019-09-30 0001048477 bmrn:ThirdPartyMember 2019-01-01 2019-09-30 iso4217:NOK iso4217:RUB iso4217:EUR iso4217:COP iso4217:BRL iso4217:USD iso4217:GBP shares pure bmrn:Derivative iso4217:AUD iso4217:CAD iso4217:USD shares bmrn:Segment P5Y P1Y P5Y P1Y P1Y P1Y Amendment to revise drafting error on Form 10Q for period ended September 30, 2019 true --12-31 Q3 2019 0001048477 0.001 0.001 500000000 500000000 178252954 179604381 178252954 179604381 0.015 0.00599 0.015 0.00599 the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility) 0 326400000 0 2019-12-31 2019-10-31 2020-09-30 2019-10-31 2020-09-30 2019-11-30 2019-10-31 2019-10-31 2022-09-30 2022-09-30 2019-11-30 2019-10-31 2019-10-31 2019-10-31 2019-07-31 2019-10-31 2019-10-31 2019-12-31 2019-10-31 2019-11-30 2019-10-31 P3Y P3Y 0.384 0.374 0.368 0.371 0.028 0.030 0.023 0.022 P5Y8M12D P4Y7M6D P5Y9M18D P4Y7M6D 0 10-Q/A true 2019-09-30 false 000-26727 BioMarin Pharmaceutical Inc DE 68-0397820 770 Lindaro Street San Rafael CA 94901 415 506-6700 Common Stock, par value $0.001 BMRN NASDAQ Yes Yes Large Accelerated Filer false false false 179625303 423220000 493982000 297572000 590326000 402970000 342633000 609049000 530871000 126548000 98403000 1859359000 2056215000 431804000 235864000 969300000 948682000 462849000 491808000 197039000 197039000 525131000 460952000 112646000 36568000 4558128000 4427128000 483745000 437290000 10000000 85951000 493745000 523241000 843616000 830417000 48930000 46883000 97432000 58647000 1483723000 1459188000 180000 178000 4782916000 4669926000 9961000 13301000 37003000 5271000 -1735733000 -1694134000 3074405000 2967940000 4558128000 4427128000 450900000 386320000 1224458000 1123205000 10197000 5386000 25147000 14793000 461097000 391706000 1249605000 1137998000 96949000 78893000 263567000 240245000 172963000 161408000 542195000 520938000 170112000 148566000 493024000 440182000 17063000 18580000 57114000 42009000 0 0 15000000 20000000 457087000 407447000 1340900000 1223374000 4010000 -15741000 -91295000 -85376000 -551000 -468000 -780000 -507000 5340000 6338000 17537000 17141000 2937000 12131000 16530000 35918000 3960000 2589000 6038000 5266000 9822000 -19413000 -85030000 -99394000 -45214000 -6793000 -46158000 -25833000 55036000 -12620000 -38872000 -73561000 0.31 -0.07 -0.22 -0.42 0.30 -0.07 -0.22 -0.42 179289000 177481000 178873000 176767000 185924000 177481000 178873000 176767000 74600000 -13651000 -7140000 -52174000 179433000 177508000 178253000 175844000 171000 395000 1351000 2059000 179604000 177903000 179604000 177903000 2960954000 2885104000 2967940000 2808663000 179000 178000 178000 176000 1000 0 2000 2000 180000 178000 180000 178000 4744316000 4577300000 4669926000 4483220000 -1294000 5151000 -19183000 21461000 40144000 38366000 122212000 116136000 250000 0 692000 0 0 10653000 0 4782916000 4620817000 4782916000 4620817000 -10211000 -13390000 -13301000 -14224000 -250000 25000 -692000 -809000 0 0 2648000 0 -9961000 -13415000 -9961000 -13415000 17439000 -1129000 5271000 -22961000 -586000 19564000 -1031000 31732000 21387000 37003000 -2160000 37003000 -2160000 -1790769000 -1677855000 -1694134000 -1637548000 -2727000 20634000 55036000 -12620000 -38872000 -73561000 -1735733000 -1690475000 -1735733000 -1690475000 3074405000 2914945000 3074405000 2914945000 -38872000 -73561000 79510000 70955000 9395000 26099000 1897000 -769000 121763000 112261000 15000000 20000000 -59780000 -32735000 -784000 11997000 5646000 12836000 18000 459000 61803000 95884000 52571000 10232000 13259000 -4276000 7112000 3148000 21747000 -12090000 2386000 3744000 -9081000 -29166000 94241000 102541000 635678000 857063000 528497000 439198000 15000000 20000000 8323000 0 1747000 10000 17870000 335314000 21768000 55643000 40951000 34180000 57508000 43108000 -2025000 0 -78716000 -21645000 -835000 -347000 -70762000 284156000 493982000 598028000 423220000 882184000 6088000 15791000 5777000 7521000 -5801000 -7678000 NATURE OF OPERATIONS<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div> BASIS OF PRESENTATION<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K. The results of operations for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> are not necessarily indicative of the results that may be expected for the fiscal year ending </span><span style="font-family:Arial;font-size:9pt;">December 31, 2019</span><span style="font-family:Arial;font-size:9pt;"> or any other period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;"> (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;">. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of </span><span style="font-family:Arial;font-size:9pt;"><span>$55.9 million</span></span><span style="font-family:Arial;font-size:9pt;"> and lease liabilities of </span><span style="font-family:Arial;font-size:9pt;"><span>$59.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="font-family:Arial;font-size:9pt;"> (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K. The results of operations for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> are not necessarily indicative of the results that may be expected for the fiscal year ending </span><span style="font-family:Arial;font-size:9pt;">December 31, 2019</span><span style="font-family:Arial;font-size:9pt;"> or any other period.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;"> (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Leases</span><span style="font-family:Arial;font-size:9pt;">. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of </span><span style="font-family:Arial;font-size:9pt;"><span>$55.9 million</span></span><span style="font-family:Arial;font-size:9pt;"> and lease liabilities of </span><span style="font-family:Arial;font-size:9pt;"><span>$59.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="font-family:Arial;font-size:9pt;"> (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div> 55900000 59000000.0 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Except as detailed below, there have been no material changes to the Company’s significant accounting policies during the </span><span style="font-family:Arial;font-size:9pt;">nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, as compared to the significant accounting policies disclosed in Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis. </span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Derivatives and Hedging Activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in Accumulated Other Comprehensive Income (AOCI) and amounts deferred in AOCI will be reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in Operating Expenses in the Consolidated Statements of Comprehensive Income (Loss).</span></div> <div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.</span></div>Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis. <div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Derivatives and Hedging Activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in Accumulated Other Comprehensive Income (AOCI) and amounts deferred in AOCI will be reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in Operating Expenses in the Consolidated Statements of Comprehensive Income (Loss).</span></div> RECENT ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Except as described in Note 2 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Basis of Presentation</span><span style="font-family:Arial;font-size:9pt;"> and below, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the </span><span style="font-family:Arial;font-size:9pt;">nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, that the Company believes are of significance or potential significance to the Company.</span></div><div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effective January 1, 2020, the Company will adopt ASU No. 2016-13, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:9pt;"> (ASU 2016-13), as amended, using a modified retrospective approach, with certain exceptions allowed. The standard amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The Company is evaluating the impact of the adoption of ASU 2016-13 on its Condensed Consolidated Financial Statements.</span></div> <div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effective January 1, 2020, the Company will adopt ASU No. 2016-13, </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Arial;font-size:9pt;"> (ASU 2016-13), as amended, using a modified retrospective approach, with certain exceptions allowed. The standard amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The Company is evaluating the impact of the adoption of ASU 2016-13 on its Condensed Consolidated Financial Statements.</span></div> FINANCIAL INSTRUMENTS<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">All marketable securities were classified as available-for-sale at </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, respectively:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">As of September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash and Cash Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Short-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Long-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Money market instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>519,693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>523,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>206,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>204,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>853,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>297,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>431,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,147,834</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,152,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>423,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>297,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>431,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash and Cash Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Short-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Long-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Money market instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>564,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,288</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>562,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>376,545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>184,233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>240,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(697</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,093,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,986</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,091,363</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>265,173</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>590,326</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,864</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,322,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,320,172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>493,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>590,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,864</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(1)    The Company’s short-term marketable securities mature in one year or less.</span></div><div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(2)    The Company’s long-term marketable securities mature between one and five years.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company’s investments in an unrealized loss position were not significant, and since the Company has the ability and intent to hold all investments that have been in a continuous loss position until maturity or recovery, </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;"> other-than-temporary impairment was deemed to have occurred.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, respectively:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">As of September 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash and Cash Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Short-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Long-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>294,543</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Money market instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>519,693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>523,339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>206,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>316,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>204,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>90,790</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>114,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>853,291</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>128,678</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>297,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>431,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,147,834</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(165</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,152,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>423,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>297,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>431,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash and Cash Equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Short-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Long-term</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Securities</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (2)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 1:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>228,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Level 2:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Money market instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205,736</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>564,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,288</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>562,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>376,545</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>184,233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,702</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. government agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>240,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(697</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>239,883</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>156,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,076</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,093,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,986</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,091,363</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>265,173</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>590,326</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,864</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,322,661</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>497</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,986</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,320,172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>493,982</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>590,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>235,864</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(1)    The Company’s short-term marketable securities mature in one year or less.</span></div><div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(2)    The Company’s long-term marketable securities mature between one and five years.</span></div> 294543000 0 0 294543000 294543000 0 0 128678000 0 0 128678000 128678000 0 0 519693000 3713000 67000 523339000 0 206782000 316557000 204371000 1073000 97000 205347000 0 90790000 114557000 549000 142000 1000 690000 0 0 690000 853291000 4928000 165000 858054000 128678000 297572000 431804000 1147834000 4928000 165000 1152596000 423220000 297572000 431804000 228809000 0 0 228809000 228809000 0 0 205736000 0 0 205736000 205736000 0 0 564852000 214000 2288000 562778000 2000000 376545000 184233000 77702000 0 0 77702000 21964000 55738000 240436000 144000 697000 239883000 31474000 156967000 51442000 5126000 139000 1000 5264000 3999000 1076000 189000 1093852000 497000 2986000 1091363000 265173000 590326000 235864000 1322661000 497000 2986000 1320172000 493982000 590326000 235864000 0 INTANGIBLE ASSETS<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>642,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross intangible assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>642,677</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>634,354</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(179,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net carrying value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>462,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">During the second quarter of 2019, </span><span style="font-family:Arial;font-size:9pt;"><span>$326.4 million</span></span><span style="font-family:Arial;font-size:9pt;"> of indefinite-lived intangible assets were reclassified to definite-lived as the underlying in-process research and development (IPR&amp;D) was placed into service upon receiving European regulatory approval for Palynziq. The Company will straight-line the amortization expense for the underlying IPR&amp;D over its estimated useful life through August 2028. </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">During the second quarter of 2019, the Company recorded a </span><span style="font-family:Arial;font-size:9pt;"><span>$15.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> gain on sale of intangible assets in the Condensed Consolidated Statements of Comprehensive Income (Loss) due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>642,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>307,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>326,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gross intangible assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>642,677</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>634,354</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Accumulated amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(179,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(142,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net carrying value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>462,849</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 642677000 307995000 0 326359000 642677000 634354000 179828000 142546000 462849000 491808000 -326400000 15000000.0 <div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(7) PROPERTY, PLANT AND EQUIPMENT</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, plant and equipment, net consisted of the following: </span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Building and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>709,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Manufacturing and laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>365,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>345,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Computer hardware and software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>165,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>41,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,094</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,504,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,421,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(535,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(472,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>969,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>948,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The construction-in-progress balance primarily included costs related to significant in-process projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Depreciation expense for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> was </span><span style="font-family:Arial;font-size:9pt;"><span>$24.2 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$67.2 million</span></span><span style="font-family:Arial;font-size:9pt;">, respectively, of which </span><span style="font-family:Arial;font-size:9pt;"><span>$9.8 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$24.9 million</span></span><span style="font-family:Arial;font-size:9pt;">, respectively, was capitalized into inventory. Depreciation expense for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2018</span><span style="font-family:Arial;font-size:9pt;"> was </span><span style="font-family:Arial;font-size:9pt;"><span>$26.6 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$66.7 million</span></span><span style="font-family:Arial;font-size:9pt;">, respectively, of which </span><span style="font-family:Arial;font-size:9pt;"><span>$8.1 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$18.6 million</span></span><span style="font-family:Arial;font-size:9pt;">, respectively, was capitalized into inventory.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Property, plant and equipment, net consisted of the following: </span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Building and improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>709,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>694,447</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Manufacturing and laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>365,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>345,947</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Computer hardware and software</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>165,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>157,787</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>41,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Furniture and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,603</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,234</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,094</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Construction-in-progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>64,170</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,504,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,421,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(535,609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(472,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>969,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>948,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 709990000 694447000 365348000 345947000 165235000 157787000 52379000 41188000 37603000 33234000 7239000 6551000 83094000 77993000 84021000 64170000 1504909000 1421317000 535609000 472635000 969300000 948682000 24200000 67200000 9800000 24900000 26600000 66700000 8100000 18600000 SUPPLEMENTAL BALANCE SHEET INFORMATION<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inventory consisted of the following:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>321,073</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>219,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>225,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>609,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>530,871</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inventory as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling </span><span style="font-family:Arial;font-size:9pt;"><span>$7.1 million</span></span><span style="font-family:Arial;font-size:9pt;">. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. The Company believes that all material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale have been significantly reduced. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If regulatory approval is not obtained, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>226,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>207,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued rebates payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Value added taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward foreign currency exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>483,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>437,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inventory consisted of the following:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.04214559386973%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>68,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>74,616</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>321,073</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>219,585</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>225,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>609,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>530,871</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 68391000 74616000 321073000 231064000 219585000 225191000 609049000 530871000 7100000 <div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts Payable and Accrued Liabilities consisted of the following:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued operating expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>226,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>207,620</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued compensation expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>149,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued rebates payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accrued royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Value added taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward foreign currency exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lease liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,225</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>483,745</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>437,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 226769000 207620000 132049000 149937000 55957000 43116000 27881000 19977000 7556000 7785000 8731000 4178000 10225000 0 14577000 4677000 483745000 437290000 FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">. There were </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;"> financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.5095785440613%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Measurements at September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Measurements at December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Quoted Price in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Active Markets</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For Identical</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Strategic investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,834</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The restricted investments at </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company’s NQDC Plan was amended during the second quarter of 2019, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC Plan. The obligation was previously classified as a liability recorded at fair value and has been reclassified into equity and recorded at the shares' respective grant date fair values at June 30, 2019. The change to the NQDC Plan related to the prohibition of participants to diversify investments for deferrals of Company stock contributed into other types of investments. The NQDC Plan liabilities classified as Level 2 represent investments held in plan assets excluding shares of the Company's common stock.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company had investments in marketable equity securities measured using quoted prices in an active market that were considered strategic investments and were included in Other Assets on the Company's Condensed Consolidated Balance Sheets. During the second quarter of 2019, the Company realized an immaterial gain upon the sale of the shares. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">There were no transfers between levels during the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table represents a roll-forward of contingent consideration. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Changes in fair value of other contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Milestone payments to Ares Trading S.A. (Merck Serono)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(83,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Milestone payments to former LEAD Therapeutics, Inc. shareholders</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,987</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Realized gain on settlement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign exchange remeasurement of Euro denominated contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">. There were </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;"> financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.5095785440613%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Measurements at September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,135</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,039</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>48,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63,969</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,104</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair Value Measurements at December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Quoted Price in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Active Markets</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">For Identical</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Level 3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Restricted investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Strategic investments </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,220</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>25,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>370</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>85,951</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>86,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">NQDC Plan liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,598</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>77,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:76px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,198</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,834</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The restricted investments at </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company’s NQDC Plan was amended during the second quarter of 2019, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC Plan. The obligation was previously classified as a liability recorded at fair value and has been reclassified into equity and recorded at the shares' respective grant date fair values at June 30, 2019. The change to the NQDC Plan related to the prohibition of participants to diversify investments for deferrals of Company stock contributed into other types of investments. The NQDC Plan liabilities classified as Level 2 represent investments held in plan assets excluding shares of the Company's common stock.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(3)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company had investments in marketable equity securities measured using quoted prices in an active market that were considered strategic investments and were included in Other Assets on the Company's Condensed Consolidated Balance Sheets. During the second quarter of 2019, the Company realized an immaterial gain upon the sale of the shares. </span></div> 0 1135000 0 1135000 15039000 0 15039000 3157000 0 3157000 18196000 0 18196000 19331000 0 19331000 1135000 0 1135000 0 10000000 10000000 1135000 10000000 11135000 15039000 0 15039000 0 48930000 48930000 15039000 48930000 63969000 16174000 58930000 75104000 0 370000 0 370000 0 9581000 0 9581000 0 9951000 0 9951000 0 12828000 0 12828000 0 2450000 0 2450000 942000 0 0 942000 942000 15278000 0 16220000 942000 25229000 0 26171000 55000 370000 0 425000 0 0 85951000 85951000 55000 370000 85951000 86376000 17598000 12828000 0 30426000 0 0 46883000 46883000 17598000 12828000 46883000 77309000 17653000 13198000 132834000 163685000 <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table represents a roll-forward of contingent consideration. </span></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>132,834</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Changes in fair value of other contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Milestone payments to Ares Trading S.A. (Merck Serono)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(83,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Milestone payments to former LEAD Therapeutics, Inc. shareholders</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,987</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Realized gain on settlement of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Foreign exchange remeasurement of Euro denominated contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Contingent consideration at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 132834000 19916000 -83472000 -5987000 -1928000 -2433000 58930000 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted product revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also uses forward contracts for economic hedging purposes which are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from net product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, derivatives that hedge cash flows must be highly effective at offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes the Company’s derivatives designated as hedging instruments outstanding as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> (notional amounts in millions):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Exchange Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Notional</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Australian Dollars – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Dec 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Canadian Dollars – Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Colombian Pesos – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,400.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Purchase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2022</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>624.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2022</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Norwegian Krone – Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Dec 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes the Company’s derivatives not designated as hedging instruments outstanding as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> (notional amounts in millions):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Exchange Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Notional</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Colombian Pesos – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Purchase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Great British Pounds - Purchase</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Great British Pounds - Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rubles – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,420.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,686</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,653</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Derivatives Assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Derivatives Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)  </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional discussion of fair value measurements, see Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Financial Statements for the period presented.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Designated as Cash Flow Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of Gain (Loss) Recognized in Other Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,973</span></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,431</span></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Designated as Cash Flow Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash Flow Hedging Gains (Losses) </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Reclassified into Earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues as reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating expenses as reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>457,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,340,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,885</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (Losses) Recognized in Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (Losses) Recognized in Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company expects to reclassify unrealized gains of </span><span style="font-family:Arial;font-size:9pt;"><span>$19.2 million</span></span><span style="font-family:Arial;font-size:9pt;"> from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next </span><span style="font-family:Arial;font-size:9pt;">12</span><span style="font-family:Arial;font-size:9pt;"> months.</span></div><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.</span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes the Company’s derivatives designated as hedging instruments outstanding as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> (notional amounts in millions):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Exchange Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Notional</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Australian Dollars – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Dec 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Canadian Dollars – Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Colombian Pesos – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>89,400.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Purchase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>189.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2022</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>624.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Sept 2022</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Norwegian Krone – Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Dec 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>648</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6 2800000 24 28100000 12 89400000000.0 150 189400000 453 624200000 3 11700000 648 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes the Company’s derivatives not designated as hedging instruments outstanding as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> (notional amounts in millions):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:25%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Exchange Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Aggregate Notional</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Amount in</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Foreign Currency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Colombian Pesos – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>96,000.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Euros – Purchase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>44.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Great British Pounds - Purchase</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Great British Pounds - Sell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rubles – Sell</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,420.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oct 2019 - Nov 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2 96000000000.0 2 44100000 1 4900000 1 2000000.0 2 1420000000.0 8 <div style="line-height:120%;padding-top:13px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>29,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,686</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,324</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,875</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,653</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Asset Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Liability Derivatives - Level 2 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subtotal</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Derivatives Assets</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,178</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total Derivatives Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,374</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)  </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional discussion of fair value measurements, see Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div> 29900000 12686000 22892000 10324000 52792000 23010000 7875000 4036000 7641000 3653000 15516000 7689000 71000 168000 0 0 71000 168000 858000 142000 0 0 858000 142000 52863000 23178000 16374000 7831000 <div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Financial Statements for the period presented.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Designated as Cash Flow Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amount of Gain (Loss) Recognized in Other Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,973</span></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,431</span></span></div></td><td style="vertical-align:bottom;background-color:#ccecff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Designated as Cash Flow Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash Flow Hedging Gains (Losses) </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Reclassified into Earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Cash Flow Hedging Gains (Losses) <br/>Reclassified into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues as reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating expenses as reported</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>457,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,340,900</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,885</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (Losses) Recognized in Earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (Losses) Recognized in Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(5,182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 23973000 35431000 450900000 6196000 1224458000 11171000 457087000 -1388000 1340900000 -1885000 -1286000 -5182000 19200000 LEASES<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Lease Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other Assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Noncurrent:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> by fiscal year were as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity of Lease Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,363</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,043</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,406</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes short-term leases and variable lease costs, both of which were not material.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average remaining lease term (in years):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average discount rate:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.4</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;"> operating leases are expected to commence in the remainder of 2019. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Supplemental Cash Flow Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,918</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in financing activities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets obtained in exchange for lease obligations:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Lease Commitments as of </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Minimum lease payments for future years as of </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> were as follows: </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,701</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rent expense for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> was </span><span style="font-family:Arial;font-size:9pt;"><span>$12.2 million</span></span><span style="font-family:Arial;font-size:9pt;">. Total deferred rent accruals at </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> were </span><span style="font-family:Arial;font-size:9pt;"><span>$2.1 million</span></span><span style="font-family:Arial;font-size:9pt;">, of which </span><span style="font-family:Arial;font-size:9pt;"><span>$0.5 million</span></span><span style="font-family:Arial;font-size:9pt;"> was short-term.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Lease Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>51,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other Assets</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>61,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Current:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,273</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Noncurrent:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>45,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 51284000 10346000 61630000 7273000 2952000 45499000 9544000 65268000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> by fiscal year were as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity of Lease Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,363</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,043</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,406</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Maturities of lease liabilities as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> by fiscal year were as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Maturity of Lease Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,319</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,865</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8,406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>78,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,363</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,043</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13,406</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>65,268</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3115000 3204000 6319000 9925000 3464000 13389000 8721000 2865000 11586000 8406000 2258000 10664000 7504000 1748000 9252000 27464000 0 27464000 65135000 13539000 78674000 12363000 1043000 13406000 52772000 12496000 65268000 3535000 9946000 600000 1811000 142000 455000 4277000 12212000 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average remaining lease term (in years):</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted average discount rate:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.2</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.4</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div> P8Y P4Y2M12D 0.052 0.054 0 <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Supplemental Cash Flow Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,918</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>454</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cash used in financing activities:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,027</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">ROU assets obtained in exchange for lease obligations:</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing leases</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Financing:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,277</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes short-term leases and variable lease costs, both of which were not material.</span></div> 5918000 454000 2027000 9268000 72000 <div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Minimum lease payments for future years as of </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> were as follows: </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,701</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>84,991</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 12976000 12549000 11198000 10574000 9993000 27701000 84991000 12200000 2100000 500000 DEBT<div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Convertible Notes</span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of </span><span style="font-family:Arial;font-size:9pt;"><span>$870.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15,780</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(26,581</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized deferred offering costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in 2020, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>357,854</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>346,078</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized discount</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6,887</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized deferred offering costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in 2024, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>485,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>484,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total convertible debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>843,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>830,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair value of fixed rate convertible debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in October 2020</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>384,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>419,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in August 2024 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>490,297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491,626</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total fair value of fixed rate convertible debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>875,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>911,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;"> </span></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense on the Company’s convertible debt consisted of the following:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Coupon interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,271</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accretion of discount on convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense on convertible debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> for additional information related to the Company’s convertible debt.</span></div><div style="line-height:120%;padding-top:24px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Revolving Credit Facility</span></div><div style="line-height:120%;padding-top:16px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In October 2018, the Company entered into an unsecured revolving credit facility of up to </span><span style="font-family:Arial;font-size:9pt;"><span>$200.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from </span><span style="font-family:Arial;font-size:9pt;"><span>1.00%</span></span><span style="font-family:Arial;font-size:9pt;"> to </span><span style="font-family:Arial;font-size:9pt;"><span>1.95%</span></span><span style="font-family:Arial;font-size:9pt;"> per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from </span><span style="font-family:Arial;font-size:9pt;"><span>0.00%</span></span><span style="font-family:Arial;font-size:9pt;"> to </span><span style="font-family:Arial;font-size:9pt;"><span>0.95%</span></span><span style="font-family:Arial;font-size:9pt;">, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from </span><span style="font-family:Arial;font-size:9pt;"><span>0.15%</span></span><span style="font-family:Arial;font-size:9pt;"> to </span><span style="font-family:Arial;font-size:9pt;"><span>0.35%</span></span><span style="font-family:Arial;font-size:9pt;"> per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on </span><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">October 19, 2021</span></span></span><span style="font-family:Arial;font-size:9pt;"> at which time all outstanding amounts become due and payable, except that if at least </span><span style="font-family:Arial;font-size:9pt;"><span>$100.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> aggregate principal amount of the 2020 Notes remain outstanding on August 1, 2020 and certain other conditions have not been met, the Company may be required to repay all amounts borrowed under the 2018 Credit Facility on </span><span style="font-family:Arial;font-size:9pt;"><span><span style="white-space:nowrap">August 1, 2020</span></span></span><span style="font-family:Arial;font-size:9pt;">. The Company incurred approximately </span><span style="font-family:Arial;font-size:9pt;"><span>$1.0 million</span></span><span style="font-family:Arial;font-size:9pt;"> of issuance costs, which will be amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, there were </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;"> outstanding amounts due on nor any usage of the 2018 Credit Facility. As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants.</span></div> 870000000.0 The following table summarizes information regarding the Company’s convertible debt:<span style="font-family:inherit;font-size:9pt;"> </span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>374,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(15,780</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(26,581</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized deferred offering costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in 2020, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>357,854</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>346,078</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>495,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized discount</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6,887</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unamortized deferred offering costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in 2024, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>485,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>484,339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total convertible debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>843,616</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>830,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Fair value of fixed rate convertible debt</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in October 2020</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>384,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>419,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Convertible Notes due in August 2024 </span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>490,297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>491,626</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total fair value of fixed rate convertible debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>875,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>911,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">(1)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;"> included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div> 374993000 374993000 15780000 26581000 1359000 2334000 357854000 346078000 495000000 495000000 6887000 7946000 2351000 2715000 485762000 484339000 843616000 830417000 384713000 419722000 490297000 491626000 875010000 911348000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Interest expense on the Company’s convertible debt consisted of the following:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Coupon interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,271</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,008</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Accretion of discount on convertible notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,005</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total interest expense on convertible debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,131</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,918</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2271000 3331000 6681000 9819000 508000 1008000 1522000 3018000 4005000 7792000 11860000 23081000 6784000 12131000 20063000 35918000 200000000.0 0.0100 0.0195 0.0000 0.0095 0.0015 0.0035 2021-10-19 100000000.0 2020-08-01 1000000.0 0 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Statement of Comprehensive Income (Loss)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (losses) on cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating expenses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total gain (loss) on cash flow hedges</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before</span></div><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>522</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,492</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: net gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before</span></div><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,431</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,256</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42,684</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,129</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before<br/>     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,475</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,830</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(22,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impact of change in accounting principle</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,308</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(23,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before<br/>     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Condensed Consolidated</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Statement of Comprehensive Income (Loss)</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Classification</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Gains (losses) on cash flow hedges:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,025</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(6,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating expenses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total gain (loss) on cash flow hedges</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6196000 5025000 11171000 -6683000 -1388000 498000 -1885000 3762000 4808000 5523000 9286000 -2921000 <div style="line-height:120%;padding-top:10px;text-indent:60px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,181</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before</span></div><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>522</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,492</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: net gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>402</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,271</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before</span></div><div style="text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>35,431</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,256</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>42,684</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,286</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>26,145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>31,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>33,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,003</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,129</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before<br/>     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,475</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,830</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(338</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,168</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(1,031</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on Cash</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Flow Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Unrealized Gains</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">(Losses) on</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Available for-Sale</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(22,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Impact of change in accounting principle</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(20,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(3,308</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(23,547</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other comprehensive income (loss) before<br/>     reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17,711</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Less: gain (loss) reclassified from AOCI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>21,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">AOCI balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>400</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(2,160</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 14181000 3271000 -13000 17439000 23973000 522000 -3000 24492000 4808000 0 0 4808000 0 120000 0 120000 19165000 402000 -3000 19564000 33346000 3673000 -16000 37003000 7201000 -1917000 -13000 5271000 35431000 7256000 -3000 42684000 9286000 0 0 9286000 0 1666000 0 1666000 26145000 5590000 -3000 31732000 33346000 3673000 -16000 37003000 2568000 -3686000 -11000 -1129000 3355000 1475000 0 4830000 5523000 0 0 5523000 0 338000 0 338000 -2168000 1137000 0 -1031000 400000 -2549000 -11000 -2160000 -20232000 -2722000 -7000 -22961000 0 -586000 0 -586000 -20232000 -3308000 -7000 -23547000 17711000 985000 -4000 18692000 -2921000 0 0 -2921000 0 226000 0 226000 20632000 759000 -4000 21387000 400000 -2549000 -11000 -2160000 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company operates in </span><span style="font-family:Arial;font-size:9pt;"><span>one</span></span><span style="font-family:Arial;font-size:9pt;"> business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed </span><span style="font-family:Arial;font-size:9pt;">10%</span><span style="font-family:Arial;font-size:9pt;"> of consolidated Net Product </span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenues by geographic region:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>562,217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>528,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,485</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>111,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369,585</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>153,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>461,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>391,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,249,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,137,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table disaggregates Net Product Revenues by product.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues by product:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Aldurazyme</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,593</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Brineura</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,743</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Firdapse</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Kuvan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>113,254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340,771</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>321,414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Naglazyme</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>94,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>269,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Palynziq</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vimizim</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>411,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>368,016</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>386,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>480,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>409,294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>358,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>315,270</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>148,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues marketed by the Company</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>428,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>358,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,150,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,005,553</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Aldurazyme net product revenues marketed by Genzyme</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>386,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer F</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On a consolidated basis, </span><span style="font-family:Arial;font-size:9pt;">three</span><span style="font-family:Arial;font-size:9pt;"> customers accounted for </span><span style="font-family:Arial;font-size:9pt;"><span>23%</span></span><span style="font-family:Arial;font-size:9pt;">, </span><span style="font-family:Arial;font-size:9pt;"><span>14%</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>12%</span></span><span style="font-family:Arial;font-size:9pt;"> of the </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> accounts receivable balance, respectively, compared to </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, when </span><span style="font-family:Arial;font-size:9pt;">two</span><span style="font-family:Arial;font-size:9pt;"> customers accounted for </span><span style="font-family:Arial;font-size:9pt;"><span>30%</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>16%</span></span><span style="font-family:Arial;font-size:9pt;"> of the accounts receivable balance, respectively. As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, and </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;">, the accounts receivable balance for Genzyme included </span><span style="font-family:Arial;font-size:9pt;"><span>$67.7 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$73.9 million</span></span><span style="font-family:Arial;font-size:9pt;">, respectively, of unbilled accounts receivable, which become payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires immediate payment in certain circumstances.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for the Company’s products. The Company has not historically experienced a significant level of uncollected receivables and has received continued payments from its more aged accounts in these countries. The Company believes that the allowances for doubtful accounts related to these countries, if any, is adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries.</span></div> 1 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenues by geographic region:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>201,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>174,722</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>562,217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>528,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>125,485</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>111,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>369,585</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>323,940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164,132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>49,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>30,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>153,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>134,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>461,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>391,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,249,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,137,998</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 201874000 174722000 562217000 528082000 125485000 111069000 369585000 323940000 83799000 75400000 164132000 151955000 49939000 30515000 153671000 134021000 461097000 391706000 1249605000 1137998000 <div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table disaggregates Net Product Revenues by product.</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net product revenues by product:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Aldurazyme</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,593</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Brineura</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>19,840</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>9,936</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>46,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,743</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Firdapse</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>15,080</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Kuvan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>120,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>113,254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>340,771</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>321,414</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Naglazyme</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>94,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>103,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>279,462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>269,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Palynziq</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>24,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vimizim</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>163,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>123,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>411,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>368,016</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>386,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 22852000 27593000 73945000 117652000 19840000 9936000 46815000 27743000 5668000 4977000 16262000 15080000 120524000 113254000 340771000 321414000 94408000 103089000 279462000 269171000 24142000 4129000 55250000 4129000 163466000 123342000 411953000 368016000 450900000 386320000 1224458000 1123205000 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>175,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>146,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>480,330</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>409,294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>107,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>358,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>315,270</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>83,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>75,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>164,132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>151,955</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rest of world</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>47,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>28,734</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>148,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>129,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues marketed by the Company</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>428,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>358,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,150,513</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,005,553</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Aldurazyme net product revenues marketed by Genzyme</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>22,852</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>27,593</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>73,945</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>450,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>386,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,224,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,123,205</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 175127000 146742000 480330000 409294000 121363000 107851000 358041000 315270000 83799000 75400000 164132000 151955000 47759000 28734000 148010000 129034000 428048000 358727000 1150513000 1005553000 22852000 27593000 73945000 117652000 450900000 386320000 1224458000 1123205000 <div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer E</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Customer F</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:9pt;"> </span></div> 0.16 0.16 0.17 0.17 0.13 0.12 0.12 0.12 0.10 0.10 0.11 0.10 0.05 0.07 0.06 0.11 0.12 0 0.06 0 0 0.13 0 0.06 0.56 0.58 0.52 0.56 0.23 0.14 0.12 0.30 0.16 67700000 73900000 STOCK-BASED COMPENSATION<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,093</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>112,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock-based compensation of </span><span style="font-family:Arial;font-size:9pt;"><span>$5.1 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$13.2 million</span></span><span style="font-family:Arial;font-size:9pt;"> was capitalized into inventory for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, respectively, compared to </span><span style="font-family:Arial;font-size:9pt;"><span>$5.3 million</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>$14.3 million</span></span><span style="font-family:Arial;font-size:9pt;"> for the </span><span style="font-family:Arial;font-size:9pt;">three and nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2018</span><span style="font-family:Arial;font-size:9pt;">, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.</span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Equity Awards with Service-Based Vesting Conditions</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">During the </span><span style="font-family:Arial;font-size:9pt;">nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company granted </span><span style="font-family:Arial;font-size:9pt;"><span>1,844,308</span></span><span style="font-family:Arial;font-size:9pt;"> RSUs with service-based vesting conditions with a weighted-average fair value of </span><span style="font-family:Arial;font-size:9pt;"><span>$91.23</span></span><span style="font-family:Arial;font-size:9pt;"> per share. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company did </span><span style="font-family:Arial;font-size:9pt;"><span>no</span></span><span style="font-family:Arial;font-size:9pt;">t grant any options to purchase shares of common stock during the three months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">. During the </span><span style="font-family:Arial;font-size:9pt;">nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company granted </span><span style="font-family:Arial;font-size:9pt;"><span>610,250</span></span><span style="font-family:Arial;font-size:9pt;"> options to purchase shares of common stock with a weighted-average fair value of </span><span style="font-family:Arial;font-size:9pt;"><span>$36.84</span></span><span style="font-family:Arial;font-size:9pt;"> per share.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36.8%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">37.1 – 37.4%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">36.8 – 38.4%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.6 – 5.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.6 – 5.7</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.2 – 3.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.3 – 2.8%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company did not issue any new stock purchase rights under the Employee Stock Purchase Plan during the three months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">. The Company issued </span><span style="font-family:Arial;font-size:9pt;"><span>107,473</span></span><span style="font-family:Arial;font-size:9pt;"> new stock purchase rights under the Employee Stock Purchase Plan during the </span><span style="font-family:Arial;font-size:9pt;">nine</span><span style="font-family:Arial;font-size:9pt;"> months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;"> Restricted Stock Unit Awards with Performance Conditions</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In August 2019, the Compensation Committee of the Board of Directors (Board) approved the grant of </span><span style="font-family:Arial;font-size:9pt;"><span>44,260</span></span><span style="font-family:Arial;font-size:9pt;"> RSUs with performance-based vesting conditions and a grant date fair value of $</span><span style="font-family:Arial;font-size:9pt;"><span>81.00</span></span><span style="font-family:Arial;font-size:9pt;"> per RSU. This award is contingent upon obtaining regulatory approval for valoctocogene roxaparvovec by January 2022 and the awarded RSUs, if any, vest ratably from the time regulatory approval is obtained through January 2022. The Company evaluated the current timeline and plans for submitting the regulatory applications and determined that for accounting purposes attainment of the performance measure is not probable as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> as the regulatory approval is outside of the Company's control. Therefore, the Company did not record any expense associated with these awards. </span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In March 2019, the Compensation Committee and Board approved the grant of </span><span style="font-family:Arial;font-size:9pt;"><span>99,010</span></span><span style="font-family:Arial;font-size:9pt;"> RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of </span><span style="font-family:Arial;font-size:9pt;"><span>$94.53</span></span><span style="font-family:Arial;font-size:9pt;"> per RSU. This award is contingent upon the achievement of a 2019 revenue target and the awarded RSUs, if any, vest ratably over a </span><span style="font-family:Arial;font-size:9pt;">three</span><span style="font-family:Arial;font-size:9pt;">-year service period. The Company evaluated the 2019 revenue target in the context of its current 2019 revenue forecast, and related confidence level in the forecast, and determined that attainment of the revenue target was probable for accounting purposes commencing in the first quarter of </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;">. The number of shares that may be earned range between </span><span style="font-family:Arial;font-size:9pt;"><span>0%</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>200%</span></span><span style="font-family:Arial;font-size:9pt;"> of the base RSUs, depending on the percentage of 2019 “managed revenues” (defined as the Company’s net product revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates) achieved against the target managed revenues, with a threshold achievement level of </span><span style="font-family:Arial;font-size:9pt;"><span>75%</span></span><span style="font-family:Arial;font-size:9pt;"> of target and a ceiling achievement level of </span><span style="font-family:Arial;font-size:9pt;"><span>125%</span></span><span style="font-family:Arial;font-size:9pt;"> of target.</span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Awards with Market Conditions</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In March 2019, the Compensation Committee and Board approved the grant of </span><span style="font-family:Arial;font-size:9pt;"><span>99,010</span></span><span style="font-family:Arial;font-size:9pt;"> RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs, vest, if at all, in full following a </span><span style="font-family:Arial;font-size:9pt;">three</span><span style="font-family:Arial;font-size:9pt;">-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between </span><span style="font-family:Arial;font-size:9pt;"><span>0%</span></span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;"><span>200%</span></span><span style="font-family:Arial;font-size:9pt;"> of the base TSR-RSUs with a ceiling achievement level of </span><span style="font-family:Arial;font-size:9pt;"><span>100%</span></span><span style="font-family:Arial;font-size:9pt;"> of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the </span><span style="font-family:Arial;font-size:9pt;"><span>50</span></span><span style="font-family:Arial;font-size:9pt;">th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of </span><span style="font-family:Arial;font-size:9pt;"><span>$143.92</span></span><span style="font-family:Arial;font-size:9pt;"> per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.</span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,093</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>12,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>10,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>14,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>43,099</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,819</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>18,815</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>66,097</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>58,802</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>39,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>37,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>121,763</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>112,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4093000 3974000 12629000 10360000 14261000 14257000 43037000 43099000 20819000 18815000 66097000 58802000 39173000 37046000 121763000 112261000 5100000 13200000 5300000 14300000 1844308 91.23 0 610250 36.84 <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:45%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>36.8%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">37.1 – 37.4%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">36.8 – 38.4%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.0%</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.6 – 5.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.6 – 5.7</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>2.8%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.2 – 3.0%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2.3 – 2.8%</span></div></td></tr></table></div> 0.368 0.000 0.000 0.000 P5Y8M12D 0.028 107473 44260 81.00 99010 94.53 0 2 0.75 1.25 99010 0 2 1 0.50 143.92 INCOME TAXES<div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The Company utilizes an estimated annual effective tax rate for calculating a tax provision under ASC 740-270. That rate is applied to year-to-date ordinary income or loss in order to compute the year-to-date income tax provision. For the three months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company recognized a net tax benefit of </span><span style="font-family:Arial;font-size:9pt;"><span>$45.2 million</span></span><span style="font-family:Arial;font-size:9pt;"> primarily attributed to the quarter fluctuations in the mix and timing of our profits and losses on a territorial basis when applying the estimated annual effective tax rate to the year-to-date earnings. </span></div><span style="font-family:Arial;font-size:9pt;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s Dutch subsidiary had a full valuation allowance against a deferred tax asset of </span><span style="font-family:Arial;font-size:9pt;"><span>$29.6 million</span></span><span style="font-family:Arial;font-size:9pt;"> at December 31, 2018. Historical earnings, future taxable income and ongoing prudent and feasible tax planning strategies have been considered in assessing the need for the valuation allowance; and based on projected income and other key operating factors, the Company concluded in the second quarter of 2019 that it is more likely than not that the benefit of these deferred tax assets would be realized. As a result, the amount of the valuation allowance related to the deferred tax assets that are expected to be realized was reversed in the second quarter of 2019, resulting in a net tax benefit of </span><span style="font-family:Arial;font-size:9pt;"><span>$27.1 million</span></span> recognized during the nine months ended September 30, 2019. -45200000 29600000 -27100000 NET INCOME (LOSS) PER COMMON SHARE<div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s ESPP, unvested RSUs, common stock held by the Company's NQDC Plan and contingent issuances of common stock related to convertible debt.</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table sets forth the computation of basic and diluted earnings per common share (in thousands of common shares):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss), basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(38,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(73,561</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Add: Interest on 2024 notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss), diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(38,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(73,561</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>179,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>177,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Options to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2024 notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock potentially issuable for ESPP purchases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common shares held by the NQDC</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>185,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>177,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178,873</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss) per common share, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss) per common share, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive using the if-converted or treasury stock method (in thousands of common shares):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,829</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2018 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2024 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock potentially issuable for ESPP purchases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock held by the NQDC</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total number of potentially issuable shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The potential effect of the capped call transactions with respect to the 2020 Notes was excluded from the diluted net loss per share as of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;"> as the Company’s closing stock price on September 30, 2019 did not exceed the conversion price of </span><span style="font-family:Arial;font-size:9pt;"><span>$94.15</span></span><span style="font-family:Arial;font-size:9pt;"> per share. Although the Company’s stock price on September 28, 2018 (the last trading day before September 30, 2018) exceeded the conversion price, the potential effect of the capped call transactions and potential shares issuable under the Company’s </span><span style="font-family:Arial;font-size:9pt;"><span>0.75%</span></span><span style="font-family:Arial;font-size:9pt;"> senior subordinated convertible notes due in 2018 and the 2020 Notes were excluded from the calculation of diluted loss per share in the three and nine months ended </span><span style="font-family:Arial;font-size:9pt;">September 30, 2018</span><span style="font-family:Arial;font-size:9pt;"> as they were anti-dilutive using the if-converted method. There is no similar capped call transaction associated with the 2024 Notes. See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Arial;font-size:9pt;">December 31, 2018</span><span style="font-family:Arial;font-size:9pt;"> for additional information related to the Company’s convertible debt and capped call transaction.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table sets forth the computation of basic and diluted earnings per common share (in thousands of common shares):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss), basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,036</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(38,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(73,561</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Add: Interest on 2024 notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss), diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>55,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(12,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(38,872</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(73,561</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>179,289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>177,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176,767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Options to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,560</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2024 notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested RSUs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock potentially issuable for ESPP purchases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>231</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common shares held by the NQDC</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Weighted-average common shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>185,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>177,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>178,873</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>176,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss) per common share, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Net Income (Loss) per common share, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>0.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>(0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 55036000 -12620000 -38872000 -73561000 937000 0 0 0 55973000 -12620000 -38872000 -73561000 179289000 177481000 178873000 176767000 1560000 0 0 0 3970000 0 0 0 669000 0 0 0 231000 0 0 0 205000 0 0 0 185924000 177481000 178873000 176767000 0.31 -0.07 -0.22 -0.42 0.30 -0.07 -0.22 -0.42 <div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive using the if-converted or treasury stock method (in thousands of common shares):</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.70114942528735%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>5,829</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>7,517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2018 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock issuable under the 2024 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unvested RSUs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>4,029</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock potentially issuable for ESPP purchases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Common stock held by the NQDC</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Total number of potentially issuable shares</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>13,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>20,028</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>23,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 5829000 7517000 7388000 7517000 0 3983000 0 3983000 3983000 3983000 3983000 3983000 0 3970000 3970000 3970000 3360000 3411000 4029000 3411000 222000 407000 453000 407000 0 208000 205000 208000 13394000 23479000 20028000 23479000 94.15 0.0075 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-top:8px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.</span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Contingent Payments</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company was subject to contingent payments totaling approximately </span><span style="font-family:Arial;font-size:9pt;"><span>$376.9 million</span></span><span style="font-family:Arial;font-size:9pt;"> upon achievement of certain development and regulatory activities and commercial sales and licensing milestones if they occur before certain dates in the future. Of this amount, </span><span style="font-family:Arial;font-size:9pt;"><span>$65.5 million</span></span><span style="font-family:Arial;font-size:9pt;"> relates to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and </span><span style="font-family:Arial;font-size:9pt;"><span>$239.7 million</span></span><span style="font-family:Arial;font-size:9pt;"> relates to programs that are no longer being developed.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, the Company recorded a total of </span><span style="font-family:Arial;font-size:9pt;"><span>$69.1 million</span></span><span style="font-family:Arial;font-size:9pt;"> of contingent liabilities, of which $</span><span style="font-family:Arial;font-size:9pt;"><span>20.2</span></span><span style="font-family:Arial;font-size:9pt;"> million was short-term. See Note 9 to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration. </span></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:bold;">Other Commitments</span></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients and certain other inventory-related items. As of </span><span style="font-family:Arial;font-size:9pt;">September 30, 2019</span><span style="font-family:Arial;font-size:9pt;">, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately </span><span style="font-family:Arial;font-size:9pt;"><span>$131.6 million</span></span><span style="font-family:Arial;font-size:9pt;">.</span></div> 376900000 65500000 239700000 69100000 20200000 131600000 December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019. The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019. XML 44 R33.htm IDEA: XBRL DOCUMENT v3.19.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Summary of Convertible Debt The following table summarizes information regarding the Company’s convertible debt: 
 
September 30,
2019
 
December 31,
2018
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993

 
374,993

Unamortized discount
(15,780
)
 
(26,581
)
Unamortized deferred offering costs
(1,359
)
 
(2,334
)
Convertible Notes due in 2020, net
357,854

 
346,078

 
 
 
 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000

 
495,000

Unamortized discount
(6,887
)
 
(7,946
)
Unamortized deferred offering costs
(2,351
)
 
(2,715
)
Convertible Notes due in 2024, net
485,762

 
484,339

 
 
 
 
Total convertible debt, net
$
843,616

 
$
830,417

 
 
 
 
Fair value of fixed rate convertible debt
 
 
 
Convertible Notes due in October 2020 (1)
384,713

 
419,722

Convertible Notes due in August 2024 (1)
490,297

 
491,626

Total fair value of fixed rate convertible debt
$
875,010

 
$
911,348

 
(1)
The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Summary of Interest Expense on Debt
Interest expense on the Company’s convertible debt consisted of the following: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Coupon interest expense
$
2,271

 
$
3,331

 
$
6,681

 
$
9,819

Amortization of debt issuance costs
508

 
1,008

 
1,522

 
3,018

Accretion of discount on convertible notes
4,005

 
7,792

 
11,860

 
23,081

Total interest expense on convertible debt
$
6,784

 
$
12,131

 
$
20,063

 
$
35,918
XML 45 R37.htm IDEA: XBRL DOCUMENT v3.19.3
NET LOSS PER COMMON SHARE (Tables)
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share
The following table sets forth the computation of basic and diluted earnings per common share (in thousands of common shares):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Numerator:
 
 
 
 
 
 
 
Net Income (Loss), basic
$
55,036

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Add: Interest on 2024 notes
937

 
—

 
—

 
—

Net Income (Loss), diluted
$
55,973

 
$
(12,620
)
 
$
(38,872
)
 
$
(73,561
)
Denominator:
 
 
 
 
 
 
 
Weighted-average common shares outstanding, basic
179,289

 
177,481

 
178,873

 
176,767

Effect of dilutive securities:
 
 
 
 
 
 
 
Options to purchase common stock
1,560

 
—

 
—

 
—

Common stock issuable under the 2024 notes
3,970

 
—

 
—

 
—

Unvested RSUs
669

 
—

 
—

 
—

Common stock potentially issuable for ESPP purchases
231

 
—

 
—

 
—

Common shares held by the NQDC
205

 
—

 
—

 
—

Weighted-average common shares outstanding, diluted
185,924

 
177,481

 
178,873

 
176,767

Net Income (Loss) per common share, basic
0.31

 
(0.07
)
 
(0.22
)
 
(0.42
)
Net Income (Loss) per common share, diluted
0.30

 
(0.07
)
 
(0.22
)
 
(0.42
)
Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share
In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive using the if-converted or treasury stock method (in thousands of common shares):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Options to purchase common stock
5,829

 
7,517

 
7,388

 
7,517

Common stock issuable under the 2018 Notes
—

 
3,983

 
—

 
3,983

Common stock issuable under the 2020 Notes
3,983

 
3,983

 
3,983

 
3,983

Common stock issuable under the 2024 Notes
—

 
3,970

 
3,970

 
3,970

Unvested RSUs
3,360

 
3,411

 
4,029

 
3,411

Common stock potentially issuable for ESPP purchases
222

 
407

 
453

 
407

Common stock held by the NQDC
—

 
208

 
205

 
208

Total number of potentially issuable shares
13,394

 
23,479

 
20,028

 
23,479
XML 46 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2019
Oct. 18, 2019
Cover page.    
Document Type 10-Q/A  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 000-26727  
Entity Registrant Name BioMarin Pharmaceutical Inc  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 68-0397820  
Entity Address, Address Line One 770 Lindaro Street  
Entity Address, City or Town San Rafael  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94901  
City Area Code 415  
Local Phone Number 506-6700  
Title of 12(b) Security Common Stock, par value $0.001  
Trading Symbol BMRN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   179,625,303
Amendment Flag true  
Amendment Description Amendment to revise drafting error on Form 10Q for period ended September 30, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001048477  
Current Fiscal Year End Date --12-31  
XML 47 R18.htm IDEA: XBRL DOCUMENT v3.19.3
DEBT
 9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
DEBT DEBT
Convertible Notes
As of September 30, 2019, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $870.0 million (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: 
 
September 30,
2019
 
December 31,
2018
1.50% senior subordinated convertible notes due in October 2020 (the 2020 Notes)
374,993

 
374,993

Unamortized discount
(15,780
)
 
(26,581
)
Unamortized deferred offering costs
(1,359
)
 
(2,334
)
Convertible Notes due in 2020, net
357,854

 
346,078

 
 
 
 
0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)
495,000

 
495,000

Unamortized discount
(6,887
)
 
(7,946
)
Unamortized deferred offering costs
(2,351
)
 
(2,715
)
Convertible Notes due in 2024, net
485,762

 
484,339

 
 
 
 
Total convertible debt, net
$
843,616

 
$
830,417

 
 
 
 
Fair value of fixed rate convertible debt
 
 
 
Convertible Notes due in October 2020 (1)
384,713

 
419,722

Convertible Notes due in August 2024 (1)
490,297

 
491,626

Total fair value of fixed rate convertible debt
$
875,010

 
$
911,348

 
(1)
The fair value of the Company’s fixed-rate convertible debt is based on open market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Interest expense on the Company’s convertible debt consisted of the following: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Coupon interest expense
$
2,271

 
$
3,331

 
$
6,681

 
$
9,819

Amortization of debt issuance costs
508

 
1,008

 
1,522

 
3,018

Accretion of discount on convertible notes
4,005

 
7,792

 
11,860

 
23,081

Total interest expense on convertible debt
$
6,784

 
$
12,131

 
$
20,063

 
$
35,918

 
See Note 12 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 for additional information related to the Company’s convertible debt.
Revolving Credit Facility
In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million (the 2018 Credit Facility). The 2018 Credit Facility includes a letter of credit subfacility and a swingline loan subfacility and is intended to finance ongoing working capital needs and for other general corporate purposes. Borrowings under the 2018 Credit Facility bear interest, at the Company’s option, at a rate equal to either (a) the LIBOR rate (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the 2018 Credit Facility), or LIBOR successor rate, plus an applicable margin ranging from 1.00% to 1.95% per annum, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods, or (b) the Base Rate, generally the prime lending rate, plus an applicable margin ranging from 0.00% to 0.95%, based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. Commitment fees payable on the undrawn amount range from 0.15% to 0.35% per annum based upon the Company’s net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Company’s obligations under the Credit Facility are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC, and such obligations may in the future be guaranteed from time to time by certain other material domestic subsidiaries. The 2018 Credit Facility matures on October 19, 2021 at which time all outstanding amounts become due and payable, except that if at least $100.0 million aggregate principal amount of the 2020 Notes remain outstanding on August 1, 2020 and certain other conditions have not been met, the Company may be required to repay all amounts borrowed under the 2018 Credit Facility on August 1, 2020. The Company incurred approximately $1.0 million of issuance costs, which will be amortized to Interest Expense over the term of the 2018 Credit Facility. The 2018 Credit Facility contains financial covenants requiring the Company to maintain a minimum interest coverage ratio and a minimum liquidity requirement. As of September 30, 2019, and December 31, 2018, there were no outstanding amounts due on nor any usage of the 2018 Credit Facility. As of September 30, 2019, the Company and certain of its subsidiaries that served as guarantors were in compliance with all covenants.
XML 48 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Company Stock Held By NQDC
Accumulated other comprehensive income (loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2017 [1]   175,844,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans (in shares)   2,059,000        
Ending balance (in shares) at Sep. 30, 2018   177,903,000        
Beginning Balance at Dec. 31, 2017 [1] $ 2,808,663 $ 176 $ 4,483,220 $ (14,224) $ (22,961) $ (1,637,548)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans, net of tax   2 21,461      
Stock-based compensation     116,136      
Common stock held by the NQDC       809    
Accounting impact of NQDC Plan change     0 0    
Other comprehensive income (loss)         21,387  
Net income (loss) (73,561)         (73,561)
Ending Balance at Sep. 30, 2018 2,914,945 $ 178 4,620,817 (13,415) (2,160) (1,690,475)
Beginning balance (in shares) at Jun. 30, 2018 [1]   177,508,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans (in shares)   395,000        
Ending balance (in shares) at Sep. 30, 2018   177,903,000        
Beginning Balance at Jun. 30, 2018 [1] 2,885,104 $ 178 4,577,300 (13,390) (1,129) (1,677,855)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans, net of tax   0 5,151      
Stock-based compensation     38,366      
Common stock held by the NQDC     0 (25)    
Accounting impact of NQDC Plan change     0 0    
Other comprehensive income (loss)         (1,031)  
Net income (loss) (12,620)         (12,620)
Ending Balance at Sep. 30, 2018 2,914,945 $ 178 4,620,817 (13,415) (2,160) (1,690,475)
Beginning balance (in shares) at Dec. 31, 2018 [1]   178,253,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans (in shares)   1,351,000        
Ending balance (in shares) at Sep. 30, 2019   179,604,000        
Beginning Balance at Dec. 31, 2018 [1] 2,967,940 [2] $ 178 4,669,926 (13,301) 5,271 (1,694,134)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans, net of tax   2 (19,183)      
Stock-based compensation     122,212      
Common stock held by the NQDC     (692) 692    
Accounting impact of NQDC Plan change     10,653 2,648    
Other comprehensive income (loss)         31,732  
Net income (loss) (38,872)         (38,872)
Ending Balance at Sep. 30, 2019 3,074,405 $ 180 4,782,916 (9,961) 37,003 (1,735,733)
Beginning balance (in shares) at Jun. 30, 2019 [1]   179,433,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans (in shares)   171,000        
Ending balance (in shares) at Sep. 30, 2019   179,604,000        
Beginning Balance at Jun. 30, 2019 [1] 2,960,954 $ 179 4,744,316 (10,211) 17,439 (1,790,769)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuances under equity incentive plans, net of tax   1 (1,294)      
Stock-based compensation     40,144      
Common stock held by the NQDC     (250) 250    
Accounting impact of NQDC Plan change     0 0    
Other comprehensive income (loss)         19,564  
Net income (loss) 55,036         55,036
Ending Balance at Sep. 30, 2019 $ 3,074,405 $ 180 $ 4,782,916 $ (9,961) $ 37,003 $ (1,735,733)
[1]
The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
[2]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 49 R14.htm IDEA: XBRL DOCUMENT v3.19.3
SUPPLEMENTAL BALANCE SHEET INFORMATION
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION SUPPLEMENTAL BALANCE SHEET INFORMATION
Inventory consisted of the following:
 
September 30,
2019
 
December 31,
2018
Raw materials
$
68,391

 
$
74,616

Work-in-process
321,073

 
231,064

Finished goods
219,585

 
225,191

Total inventory
$
609,049

 
$
530,871


Inventory as of September 30, 2019, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec inventory totaling $7.1 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. The Company believes that all material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec for commercial sale have been significantly reduced. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, as well as commercialization and marketplace trends. If regulatory approval is not obtained, the manufacturing-related costs for the commercial production of valoctocogene roxaparvovec will be expensed.
Accounts Payable and Accrued Liabilities consisted of the following:
 
September 30, 2019
 
December 31, 2018
Accounts payable and accrued operating expenses
$
226,769

 
$
207,620

Accrued compensation expense
132,049

 
149,937

Accrued rebates payable
55,957

 
43,116

Accrued royalties payable
27,881

 
19,977

Value added taxes payable
7,556

 
7,785

Forward foreign currency exchange contracts
8,731

 
4,178

Lease liability
10,225

 
—

Other
14,577

 
4,677

Total accounts payable and accrued liabilities
$
483,745

 
$
437,290
XML 50 R9.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Except as detailed below, there have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2019, as compared to the significant accounting policies disclosed in Note 3 – Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Leases
The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis. 
Derivatives and Hedging Activities
The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in Accumulated Other Comprehensive Income (AOCI) and amounts deferred in AOCI will be reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in Operating Expenses in the Consolidated Statements of Comprehensive Income (Loss).
XML 51 R10.htm IDEA: XBRL DOCUMENT v3.19.3
RECENT ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS
Except as described in Note 2 – Basis of Presentation and below, there have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the FASB during the nine months ended September 30, 2019, as compared to the recent accounting pronouncements described in Note 4 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, that the Company believes are of significance or potential significance to the Company.
Accounting Pronouncements Not Yet Adopted
Effective January 1, 2020, the Company will adopt ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach, with certain exceptions allowed. The standard amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The Company is evaluating the impact of the adoption of ASU 2016-13 on its Condensed Consolidated Financial Statements.
XML 52 R24.htm IDEA: XBRL DOCUMENT v3.19.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Contingencies
From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition and cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable.
Contingent Payments
As of September 30, 2019, the Company was subject to contingent payments totaling approximately $376.9 million upon achievement of certain development and regulatory activities and commercial sales and licensing milestones if they occur before certain dates in the future. Of this amount, $65.5 million relates to the acquisition of certain rights and other assets with respect to Kuvan and Palynziq from a third party and $239.7 million relates to programs that are no longer being developed.
As of September 30, 2019, the Company recorded a total of $69.1 million of contingent liabilities, of which $20.2 million was short-term. See Note 9 to these Condensed Consolidated Financial Statements for further information regarding the fair value of the Company’s contingent consideration.
Other Commitments
In the normal course of business, the Company enters into various firm purchase commitments primarily related to active pharmaceutical ingredients and certain other inventory-related items. As of September 30, 2019, such commitments and other minimum contractual obligations for clinical and post-marketing services were estimated at approximately $131.6 million.
XML 53 R20.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2019
Concentration Risk And Geographic Information [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product
Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties.
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues by geographic region:
 
 
 
 
 
 
 
United States
$
201,874

 
$
174,722

 
$
562,217

 
$
528,082

Europe
125,485

 
111,069

 
369,585

 
323,940

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
49,939

 
30,515

 
153,671

 
134,021

Total revenues
$
461,097

 
$
391,706

 
$
1,249,605

 
$
1,137,998



The following table disaggregates Net Product Revenues by product. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net product revenues by product:
 
 
 
 
 
 
 
Aldurazyme
$
22,852

 
$
27,593

 
$
73,945

 
$
117,652

Brineura
19,840

 
9,936

 
46,815

 
27,743

Firdapse
5,668

 
4,977

 
16,262

 
15,080

Kuvan
120,524

 
113,254

 
340,771

 
321,414

Naglazyme
94,408

 
103,089

 
279,462

 
269,171

Palynziq
24,142

 
4,129

 
55,250

 
4,129

Vimizim
163,466

 
123,342

 
411,953

 
368,016

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205


The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
United States
$
175,127

 
$
146,742

 
$
480,330

 
$
409,294

Europe
121,363

 
107,851

 
358,041

 
315,270

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
47,759

 
28,734

 
148,010

 
129,034

Total net product revenues marketed by the Company
428,048

 
358,727

 
1,150,513

 
1,005,553

Aldurazyme net product revenues marketed by Genzyme
22,852

 
27,593

 
73,945

 
117,652

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205

 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Customer A
16
%
 
16
%
 
17
%
 
17
%
Customer B
13
%
 
12
%
 
12
%
 
12
%
Customer C
10
%
 
10
%
 
11
%
 
10
%
Customer D
5
%
 
7
%
 
6
%
 
11
%
Customer E
12
%
 
—
%
 
6
%
 
—
%
Customer F
—
%
 
13
%
 
—
%
 
6
%
Total
56
%
 
58
%
 
52
%
 
56
%
 
On a consolidated basis, three customers accounted for 23%, 14% and 12% of the September 30, 2019 accounts receivable balance, respectively, compared to December 31, 2018, when two customers accounted for 30% and 16% of the accounts receivable balance, respectively. As of September 30, 2019, and December 31, 2018, the accounts receivable balance for Genzyme included $67.7 million and $73.9 million, respectively, of unbilled accounts receivable, which become payable to the Company when the product is sold by Genzyme. The Company does not require collateral from its customers but does perform periodic credit evaluations of its customers’ financial condition and requires immediate payment in certain circumstances.
The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for the Company’s products. The Company has not historically experienced a significant level of uncollected receivables and has received continued payments from its more aged accounts in these countries. The Company believes that the allowances for doubtful accounts related to these countries, if any, is adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries.
XML 54 R28.htm IDEA: XBRL DOCUMENT v3.19.3
PROPERTY, PLANT AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2019
Property, Plant and Equipment [Abstract]  
Schedule of Property Plant and Equipment Net
Property, plant and equipment, net consisted of the following: 
 
September 30,
2019
 
December 31,
2018
Building and improvements
$
709,990

 
$
694,447

Manufacturing and laboratory equipment
365,348

 
345,947

Computer hardware and software
165,235

 
157,787

Leasehold improvements
52,379

 
41,188

Furniture and equipment
37,603

 
33,234

Land improvements
7,239

 
6,551

Land
83,094

 
77,993

Construction-in-progress
84,021

 
64,170

 
1,504,909

 
1,421,317

Accumulated depreciation
(535,609
)
 
(472,635
)
Total property, plant and equipment, net
$
969,300

 
$
948,682
XML 55 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) - Not Designated as Hedging Instrument
₽ in Millions, € in Millions, £ in Millions, R$ in Millions, $ in Millions
 9 Months Ended
Sep. 30, 2019
RUB (₽)
Derivative
Sep. 30, 2019
EUR (€)
Derivative
Sep. 30, 2019
COP ($)
Derivative
Sep. 30, 2019
BRL (R$)
Derivative
Sep. 30, 2019
GBP (£)
Derivative
Derivative [Line Items]          
Number of Contracts 8 8 8 8 8
Colombian Pesos | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Number of Contracts 2 2 2 2 2
Aggregate Notional Amount in Foreign Currency | R$       R$ 96,000.0  
Colombian Pesos | Minimum | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Colombian Pesos | Maximum | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Maturity Nov. 30, 2019        
Euros | Foreign exchange contracts | Purchase          
Derivative [Line Items]          
Number of Contracts 2 2 2 2 2
Aggregate Notional Amount in Foreign Currency | $     $ 44.1    
Euros | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Maturity Jul. 31, 2019        
Euros | Minimum | Foreign exchange contracts | Purchase          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Euros | Maximum | Foreign exchange contracts | Purchase          
Derivative [Line Items]          
Maturity Nov. 30, 2019        
Great British Pounds | Foreign exchange contracts | Purchase          
Derivative [Line Items]          
Number of Contracts 1 1 1 1 1
Aggregate Notional Amount in Foreign Currency | €   € 4.9      
Maturity Oct. 31, 2019        
Great British Pounds | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Number of Contracts 1 1 1 1 1
Aggregate Notional Amount in Foreign Currency | £         £ 2.0
Maturity Oct. 31, 2019        
Rubles | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Number of Contracts 2 2 2 2 2
Aggregate Notional Amount in Foreign Currency | ₽ ₽ 1,420.0        
Rubles | Minimum | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Rubles | Maximum | Foreign exchange contracts | Sell          
Derivative [Line Items]          
Maturity Nov. 30, 2019        
XML 56 R9999.htm IDEA: XBRL DOCUMENT v3.19.3
Label Element Value
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 20,634,000
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (2,727,000)
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Intangible Assets (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]            
Gain on sale of intangible assets $ 0 $ 15,000 $ 0 $ 15,000 $ 20,000  
Intangible assets:            
Finite-lived intangible assets 642,677     642,677   $ 307,995
Indefinite-lived intangible assets 0     0   326,359
Gross intangible assets: 642,677     642,677   634,354
Less: Accumulated amortization (179,828)     (179,828)   (142,546)
Net carrying value $ 462,849     $ 462,849   $ 491,808 [1]
Restatement Adjustment            
Intangible assets:            
Finite-lived intangible assets   326,400        
Indefinite-lived intangible assets   $ (326,400)        
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable and accrued operating expenses $ 226,769 $ 207,620
Accrued compensation expense 132,049 149,937
Accrued rebates payable 55,957 43,116
Accrued royalties payable 27,881 19,977
Value added taxes payable 7,556 7,785
Forward foreign currency exchange contracts 8,731 4,178
Lease liability 10,225 0
Other 14,577 4,677
Total accounts payable and accrued liabilities $ 483,745 $ 437,290 [1]
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 59 R66.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue from External Customer [Line Items]        
Total revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
United States        
Revenue from External Customer [Line Items]        
Total revenues 201,874 174,722 562,217 528,082
Europe        
Revenue from External Customer [Line Items]        
Total revenues 125,485 111,069 369,585 323,940
Latin America        
Revenue from External Customer [Line Items]        
Total revenues 83,799 75,400 164,132 151,955
Rest of world        
Revenue from External Customer [Line Items]        
Total revenues $ 49,939 $ 30,515 $ 153,671 $ 134,021
XML 60 R62.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Summary of Interest Expense on Convertible Debt (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Schedule Of Interest Expenses [Line Items]        
Total interest expense on convertible debt $ 2,937 $ 12,131 $ 16,530 $ 35,918
Convertible Senior Notes        
Schedule Of Interest Expenses [Line Items]        
Coupon interest expense 2,271 3,331 6,681 9,819
Amortization of debt issuance costs 508 1,008 1,522 3,018
Accretion of discount on convertible notes 4,005 7,792 11,860 23,081
Total interest expense on convertible debt $ 6,784 $ 12,131 $ 20,063 $ 35,918
XML 61 R54.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of Maturities of Lease Liabilities (Detail)
$ in Thousands
Sep. 30, 2019
USD ($)
Operating  
Remainder of 2019 $ 3,115
2020 9,925
2021 8,721
2022 8,406
2023 7,504
Thereafter 27,464
Total lease payments 65,135
Less: Interest (12,363)
Present value of lease liabilities 52,772
Financing  
Remainder of 2019 3,204
2020 3,464
2021 2,865
2022 2,258
2023 1,748
Thereafter 0
Total lease payments 13,539
Less: Interest (1,043)
Present value of lease liabilities 12,496
Total  
Remainder of 2019 6,319
2020 13,389
2021 11,586
2022 10,664
2023 9,252
Thereafter 27,464
Total lease payments 78,674
Less: Interest (13,406)
Present value of lease liabilities $ 65,268
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Derivative [Line Items]    
Derivative Asset, Fair Value $ 52,863 $ 23,178
Derivative Liability, Fair Value 16,374 7,831
Level 2: | Derivatives Designated As Hedging Instruments    
Derivative [Line Items]    
Derivative Asset, Fair Value 52,792 23,010
Derivative Liability, Fair Value 15,516 7,689
Level 2: | Derivatives Designated As Hedging Instruments | Other current assets    
Derivative [Line Items]    
Derivative Asset, Fair Value 29,900 12,686
Level 2: | Derivatives Designated As Hedging Instruments | Other assets    
Derivative [Line Items]    
Derivative Asset, Fair Value 22,892 10,324
Level 2: | Derivatives Designated As Hedging Instruments | Accounts payable and accrued liabilities    
Derivative [Line Items]    
Derivative Liability, Fair Value 7,875 4,036
Level 2: | Derivatives Designated As Hedging Instruments | Other long-term liabilities    
Derivative [Line Items]    
Derivative Liability, Fair Value 7,641 3,653
Level 2: | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative Asset, Fair Value 71 168
Derivative Liability, Fair Value 858 142
Level 2: | Not Designated as Hedging Instrument | Other current assets    
Derivative [Line Items]    
Derivative Asset, Fair Value 71 168
Level 2: | Not Designated as Hedging Instrument | Other assets    
Derivative [Line Items]    
Derivative Asset, Fair Value 0 0
Level 2: | Not Designated as Hedging Instrument | Accounts payable and accrued liabilities    
Derivative [Line Items]    
Derivative Liability, Fair Value 858 142
Level 2: | Not Designated as Hedging Instrument | Other long-term liabilities    
Derivative [Line Items]    
Derivative Liability, Fair Value $ 0 $ 0
XML 63 R58.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of Minimum Lease Payments for Future Years (Detail)
$ in Thousands
Dec. 31, 2018
USD ($)
Leases [Abstract]  
2019 $ 12,976
2020 12,549
2021 11,198
2022 10,574
2023 9,993
Thereafter 27,701
Total $ 84,991
XML 64 R73.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Income Tax Disclosure [Abstract]          
Valuation allowance against a deferred tax asset         $ 29,600
Net tax expense (benefit) $ (45,200) $ (27,100) $ (59,780) $ (32,735)  
XML 65 R77.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies - Additional Information (Detail)
$ in Millions
 9 Months Ended
Sep. 30, 2019
USD ($)
Commitments And Contingencies [Line Items]  
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones $ 376.9
Contingent liabilities 69.1
Contingent liabilities short-term 20.2
Clinical and Post Marketing Services  
Commitments And Contingencies [Line Items]  
Purchase commitments and other minimum contractual obligations 131.6
Third Party  
Commitments And Contingencies [Line Items]  
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones 65.5
Completed Programs | Third Party  
Commitments And Contingencies [Line Items]  
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones $ 239.7
XML 66 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 179,604,381 178,252,954
Common stock, shares outstanding (in shares) 179,604,381 178,252,954
XML 67 R7.htm IDEA: XBRL DOCUMENT v3.19.3
NATURE OF OPERATIONS
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
NATURE OF OPERATIONS NATURE OF OPERATIONS
BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.
The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.
XML 68 R16.htm IDEA: XBRL DOCUMENT v3.19.3
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
 9 Months Ended
Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
The Company uses forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Such exposures result from portions of the Company’s forecasted product revenues and operating expenses being denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. The Company designates certain of these forward contracts as hedging instruments and also uses forward contracts for economic hedging purposes which are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from net product revenues, operating expenses and asset or liability positions designated in currencies other than the USD. To receive hedge accounting treatment, derivatives that hedge cash flows must be highly effective at offsetting changes to expected future cash flows on hedged transactions. The Company does not hold or issue derivative instruments for trading or speculative purposes.
The following table summarizes the Company’s derivatives designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Australian Dollars – Sell
 
6

 
2.8

 
Oct 2019 - Dec 2019
Canadian Dollars – Sell
 
24

 
28.1

 
Oct 2019 - Sept 2020
Colombian Pesos – Sell
 
12

 
89,400.0

 
Oct 2019 - Sept 2020
Euros – Purchase
 
150

 
189.4

 
Oct 2019 - Sept 2022
Euros – Sell
 
453

 
624.2

 
Oct 2019 - Sept 2022
Norwegian Krone – Sell
 
3

 
11.7

 
Oct 2019 - Dec 2019
Total
 
648

 
 
 
 

The following table summarizes the Company’s derivatives not designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Colombian Pesos – Sell
 
2

 
96,000.0

 
Oct 2019 - Nov 2019
Euros – Purchase
 
2

 
44.1

 
Oct 2019 - Nov 2019
Great British Pounds - Purchase
 
1

 
4.9

 
Oct 2019
Great British Pounds - Sell
 
1

 
2.0

 
Oct 2019
Rubles – Sell
 
2

 
1,420.0

 
Oct 2019 - Nov 2019
Total
 
8

 
 
 
 

The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet Location
September 30, 2019
 
December 31, 2018
Derivatives designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
29,900

 
$
12,686

Other assets
22,892

 
10,324

Subtotal
$
52,792

 
$
23,010

 
 
 
 
Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
7,875

 
$
4,036

Other long-term liabilities
7,641

 
3,653

Subtotal
$
15,516

 
$
7,689

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
71

 
$
168

Other assets
—

 
—

Subtotal
$
71

 
$
168

Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
858

 
$
142

Other long-term liabilities
—

 
—

Subtotal
$
858

 
$
142

 
 
 
 
Total Derivatives Assets
$
52,863

 
$
23,178

Total Derivatives Liabilities
$
16,374

 
$
7,831

(1)  
For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Financial Statements for the period presented.
 
Three Months Ended
 
Nine Months Ended
Derivatives Designated as Cash Flow Hedging Instruments
September 30, 2019
 
September 30, 2019
Amount of Gain (Loss) Recognized in Other Comprehensive Income
$
23,973

 
$
35,431

 
Three Months Ended
 
Nine Months Ended
 
September 30, 2019
 
September 30, 2019
Derivatives Designated as Cash Flow Hedging Instruments
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
 
 
 
 
 
Net product revenues as reported
$
450,900

 
$
6,196

 
$
1,224,458

 
$
11,171

Operating expenses as reported
$
457,087

 
$
(1,388
)
 
$
1,340,900

 
$
(1,885
)
 
 
 
 
 
 
 
 
Derivatives Not Designated as Hedging Instruments
 
 
Gains (Losses) Recognized in Earnings
 
 
 
Gains (Losses) Recognized in Earnings
Operating Expenses
 
 
$
(1,286
)
 
 
 
$
(5,182
)

As of September 30, 2019, the Company expects to reclassify unrealized gains of $19.2 million from AOCI to earnings as the forecasted revenue and operating expense transactions occur over the next 12 months.
The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.
ZIP 69 0001048477-19-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001048477-19-000017-xbrl.zip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

MY=BIV@7N8U'U^=4>C[_MP<;71&0*&0,PL@ !0Y6'"@J"N9',*4A5%\*EV<4[ M&N%Z0G1HVWV#C3:L(?SDY$F"3ZS,P@&_M/EL]M#?.7X@U#-U?BL> UA^J:KS M;^5TNF7P:5,\XP@C89D@X4^J)5 "^@T-\0RK.A!VP'#U'XY@W2I_V8!F:4< M:DZT<#$K+++",VR@Y-)+2AEM%?A_Y'"I'IOYQQBJ_C%,-8&'43= ]ZF\C8F' M-]1C"W=V%N3?'FJX-6PV*7[KCB.?%Q>NJ M[S?Z["E@?XU-,KSZP M]",LJ*\^_+B$OOP]>JY'=@<>]-BV!W[_3H:)D$0H803V% HA,)*>66LX\!KI M(YYG?;RFOD6%?GPY@TAA2)USF(6:$1XZ-[/"V? Y 13MD*POT8;W_FWT6OKG M0T%).-O%*[.6:GZ.P)Y<_-[\F$-N^Q371D+F +9"2DJ"=4&%X3I 2)P6W$#A M->\GI^^H23$,4L=@2OL#8%M*9<)0HK$7S@3^2Z&U$1:X@&"\9$;C#H>;TRRI M]LN(;N@,;+:\G''7M[>71;.>??L(QGTM,.=^+%6S\Z> /5Q6=7^SD-V8=WIO M&1GUP1ZEP3!5AE(,M$*>,^&@D6'\1J35\;R^Z_:YN,[+>)]AC(1N0AO^=Y'7 MG6N[46JF 52*46TAM,$70RI8YUII[3R$SK#1)J 8L*6K8Z%[>#C;'CA$O;Y\ MJ_KH/&M1&8PW9B*"D$62&NHD ,H''Q\I!;CJN[,J=!2$0AT!12A,@V,U#,9*G@- 348?7RVZSV-/9&7& M*>&MA1)!0#'%\=($33030C.,NF3I'38?^$C) MC36A)O06:A5G)'A>G&#=Y3;C8;->CI4[^V.:A#OJ(KA:?1+HF< ,&RTD8 *3 M *[#*KCRD@OF*1<&8=QAYY']?V-1%V"3'8>*%W$5SU?\6OJF^XK((!$*6:@P MX99JSB5EW./@3L1D"4*WVH(\(@IMO=CN0C,C&&6>>VLXHQQ: 0E'A"D'.)04 M='! 4JU!]TV)ZDC8CJT?ON[M'B@IPUA!QJ%01.HP#'KA&+="&^4Q88B-_QS7 M*+AV,*"C)-@K7O'!LC(A,8$:"^"]#^Y_^)5Z0.(I2.5]F S'ZA2/DV0'0#I& MFKWB/1\J*A/&$BQ@6&=\=&SK NLQ8A3V=,%WKG4P9H'E!' $ M&/50*NB]EIQ*0903J-7:X!%JO:_+?<".)J/!3 <(ZIG&5CTNB R < M$XUVN,2M]SP!H"#8-Y#CF)T!& F9T!PH!(DGQ'<(8D[C"A^51 <@."H.;?=$ M6N]]:JR$#\Z^@@"%7N2%X82(L48($>=5& F5[;"0-;JH[-X8LE?82:JF&2[$Z6!6[JZB!RP\\" X MEO$R8JNEIY*SX!8 Z9#HL&@_NGCNX["O[R88BRG49AI\MAP"H8(H[[$8[F8R4A7T#/K8-XCX"9W="]$8C:P^84@Z2U\(L M0E 0ZT$PAQ2U7*N8+P@X@*3RGOD.-Q>.+."V/RKMLQ.?JF%2=?Y7JKF%MZ^4 MV V "0,=C W!-0R.&I PO F =Y XH'B'ZU9'%IX[&#,309]ZK:V+Z^7C M>QA]5?O%?%$O5Z"/G5[T.>S-2K&UUNWFQY82,B*#,VFTAMHH2CR22#MO. !< M$J#=$9.,MJG!OC$N!\O,+&4:8A]\?<6I84X2'(BO@_^-K6"RP\GD-)-<[WS8 M.E ,A^QQ9JE7\?HX^_*M6HX8W?OBHZR,6$NE#"AXI:FQT3'@P$"H"5'8D=%? M!CT&MG5!='PLB[$9_?'L05H&I0VP V4)Q)0 HQ46F$#+D97A'SHP+4W$S'B8 M=BBFH^-:#.'HC6H/PC*+*"1$&H^EH@Y8H3!3WH9A/[@F '280=.$U8R&:8=" M.CZBE;?]C6D/PC+*" . (L>/ .1;ZH-%4QF 2&MK!0N8Q%$\\PYP[8#"2BQ7HY1UB#)& M*,720=5J+RC%N+*[VJW*9=AKCY%FH?_ 4%^KH#0,<. PIIR1#K'I1PSC.;A1 MMPX6W: [QIYI>Y)L0T\2#6*<*P2*2*F^H&NT]$TDHTA]P8XS# M I1@X\,LRXBDU',)%23:<:YMH'R[ID^Z7[.^MWO_;9MUP=!F7&FI$+2,4HZ= MH)8ZBCP2P!#&W^9X>$"#MMMQ.0RUHX:/[&;(MF*9<<9SI"FUSH5N3*2.J=$1 M5] 9+OAH<^L,S(\>,3ORCN_C!>_[#R*/93.'$:="0^64LB-0X!@;*13 MK$/2O3'DC.U['#D8N*,.):VHLJ-D!KUBA&!DH.:4(R"1QQ3$?)2(66\[G# > M0W[8?@>4@V%+[)6?+6YNID5<2\BG)F^N_+3ZEMA)'_8BI]_BL:"X_+!J_VHV MW)>*>;SZ^;2H375]7?R>A8Z8OSWY;]LOV%W M^!$SJ+NZ[S'4/WEI4Q&>^*-DIX MIJAG4G/I'";28HH5H$=T7-K7)=Y[/>D%E:6D3'/&@:30((.BBRNP)@)C"CDF MC([W'HT$+*A2(IO*9KF_P>=D9JK9;5'/XS5_\=+S4+V3BR_Y]RW7 QLR.>4;-YN42D?*V>(+5ZDK- MXMP'H,/CF\5\^=F3BS5ZCU*?S$Y)Y\]A+:+3N@JVT/SN=)K/YL$:=O^S*&^N MG[@&R3YX!'OE55T>:?/J*Z&MCAS6NDVU+4/DMF(9,5YA##4 FE*DL2(ZS W2 M"^&()KK5;G_BVNZZX7Q[PS,_KF8Q%EULCSL%#SLH,8L M_#A9KN\,^-7;8K8H3%V$V3S8C5&']5)+J/HO1759YS=7Y>3)'#\B58Y@@QR@ MI2V;_/*R+BY#1VE.+D*/"VU[OIC,U[(:?;=^,';5OU3S?+I!_[PISD]FIZ%( M$/DICGYOH!V6E;FO0O0G7%"N#EPRBV8>'+8Z"C+5-,PK591\6YSF]7P6O?&[ M1_F?B\LQUG7HL6I_A392YT79^;PNOT8W[DOU*:\O@S/[T!;#(KST+9DV?^T(@]EF1=97,1_CT\NG)S?QQW_FT\4*ER88._ M;4A04RT@N.N;:757%)^+I0NZ%Z]VELV LHHXZ*BTAF*,@W]JH0@_6$X8ZY+$ M-LW&0PHB]8UBPJ6GB,2O>?U'$>=94S7S=H/1J\4RABAD%G#%8VRB-!HQ2 2% MP&*@>)<(]S1G21,-/'T!F)@JGZN[?-IZRMI4(M-& RRY$PJ 4#\IF:7 2KR=KF:M)>]LJU8!AE2WDOJ M 2?4.Z?H+FOU8LCC*^W?HM2&= PP("= M0#"&OJ-@H%,AJ#,"4^1@AP 9_N8;OW_\DIT:6#MD.Z'9=GJ@K8R,28<,LRIP5!08#GB#A&E!36M+@H8N#:?\V^_!C^Y+O-ILPS*^UPT M17V[M1/O+IPA!%V8:3R"8<9R#DJ(J"0:(<-]/C]=(91D8$[RF,1V&"X_$Z>2.A8]81@&)>S+&O M9/7+C]Z 2DX07\[*)@S5OU35^?X$>;UTYH6AA,;5%^XH]49(P)UTA $DB#4= M[GQ+LW35+T%Z ^KX,_O.OGT=P X5T% !4 !B;7)N+3(P,3DP.3,P7V1E9BYX;6SLO5MW&SF6)OH^ MOR)/SG-6XK9QZ=4ULW"M\AJG[64[N^:O/!DG)DBR2 M<6?0U=V5F1(5 (%O?P'L#>S+O__O+S>SGSZ7R]5T,?_KS_0OY.>?ROG%XG(Z M__C7GW]_]XM]YU^\^/E__Z__\>__SR^__%_W]N5/87%Q>U/.US_Y93E9EY<_ M_3E=7__TC\MR]<=/5\O%S4__6"S_F'Z>_/++MM%/FQ]FT_D?_Y;_]6&R*G_Z MLIK^V^KBNKR9O%Q<3-:;[[Y>KS_]VZ^__OGGGW_Y\F$Y^\MB^?%71@C_];[5 MWB?R;[_SW^]7-\W>/@P_+K] MX_VCWW7])]\\2XTQOV[^>O_H:OK<@]@I_?7__O;RW0:27Z;SU7HRORA__E__ MXZ>?ML@M%[/R;7GU4_[O[V]?/.KDP\UR_I>+Q)VOEZ]+2]FD]5J>C7%1V_7KZ\J- WE>C*==3#CSL8P M#&3O;F]N)LNOKZ_\]63^L5R]F#]HY":SS*\5CGYQ,<4&L]O\POO;Y1)?[#?E M7D[S?R>S%_.KQ?)F\V$U)C;KK9]IO%G,IA?3 MXS2HT+2# 2*Y;J;KO-?GU\4OYFM\PU [J## "DW['6 +0K3KM9-IS2_QC2[S M=Z]0K)Z;25Z4K\LUKK05X&_475\3>8>O5[DA VY$ MD]5UFBW^;(;_P9X&&?[S6V'[R1SN=XBIO5LO+OZX7LPNT9*)_[R=KK^VGM7^ M+CN9$-I<;R8?C^KBWSW8P9>'\L/ZV/<^?*:CKVRQ)%=LWM% ORF>BSFBOYZB M0I4_KS[6:CUT/=P7\W6)&L$Z?OF4F?UZWG[\];KL:$+55.'OG^SDZY?3S\BL MO(ZMULO;.RW@[^7E1]0"WJV7N$!\K* U>YHR,&W>A.[^XXAIYPFT^5_3&:W MI9\LEU_Q3UM[_O75MQY6'2-0_RN'!.3^%7\TFM7TXSQOA':U:_"@%S2/\[E4 M-K,[1JK#L9P:PE>+]9A0;#ZU;VDPZ_H:\(/OG#W\:5=?QOB_&UY<;M<(CTV9U*_K_"G ME^7G['< 6^SKC M>-*BD^&@EO@QF_W;K>CX8)Y_OH>A5'M;#K?J85C5R'RX50?#>HD[SO%A/'ZJ MLZ]ML=17[J"SP7Y;.S>_^\6JXHE9Q>8]#/2WR7JW?.^^M;8&VKS'/J8SG4]O M;F\V'[^9?-UJPXMENL4QE?]O.5DVG53-?GN8VN:VON%+4+67'H;]=G'[S?3H MA>^QA.N]N/V%G6?Z3V=T57&NAU.JTLTE5VUZ>>[:#(;S*JT3FXZ=RN?6= M.3:0_2VZ&$ZYSL+^;OKR?+HS=K!1GT-JL6&V+2_OJ;R[(??WHHX M6<[1(L]_W_REHA+;PU?U!<"W =CY>AJFL]M\=+9[(%\>QR_9*ZV\S(>$^8[\ M=NNI\_IJ\VQY^:W7!\-N!%"_0^D+P&I+6(6F'0SPS7*!*]/ZZYL9FK^X-66S M^5->TX\-[VC#/@?78CEITV>?4_I&Y;V/("-:SK')E_0YZ6IO0L7F'0ST;7F1 MF7!QD2\L<6G%;Y[CCQ?5#N:KM>YDF)_+^6WIER52UB_F^6MWV@7"\[=R\7$Y M^70]O7A Y.-C;]SE:2;48@GHY]M. T.8KB8?/R[+CY-U-EWQ[4767=Y>K'=] MK=S7W0>]8=-T"*, [/T"K9=GAHSFP^7K^1ML@EW>!>L,!6&+08T'U+M19]4K M?EF72WQY_.UJO;@IEUL'X]EL\F&QW%R\OIDLUW/\W'W]UO_;\N/0F/CG]D)7\]XN7D^7']3;#:DEBE;1=#O'.P>G#]_,!TJ!@05:^73H;][=#W87!*#5.C M1A?##/C!*=(6NM6;R=SCU_+5# Y,=(^;KRBX:7?0]S!0K MK@EU.]H[^,GRXF[\NQ\?3N$^W'XZ7_]Z.;WY=??,KY/9$\SW!/3?Q>CG9 "P M&?J#EET/"G_.L4^+^2^7Y=7D=K9N.,2]_?0XX,7-9#IO/]Y'W70^W$WOO]R4 M-Q_*9=.Q/M='UP.]QOZ6%[K7SY.)I]^ MS6OAK^5LO;K[9+,Z_D+H+M?(_]Q]7#Q-+6 O__-VZT]7=0((9/EB7=[SO_Z,XRUZ^)9"1LX55XYS;@ 8JW""8(;6+@21O@P=M$%/=4? M[UON%I5:>V+.OS,"CBQ.AS2"@A]L5M-_NY@MT'KYZ\]K5"&_?;B8KW$EB%LU M!A?2\N/VMF[$5+9?IG76@3K=%C:!82%8JX( @4*UU!L7F=%)24',@$0^L.D= M)W9/I.J(R@V@WC!YQ*0,CW2^#FFY[;A0TB7KG(W6"4,$T8Y%$8/!3[E.$ I# MK&QKB/IKTC\';>D"/G9:_/;)=.Z3EMN.""4%!))Y *@A6 M6OP=]T/4]!11*HDA:?FI[[9YKK)PU_,-U%CAY7/ M@^T*)X@E-G#\3X1 I4D"#. _(3"91&K,*?8C:I==8CD4;YX,]>C>^>SS!<[* MDF"\(L01EU!_H&JG88C$K#Y39:\C@2Y. .%Y\40UJQU56J(=E1#Z"AA/]@1?IQ;[#L7V/%D)1IPD$IU#ETKA#2VL<5VC2&GS5>/.=A/](*DE'\ U MA.R#MAO@:N_N$D)RZJP"T5(U,T!B)"/4R&TBUVXSVJ.3QZK@#&A4>S'%)4 M((W0 >DK/2$B6ND9C$SM=_7'DI.)0LX)0SBQ3+((E M(+G5DCOJ&.7:B:!B:"QW\2-I!3U .3QI1B_1Z__ZBY>:A9X3FU8 0/ MVI!$*:>2D=T.")Y[<69Z0[?2W4N9_H$\9TZQA/:4"=1Z+@$G:HC2W@9G$6>P M?-!3^,HG&<,SIAY,0Q$B+9;E].,\?KG8E*S!7_^<+"^/JB"'FA51*E"*!@2/ M@B/*.)P@.,]H$I2I$9Y4=".X16\8#7?1MXEZVN9>% MSIED5^7E^\F7@[=[M7LK:#)64I4D90& $2NMC )_!50*18OKE\&N]$[CK]8W MTD,Q<)=M9_YQ%T%U2#W^[MG"Z.B-!6J$4TR1* W[ R[LS8D]; M' ?GQO<56PZQX]O3!;-$(4+6N9!0,=-:6 HV&!-9B+*%JE+_)/4<^=$8R6\, M^?=?GX"(P_NC=[_\<17F&]"MOPH_< HO*_CNU^VJ,)$(JCV1P0$8U*@C TE# M\J"U#T2>SD&_XE2.^>/7Z:9@.!8;+(V$$8@^.D%"(-&( $$&&%*Q.>A^WY^8 M]]_G=8W>J%WJ^W%;BL$F8DA,,@@PBFABHM$R M7.PJ"N<+5. _MA02TOI7K0 MG9>720S*\)A"$!81"CJAT;D]IC*&J\3/]+RO(X%6\D/I&,+SXH^WG'(=A8N* M9+L0=7\E(\[74%SC-3\-/5IY*77+CGH _?A>2H(X((D$QB&@-D M#2$?IFJA MC>=FA"[9+>7:TDNI'EXGX ^._O?YLIS,IO]57GZKLG$WN3H$JM15H3GX[)B1 M3 R0[_18I$H%92%XAN"/[PRG-P;U =AQ"GV?1"-_\ARS\WGC1FO;RX**+0LM MK/*2 P,M03AMN9611$N\5BZT./;M[6"F&Z'W@\\)EHG&(4#5HU!$T)'#PZD7ADZ1&HPM]T>7N93%J_+/??EVCQC"M?HI M# 0A?&(JATQY?(^\52P'@X+2J,8WOXSL.9YG$,.X3RB'HE6^J7U]92\7FXQT M1]>;YQXOO&,65U5F.%""$U2@[VP\*Z)T9VHF]R3>Q?"(GA.9! BN$@+F@@7- MA2-)!RN8DXHZ8<;E<#L"JM3#:T#=9C?_=[G:\&1YN?K]TR4NQ_B\)JR*7G.\ M?>$#ER(Z7*1S0*_PUAL%G!%N' 14XL=G+K<3X?<@#4:0U_[%74+@O F_ M7VP->S3:7E^]GWQYNYC-=CX_AVA2O9<"!&$!K"()ETH@7+N@HTS)BP2:A$$W MH6ID&>XRJ3<8AXMF7US\<;V8H4!66[OAX%W0TX<+2HCQ.C(1T$*4E+I ;7;J MD5H*W%3'2(X^9/;=S4]+H(82O]^^)_A:Q*NK,I=M?[('3^<7TT\S?&EV#@GW M2_ !FC3OM! ::.(D6A<$4.>U9!3?0J]X5(!OZ?A.X8:@TV" -CZE^Y[P6\WN MWLUEWR'=T89%3O7A'5 #AH'1VD8ADL_'"Q+GPIM3HK;58EM\Y+FT_1FR>P^V0MUVS'G$U9MP8[JUE'I(PF@=0P8G$J#?&-;\OZNU0 M;XAU9A@TA_,J?SR)?+B=?>,>>=@U)5[[S@MN#;,N@F720K1&$WQC@Z4D\2@A M-<]N!N?,P<&!'6SQ.WB<^N7-8KD1XS,3HH<6P.:]%DPQ%9D67*H$1E&=@HQ. M@$6-@0%O3D!YS@0<#M$Q,.\.N0/3:LB^"CT7$*/QH**4R@!PXC2^IH9$)90( M251*IOTL ]6/RL#N43VUD_QS=3 Z2Y[O)JOI*AY%L?WI6+Z_*;*Q:0J M>>;OL[P.U?%Y><#!OD;K(D3!O- Z^FB $&M:SSS6^ M8LN"&F$LMRK%!* $?C>S,5K!4C22VR'/O9_UAN]%)HL^,1JUS_MIKOYYX(XH M#LR"!A^#S03WSDQ6MWVUT/OG"YH07II(G-&@'+<)T4T M),E-,HX'H\R_Q&U_9?%6N<+M&-%S(A-%PT)2H0S3"6).+L@9Y\8:PQ+.;-" M]9YN^SNE2CV\QG#;+UO>]M^W+VSRA*9 'HV7W^ZK,R1*>L[GK-"^H MY:@=6N&D$A"!&* T$J[ .=09N1Z/R'M7>?N!K',"W%7N?.[^O5K# G)"21.) MBJBAB2!M1 ([XJ408'UH_IYW?GEZ,J$W!:O70Y)GC@Z>+\3;V6&%7]S<3+<; M\:9(_0;Z M/%-,,E *%3+\LZ8^!*JB$(,Z*5<_#NE0V-5HU!^D/P;/DC;8(T-H7P5."O7Y>6;Y>(_RP/YQP\\75":8D"U M71N0$"5BP+WTEH$C5&LVPD"&#O%?=(W/4"^\NUVAIK9:V8M_WDY76^@/JQQ[ M6A2,<+0-#0VXK(&)6DL!RH(7BD7R'^KM29JA>M15R!,KT"^6.PRYKD!!J3/A *EFNMC#'> MI8V]B9OQ*)6*X;E3#Z;&JL3[Z^GR\LUDN?YZ6(EX^ESA.=,VAA $SE=+J@$H M")<$!:>-'O+ HZ+ZT"'FB^Z0&=J3\7[[/*PU//=XX9TQPFJBD^.@G#?)YN33 MBMLHM'7-9=Y36;-^588.(#J5\(\NX\\W*)25+A#FLD> ]-Q8YN-N0[.!!W:F MFD$[21ZA13_0G1MS-&&!,A*UXPX4H#Y$ C/*24^D,R.M1S\$+^H!T_S( !^9 M7DQFN 2^6:S6OTV6?Y2;>_U=2:\C1PB56A=H(.=$-L8&JT![C0J1)VAW.VL] MKK*#JG;5=(*V0EGT#5*+,Z*[PY(WDZ^;N?W^*2L\U]/R\^;2Y/65+Y=KG&W M#V:+3_FS36+TC]GI?+'\:B_6T\\HB7*5 <+==CJ9O9O,RKR-OL0)X3LT__C; M%#]8+^;/EGTXS4 *#90QE2LB1 =,):<3"\FR("AN[WQ$-.S]5F[3(&LO8+<0>DO'>5L1<7 MR]N6A*O162$HP4V%,!$4!6^=U9&S(),&;D54S:OI=![P/QB9^H-O6*+L@G@[ MYWRXGJR M*K^!]K;,$&^F,)_>W-[8F^Q N/W[NCR4^JIV7T4@W@?#+$480(/52B?A=4I: M,4BV>:GCS@/U^V/64.CUZFB)6%SF2F,9E-5B-KU\4(?IW759KOOS?CSVQ=O0 MW6NTM=#X&G(4]U4+5JB:[/+%#PK#HP$\'_3

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ⅅ;'@:*RKC'I97=2X*L;!SAR.M5Y-E*A=1V+NK@1^9#E3*-!H1["'S JM MJ#.V7M#BD3%)T^$MBN=*4VD 80I32@ 0.MY&C!!3!"J@=!)!NR_?]*_?JKWYMVHZ?R(H M@@ )Q)& SFAIB*_G'SP)27;;69[^+94$.N>ATXYS"K34PDF,B ILLS;\X: 3 M1.6/K=:+KF"IO7:V6D':8-SI!E:=/.8V[MMO-5IT5 MM5>QCC=^G17/7E:\;EI\F\ZNBN7&^#A3-0^9 M\BI:7*S*]?JZ0EBDW;81VS1L[4;-^Z^IM.'STU11EW'TL^KZU -;GVUM3C.2 MGJIL@R'U;)4UDG8@NYM/#+)GUC61WJ'8YZYB>J1[-6'02^D Y\$PZS$'U- LQFI^^5PE4J]+&4$Q$V3 ML^& 2Y\5,Q*JYO+NR*!(_RKV/\DZ05A1H!DS/!X5(:WP@FS"V@.-D.MA6GY/O2DS^?1IKAG M.?POGA'Q?7I=;556D)*0UE+,55SY@*FTJ(Y=(]/.9D@J&$F+C=*00H0I0D9A M([2Q$A*'+*5)AZRTR# WME:#NEMKB] Q*(O+[36H<9P@6)S&S'Z5;T;-DXF> MQLV]WK6A1;0TZESAM#J-(7YQ8.ZPX$P1\@@ZL]3'.."9Q[7% .]S&D ?+^Q= MN9PMKNX?KSOA1F-K%462 PGBA802[Y(?II+602<5# B#7F.BN#)4<"6J/X;.B6N*GWMK-%^Y_?GS]-_7& MO?UPD4;3?JNA&4U/5@-I-'T2F6?%QM;BD:/"A\5IBI)'<)JE0L:!TSRN+09X MH?O J0I9\G+Y,R3$?YM>WY:[U8).&$D=\H)KQ1$T2@E;!S*#+FG4,ZUD+.,R M1:.X#/U82KQVVD*N$(<40 :S+XRN8[KJR)=[>Q-70_A,2WHI0TX%*XS$T"-LM1$D M'7NU@SM;"O+\R;\XN/[Y.WLO:F=;-4 MY!0RIR4CAQ9N$I)H8W%@Y,FZ:0W%.\+!ON4?!PE[]VJ1]Z5-O@AT<5-6^T;> M36=7DQ!R!'*DN(',,PFUJB^@]! X+Q(O^[S[;!4Z&(XKP6QX(',*>4"PET@B MK:1)RC+:CDA5>V/BDMU995RQCM8EW^>9)EDS>.54*PU2&TN*S6:B:,O@UVX> M"G$$.&TE&P=86EO_\(K,#BHT!T4(N7*UCD6\+=<3H)CS4D" !=&2<,;]KLE6 MUMLT4-Q]-M).2QA*8(Q3(IWPD ?*:6FDIF1_(?U H-@8EPJ)1+F:0B*?4JF0 MV%A2 >(L+H/8;H@VTV^ST)3-_E7&:;O-#YV-X&[*>](=Q4H[D<>"E9;6/\!* M%Q521D5BQO,V.!>^W)]T-+]Z9(F9G:TNKQ>KV^5^E-H0RRQ4@#DL'(#4$N;K MP'(8)AUMT=D8Z@S6$'LH/: $*<&U)S*HI@F2EJ3=Q)NC_U;X\_?%V_.WKZH_ M/;AK\JWMX^BB_+79?$QZ-!798K@ZVGY6;*T_.!@N#F,_>K#1WH633O-UT?R9 M ;9!JG,&Y0;4^;DVXM/-ZPN+Q>W<;W']&>\2B.8%3Y9WI97 M![? /U@%8A&"7"/)$/3*,VRYV65>G(M&/=I^+ $>0XJ1DM)+*BC0(-Y@AK%Q MU@$GD^; 6K0.M1UQ0\5T:W](+%MC'X[>!"AZ/WUQ97M\N8(ZR_EN'WORV65?ZPF5W[4]/$(%9 MU=P#B4'5V/=2)8^T],-6]6F;^8%]79PBF-(Z@>?++]/Y[%]55,5M[8OKV=5F M\'M^]2X$5AUQYY^W:13]&$.$]90*IK5Q5&HM#(^7?,>U5,(ADO%YDT3(-8S^BR]'!["XZCH-@'7UX,+#=79'& MA^377Y<[_*I;='JQVPUT4X0P:W U!B!N">$P#I2$,8DZ42<8P5A8AB4 M\>)F:ZF'3G@O"+',,V.ULKDW)^^,"6E%,">1,MTD; :;P=1KR9SGA,MS>,T1 M48X IQ0<4%"=@6!0@K1;2!1 MX+CN@T4'Q3'B$"00"$4PE49IB9QAAG(./<4J]U*@@\#:&-03DU($[4:F3%JV MYM-S,@Y*J+TX+3C50MEQTZJ-0PV9U5JK1E,_H7OX9GH[O_SZMVGP<[VX7'PI MY^7[Q8_IM^GR^^)[>?E;>?.I7$Z,DA(Q9*3PB#,9>97L//5QM#BCJ7%H:D)(_[]*=U@+N8D(J>! MK9&^Q3\V=C9L.WH6.F$*Y22"MYLJZ4GX9O,8375Y:KZB=UU',"_1OT^+G&]B MR_&^-[-Y^7I=WJPF0&C"0Y^?8(*-8UAH;NLX"RU:TO*Q1QZO>#"?$*@A\ZG#KWV%XPK+BI+6L) ME@Y:)H)F&!E;3RQ$,7?VG17Q<-;%YZ*V\40L>E*S)FSJ+OC(6-6#0T^QJR^M MDEGV]\7RGZ_GU=G8J_L!J(VP&L5E6T@!P93P]60>4U;X5C [4I[3&FE/M++2 M4V.EE)0"XP*Y#082Y>Y71\M>S>:OOFUL:\FS+GHF FT@*5L3+=H7U[IM+1P+ MTYZ6K0G4>A!]9%3KPZ.GL-:;6LE<\[/Y;/6UO/K+8G%UKV0-N0:6 \PI2$= M9 S(71QZBUIQ[4AYEA"J"35(6D A,MJ::DN+(=X%&UAFKM66%5^B:2VQUD7. M1*P-I&1KK.WTK P<"]6>5JT)U7K0?&14Z\.CIZC6FUK)5(M[,>,&;ZVE]U!C M#(3T$-<#,"RNA4@YI?G.@RVRP&$(-/.2&F&$CA<#,B>@#G^;M(N2TD]A_A!_ M)>0+6XM:@JJ10HE$ZENFY)@JCIBL2 M.EKA*%/&(AK/V*-*&B$ #(@$'FM-E3#Y@NB9:W9/MN:]FZ!'0G*@FAI'$ _E M[.(DT9 )%/K0J _EC[4.DOYS@J 'P2XC$776"Z.\QEM24 @%3>D==;;% DWB MX(BB@#HBI+1(:X>U9$K0["-"%Q_.S7^^TNK"V<*<__;.O;U0'UZ?OTU+3;)7 M2,_H'J N>F9W-+*HK!PKO1_7M ]\=ZRM%\;OKMZV!7@O*C+F97?RVOOCQ[" -2%AEK*5?8*L^D0W[3]4'4$ ";PJ*#"<83'CB% MB&&::N9D'-4SBOIX" 0$&4&QM[HX,+O:^+@U?&3'IG20^1@[!JB\D7!C"$_O M,V,P==-YL=G-1..1"Y8:Y(0#&%.MC:P9H,-_DS*X>\]&1G.,H$(0$0JT$-A+ M&+YUBEGB;5(/KM4Q)KL(;[5K,5FJ5%SVKU)K!)YDA^(])1I1*DVSL9$GT?HG M:=)&A::$\-/9LCI67?_Q M;D!20G( JU>?>20D]0!L MHX%!8I+V)#8L$H3RC&$"(".I9$!RIJ$@U#((F/6Y>1)-V]Z0M#.NRA?>JK^E MD:4OB9L!YP3JIG'HF+ GV=#83+$CO.I9\G%@K&^G%EE?TY;0^ZV MFK'=P@24AX 3I21V#% 2K"%U8 H-DQ8%I)6L@ ]N^Y 8:D@IAXHQ2V$H509K M%+ O#X']")Y(PL&U[A.()]E!F21=$S+V6@4C V2_OCW%R0P*)N/R]?S;[7I5 MT1EM=^0XP2$(_2'KL9/"0!TRESI6.5"F%1P?*8?H\%S#05SO3:'#@G%/D%7< M&@^)S;TSO+*E0(GG'G<2+A%RF35KB[2S8F/86;&5,'F77L]$>ZA3$WYU4'=D MM.KBR5-LZJQ.4Q)M1])LN9I]F6^."]MDB5YH+5U<8@B<5X@36L>25@"F0.B) M(B#R3CM $0]DA:'KK0 6*FYE=TC2M/4)+?A3#U(?F)6&HK;*-:/0 **E >@1 MO4[2MWQ>XF<-E! !G$=*AP:F+3Z MX4'.27MM3XB3A M)E'/L0(GU8UGD=-*E^;S=)MRRBNUVA:]GT+<9E0*04T1M)(S8K1"2EI81Y"T M**FGU:0\'1<7$2 IA8 JA#5"RE,@L>$$0)%[!_%^^F-5[,TMU&HW87\PR9HZ MU=>#VDVG_X85.G5*<*?K]#%=3]17:R#:T=G#_B0?!]UZ]>C!+&/?:C5EWMO% M_&I7^+8DYJB!R'H"5>@LQK^HJ:/.*,]2&/?8\[6"4N+P/(X=M1 +R4(T6V"< MYUZ3W"!HTX>+/I[ MR=)PHZ?A?;HL+[Z6Y?I-5+#N1AKKX_%$7&&./ UEQT."M^'"".8IS'FR$ %D M/*I**X49I=C(>#FP=-AR;Z#A:1OHTL&SM:NH#"MJR])0TU[ 9KP91+LTZ#PN MVTD&DIY2YPAI.@LZ#MQT=V/1\XO6'3SU=!VA1@"(%20$:^^1('@;.2(TV4E# M2D>*$43$ I!77E//B7#:Z="="2D=5-+GOGXT%WR:BM@>/QGTZP= )QE>>EJA M1 @ERCI>#*4ZT@!$K;1I?*'6^FNYW%YOH:H+&[7VDI:4^RJ[R]<, M08,HEP:@C6CUS38;HT[4S7I*G2/PZ2SH.-#3W8W[EV_UHTL2=N+EP8^4B#$# ML9\@*'1**J/I;@):&.'3R?-$.8@Z1^-5A-QI&OY1@:Z":D,-E8C)W*/9FSAJ M#9VVXB5P9P#=VJ!G;]8(Z/.X1L\!J*.R(V)05T\>PU OZC0E49/+3>M1U/"7 M,DYJ3WV\RA1B9^O8BIV-%#"E%(N)(MIXBUSH@[+@MR(F]&XL]L"%<,_,*=7P M\N$TAO4I>S.DG4CQ-,(]N+5[^L2MW:=!7G,-CQ P0T6, X@Y'%MD?XD[)6X/ MB]5:"6(!9QAXR!2QDM>+F 55-FD_\;.%>2LM\L SC4UPT"G.@7!8:8.-\3+W M;IA-/G*]F']Y%7[[ICT-NZO:*JW+*VC'W.[TM'M.K>997GNAQT&V_MPYGN]U MU2G]$(0WNVL@.."<&>R000X8YXA ]69;R8@4[0Y"V#^? <@@)RZX@JA"0FEF M.1=$(6\@\FJPQ5,=;GAII5LS-.66+(U&J6IE/A[A38-;7KH(. [*=/+@R:,2 MVJJ1SI+=YI?SS_L/JRYLZ+L:[C "C+O0>5%<8JOK(.%:)UWUTJA BH73Q"@G MG:(,AMX3M)A")8ET%@$Z'&TJ>\Z*_?ZOMLCI(F\J@P92MC64'HAZ5OQEN5BM M-G]P*DP]K5HC;O4@^MA UH=+3Y*M-[UZ0EV=O?V<,*0%L%@J(K6 $@/,ZO4_ M4G*7N#"]8:'<2ZI#PN$0L:'#ZW7X*B2-4'AI0HJ2>Z/,073N;,J&O02I>T%? M'I5;X^]1@6L$[OYP5!C<6=4>A>F5\")PV,*M-"2VU2WY,(3](7[[J.I!7$B=TX^L%CI9A-- AAPU_"T^U$1(%YQA"0B,$M1/Y8O+@ MH)(#PTYV1.8QE8[$72_BCB/6^G'EJ5W]W?7I$E,'1^E*CXR#%GBO""<""[L+ M*A9:P%9'C#Q:$A, (AR<8CQT,C 4G$,5'*;,&&!A[J3"J]?OB[^I-Q]=\9M3 M%Q_?N]_T#ED;$?0IWL&/"C0B5"*EW@\5*JA2\-,-56H93+ MEE;K:L>I+3^MU?S*_9_;D&IWRVH@>W^K"G A#2#.,00Y$)P@[3>!II3# MH.EIC@DE NLY1 (#P"!5V(3R0C^! 284=#[G:3\'1IX5TSZV^3V?7<8+=+Y87X=.]5=7!NWNH. -4:#T)YP9)# F(O8HZIK5OM%VC M7XMDZ&XHBXDD6E"*O/98*L<%1X@"(7)/B==^Q$L.HQ=GU7^+ V%4C#20&51/=JYR/M-ZGJ:[3-NPG\GEQR@!) MR^,WV<$A,TPW,]YXJ-&;4.@UA0(U 2"N) M$(28>V 4U1G7,VPS[U.EVW=U.))2MQ1L'&ES6^,7O;PT:>_[^_+R>KI:52E6 M;!W.;]?GG]5E:"]NJ]NL-ON!%C??EN77G)) Z]$])9$#KVE&LDB46(2"ZUL=CP[ GP[^]8>54L;JL+P _\*K8[Z@X]*S:NI8WS#56GS=@WPNI,8^9]!]*J;GNC M3G&R<<9^]#_"ZH$K>!R,']KIQ4F#*JU-V:=X#2QZLUC=S^P$!5)1IK$4"FOC M/-J#!WN4=*M&5UL@9$Y339FBC@(H%.*.:F"<=1B$WN%PK8CY&N\N716S^1WR M;$\*6%5$.C>O(W:N;Z_B\5?UWNQWY7*V.,JH7Z+G?ZRZ<_??K%5QOL5=>'A: M.Y3]/6C6 (WI%6@YQ-*\M=G6Y*D;G8Z:'VEMAJK-<30S@WF[.$W,#-A9F1"$ M'&.$&6*QTR:\N5#$%7+:*T0A2-K8T<&P@P4KGDIDK5+<$DKB$!XT4CLDA>?Q%.51 MKL+RX[[VNAJ7]"8X@[:)T!M8G5>#+1GV:JSV1OH6^N4&_/1R1L\ ( MK953FDA @-#(U>00GMHA4%]?!^*QAM H%!2A&&J)XIEI3"%HL#(F]S[OEP#[ MII66%_<9ZFM8X)_DR-=N:F> ?F(UOFSLISK;$_A;:9P;_=L30BBT3%!JF,)( M62T(\;ND$7F:=.!01U,0(9#&,6K*.+6*J?!]Z/]0BN(A&3[WC;2;^>:[T\WQ MU=O,#_PEU.!VF'@8RC>MG[R4SU UPU+^)$YKUW9+L3;&Y4XM=I-Q883IX,)V&H1X]Z>DXQY M'%7GV 1F+ZJ. VP]^7)_\K%'A=+6_>Z*VB:ZH10%XG53 &B@O<80\FT@$8]4 MTI3AXR5P) VC2!DH 56"*,\H89X*9^+X2NXAX?NAE$:AEJ(UHT]^O;I1YT3] M[D=E>78E=5L9QX&9CCX\NJZZFR()IXK7V5;L=\5>U]MR'7<]^.O%[_&>PO+= M=+F_3]-IC 4%F!)H!092$X3KV!&4Z<2CQ9/*5H0Q+;ETB(1\@7()A7;2""@4 M5$#PW+W6@W[001_UK'@;3SBK-I=%NZO+'J M#DYW!GF*JD<0F:M^Q@'/;-X]/)(\HXK/ 7>U7$_>+1=7MY?K\^5%N?P^N]Q, M4R'FA!.(2 >XM%!A)>4NAAEH=(?GDP\G'&H!J-4\=(N%%Y(IJ3'7R,F0GN+< MJX.W-E7K=K=F-0-B>[6.$V\0H=*0]HA&?707@Z<'J K?W <;C1-,+Q$L)C)(:4 M R$Y59H+HAD&VG$;+ZK,WN7K QIM=&M,CLR2]8"//CI^*0!YJ,AQBG10<#0H MZ>+#0YYT5J1IAV];WC;'$18PPD,7DFE@4&A K?';H* A[4D:/[K[9!IZ(H93 M2[WCE$DBK*..&0"(4\R@W.=ZA\RN^+8-C67YO9S?IEYUDBA4LYY6/HW:4>,T M/:,[*ASI][13:QR]FI:V+_IX7]H>EOUZOEHOJX-8WL]6_]S<*VXHLYAQ"AT* M^0QW4*/ZO3AT3Z AI>M%U'.#IQY4G#Z[NK$\ZELQB7ITP\B'\ M?KW "T-%)<%62. AQ)!M[O*IP@D;T@Y+CQ2$/%0@#C08S*@'6@(NC+):!1^I MPKE72AT$5FU<6RBU43$52ID%; VEVJX338D=$Z@1E#KH.C8H=7'E22AUUJ?Q M:=^+93G[,G<_+JO##L*WOT^75[LKK3V62$C,L#.ADR")H=MP8@2!I%SI:$$N MY!&<0QMP"ZD&7.K@$M4&04\@XKDGPK;&%)=;U1,[5MTT;(:DP>1+0]+6K**V MJZBE/$T_[)A*1[C4B[CCX%(_KMP_WKL_?=HN35=7_W6[.8FVZ9K*-[O;YQPG M "LM0Q<35&;8@Z33;?JTBSF,.>8:8RPI12AVH ! S"@N)$ M+(_>^Y*Z4OI-VVLM!ZWF9J0=:PVG@7G@RAUD*7R'FC@"_U/4]SC:BI-X_LR* M^>'4;]X258/M/LA79^5_GZV_FF!F*'T9&L7-X5_Q^K_PS]6'Z8\),Q8!@ZUS MQ"E(($9.[5!D=.+AG.GE0R\5@]PSB&Q0 BBFF"/A6\JI(MF7VG>?J\@B>E/^ MGU;O5,Y7UFYVF^U&!7X/!A>UQ6?%SN:B-KH(5@\-\V19CT([7R6-!$<">"8I"8S*'<&%>76HC1,MI"K&03S*I6&N+U([CF1 MLI#K@19'N-1>MW%0IX/]B[[>H);$V)^,.,$8,@I#=3(%L<"" ^5WF0!%27L: M'WL^4H"'1%-I;3UUH:])%*3*2NF0=2S[',J'Q7IZ77RI5HM?5X>/AOY==5/( MY[A4_&M<^-L6)"DJ)J(DDX!M87+G^-83$64O21.FM!!P9%1IX\%37&FM1N-] MT[??OEU7NR*GU]LSGR^^EN7ZT3L.)3)&.:RLYI* $"V8N,V-1ARC8%O2-NJ4 M@HUUP5./H$2>8D.40]@JB:F/YXF;W(.(%Q_?O7M378VJWA1:O5%OC2LN_NK< MA^+U6W_^_C?UX?7YV\2MUKT*WXQ2)],\#5^'9M8'D1>5H2.Y8S5%QR/,RU(= MXX!A'M?N;^C.IU^3Q?Z;<_ O?U:K:3 57F,=,CSEH:+Q^E=O0W@ZKI% K-$) M<0\>"IU1X2^N&2748**(HU(S:4,'"'J:>X2KMJ7Y.OXT28Y#*ZL::4"JS1AL MA\^AWX\ I+4TIU^&W\[L1<=7HEE07VX?/5'7U]MB9KMU_9*''IVV$FN!%?44 M>2CKMQG#9N> '2W $&09U-Z&?RD-C3WS((2)AMHI'C[,'.S!I&)O4[.0[R;8 M\? ?3*LT%-R5J=7*M%7-A%5Y^:SZ;RPB^OKZ3*9%4U$:8_""LD_UM',9&V8E&3FGCPKO*J3&:0$=%_<8JX=.:__A CJCV M@D(F4;QW4ROD-&,@/!T81D'N(0TSG4^OV@=Q(TD:!G'?:B3F]E&(TT1PR#FSA*C6>X)$K.X7MQ\BB'\+OQ0<@ W4:1I /T:'' %\_NYH "?H,I8 3C'Y00 G^]LX@-W']Q,1.HTLY(LRO)U.:.(1H=O7 ME7#.&ZUPOO- @X$C1(;D'W&*M9?4.JD5,))BIE'NJQ3<[3(Y;!OIT#!L^Y8@ M+6RC]\5F=7UAXL'BR] =.ROBQT.&WY1;*>@7E=GL4=R3VO4.1.)1$3+Q.<_L64YIXONCQDC3C "A/ MF82>AGZ^C'F&8THHSHS7N=?#F^I[*30DVFY-_'4C8S@P((X#B'3CC 0J:L'=F% MD).JZ7S\_HF(,XD\QL R0#WRT@GH0J\9,TF!X2(S>2I#FL_$)RAQ'";Y1$B# M1CR]?[9:SRZGUZ';,(VK._HZKJ;1E/Q.@R?FX],U.OUD? N;%UW>BL1 KL_/ M$BX\.M[!(%00PP11PDA(MHT&FB$"&0P]ZQ$& M/Q'6[=0Y?6"WM'O1];U(".[IC\,7 MF4O( $$"*^V<(5B$[NSF1>:6:]@XN.\\%3-(+6>."!'/8&3*:0V(%I;AD(>( MW&?4;HU)".XT31H$=S8Y$H-[8\>0P7WH^5/!W4J=$01W.[L77=^+Q(.H%ZM9 M=81%S/LM$=XZBZS$PB+IJ9*\?IV)!X]G21-LR&\;*JD17IMQDD.ASW4X,AH7"NIQC'XUL[T^X=.M_<_ M-?CK%=[>V- I4)Z$-@Q)'KL*]3N.H6RTM/6)1T,/"(<^E!#BS?:VJ0EU9@HF'H3(263VU?=L$)3DH%#I^K!?(8(@64()0XJ"PP1EA.$&), MT=RWVER4U]>)^WI31&E&@%QZ)([712M.-$-WH,"1P&^CTSBBOI7E]W?#MO:^ M:;R_6KAB/S;61I%O"9%$F+]VC$B<)][_^1:&\ATCB"O8WA MB\XO2%JHO[V-#S__O)W KS?=[L]N7_VUO+Z:6&8E LY)RA%R(M^&A8)+86<.RF%%119KBPE""+)M%"0Z=R+=C=6QI-E3;N5/WTIVXPD)Q U MC3)[/>M50;O-]@=&%M'*81G43+DC?.I9^G&PJV^G%EE?U[97U[Q=Q+[3]%K= MQ(7I$R&$4E 1P#402"EC33UD;[5LM@#AV4(8@XHA!AT.V8/ 6D'H0ZA+(;4V M"K',7%-?OBS++]-U6=1V%1O#BMG\06BVOZP MN:O-$6YUEG,S]<]C,(03:H3!5"/IA3-..LE, M/<9H';5)PR[-2H1("PDEP<9(JBV43"KE.)'",*%0[AO_:B/3$-23F,UX-+R. MJ=.V&_N>2[J&)54CU8Y@JU_5Q\&PGGU:Y'Q/F]'MT\UR/C'1^]AYBABM[B.< M7_VE7'Q93K]]G5V^GG]>+&\V]R1\6E5=K(FW2DM)& 5""8\]#I1U'B%LG*(: M/K=HHF6I2!J#N>"<84&Y@!(X2[3CG$!I!,]YX-BAK44TM@C6%GMSBP-[BW_4 M%C>\ER97)5PM+JLK)JM?&W-EW#&T9:4L8Z7$Z]N_["MEMK?[3TWI&>6HF @D M!A41VPGT"!HS*WU:1N9V;C'(VYJ#FA^FGZ[+20A6K'C(7R@+'2Q%O&>RCE:G M5*-.:ZMRC4#($L0I5!3I@ :!*($&.X&15]G/M4DC9V5S%FPVK(4^&Z[^*R!K MJW5R[7.T5_W7P?]+C56E3N>6*DWCE]1,)7K6JHUJHU[308L'1NB?\7+?:DD: MD<1CYBD@T(>>M; :^VTX:@!%TGT5Q\K!''#-XX$5&E(,B5;,$B.8T%1J@?#P M#5 T+6V\HI..S48IAI*P"2V6K<400?'06(N"U)5)HP<"+ M1%**CBV1E$G"GI!TDE6P1S1*@5(+94<*I3:>/ >EUNHTAM*RO)JM'Y1;;\OS M 'LKO6!&0\.H,F873LS1I$F=XR5Q'H_=X.$?#*GW0E@)A9"8&\6C0Z7)^ M^?5FNOSGIC?BXFXVPPVGWG)I/0%B&UW&>$4Z]NKN%F9P*"NXQ>.Z'PB$0D@( M9K6&/&2,V8^^?R3&=O9U[M\ERMJZDY=/T:U-'&\)6=(/8O<(8#-D(5M)SR2@, MP0T%@-Q*8P&+HV\O&&*ILK:%6$9%^X38.#J(]]1*PEA+H<>*L;;N/(NQ3CHU MWFXYO2Y7VUOLWY;U5J^8) BNL;6(H'C?GE.Z#C*)FIVQ2O!D.+=[DNMK8E[LALIULS..67+(U(6U,.,72: M'9N/Z7*$/=UT' =P.OIP?S]G#XHT18NZO(Q+F4-QE^7L>YP@K(LSCD%@<&B\ MN<(*$DOK-5\&>I(T%/5D(4X(39US1@A"6<@9I&6>&$>%8MB(W,/CM5W%WK T MP+17KQEC!A$N#3./:'8BT#PESA'6=-9S'+CI[L:BY_UJO;@) M 5OU_12P(&Z:,-93SJTR&-5#'M9HV6A+^1./E@ "JYPTFE!JF56 :P.I5@8I MJV7N/:.U,2E'QJ7+KIR*A@UC/DV$8G=H"8K #H9^4X0E2=)?M],#HP8=%GR]2 MRHKX;0GG\SI189P8%5Y[YP#&GCL(I:U#P4/L)]_+Y:=%LV7O#Q[.B><&>9),IPJ$W2R6N'=J1'Q'G3JZ;:RG2<& /HTQ(5P9CGNR&]*)2R M=CRK4BV7A]>*P:Y+O^\[]P@J.ZHPA@7<[8U?]/(FM*#BA]\7]2M\(HZR07#-JZU$8@@*W32@73=J!AL:A'S M"3(E4#&//BVI&(SI0L4$A5I0,8]2':F(>J+BSKGGJ)BNPHBHV,+XQZC85H,T M*H9ZJ^'K V@5DYX0Y)U&%AI+G2>.0ZN%]JP-%P\>3T.JH*04T"M!D8;AD<(Q MSB!04D.;-"W=D8S1JC:1GR)6"ATSJ=26C]&<3H1,T:D-(S/IU9&2N"]*[MU[ MEI,ME!@3*=N8_R@K6^N01,O5M@@4Z,N5X) BP1WRH?N^ZPY!!!OMW7OTP<0[ MH8R2" I$@:+*66Z5 C2^+=KE/DUH9TZ+H&^L30(8<\C2#HJK+CQL+$T+%N:0 MJ!L'5YVW3]]U[3D&IBHP(OXEF_X8^]KYW^\9&V]F\_+UNKQ93:PAS#M,G)18 M0,H,]/6\G+-0N/[/V=B7#1#4UCE ' XE*RJM9\103,('AI+LDQAIYSU$NXO* M\"R'/B1421,BG[8V$J']4BLBQPD<>2KD_Z53.'8*/=G2Y--Z#(U11N]:GR/&5_4QA6?;E=!^-6J6&W,;'>.>PM1 MCS<_PZJ9UM#L9=Q95=1FG>9X]@?J/,*T_A0=Q\*_'OQXXMSUKLJTWI'UKES& M#Z9?2C@QAL9SW$,N#Q2SFGO@ZEF&T(,DW;:4'A:$!"+,$$D,)#3>RH@\U-1# MIJPRC/-!T^>8')P5WW;F==R+E21H,R -IF77Y/>L>/>\C,-LOCJ0Z B8>E%V M'&SJQY7G-ERUUZ?]CHBWY7IS0/)Z F@UZ$"4K^YH(03">F.C%X0T7&;4J"B/ MI 64! 8[2&%<9RDHY))SPCB"-&DG4:O,:;?2?[DS[ZR8EXG94C_#X-[W81^@+%]B2/-XO5ZFQ[(/O MT4<4_ (OGH1 M?ASXZL>59_=5M-:G\55]Y715KG;'$=/P- L,4'&?F!/"^S@ KQ@'7F#GF]XF M=>^I@!M-G3 XWFT)0VZ(M2<6"^JH<"[GF5P;0YHE8@\-5D!00I4 #@+*0!T WJE& M%]4U+L <$HP"H*'R0]V0$GOIE8W%@9$)X[U]J-I@H'U@ M0=,XL]/R_!$MV]V[T(>L"06>&@;O4;L1 M#'OWZR;VW>VIO77^M6V679Y,EE3<\_5 MJ@Q=N/T(>&7OV:YI^'E6;"T^*X+))\M24_0\DL-FJ99Q9+AY7%L,\%JG]@;C M*_NX(3]K,]Z7<9_>577]ZFQU.;W^W^5T.2$.*6@\4DA+QIUVP-<]QWC[4]+= MIUW,X(1;ZQ W\8IKX;262#N,-&0\])9S4W1G5,Q08K@EWA"?4?^F/?=12)^- MM*NSXDX=;>POH@-##PVT%?KH,$+VVAL'D(=P],'PQ$#:]@KKT&9$$S[\OIAP M2(!2B#K#M E]1L@8J0D!+4[*;%/+QM9:8P#75E%JH9.AV9) 6TXMYXZ:S%A& M ($,)$X1MT?\9M(U)W-C>AMM/KKW\G262D=B&IHML -Y;I1@/#[4O'2#GC/85>4,H8RD5H*S4+!%RM:Q[C"UN6!:%4ZLMU@XRH,$5(2L3U8^O2I 0/)VS]*>U=V$))&J\<+TFA=3QQ-JIZ7A]$T]SI0M(6.62 Z M^QY83IPVH;OIB112>"00W44YHHAF@V@L7 BNL(BK[C2D "G)'$:86Q(^U2S[ M;%6 Z-.'"@PD;P:(]JWL,! -5H\8HL&ZOB":4CTO$*))[G6!:+J.?4-4Q66U M.UL4\$#&HX08! 1J[KU"NZZG!5GZ]G+OT<.V3OR]D#:=M7ULG#;TL>6S.VB M:-_@G1CJ-782AY GT!G$0HI5!S^0ADS6B_7TNE_63AB7$H3"@.&$2FX4M"&# MI,99ZSDW:?=![NQKCM?X*]L%B]^V9N4![?/R]LO67I7-C--QXK,'8C:NA)<% MR>9NM>1BHFZ]H/#C_&JVJG;YE%?NQV7X4743OYM0"FA(A2# 4&DJ%8=X-_VA M.;23>?EE&GZI!S(^:0,6SB@@D?1Q13D 6H@XST:,9\)CTFQOKMP$\Z&Y23'] MY^)U,"S\4.+.P4RR]\#+O'IG@^>AV<7&[F)C^(A(^I2V;;':N:Y> &.[^Y@" MW)X4[;;8_^=$,F:YY,@S[)V/QQP@M@UT2Y%M=#+ELV5X*"UQ4"(F*+9< \ZA M#IUU.GO1:$5]JBI-R>-G\[A%O\GJ?20ATP9[X4DHW\"0=J@Z@BQ& M2?/?"<5ZA9#G7A(%%47>:B^QEEK'Z[F80"@SGS:6)F\QZE/79F0ZD:1IL-H: M.=9-1S12A= MUD24]E1'XT5J7PXV0&NO6O:"V(-%]$@2CQVQ-O2W%64<6E*O9;',VJ2M/TW+ M-(1XAJQ4P,8+Z)5"6"& -$98Q+_SKQ!*W/+3FY@]0#.3COV3\G0;>QKJUQ:) M+6K@!7"PC5,@ZZX@-73W8-P*K0C76C!(C- 20 MHE FTB'Y]8A;$>CO!]BJF+B]IC\Y^P-@[TIFY-_PFVB:*MB1?DF5\'+@E^96 M"_:UT*U7]%6K'#VV3%$5QS*UT5(9M8M5QFW2<42-"[70 NLUL,(1*KW2"'I% M83Q.'R%!!TC^$C?%]"=GC^CK6\F1F0;.E;(BF[*-@7+B=&4(04 M%HY9[) V-MZY:_#"**4C2C/%\:4%D!1!Z"A2BHA8R(LB75.>I,X&7**#2C= MY>R'B+TJF6/!S;B8UP%SC95^&61K[DXBS!)UZL2O)]=2,V7CA@7DP_^\@Y8A M6F_[6 ,R-D19Q*GRS,PA/M6ND9YD[0"ZO MOCT3;RQ[0Y*43(5AYQH9,1F[^]8$DSTIV(F9$R.]4!@0C9@B5A+-F-@&K7=5 MHM>Q*SRAH1LH0\[#=7#)AAX_8IN/RFPE-0BDWOO1]4#3;C]*I?*QR$U%H'3$+;? MMA8L+NX [%#%4C:!VVMU=MJ^E::BES]M:>M!4[\9GBJO; MLNN59NW$>J3=&4+Z$5Q]EMO#Q7 OFP-!ZRU?*WBSWV;N#P,LL^;VOL9/,G=4"9ONQJR=EY MP]F7IRD-:*_J]MN0'FR3(-8HP 7W5DBDB'&6X)H&V-D,K>=!X938X"K23#!& M#3-2(0VUQEHAR"%..Q]AH ]= =9&CX2M%H@76'XK%VP"G) >6>&FL$\\!@R+&D@&&4>\JE^3Z[G!+G:+MZ5W>@ MUNOH)KS!:B1G"]9[S0S;8,:L\T,HZ(-UF:S,$@!+9Z *(]J5C;S!"S'OE3!P:$H910(PB%.#0,QW/ MA609!<[0E/6N[3 MV='ME$-51\9VK/=J&;89^QP>.'0K]L1>UOSRO\ V+,V_ M+DU8"R7SM&!Q$X643&CA!.?#:^9A0X1PO6M[8#M6#'MGX-51TY6["^JV7@%BR8/W@+]OB6 MN_SRO\06+,F_3BU8NI*]MV!W]P(RYC2 "&K,-;7.JD8((B%X-9Z0B&J=DEH K!0PAAGT_IM0VY+SR!PSPU=K]KF M;MM.)GJFYJM7\8=JL89LH?IHE!J+_,+:H>9^M6UZ$I7KI[5Y@!VMU0"O!$-SL[H*,17"@(G&+,>T:=\LI81!",=Q(3;> XKY[,+7P? M35)>Q3.V3RV.&!BTQBH,EY">]?= MR:3&KR=-^VD))R'UQ*'%=5QQ[[QQGJO]Y($&>E!-YJ MRKB1WCL&H/&20,EITJE]AW8UCN"^CH?H2]P^6K5>5@VK:)]-4:_*9FQR MLKW5Z7YY_=S;?KQ<^RO"B7WV>7 MY<77Z;+4P8(KL[CY5LY7U1NIKBOQPU?GG]^7EXLO\]F_RJMWY7*V"#^W6J\^ ME#_6.OS,/R?8$,0)8XXP:2FF%GCJPW=(&X4,)BF'".6S4D,%M9B[JAV+CJ"K>C%X5:+L./E)OC+K=5>55QVDR_S=;3Z^C'V;:C5OSCP_13 M>!VB,T7ES<"7T&:KE4<:A_&\">,XWFD$.BS&%J-M6[.]@=LX5+]/EU<58L^_ M10M7?PO)_<;JU>KV9O-9%7Q[(SG V%MDG? $80>\$:0FG:>B91/6BVE(.Z@L M9@! 1863"C#D 7>:>N\1 4.W6\7&]&)G>G%@>]N6:YA*3&VN1E=_B6W48=4] MUEY%;\[NU.KJ[/%Z'5%KU4>E-&JB!JW]L;5+PSK_9&-T@CIH-(YFHI[S];(J M^?UL]<_0F;LHOT0+WY??%LO8O[.SU>7U8G6[/##%.82<"S325"OEL./2>8:E MYP[(\$7C-7QM#> 46NNXHQ(S&D=*K! $&:N)-"ZTU)E;D_?N;^[M1W=6F/?. MOOY0F/.WQKW]\%Y]>'W^]J)0;VWQ%W?^E_?JW5]?F^+U6W_^_K?JSQ(&C;+5 M38/!N3%42UHC<V&]>L1C-7 M_G8="OUM-I_=W-X*LU-X:W'!_5G3QPKV+MTP.*)X/M'5$[0K9=!;TG^_*=0(P@BX0.C0@.2AC)A: 6 M,^P51S0_4!N>!9=5Y+Z1FD??[%"-9H\;JSMA>P%K>C6]-+2V\+ U7-NJV3M> MX^$R&T.@]LI2KQ5P'!**14BEZL"WB-$L=-T73ZRCAA!("714 ":E=R%_MW&V M46N?=G-MSL/)\-Z;1L?L=BC?:$0Q)Z QK3K6Q0C *44CM,'?: MHO$&E73'6Q-U99:]DS5_8%%$PXE M Y)YX@%B*.YKAO6^'-*+G:G86/Y7Q0#FWO5CGR)JCW'N\O;Y;*<7_Z<_$6_ MFV@KI<3,8:.A,!!8P:SD"B'A).*HT:Z3.P\$5/J0Y4+)XZ(>Q25Q&@=".\$! M!B3WS3]_"6W$NM#+V7JV^EJ\6]S.KQKN"$F3Y3B5LBF2AIR/\UD\\.,_PQMV MM;@Y>TZ.1]BRJN&R*B__]&7Q_=?:LPUHT4J>TR*AG-9GKO/##N4S"8*T*]I00@R9T7UJCJ M\ \!7.9@?G_[Z;KI\1=I0C0,W[XU2 O?][>KU6QZ5CPC0X:P#7X?"]L46482 MMDDFWP_;='^;]CGBAM9E^;6_?>_=7]7_+>=;F-'$L7?96,V"?.KHY03>!^F?T+U]Z. M[;(]EFHF)NJ'@I92%D]+3 ])ND/<+O\8U1LTVCDD6C%1K;BE_?5:O6W(LK8[BY- MEL3C+=2.9!R# 3Z-5&,X=:I,$S.-V-15W4YL%=*8>!-2+:X_KF_+9?CV\J&\ M?K]O;F5JDEU?.A?(E'FOI7): H^]P+$.8 "S(M!M"M$E#TXQL11 &U,J2J54 M#-9G]9 E#%"6U%2I"_%MY8W]9NL[SO%6U6PC;5'MZ@;EII]'X@WWX2W1CA%/ M:H0TAMSA_^D _UK:8BMN<2#O6;&5>%RN3,7S"'=F,\TTN#2?>M5(4SR-:YMV M*9_+N[JQ[O-QA01"6A18GEO+E!1$H.V2=M3AI"/ ;X^FO<5*,&8XAQ1RI;BB M2@M(B.#A7[E/3S1+]NJPK579I:W5 ,"VX\IQ,4TCQT:V7Y<;X29 A6_"=83[ MAH-Z&F0WH#Y5KDF9'#K&]?O;;/F/,L8]=3.G9DAB%;=A&"88Y(;H> JX67". MVJ3CMD<'$BAD]LP@P0@-GTN%MT;PJ"]Q&-CES]6-V=TB% MA#)&%37$6N"MHY"&<;>KB5F8=+;JM3$@"11K-/+2>"HQE)8(0QWPP D)QZ.D M1JY>I)2.8!(?906O&Q7M1#HM"3U%YFW^Z8SEI*BGNQ8OLTY/5%IWF9S=E:N0 M6;J_KN:K\F+VUS;9W"T;[) G0%%O&%,<*XU(LVRX2;M_]-98#$/#-9+".$"- M))IB:74\+"X9!R!W8O?O=8?\V?5U6$SKV5]=":@WHNV(:$PPTPBIEJRN<6UD M*X)P3>GK1-ST!EA'.&HHF*?!58-I\[2=X: HM>4N6R[GWV?K^??RA>212Z%5 M^(=:3%!]QL8U^8V]BLNPAS8[V<7;5]7'$8=-N1V&C IC'87JS] MFQXG8JYC"!VAK4& G09G#:-*E6'B)713;6KVA\]@'(PH"0E9")%::^>,8S"D M*O_X$9>$QII]\3M. M1V-#URW!>_S(4$R0WV*DX7%,Z$,Z(I[=VHTVN#Y[$&OK0WL_7G<<@1?8>TC< M)M J="A-JN%G5>+5G>VVZY/=V.<;L9="AK1.0(:!(IHYZ['?Q46>@;1&G^U' M-?&Z$F62F."HXIZ)A92$:!L[ D'V<[2UH(G7=X9#M%VD>1HPTXA^=R3D^6F1 M%\Z)C'R'IRU^1X+2X6TPC0@U@UY/;_)D0J[[<;LCAU TX98A*(P5.M8J!=TM M6(ZI3KF_F#*N-Y(#'N(6[#SUF M %0%(>6$\6WY*Q<1C1\4EECS#C%$FD)"=8 M R&\MU#QW%7L0D&L\*&3-I*J22C M7#;+B0B0=/+DV#B(086I] M/R2GP3E]E7BMPU8?3/K5D=[/%^6[P'4AOQ#!?<=%@B @%BO-H=BY<*237GA_ M:RPI#0TLJAU&E!H.I%<8>4Z=Q]0AF?O)]F-ED"AD44LY2%$I =\^A:4\T Y7 M7&J#ZH@5IAUB M1*F4E Q36Q+*B5 J[=1T$Z4I_FCD&9UEGN!QE%>Z8C<5)NDL_S/NZ(=$M];) M<!HSV).V#1EC/\ M?#$+RM7#?)Y_O5U_O/E]5:H0[*S5?7PY_K\W9YA=O#TI$(),:R4)HTJ"9H%@ M#I(Z(+8=,PQ&#. >0L.H5%0:"!@FPB(8NS]FOVE]($L:P0P&:CO6.06>:52T ME; AHEK(7ZN;7X.812WG6=$*[2PDU1*^(\PUM &F06>#:U7EG;;=B>_=(M!# MN5IORU.7B$-DJ&(,(4%(X%V+4+,ND3%)QXV.C2,)!2$*5 [%SAA22!)2$VPI MUE#)($+V';.-.-W:E%H(7 AD$8U2'X9U9XY!F67FIM%79I5Q)> M&@%*'XB+(T:HHYXS 9GW7@KE@'-4P7RS?2]4T4AULB+FZP =61$#H#J-)3*$ M(B_?'>B/3=M%]&$6GVCZ>+.MDE2+U:5WF/FP8#G3"CKDC?>X63S.X*1=W1<^ M'EIA->34 8;J \40ZL +4D5ME":9(_4/ZN+WSZ[XZ(N/G]QG=?'NXX?S-!_: M!;)V?),9K32>V0A35#?%7IP3OJSP')LC%-,#R&E02Q\%JL$F56)CMZO;\OKA M+@QU?CM;ECIX_VMST+):+9>Q.U#]")S^L?^=[<-P*C85VMPY@(!X0#4S6%B* M$';$$^?#%T8C!$328^G#2>6()0$D&=\[I@80+2T#0 /I+'+ Y&X6UR@25V0M MYJ]?HIS%H3+%H3;%EQ^/?G&K45&KU.T6U(@F;L>8T[1N&M&.;-@\[>Z&LL,1 M4A_?UM/P!2?0^VFSO1,AWSH3K <(?Z6^&F(X)=HI;#TF.)XE(N'CM]2" 01) MG8L??[+6" :O:1EG5" 3#^*%CP22" P,R[Z+5J_O*$WB9?XT>%KFQMF024R' M=Z"X_A0FV(?9?;F]P8$P MDP1R R #D@,F/&/-@K%$ID6C.004P(/XEJ,.4%)/K73.TY"/ANA*(RUS9]3N MOQ[FZQ^;Z",QG#R)N5I&EE.W5'>:/,G]LQQX'@L63VF^:=#V:2%X&D*>WAZM MVJ9^+E?KY?QJ75Z?KZNK?_S'?'U[7BZ_SZ\V@OU[^'']+L?B>E[74K;W;Q!R MG$,LB9.0(N6HP'Y+.AA;UZII?9_Q(<=<(@;C$S@4>BPITU(8ACPQCEF4V07L MI2YJL8LH=[$5O*@E+[:B%WO9$[J(YC++<5\P%8ND47TW8[Q]*7 \JR3T?)V M=;KU@CVPTJJVTI_12JNME3:%G>];*UWMQ._;(+8;7"_XV3' GT!#V=P:5N-- MY00G>/%G=7%;/:QFB^N+/\/,_A&^$65X(N'OB_G&1:^BK)_*Y4VUO(_'?9[) MJ 0UG##,@*4@GK2.VY;;%>\P:74*,(]D 'OI#>4AD+!40RD:]:3R\4W>PO5.VMII3OG_8D,G M>/-)&[R;GS^1X=N% T/C_5J@<#*[3B"$.)WNU1165K>PX\-\4:[+;06X^5D99!+G-W'OPM M6..VB&S0@H7^?)V%NGF=<4R;%EU,SJH]@HM&EY.&%N,8N5MD,3EC=P\LUHW1 M%XW18^&@6#ZM+3Q$H\\.%O2W Z,/5UT8&.06T<2HMIQ6,#&NZJ_$$B? /ULH ML7EU^X5 QS')'!$N$!'GRF.)=OF-AGFCB%=DLA1:201$5D*JI10H+$8/-,;$ M>"ERWW9,#R V>HP7.W2U9::P800SCA@Q/#/F6,%"5ZMFCA-&L.X)0H3[C95/ M&QV\#.V0@4%/X_VD,4%?K?N& X.@/MBIL->.'KS?]:030" LD(AW>K"2-$0H M?$LQU&*7U+-E '$0P%8*S0S0B@JM!&:> $V-=-Q;P')?16AQ2OV-0^KON_;, M',.8 YT0&]>.:0' 2"8\S5&R-X'OK9(+\B*LYM9&GX7].CD(UK:4W4F[SL>ZZO?I[^,7UZMUB M(_JEH(35Q\@4YTA3QQ'6#7UI"),>:$\Q!3)A7%4NL0O'//C3%"2>BR M7[^.HJ[.BJ]1JL!AO\P7Q:K^WM]&2F Z6BQS,I/?6",G-F?%5J6S8J-4"#&* MC5IGQ8=R':]I^VIY4\YC7X61'T4?UDPYTJ!^\V$:+NE4R@^5'@UA@],XH/\H M8_?2X#._E\O9U[+^H9VM2S^;+_]]=O=07FJHL/=&8\XX(00*19MB/Y5FX-N8 M \MN%+04*THP-10@I+EFB'#H#30H?VK5"/CK;"-A<1,D*[Y'T>*!@(T[>^3@ MKJN[N]ERM?_I27W= )/C%,YPW'DQ)6_9:%YL5=_\2A&5+Z+V1:W^S^Q!W[3M M:"YVN%GVS^B#!T0GJY,>VHK9O?CF\O^[Q6J]K#>H5Q_7M^7RXG:V>#D((:@N MB3' @-*$ FU\N"TK,^UXTH.'T]$*BQ *<<>DAXX20P0( M.2 !M'@="3+71=^*ZG^?/[[-%+J\:?3M)S\N#/I9XD"_LF2]*'GQ 3"B>'F M[?]=\<: N)TH(!G:\JTCEG@$Y]UJ]5!>VX=E?(N@%F>3ANZVQ^,O?0I\=ANT MC'VY5I<84:PQ9< Y PV&RF/8. 1/==);7YUE !)B##!S'%/-F1+( X24MXIR MB[.?7JKE*^:UX,7#(JREHI%V>YVBD;>( O?(Y7,9J:77GH!]$GULC?Y&Y&(C M\\X'-A668Z8:>Z>W&\#''%9FDTW$O>36\JDS& 75TR>;'ZI%;$=67G]XJ*]J M$".=4(1Q+0ER(0F@I&G@SPA7:60_FM10.48)# (30+UQ6@I%J:;2!YD=S=TG M\>_;1/#%VU>)3[E-R-2G3O1R6GFJB=Q.Y_!EK?4_2X;VQ)@GR<"Z3JB)N,#I MX3):!M7/,-Q$#O)160\\A".&Y=5R:(+9H>%8HX$=Q MJ4B.6K),+>H=5N^K,-O/BL/'>1L&S8J_B3S(-$EKK M_"33H5NKG9-/BW8]>/+9X(4 9BI6GT"/GBF@4$UK+2:$,;L-SW>+;P_KU4:& MS^7WSY==R?2"0M( Q[5A8#)P$ZJ+,-CA]0I!"&&.G?N_.E1%#+;<,VZD;98U^(F M.)W,-FD17DS''&D1Q/Y03;&1?$?]6^&+1OIB)WZQD;]C@)#95@DQP'1LULW- MY[9=.R_>"\77'/4XIIF +QY)T6KT:3^P1S7E//SUK^KJ=AY^$-?*@4PZ7O P M@DNN,&!$0HN;/4&..52#.M6CDCC@'+$>RMC*S3@B%5'&0DB9 L!B? J_>K41 MN)CM)1Z8KOL99R#O.II=LCG8K0;%@0H9?6P_HPWL9D#V.@G<;G#Z)KJ=0=$.%M%?BOY)B[8"AQ_?B IU11PH G4R"JD.=RW-.54 M@_;OSV:23V 6W]Y&0#!+'6("<^>@H$(:YS'EF9UTE.9)';[)@&NA&X>=N>@Z MA"$SU=U'MN%H-?>]V]BHUCB+LTVS^]'J[4.8/G.M?>0I,'J=O?]4R%=C?QO[ M(>OK UIZ L'%J1'H6UA0+C^7ZX?E8AL7ST,KYY^)^)WL12&FVE3Z^N3%/>?,FIW5:1! 3,4Q:E+"UPH'4 MQ4;L8B]W\3%XBL8HM>@=T_V\\8CV&,"'G<, M+:MQ9WF"YZR/G+];U!O@<;Z_+X.S?C^??0F>>_TC"+)>SJ[6EW4#)".AUU81 M"S!DWM3+W(I8R&_5;2-EO#"W9="6>""#IH JZ0 RWFO$L.7*9O:(FSLJ!V(F MD.E0B+;P;"< ,\V+/<.QJ$4L=C(6?S12ICRW-A3$";[I!%!W\T,;R.<'D-_5 MD-\ULO9]^:P=$J_YE(%QG(#_&%JC*M^L2_ +3]HU?"[O9_-%R.5J"2[*Y?UN M<. \!%PJ833Q0NL0!>+M*O/6:=':-;0?4A&,6)B44&A&.6/*2(V(@ !+BC'- MO4NZ:S+3=$E:-J)NUUKXS/NZ&<*/U?$ZAM0-Q;.)#30)[F0YZU]-E) MN74F49?AH9V @\F@5)5U.J9= M/_WX+8R[;@9\4QIXZ7SP:&CW$ON9]P[ MFZEPOL"6V2TSC9N6^=2K1IKA:5SJYXMXC:&M$$90+;BUQ@(:1Y72HOWRIJU" M]XY# B#7U&YSU!LI.W*HT/#W(Y%3XAP&H=N!9TP M@Z9!>80_,]ED&NR92[EJE'G=O=AAYZNK^,KAY]FZW 6_V".O-,8*4 >9%\(I MV2QB0#CN6N9X<3"CG+1Y8P&OF**. @M8MNR':O6F1'>*!ZQ:.9FZM0\1(8+4L4O7"< M7G&BGSI'RA(#X#1(0>)0CNW.[*5U7GND%)5,:(TM4$!MEID$WJ%6YY4[#\ZA M@D0GJ >B"Q"-GLCM0,J&2Q N M=BU)]+'--(+J?.JEE"3ZXSA 2>(E(1C2Q#JJI,'&<*0%]+)9X)0 /E!)XJ6A MM6$ \9!9"(XI@DQ2A3@!TBIMH53^9RU)=(*Y=TDB-\+#EB2FP*%I8'8K2O2Q MRC3X,Y=R[8L2_3%LRYWOR]6J+!\3^8=J_9_EVE3W(3FZ*J]MN;I:SNMVL;NP MV%IAF4$2::,((N$+:)O%'5O(IG!H1Q$40@IC!Q5G@F+CA.2^P\P])++35F246:YY_N,* *,HB1""M? M4%F_O1Y4,DQB9F1F!Z75^;OSXJ,O/GUVY^[#A;IX]_%#6G;0 ;%V@7]>L-*\ M1RU+?6%X)TWQQT7YU[K08:7\8^2(_1DR1X+Q[BA.(\[N(7\UU'SJ4@2>S^X. M'KN)992[:O6P+..DJ>?,I8!"&JP=4!0&S\0<\&2S3)3!G-GTZN_;8T+C7,@% MO.<$4^&]1,+$UTZ$A%P1D/NJH7_W07TP[]3[XMV'\XO/O_\6*.>\2^UW '13 MBK[C MNEVALD?/3PV%[&$_)42_#>K.X.!_\T.&UPK5ZLYPZ-6OM'B&?KNF/* MQYN=()^JU?Q18<(SJ$/:PQ&0C! "F ?6*BE"YB,%5JT?7&HSEH5.&TR(P@2& MW$HK%\B!88P<5AC+C&>A=N+%T&&_4!L)3U;R:P/;D54Y*.K36)+#JO3LI=G! M\6J[&%5(J]:K_=4^AA$6WEKA.+):P;@!OEEVRA,H4V*.)Q^M':68(.J-8A0B MK[5BFB(.O1!"X^Q/]IR?N]18(A6<=IR4$98S#$3KI"-@TB*.K M\-4@DZ8+&9B'Y3)PT=X54R>U 6&>QU<^*&+0FF;::XMT.B<\'4%[+>+I&H4Y MIR&\$(#2, J!G%%F76YJV(I3S&KA$C<_.V*60A4YX>K"&&=%@]AIJ>,)+F\R M2%<ZD_,E M(0(8:D+$;PQF4@3WBILEXX1J]>Y VHAA',*0$-XI2[G%4J/ JD'Q\%V@8>[: M:I2NF"VNBZOX1;F7<]RUU JK(VMK6*RGL=8&UJG*.3L37?SWV3S\^:[TU?(\ M#'Q>7CTL0Z)1KFSY9;W_TY89+IF2G!/(#**,HK!".9+;5:FY8_[R>[G\4K5V M_XFC6V(LUSS>V_$TMGD3%$-'@2(.8L-(R@H]%+1]@GY;+=>_UGT]YO7SX_=' M%^@XD+>,'4Z(=5I4$>4I]@*=%3O1?[VIEK^N@O"[D&/D.",-PV,12"9K3(,O MLVGW-&K)BF)K#MWL$*T^EU=E8.\@SH=RW0PI()%:$X"H@-9#3S0FS>HE(<9) MRI:.#F0LT(X 03RG!D?U5)C&BD$ M1"YK\4VLA7+G7!GQ>+(0X-Y%N@1A(ZM MQB& G<9O.K!>/:JP)5Z+[0!9NP@Y,UII0? &J"<%MI'OK3[# MXPA9] !O&I311X&GMTO[8M&I0'_)/3<*!WKB5B#*)A M,'\)D8LOH0FEF:'2,2TI(,1XQ+F$5J?UE-T)T7HM7,2_THLT$H'J4(T?%*-> M5?@3EM[;EMQ;@S4-:N@H^[$2>R(":83P(:CUI)(/J48.0\29TU!0[4W@HLV4 M-P[AI,.#KPX20B/(A2.<"DD=5X)II0+/005"EJU5YMAB+U&?K;LNX*7P16;< MNE'' 72GW<-[CLZ;G-(#T"G12Q\U7F2:WK@,O8>P%^A2.^20HE C::0#U#+5 M[(<;@C7(LXUP( TCL9SA"%I4%0#'YC8RX ! TYZQI+V^CKM)+RO%E]'VDA( MP7W8O81,@&?83MA+.LT=A;U\ VPJ=##+1)@RHX(=MQ8Z8]F673\MJV_E6$X\ 1X89S%FNUP*:MBJ57#:@""DV Q)%$(>BCQ6F%/. MM? V? NBW$GI7L9M4MJ!K88!MAUKC8YI&GL=P+G+76"Y_4,O#(,(8$!2#UQ >:\L@)JN.#8AX Q2'B20!4@!KQSCYL4HCF\>G@DY5M'X1E79G@SJ@. UNZ:G#ZR>$.B.2=B;@ M4C"-(/&0:,<]]$!PL@O-0]C$TT\'!08TDDKIF"&,2D=#4$:TA\ X[[%P:9S1 M]5A0]^- ;T/2#326$$=AR#C=OV;F_.M49G&*D\5^L6-]T2=6S<\W[8R MG);3^<;IVY"T1 M.T)5@X,^#3(;7JVG3<;SX-:!$)\V+G!2"0^U9&'2: 4HLU)M5Z,+WKXK!3X= M!G%)K430A,^,S]@*@@&T 'IHJ% J]YV[INW&W5["U*<:>D"83&@YT>M,8:=O M7O(Z0NTHJRNLDR.ISHJ\3DO]L$F] /QI]B.>& I<&+ZS?-AWGSZX@AQWWA'U M')B0=N# AU@V<8(#UI$N]X';C"M,T%H#K8%#E"HO#488(P8< #"P%6P!X+-/)8(9I+,XLFKURMWAX]%KW<']8S1?E:F6J M^R_S1?T<@:GJCL]AS/#5:GY=MYFO%KMN\KO5K"BW! KOD%>$(:MQTP+0"2U< M4K/W[F)PC+@UW"$+'44&2 640IQ[+ /=F-RG\PZZHESM)(Y?[D5.[!&?T2+M MPI:)&",MK&F$+@ZD#O'-WB2/!#]X&>-$=\>Z@WR$C4>PW#3(>0Q%G[;$'PO; M[BG@)7& 0Y(%P2RZPFILE;/ OQ7DJ=^X6/9]A@*[ 13C *XB%O2;1V6$O+ MO/1NE)KWU?/$KV_>]S9N7?.]02'KG^>=.KE+2NI:8S<-2NJCP)M)7"(6'2CD MA1MS!GGA/)7*$0F%T ;K)ISPD.NDY^N/CP0-"!\?'T:EA%J.E7.4Q*L'$AAM M?.ZG-@YN@ Y23NJ"93+#9(:Q!]E,X$+M49S:L5 /?"='2'UT>9V;>B/4NFEN MM?A>+M?QQ'.\@'9X:D 0J@ /GML033 !7-&=XP8\Z6S0ZZ, )!323,;7TJ@ M2(>T6SC,L2 >"J5S[^_MKLM>[44LKH.,'>Y3],"R'46- V,:/1W(5-@:MU,= M'WH5G2.DU!_1:1#2 'H\[1X\$#(9JV6'=V2%L(18YYG%7N#XSC!O%E@("7(7 MS XD88;IL,HM]UY19HC0F%N$.=/82)S_P,(AH9VF9)9BEFQ5LTP6&:UP=BH2 M[07UL.6S#B:QG>F ;:,2@ZT,U@KP3S4X0?6CU+''Z)^_S9"R66U M0<'I7$0[6;6L76VL-4C3X(5.DK]>]TK4OOU;L*^>(86,86Q4?&G;AKF.,.&T MF>:6N*1*_)%AM"!,6,0E)Y(Z!"6@$'.IJ<(*>I.VO]?A*,6!9,VY];*6,+$4 MWP?)=H0Q$HAI_'$HU/]LCJ:K]7HY__*PK@^>K:OBT^RDA?E.9]0'0'L:1#2$ M(L_>RQT(F_;%^/O[:E$/NWF8A4%.BO^'_ O8?3BVVQ9?(_2_6M! 3@# MF_\7J]NPM%;%[&%]6RWG_UU>_Z\" M XT_K1[6JW7X(F3#9T7XV;?R:CW_7M[]^)?4$G^JA=I6]C,:)[6@7]OE?&.7 M6IJSXET-Y=CU_,>8'"WC=X1O&MS57?QG1?M>.+0^F'Y]73\:/KO[-)M?OUN8 MV;=YR#L.1K\$#FALC;'4,*$E8VA7E("*BK3&X"V&(P $';&$/.BIK#!$8TVX M@@1A#[*_4K63,##8_/K7^:*XV@B9>(%X &#;$<[(F*91T &<4;HBP+F5+U;/ M]_0T\JG^-R$[PE #XCT-SAI2H:=']X?&JD/\M7%X[O[;7?6C+.MO72P?5NM+ MX333S#/HL!1:(P>;+JX88D+IY:+\.EN7U\E!V:LC6F"M=(83031E""I#F":> M8!/B#H]8JW4H-^OP4+B4B.#;;/&CN#J(V(K;\NZZ^/(CEF/_ZV%V-[^9AU!K MU[0H_I5RL:JW&^J&L,4OZ]NR^/!OUKS>0#&?39*#L+S&Z!V7;>.QLZ*12.NFP?U_>RO U+/&11 MFR96[ZM5[%_U\>9B]M>EX(Q81QC6@ K)A0*>[Z(4Y),N2J>.[31WD!%M! 84 M62>L=HAKZ@S"%D*0.Q;RI-_K%T!1 C\63F4PS#1+-IMWS2Z(946Q+KI_+ M]6R^"&P^6R[FBZ^K ZE"0#6_FJ\O.3%(0KN;KC4AI?#D$HNTHW6/MN\7Z-GQ= MMU8'12[;ENJI]U&3]D];0SH- NJCP)O[I8E8#-6R\!(1Y#7@C@JJ YL1X3%I MUHMGRG<\W?7R8( Q (63S&A)C2+*J3"QM.?QX56(TUK@#'#DJ][P'(J,^D/= MCII&13F-J%YN3#BM;H3MSI;U0W8:?#6<.HE=!Q-Q>HO+OMPO%Y?G5[?E]<-= M^?'F?;E:E>7[--L9%Y"_[6&BI:XX [:\&+/Z+H12W[ MZ^?C1C3-=16RHA!CUEM5TS?1(W$[K9>MJ>YJ4\WV"^<@@GC]4-03YQ9AJ5T6 MD!C4#JL/4"\XL5%P/ZUC&T?%:L1YG!C,US)\_%9?3EM\K879W5#[;;:.#^+^ M>"H)%F$A\_@2F!.23#$E=>":!$4ON4#N-S9C&U5CFF3>"6D-7(D*+' M,^I,A1 X=]?+P^6\E3 2;/C33HVN?C"K55JF B-2(?V6&:1T5 3239R:O@T_\B.9EM&]O/%+,#3;LT[03Q0U%D/ M'/0F1%+V91B+$3V^S2O,O!6 MB;[\.Z@-VO'NJ>!/X]M'^$Z391. /,*N.EHR<"::,,94Y3HITSVCB#8+.JPO?;%Y3[ MB4&P#-7.>+&L?+,UWMW&>)L3T?.] M%GUKS;U >ZWB/(XE)E!W'DG1:O19GGAB;5<1]P\A12A_FR_F]P_WG^,2N/LT M^Q'7PLI7R\?5F:?U<8"1AD3'#)PH@@Q%3#5< &A:9#^,1)AR;R32)M[^148J M*7&\)&J5,)Z+I.?K^U9)-@IL\X%&@R+8N=AH6/QG.5LF5DE&LEN[E&)Z)NNX MGQNK6!N3-$;;Z/#8:D\*WJN3)RV#X'_LJ-^H]IU&0C2RSD\/%)X \;8N8W,[ MY&+VEYVOKNZJ51!OUQTFN"-ML3,"&<0D5 *2$!4J)JP$%L"V;YX<&P($II+& M<.\QH-AC30!P4C"*H)4X9P%V>Y4JB%7LY3I9TZ,C&!U9RD,@.XT%.H@FU?#S M+FTQ-??&PYB;TD=_JF[N^K/&!U> A];1D.C(*'(AXS+.;U=5)#(M.BJ MS7B&*V4YH@QB3:G#JDX]$,3>,FU%[O9(.XF*62-2,?LZFR]6ZV(6;T5M+MJO MPS*L#_&D!4Z# -Z.Q<;&.HW-=AT+(I]MY-LT/=I@OQ-Q7%9K@=D1=AL2\6FP MW* :5?GF9S?6V_&M^RLVS2AUN2AOYNM+K23#3FE%.<*0:@ 8:Q:@$]I??B^7 M7ZI4SGMM-$]D2'"A8ZZ48+V5'.BLWE,O[..C!KKND2#L5\E=JL5582XFVZP2Z ML#"3#BV\.()UC(0%CB$WP<-2IP17U%""(0 (D;3&Z>GAMG7Z(O& 0C>@6AY/ MR(Y1XK[<[@6+FEE:;;7E.9GP$C#'SB7T G(:=-)3AZ=G$@9 I"V9?%K&S<#U MC]@!;JT6U_$FW;?[PU<-L3: .*L],@9I@:20KEXO4MC8WZ_E>GE[((M4?-4& MPN#K*2="4B6]-=AR)KSF&5/,1K:SNA'>>G>'M);O9)[Y3<2.+*KAT)[& AM0 MGRK7O!QHX>WCB/W:-XP98A@$A@(1UK_Q"C5KD$*;U*PM:6 AB##6(0@(_P\)\KSY<%.J#+=R__?[NTV_N0V(P,"S> M/3DO-]1#TM]ACG*RH"(%R2ZTV,<@$V?(7JJU)76.L&L MR]VO\M%A[<=A_E[29G>_Y<&Z7G"V+[GD1++[V8D>(&:KP3Q!ZHT"3%=&5P8'J4,;=2Q.2Q2#/2>DC"M": M/9+0FR)YI"EPE#LZ8-&-.C[,[DM;W<_FBTO@K' B#.4P=@*8D%]L72W'0J.D M1UA>'<1K1JQDP9%+5A^O,A(B"060EB#M<]_$?;)$SHHH6A\R2<&O"Z5D@JX7 ML6Q0*_[8R'52@MG#TYIF.B Z1;+IHL91RNF,2[O>9>5B7BU_7ZS*JY"877\N MOU=WW^>+KQ=_5A>WU<,JY/EN_O5V798+$WX^7_O9U>86;GG_I5Q>:@4M-R%^ MHL%G##SH++G077P8+KQH)E8\&KC05OMHKT[G?6 M#\$7'-VHAIG /;315*U.,/'3HOE_GRWGL<[P>;8NZZ0!F5",N)"]BP5(3HV%=?$,.=M_E/.&WF**%!:U)Z.4[MH M/2M$:9[I$3HG2?Z?@G$D)N^,VS1B\>[B5P/-G^XTL0WR.;!2^'A)XZ/77NNXW:*\$\8(R0QV"*FP]G+7"P>BBK98I9-%!IAZ MT<5)DOGG@+2DC$3TID<:J0H!L1S?C(YG&0!OYBIV Q5;"#2/]4@OYM[?SY5PG1]_& M[OA)T@&QGP9_#:S3\Y.F@R/6EN7T;%53Z780A#6Q@$&I&#- FT,#[VA$EA/D:=,0ZD9=F%,'<9D7N9NQ_GL%$&4K*A%ZW6>*P'$ M+ANE>?#KM4_:#KH1=DEWV+3>)$U'Y&GN+[[.ZA/B:Y>8VN?AR]6O0\ )8*;!_9*9S;\NL5T=7FK7*UC ANO58=( MTAA$?=S=$Q0:!80RNUH*=L!WSRB?CZ6ETMY@2V$8#+/@$SA4UB-KG<<.ISU\ MGDZ,C4#%,I9:JD5Q79;WY75Q5\WBUZNKY?Q;^][I@P'<);S+BVVOK/.LV.%< ME[1J\4X9\#W#JG7,UQWE:7#<8-HDIC5 M7>V$+&[*WSP#9=H;P7?I M=7R*;&>U('SQZ6V7-UKFW0KDQ#1\6,--@Z5'T+-%@IX#V6XQ;O,"I V>XS(, M@+4'!"-%P]S#GO#FP#AGC/=(U!\-X[B'QL=.@!Y0;[26#AGNL5'>6"-Y]N+E M]EG4ZSI'CV2\^%XNU_-(P-=![#X!;!J>74+6;%#V#%)WL-H3!Z6' +4.0SNA M.@U*&T*1HZ%F#VQ:79R]J#Z7(0!RL^7=C]V+)O_U, ^4N=GJ^?BP7JUGB^OY MXNM_S->W)BS6V7Q1/XQEJO#M6%%;_>_9]_)#M=9EN?BMC'T4;7QMQ&FN!<*. M0.F: Z9<^W97_?-)YX% D &L G04::^8Y!!J29ST$.#<9WLOJF(9E2K*J-59 M<;]]UFBY56P;?!;57K7BSZ!;<;51;OMJW=5.O>(VZ%W\.TZ=1=K!ZK4]1*W3PEM76Z!N=B@.EBJA5L55K^\[D7K$B:E8$U8JH M6_';3V#TA%O DS=^MZO!CY=^CI7?]_)P#N!?B -.;^0)7#,^K?[55)9;0K!R M& P]3>O>W;222E +E>;"@R!52.N8)'*?%GC8.C090!:ID 6$X-@RGWJ'A7' M<*&4591BD[O+_/-<['$C@K-B?I,GZ!C#CBU"C(F9,"V@>)3R%1^?E="*=S=Y M@H68MI*[!L$](?T-9<_HK$FX.#'U+8ZS9+H]L;8]HUM M4ZW6J_K \*4C0 L*A52> "4<\(PTC( P33K,^?HHR%LJN#6,>$RUQ%)BC' \ MP"@%-7*<3?S5ZJ%^/_$JRM7MH<0.^+6M=HX!79=B9X-:+=*)CIF_@LW1.F=? M/*=2YNRMQRL/K_5%ILL.^J4@R&LMN;>8.DPY4GI7JO#>=#XZ?HEA?$L!<8N MHLQB1>-3<9H([0S'%F8FF,/J4=\M[+=!2M^5'A2?Q(WFW3V5QUO.I]L];KDA MW!JS:3!%-]&/;-LFZM_[39K]HPZ.6")%<*06\EC/M,SC[N/EK;J=?S&]5V=ZO363COLT6&Q(A=J^*],5J[:,YV?S97Q-NGP_GWV)N>"\ M7/U6SN)#-MSDCEX(W>2)L9'L6G#E;TPG1CQ]=/E-18; *$3!-5/ MI=[V786022XDYM9KI( A/I[TW"Q)"5#2N?#\T@IF0KY.@0'>4HF0$K$!NE>0 M:$@-S;W#LH_#BB\_BF&(\G26'3V,'L&H7>/J%^QYHJ;2V?$>)V#N:>N).9+3 MXY$OI![$4JW.UYEJL0Y"E8OUI]F/^O;!I@FF!(9)Z@AUAB&%". <-4Q%/6IU MB?3H !B[KT**XZ'<1 70'ADM+8"AR T>^U[+U:QE2OA/%1GT([3^VAXI3'R MJM0C7@3#E9RO!^ MUS#4<2\$MTQ!@3T+HC*V6SAAW22=:,@BH#48,^8U#AZ+:L$E=S"D9$(+$@^) M)W6HG% ]_GW7YL6GF06C9Q1Y)L TBO-M;#_U#&1GGW&2CO3I\$^79W2 (%]J MT=4>)_!U9G9W]7!7?_FYNKOSU?+/V?+Z$@EJ$17 " =UO&3$D-Y2G@(B[2A? M?FF-)D9AKQ20D%(,M,,"*8-YX&<]9GEL2"8\*PZT+?Z(^A9;A4_G%+M.E]$] MY @S90KNLM,DF;KW?-EVX[C2GO/FG\ZO]L4CGY,=Q%+)'GJS2KN)8?]:ED!@0AP1DQ#(<^S^BYL2/,EZ9RV_E%8&@1$<'.:YU$YWB9$W:W1$>J+1IR?#>;QG7G*_@55_[(G\WI#F M:>/K3C(=)N;?3H/!:S[MA!;)[<=>$?7OL_GB?;5:O5M>_%8W6<8XU>O\<7C/9G!D\:;XI]7-[UXRX#.1Q- IDKN3L)8_?R6L1B7151R&(K91'%+'[YK5Q> M_:,X+Y?5HOI;P@F-"1F_Q3F9G]/NG<]"'OK<_VCG>$?LZYT^WDT=3F4+OC3:-9Z+4#4].;(A,X@C5!4*I)+^M)A%[GM[-E M>5O=A9FQNI1*0BZ"Q$8[*'W<=E!;&M4<"=ZN]#&FQ,IS[SPEUGI%.20"6R^L M58 S[H,?R%[T>#GPNJF6]^6R>.^4+2YNR^7L6_FPGE^MXF-Y5_]2K Y4F(0_ M39L%)PW LIE_BM'7^<\]4281=66;,#U"KDUI]/YIJ>SA<.+,-Q-G^63B+'<3 MYTL]<>Y?)*!#AIENN'5HFO%CK4X3XY\ZT.J&R#A15@]KC1EB?2YG=_/_+J]C M::Y:G)?K]5W]4=7-_AB .=S^B+IPBI0W\?:Q=LA"U^RV:T=LJQ.+I]7 $ *9 M4,(2:JC&0#KK,#%0!![QA.1^Y[D1N/A:MT->%*N=S-L7I7KL.TU\;HP7BIUV M6IPV.-O-L+]O9]CYHQEV<,#'_-/-L/%CN-/.M&D4TH:><:-&>LD&S!S[Y9M0 M_SS18$:,,L2'N2TZ9L3HJV4Y_[IP?UW5YV<^EP=IX25"#FKB*-#*6J0]E7J7 M8GL%U/@5N:/B,J:5TY(J%MP)$E)S9!TTG%L+I"%)_9P[E>.VTA7E5KQB>2A? MI$[WL*R*ZW)1W<\7LW5@V.G$A_UFPGBAX&A3X+117S.7&CV+1XK^;--C_#AN MM&DRC4+4B'$$08")-@@A MJ!R-K>,WE*BHH]M+2FYQ?=(K2@A1IPCW+)"V UQP[6/G)L0M#W%JTF-CCQ4: MY(+2>5@.VQM*H+ZA)'^.\[83NZ72TL@_]SG:@3 8YY9*DD7:$EG]B-I%X,V+ M\OY;M9PM?[R[_Q;DCS+'@[KQ[:KS*%9]?U1]G\WOHOB!9:_JU]+\6 MZR!_^'>C03'?J9!V:R2W7=I=!9F02=(RJXTU:F/L;;&7O8C"GQ7UPVQ[^<^* MG0:_AMCXUU7085S?T0_O(TYB)$-.PQN,I6QUDL62QN^FNK^?K^L=:;6XWL5- M5T$".U]=W5710:DOJ_5R=A6"9:.I,#","S&S2F")F?,(8<,IT:SMNQAI@P+E MC512$FD-5=AK;CT0P"&GM.,TXZ[;@9SU8T:/)"WVHA9_-,*.W.DC"<@CRS^/ M0::QVC/I5HTQI9,ZV[XJP.;%"N1";LL5!D!)1CQCT(/MVN50H/97D-X! M9U*/W!%Q[=HL][&7N3H4LF^5]2W]7RN1#H;;!.J;P^E2Y9A9J0';B]O!^L=% M^)CZ'1"AG,(&.%W@3L:'0[%-A3B6@' MT^=9%#LL4CU)+8ZZ?0O"AA#92 VQ=E) ?BI2&XS14I#MQ6B90!V(T39T=I)'=M[$*YW0.F ]:4+K MHD\[0NN,5-M4_-M=N2ZO/RVK_Z^\:AY;L) 89:ST'G'(P_+2FFX7FE38XY0$ M_*7/A] [RS00DC+J6"!F;)A1B&H A4"Y6R_OI(J/JW]=SNY3[O=UA:Q=9IT; MK>1\>@]4E*C;^S+= $M+G7,#USEA?@S@ $GR"YH>28W[X#*-A+B7!M5PLR0M M3M0/J_FB7*W4U7\]S%?S.&OJJ%0A+R PX9.I9 (3SX!JICT%R*9$AZ^-@0 V M1$@8,C]/I1."$B1&B[DU(^5/O3TQ[0 M$Z6E;P*62%K=P)XN?774IP61]4&J55IZ<3M?7G^:+=<_MC$:L< H(BW!@$"H MF5;>;M>8 I2W?_3TV2<;C(1RUEK"8[M.*"B%E&A/(-5"BMP[P+4\12U00DJ5 MCD^+[#,K-&E\%*8\IG2)TD:WP)E"/15R\, MIQ%P]5/AI>.V_?#H2B?;&"XL 6T!THPBSPR6"AG7+ Z++>I#*-LA!$ 6(N"$ MQIIR&G(E8)'DFAG M#3JYZ*4MKAU(Y4,D/6FE9/D>"\#DT MB4A.DUQ2E7B# M7CIATFX[,?Q@?C6[4XOK3]5J_=ML^8\R;FJ>E\OO\ZOX:-_F+7=LO16(042E MI] JKWRS:A1TLOWV8KOQL&%.$R"559P*(Z03!D@!M5*&?F][D#Q\<:4RW7(86SXQEWU+7XO2/BY_!J?]JZ6/]35 M>OZ]OIL<=2B75_/97;R9'/5X'WS:8A4^?]?G>A5\FZ9..^:L0Q(8(HW4S?J4 M6+M_D:C^98P&O6+V+U@\\V[!H%]Z_VTLYN3FUFMW.K//*E2 M??1N/NW>XHC:%@?J%A]OBJW"Q8'&M4_?ZUSLE2[V6A>UVO6O[A3?O__QD\^E MI"CB9YY374.2DW-5_\!G9+.]'D5-=?Y,(B2;+#C53\$!68+%O=CMA#5$41?$ M-V :? %DBLU-.A'$BL#U!G$TQQDHT0/]8*I?% M?ZJ8*1L(W6*CO#9)C(%VC5;5U=7RX;@@@:>,$\PPKH7RPF&,2$-:2JI6APA[ M#$\@4)P"1"R'-%;'@P3(,B\H5L1Q,U[L5>M[1FPP*>E*H<"J\.X>3#[I+K:!,3>=J,YX)^4B\RBX,ON+Q^6^5R;>5@N MP]^XE,H)21#3"AM#A3#"--NN!D#E$AYPZB6'#4[>>ZTE<8;*P#0,"\0#.)XX M)T52.YE.+S.][.R*U6VU7/\:G.=];IYM;9%<[B^'*4;S@F?%5OS)F"FW5\QA MKM&=X]MFR^@EMT,/ZBQ3K?*S^LQD/7N[SF[(MKWT\2G,[=O9JMP?Z/A-RK*LF 'KG%DL\X MT[C@DE&_:JQIGGCO[EO=SV_Q]7T9I%E]#H*XO[X%-U!^*->7GE-'E17$.B80 M4L@92!3R'DB$#$R[?G=T)&:D)2"VIJ2NTT^.FSIH<(:=^Z*2\ M0%@MSM?5U3\^S98?E^?K6<@8ZS=M/Y7+\]O9LKQ$4 G-$+2"0\@]]]*2^KE2 M!23SR*>]_O#V>!:$11R/T&+-J:5>F)"DQK?9D*2289B9K38B%JLHXUEL059\ MC^(5O\3CGM7=W6RY*D)$6ZRBL']+?1!B +C;D=C82*=N'=4@GV] #@*&!5ML M1"QJ&8L@9%%+.?ZCCF_ =H3>A@1]&C0WJ$8O/-LX+%H=:*\>9J4>UK?5:VK+#VX;2-8,5>LI/QV%.(VO%79V G MQUO=-7F=KWJBTYFGWJU6#V&T0(F> <@ 9] 2:6*!N%E'6O!6S\F^-8;W E., M.!9,4>M]2*(PUYK@0,F (WT*?IK7H@W(36WQ[,A+&:#LSTEGQ4:L$Q/21H@4 M,DI$(8B(TMLA*BYU35BGN\ZVE M1J1]T:3XHQ%KY/:VKZ%S9 WU!G0:ZZ>_&M7 $RUMW9Q?W9;7#W?EQQNU6,^O MYWEC69^O=7U=W#]?EM0^:QW?G'C;'CC_>/)5S\P"[-<)B38&5 M3!D%C.5\M]JX8$DIRL"B(<35YG4U&4(FK(2QQ#C(J-20"THRAQ.--O%:\*$^ MQ5ZAHM&HB/.L.- I_J67EGNM6R>#M^G;"QTUCY%';.PNG#6N2()SB1 MZ:?A/TZE?#6)Y9?FJWJ*IG^\_ 'U*Q6$&*0D@DP!8*D-_]';FT(2(P^3MCMS MRBDI-<1#BBGGE"L1(F9) 3.(J2X2;I(U,&+O<)H:1[HI'9LYXY^%A.F^:;7 M_-$IGMK)B/ 17S,%NT[#\4P"B6IZJVX(E_1A=M\\*BDMD@@Q:!36"@FOJ5,- M'T'&DJJE;P]&XW:Y9MK+^ :X5YQ11*@C,(S-6>[3QZ_0RUD111S"1:3@VH?G M,T$Z"%EOT#S1,T9OP97,O!V0GC)]=E&G%0=VQJEM;F85\L/ MU;I]0Q]2D>%F'F M%>O;LD D:+6)*W=0093'"?#:=@@=2-I)VZQD7<#=1$D+H+(12-SL1&ZB%)W M>D$IBT'2^DZ2';1H-(3+J5XTU 1-W^>Z_W54_ MRK+>6OSX+4[([7A.*J:,89#%<_($,8/I=L411-(V'EX?!2!@",>8QU>1 6:* M4RH-#9.8RI!(Y'ZD8B/+JEA7Q;?#W@Z-%TJ+L7N V7+/=!0<$\OS,5'\]4M M[KKIY5NHY3+\2KEIQ["1\VU/D65V/V#RGSC4A5H7/99 3!#S<522)#^EK"C.]/(*SG%NHH&1$4\.! MDL)#BX@ S@J'DYQ]!U;Z/;B'U;J^Z-=(MPV*'Q;SU/>).V+8CI#RPY=&1GMY M-B>B3L0Z+\)RA''ZP3@-MNFI0S7DQ$I\:7)[LNK=-N.\J![Q7-,HYE.8:5LY ME"(^+!-A+=702@LYW[GSV!7)Y-%-&(99CVP( *F#5EO-N2!84F( Q&.\ M1+G+TK^%R'6QGL_N[G[L,_:;D#NZ\T^?=C%56KZ>PR"M\O43VR(U7]\?_"P: M@8N+JFA$WOYHUR(K2MTM7\]AD,1W+4]JF.[O7#ZO9L6U4?:R4/N',%-!>SWS MSVB 263^.?5[^G!F9B1;GU.,H\7=OW*QJB?VP8A,*"F-HTY[2;'#U NR6[T$ M)C5Y/#:.84@!RADG)/R'$!72!HQL2!L01W*$3O\'*_2VO+LNOORH"\T?_LV: MQ#. ?=!L%VN/!>2@Z?^) O C6!T[-S< PM,(Q@?1Y.F)ML'0&>EXVOO=4\34 M2V.-=XQQP:1"(2:1S0I4/HW/!A.*A#R&2B@B@V?I M1VG?I[Z./KYY^QQ=.+%E!SGBD,>H4SS%]O[((^\GL_,T?,+X:@][&*TK[FV] MS8=R_6YQ5=V7[ZO52GV?S>\VX?E!S'Y;W04CK?1L-;_:72,"U#.G!)0QG .& M8\)-PSZ<.Y/B7+K*X*#&AABC'114**N"%(H"C&,7),YR7\7Y$-+C99S<_YKF M ;)!WH[PIX!V&K\'B8N-R,4O4>B_%3NQXQ[F84UH*_E94+0"SE:OUQ<7#TS)9?8F/4CS<7L[\N@8Z7.90!#&@AK?"8 MNF8]/Z^E^+1LHB+-OZ M8/&B_<'B 7%MQY/C0IK&C(= 'AXBCN+5G95CC2&(."X1OHG8$>H;#NUID-V M^E2YYF6N^-#&@D-Y?1GR13M ^,>+U1K)<46)KV(>.$W,@GC]2M&]8 MX\2QXE:\0:+%5 --@T(SZM MM1_;2F'GJZN[:O6PW-1H=_4!PQD(R2*E3$)L+(.(ZBT!,,METC6"@43BT@() MH'8 0VJDT$9"BZ@*F2N5V+',T:W048R/TEI-@G) 0@ZS2(_%P\GZM:1 M;KL@V/H]N^=-=79]28D!U!K\_Y/WKDUNW%BVZ%_);[29.-=QHX*J2I5XNHI4DRS9ZE]_@"239+U80&8BF3YW.D8NR7)B[07LA;WQ MV) :!2&'1!C@]O$945F5TTXT$S2!.F\)TR*D#4@+P#PGTC#NH5,HJ\YNES#X MN4HL[LN7^JI92=SN6G>KR#LXX6E2.1+7>;I8D.8R[^&]2.()21R ^6GHWQ"& M/'X,;RANTC>;KE;-V>_9[6[-8OO(RV:SFG^^W[2K&7&Y>-T<](KKQ0=TER#> MD:>4"A57B*G'(2EMO5$PGG6>JB\6!T+P3( !F!BJ&-(.4\@-]_$6/Q.E-ZI: M/_U2[0]UKCN6B"S>*ZD;6=/ID-QMKCWR_1KN[FVJ(_!QA7OEDAM'0,.F-HT X" MD15D+R< Y!W8RFV;A^B. LFW.9;.:O%_3NEVG(<#'KTM8,!F*QZZ,\VQ4* M#N+B'B24.2 Y9 JI]K(]XPIG+1@\WX)1QD@-@",440RTI!8X(U5('1A2OO1; MTD^WU./+T<>ZN5M0'>1UZ8XDIZED>7[SM/!IZG^6Q=%G:3DA:OUHG(9T];3A ME6>.NC#258;:DPC0$VM9B"2I5$ ;R^)385L?X4+SK'NV+[5AG51>A*236T^A M1,)8&3>Z#)9065YZFR=%BG916Q$Q2J:ZFQR58+F_()TE GN!F@Q1RB5SFK*4 M;<4KPM2-E?X%385@D ,) R=,0*2!YKLT1RC&B$DKK_UZ.]!"RZWE$D%*E?)! M:(4&7L5'&CFQ696'.I71[ES4]"]0@3.5W(FX4G\[DBMPYC$S6!5[UZ1%=8L" M&T.MUEI8C9PD@A.^JRLIC 0:#%S#_E'K ,LX@Q(*:&&44V)<@ Q211V-N\A MH$(5[*$H4L$^MQM.1P=3X#\O:DBO7M]"+E6Z/KMLS MS4VKZCKTS";TS*;MF7H'_>^]2]_ETO3,5%2:\$F4O2MG76ZY^UXL]IW,8J7] M[:^[YCT!P!.OA("@>3D>LC94M!1R,LPL]J19R"2F"E& M:%080V-HEXH 1E@ MDF4=A2[U L8(<<[H- M2"3#'KLP' UE "K->7SLS'FB)019Y3(Z32C[EPQ^_?C;R.=MJ05(,_CY&12GVJN^7]8G-)K'(4!_J9)A$$DF AZI MD%:*:AQF66V#?'E=ZM^!3OBA_=1'FV7/_NX$GH:E%TB*T \Y<\'IECQ5W#M'$0&$A?0/9LBPQ!+M58-L>'5&+Z_8/W)^QGGY]N-+] M"(XP#%'AB.;,$RD8<=:U;L>,%5T*LV6#B(_"<<>(,9C3YED?9R%2FG"!.$>E M*V8<*=R^V-@.FX;HEC?SA2)RA7E-?QAIMFDNV+S_ M:X294! C* ST /K4<"BML3#$#=;6*@U$F(ZT=AA9++&CA +(<#FWW^-K+D<< M(?Q_JBW&LUT43F+NA#% \A80 U3"FL4C,%:0^ZI+GT[[.!PVQDTL\I! M+D^9*C4\15WEZ#5VRFI.TWB*N.01-C$5R03_DEQTX2!]#6A?%7&W/X$X#5^S MDA.F.89. 0UW0QY+I;(*4#W].M<,>!FA/W/"\//J'CY%)-5^JF(10]\#]9DNG'1/(VX_7U M/*Y4SVX_S.8ASS"S;_/-[+8]=>:@D$Y1&)2)4!&$2IO6(Q3'*&O[\&1+PE%H ME2(&.DB=DX2=6I7;1""IR%) ]GR>!=L0(:2"\357^K5JKX^?G&UO=A97^^>VEWO M($C-N2+(<(B\8=A*J%3K:AIBGE4R+J=AJBBGSB+FD:7.4:$PUTH[0+37D)9> M&8X89XL?NQG_/^(3SOI'A^>;AR4[3=?.QG.>S+4PJV.<%]4S[SZOSZ1[.42> MD,$B_3$-52QCVN-"<^7X2P[OKJ[N[^YO0]YY_7[SM5Y%**OZ:T S_UYOEY=W M[1/IC50AWS'>>R@$LH[M?)@0[T!6J)?H%;SW;WVVWBO/3,2'([YQ*CP+*1G1HCOS9LGU>$^!(^( MZU?G"1%363L5+@[._#1$LH!=C\/(0LRE'T3?S.:+^KH]I=6>1$<"0 8A0U() MXQFW'+0>R1#.JMKQ0A/>*0SC^6!I,*64"$.I=X(C@[3PHGB^>R1\89J:7\TS M#PQT92Y-RT8@+4^X6D"'@Z7GD:OGB3FA33V9G(80]37BR3'^ 3C)WJ=[NW^M MW7GL'24QSC,F:)D"GK=.@IG(.L'TS.>-Q5(Q2*5&DE*'E;+:& 0P<80KGK4W MWF^_+F*J&E!=-^TR2,OWMWZY^F.VNKYD2A+LK*6*>89X?/;,[>=@S%1V MN?",MJ7P'"$O<&B06HCC>]C6P! %:*&\SRKUTT%[6KC5WUK _Q9RN!>.Z43< MU0YXICX-WB5IXG7.WLA3M@(=4:[V=SJC)\]"ENF;:>AF,>N>J^5=C,7DF.U) M\5JK%!)4.$XAPU9;HUF[09/KR6[V:+Z_#G+#:) 9N3]HP2G+N#,5&"1KB M38F ,R'<8<1KKGS658_'<)(=5]>3"05V&FDZ\UZ?5]?V_M5:.1#XY7_ M-;N]K]_5?S3_9OVNWK@_K^KU^M/L3UTOZB_S3?AINR93+ZY^;)%>AO"16J61 M,I!Q3CD)&>K!=4#2J[&#@]((68\8%"&VI1H*320#EEJA& 8*E5Z]CUBC1*UW M!7GJ;3PQ#W^T:&X+?PM_O<,U[O$[[[3N3;K?N"V]-:/:VE%M#:D:2ZI@ MRO9?KZM86'AK316,J';V-#\?+-J]3S#5CLVH%#35#NY62>CCOF)6Z.CK;4=O M@Y+J>]/1B]#1\VU'+T)'U]N.WH3._;SKZ/CS]=ZRBYT/]RT\-"#-S\RT9^O) M"10N.HO9RS-[4-_$ EM#B3$HQA@8$6UYD\LT"D*]P[O$PBVN.Z<51G*D%#,2 M&RHX44IHJAB@UAE$\PI>/@23+ 9N^V!X3D8QQ5@YD9SI7U+FN A3K(.8.>>XIE#OU\VDQ!W2[J>-",*5$U*+^!R-TTQZB+1PRL0" M'=AD[2H.D'?KK9>,O0OPF):3NP"=.9R(;_0PX,DN0$\NQLLD+Q&1#G-EC5?. MBY#G.K'?0H-AIALWA[Q4'#H*XNNJT% MN0AQFI5QGT0(3)R;1/9XT42GRR\Q M&AT[R7B]P\;*&P?MJS-GC-/KQ;&3Q$%[_R[NL5!AO?8 E9 Q=(2@J!TX[1 MD/]2+[D1W)6O*Q &RNZ^QM41^MP+?^?NTK0]L[]4;^9%".K#&_/L]9M*K5;A M+S:'="ZJ_9&$+\M599;K375DP]CW$LMVQJFSZE,9!]/(!*=#QY,+EE,!EIZE M)F->QWN)^L>[Y>*?][/;^9=YF*N?N2OU(;CY)0+">$^YQUX1;8$AT.[TCW-, MZ.6BOHG'V#\EYJY%0$I+E33(":UBN" T)0AP03$F*%Z!3!(_N16_)_8D"^&# MQTJ^QJN?GW\TKY2D7_\\8S\FY++3[;N.]^7WYE2?EM6CZ_-APFJOSU^TK[#O M[_,>&58]>Q^UBK9-OL\S,M_)]WVW1/A\8R M+RY!^TMI\EF[> )9\WGM7T[% MV0:..-3552RY/E_<"D$P!830BW!$$(-&-_K%_2&)B^8 M%\:)L$* (2^1P!2:0# (Q!+I G[ '"F<21^05_,&>EPOCS%'(T#550-RX+FH M9*\.%(E,I$.+Q21'W;XU\")U3JK,7VU(#!RH3&1H% ]9R@V1X:*7[GW1)XX9 M803\12*:,9C(C6U&ZYWDJI[;V_KS[[7[\J6^VKS_\J[^XX#RPVJ^N)I_NZW? M++;+/>^_J.ME\QCZI4-2$NL80L8Y19FUHJUJR6GHT;QG]7H ,4@2Z)D0TA+J M8:QSRC"USEO%#'#E'W-]LP].MB').EY)FQTDZEL+/K.0:,&^25O^2QIW:[_N%OM>A'+F3:F>43Z_$C=-TT5MK',/1Q#=6Q MN$U5\9=JW+Q=KN.6]/LOGV9_7@ICI +:*BX)!!]3*>MV2EL\?WP];=&H;C--T=G=X\A=TR^P!?^UC-WR+$ M?[MH3DP%0?UTXG!;$2U-8>Z$:@Y*_#3T<5B3E@4':I[FA<\?VKJTB'@B<)!6 M+R27P. CQQ-Y!:4??AD18[P5F@# : "NL/;6 4\ LU3KTF\.1D=*4ZTB_O2 MBQ..TXVS:7A(1^S+(49-[YL,5FFOK05ALA904 ",TA:%T(5E;6;UN^CSE[S"D$K?-)RACP&O7V'(XR*]@/=J M_KV)Q]\LUIM5L_2X_GDV7T17U#_^H[Z^":/GU_JV65-9?YU_TS^VOGJHM11I M#_]2_WCN8[_.U__8OJWB FHL 7$&HP$!#3,.\Y* X)IU&95*Q#PIO3X]B'E+12$"F\55JMV3G^T+,@IS M:9'VQ&A.C?!>HIVZ6<]95O[T0A,A$],6 H@T-Y03++QEA,8*Y0!!2D'A.6B/ MJGU#=^2%B6=).;44T8_%:7AT7R,>+S<,P7;?6U.#KP1A #/E$(4@OA, M]+9V&\JSD+Q?52](9 MH%Y46[#CJF4JA2?TF(9B#F_6LO#HS7T\>;U9J\7U+FY=7PHJN&-::87B MP2ZK -VM)B$@/"&9AZ<>?YYR0*50&+/XU@2'TF@O-18TV$6\S=H;[G0DZI!M MU3M,U6Q=K>IOR]6FOLY]4#F7O,333259RSRS%*%4L\5UFYR^7'BRT%O*#ZDX M=;"H*VO34)KN\)\\I-R+AR&.]IC9^JN_7?X15YWJ5N%"M'$[6Z_G7^:[9:;Z MRW)5QWUX@+@"F")C#<9$>@'0D=M8,M0!H$Q8UEN A)-Q_YYJKR01AH??!1EV M08=-X9@MHJTBW&JW>-?$;NMM'%%OP[<=\B: VRSW;S4-=X!HZ)[L?\SHC)TX M^&&DAUU+ZK'1EU4GQNSIG5X*:\_.AYQ*M3ITU#^<5RJ*/?Y:Y[/ M!, M2,5*/_OS="8X2N2[S0(#,)R[LCD&N5T7-1\N9#Y(VIM$_5S+F2]PEK22V9?O M:W;B;AJ#TP/],ZMV'B?17G-=U^+M?0Y9OZ^_U M[?);7"Q\N/>,J0FS,F,4(26<4TY#M',,!PTU>4\ZO]Z>" &>$5A210P5!B@- MI"0<4>.EQ*ITMMQ";-:JK@\@@%CUY-'IHMI)O$]2WX=_>_%POZM7L-K2OKN_FB_EZL]K>;=PM M;.XP4!%2$N,-(2Q#FBDPQ)@ M55CR=F OJILMW,979P\ 9[Y?."SO:3IX/LKS%''/]L]';#_$NM\C.9,Z9E%Y M0B?+=,DT%+.0;8]OF!1D,+GV]FW#=7W=U"W3CZNF[C!<:J0!19HBZ@AG6!H! M9>O&1!J=M^&;V"@C#HN0-8>X&%' D50"^9!/>T<@$J#\-O"GY2:X\/J%BMCM MWG!F9>R!"$_3S3,PG2F8K]6G/LMQYS3:3HCCP+Q/0Q6'-NIQ;><2G"5'DU=? MZ^O[V_K]EP^KY;=ZM?D1BQ=MX@[Y/^_G35"[O=< A/ 80^.\-S@>UF7MR5V! MJ4,R*Y!,;=0:X2#T3AGLJ TKA5X*J3B@C!I<.$8LD5WT=0@VVQ/>K0(NUU] M&X[OQ #R'%3G26$_ELO$BHFLG0H3AR9^&EHXO%F/@\,RO*7JX8N-ZA^?PH?4 MG_-X1)L9Z#EFUB/*&$((NM8U)>)9.75*>\1KHB G@HEXI0RH$!$S3!B47'C. M2E_!.NF?%U6$F:>!@W"<)G]CTSN@\FV9K7Z/&$>6OP363BC?D)Q/0_0&M6A9 M;H0.)'6Q7;N\F\T7EP(Q'4\O*.PIMU![0.7>#2G/VFI-:4\[Q27F1ANK*'9 M4Z^IX8)[CK3262^53UKJ<2XF4,)BSTAO#+;+&'^='\/)D;B!VTX1N?&+S MI.X!I_O?'$,\TPY($G$GM&Y8XJ>A=@/;M"PY5/,4;Z^MNU9BW48N:&A(Q/5" MZKG>>Y^V(BN4>_QM9#GGC@NG,*+.J1##0""=-HC%U?S29^9^F2WNO\RN-MN' M@Z/;!;#+51Q8/YJ'O#L<=LFF+TV\2C*7)U-'2VQG4:-'3)S0G:Z<34-A.J-? M#C-R >(*-SES%.E4,T%=,3 >2^$H,5P3IKBQ % &3(@B M"@O2'ED3!W5,H_JPF"9((Q&8IT$3V"C@8?:(>%5+!<6_M=ZD(!SQ#,%) MCL"TSF&HA4IR*@6A'##A6;O021US66\E''V66<64#XX&I* @"*,.4AD326R9 MX;!T,!.1Y&M'*B7I>E& C0X:<3Y92)*"3)*FX_ZYP)]Q^4ZVIZ_N-L43K^*Y M\C>+#ZOE31@IAP4"+*6AB'O$K*/:\S#<=Z,<6*3REGA/-(090@QXQ[A4U%HE MG3#!6 &\#3^I\NN\!VP_S1<_?=NARUWA[4-EZC+O2"SFKO4>8#4OL>Z G6W% M]V663B[[#D#N-*1G&%.>+ /QD_O$XEO]^6QI20(8V>A@PXX[:W!OO4L8D!6 M-<2$YH3D0A#!@'."*A5^AH8S%W([27%(%LYY'K%'M?XAB$Z3L)$YSA.R >@= M]TCBVX3:_ ,R/@UU&]*@U/.(7;GJK70_K^([E#RD==!H(9P1 $D'XX9-FW!X MF/6NSRM-(2X10(Q1)^/I%JV\P9I:C8GS!A0_NG-PP6][%]PO-5]4-Q'C0-J6 M2&U/71N>U0$U[:+Z^22AXZI9@Z6+DN5Q/'$5RS0F5<&Z<)1 M6;;UMU5]-6]N*H>?;^OX0RSI<+=<;>;_:O[\18R77C"E'>46"2^$](B(O3-: MK,'EHKZ)K:0IW6"PN.%4&!JB'XXIU5:8$ 89%-(Y3FG(R).\5VZ]]]B"9"<^ MLJ2Z/C(EL^3":-V4IIG3ZI].ZGK<,<B/'*) MAX$ZX81NC][/TU#X\"D8Q401S9"3>20PSC(/+ M3:Q)TS/BC0V%SS*&0G:+ :-420&4)!Y;&*9)!716R9<#IF0!V9;6^78ZZEV, M74'Y%&-= K0 MKS_5?VYTL/H?ER&5U?&8.'&:::FA$P)[AJ67&@A%<58UE[0F*>/" M;$7O1_7[[I]G4[XT]DXHW\#T3T/YAC;J\=7? M$IRE7Z=9K^NZ.3._?MRBXX8%G65&$V YMP(CT;JD8##S.LW+[9AX798)"(/3 M4T:M<$HJ+JD"3EI%\A*MCM=ILJ_/]* M3-JG*M55^+/Y9IZK3WT(39.GD;C, M4Z?%^L)S>I\O2N_N,H.ELM%^''J^U9^^=C M-:*!)LQ[*[V&VF$&(&M]+*0V6340LAM'TA@1%\E/$_Q3K(]'0W,9?2$,A;KG&GH93GSEB,-\LS0 M;[Z>W=RLXMF'^7+Q_LNO]?=Z<5]O*S<3J077P8.5L-:%?W+8'"W5GOD0MV1E MH"<;4MY()JFA'@C* =362,^88QY1@XH_0?006UP=VJ'K5CJ^'Z>)\=]8=&9& M@)V9+!/[G6#I5/0W!+G3T+-A3'D< 0['3\:%J,UJ=K7Y[_GFJ[E?;Y9W]:IY MH=)\G2T6@H1C#S8M3K#6ING Q@>DJ?1$ MA9C70A6B8$XLUJRP;K48JS\"R*I%>;%[V/3\MX]?4^P&C+/R -M>?">P"\ M0 (H=\BM#*99A^52&@R!;(AT V!#Y66>H*1\$8@X(H_>_;+;/6/.IYP M__RCBF4@9XL?F6?B!F$U3?!&)S1/[A[(VD75(JPVRZK%>*[W MIR%TPYKT^"3<\'QU$;E/7U?+^YNO;Q9!%^[JZ_EL]:.M)ZV),+&\B/4@Q"). M([7S1PXXXGD//":UJ$,Z[[PAW!A&L6?"8^LA@TQ:#+@K77#U6.9^KA?_^G&7 M^R+X,+SFZ]PXE/82NAW$ZACC!(3N1>82E:X_\].3N@%L.J%U0S'VFMA]OELM MXH6+Z_NKS=K]>75[?[W= 8E_\'Y1M^73 #806ZT=X@@%+\0([KP18I=V\2&Q M*8<$T]P[1(2FBE -)0PB@"'GA@%56M[T:KZH[U>SB\K/5]>S;^OZHOJ?]]]G MBXOJW>SF=A;U;GL3\;_F=_-_S>_2Q&\HGD^KWADHSI.[%ENU!U?M_J@*\%Y7 MNB*<7B^O[N_:\]Q3XO8!L'R.ZSW'WW8<+Q?UWU-GD6AO,S< B4$S,Z0Q\,R4 M,#!UYYT+AC9F661XY:O_H0W+>"R):2F0%A%,L5&V=9@0E"4]>?3\EZEFQ!,D MD=686@8DBB=4A.$68LE9Z65*=7L=E#T]8NU(3[I&EV&FDR3WU-\,>O+EM@Q- MO=2U@MEA^6E!3=7/?"ZF(Y<=L#^CCET9R+AP'YMIVW!&:B,8D41B0QB% K3# M.006_/)[O?J\S*@J=?1MB4# BX$7',9#1$HY%!J3T%BF!!0YH_D81O)@WEZK M7]2;?82PVAX>&+_6T8&6$SEE-_JFD3MVQ/[T;GQG!EYS@/5J<_DQR&%S[NWG M>GFSFGW[.K^:;;=4#:)(&@*@U=0(YZ S[8(,],@E'3\[W8) A"D-N37,4$"A MILP[9T1P<>HYR7*'#M'!,9ZT"; G8:?CA/&XRHL7CJ$,<=XBV'DD%.%WCT7B M)!'/B,4PQ)U7- :R83GD4,H0D?KF<4N[["FX!,1+H9R@S$@L&6[7[Q"UF*=H MQM'G0(B4)..4(^8I%5H*Z96#2!OE 8*E3XG^MIC'S;-&CA-O .5P<5H."M&0 MY_N_O7OSR=GJXR?UZ435H&=\?MTZ_;J^^OO-\OO_V)D3_9ZWOXENSX_<_F#R M,S[>@8_S.G07P,O.?9\^X[O[6+.KK7(OL*(P%F0@@GCC.'&R':1>D.1)_L%' M#:>::\%T++$'M%-$46-$^* VC#-7V&VW6-)G]#Q"7I_$BW&1Y[M;&,/L2"?- MV,=VOS!)=Z+F_/-R-]C+GD,BW:7?SC;SA;JK5V&.;\>QLE@Y*CUTL1@XEA:A M=AQ#R)/*#[SP:26MQ#[&#$!2PX(5(*0AL92F4#;,=X7=NT%4[2"E>WD7CE[W M]<+TY'G\ V9&=/RG)+S@_CW8.K\(] &_'&3$9&P4_EJO-^^__/=R=;M_X4TK MK[@T6.D0Z6..H<#M8-=8I>\4/OTTH2*^VH6XH9Q2(+1FC 5)"RZ$ ':EP_0( M*%Z8_"-"RM@.Z\!1PG9A67KR!*%AYOV7JD'39<>P T496X9EJ>JV9_A@,/4] M@/'$P)H#KU<8*53Z(L2):^=ONSZ]U9_@TS)[%F[S MA+Z7^;\.#68$Q/8WMW.'/2KO=WY2GY]L/5U_KZ_K9^_\4M-O/-C_^> M7]=O%E^6J[L&QPZ%#SRX/X-&+&:W[2VTM?[1GF-3B^N/]>K[_*I>;\L18* ! MP\C'_0P3DB1C2'LXR$NELF2P#$(E,05,-L^/4DB=5@!!)$,$;6+)T=+[1ZU+ MQP%6M;CW]SW7\=+%_GQG/(3<@N]6&^5,G9PFQ=/OW]S N5#7EKG^48+]$]/! M>7M[&G/(F3EX?!UE CV2.EOE(CS,G@ +#7@('KGR8>;4A'&U%2L!M4$^9T;J MCH(0[1""#.LPARL)A !4(F>](C9(*#_KK-,C;"_8+VF3R#2Z9,B)XHS1?F6D:# M$$AA=:L"RB*:=_JZ"P*KN.#28Z>-I48K3:UCQ%N+'+-89E4S[7%&^SSGLCL0 M=L+52](_#27 M37V:C_75_:HIXKZ-!ZTV4'*I%2)>(JRAAPHBQ83GD$G)DK>0^@+A4"+@% +: M @HP$ !1:$.Z&G HB$M7BF[AQZV5"'[[RY$)E8H/I+9&5,&*IOA3=; C;PU@ MG-Y+V-R:4L?E!6K_E_99QF[;E/JNV][N][;TW=+KR>)+&X!C=""&D(V;D^%@AFE>0]U8Z7 &H 5#!#41F/ M?W- J;4TUDDG0)<^S16Q5/#?\]8J>A&7MAHQ%F=YTUA$536P+JHML/BD54/A MF6H/G>#I1'XQ!+O3R",&L60Y_-C+4Z(WB^_U>A.GY$_AOVONFG&D59 X@AC1 M2"!'-3&M'X4_SEIM?>;SC J,L,0<6D&ABB^@8$E"ML.5X$:57D8](*HBI#SY MZ<)6FNH4)BI/;!YQ=):*W4\).:$J/=B;AICT,6 YV$CJ(QUFMJEOEJOYOYK0 MOCWQ+I7T$F/FB 4(VQ!!T9US$$-=UE&"A.9$G.@UMIH)0Q4.$0#'!#.JXIM_ MP)4.:0X(,Y^-&H+)+C)3G,2NLK,^4Y7LU^E)%J%>W$Y1E/H9=%*D!N J^7F MD &V11H]Y@)R8S@RF#!@L9%[E^+$9CT!Z M^2_+1?UC6P79WR^NU^W%+R8= Y 81AP4W#H#<#N^A;8NQ^5?: )2Y"G$6D.$ MJ=14:TGC?5W"J+&&F\+NWZ"J[AI8U7RQWJSN.P0D7>E+DX<1F,N3BBUI6T15 M ^E,PO$\,R=$I">5TQ"4OD8L!QU>N<\-K;XM5R%^L?7GS6'QN(UAH*900,,9 M0]Q#B8FPK<,XR;+RG],M*8.@"G.V%(I3H;R D$+KG.>.869*[XSNP577 =W1 MMDON@T*]V$R,3D8C,C-@V7,8@3W8?SQ/%'.*IU.!S2#\3D.:!K+ER;M PS&4 M+E1W=_7J:CZ[_3#[=GB5 SE%B#6.2T+CNA!5:.=2U+N\!9H76B"284XH(E!2 MB:2B(:%CBGM+O>""%!>F%E3U+:+*U:-.I*7J4&F^-CR1E_Z,I,K*;Q]_7GZO5XN89*B;>G$5=.Q954/0 . P#JD>U)(( M#%V[3T)1& HY2I/<*'!6*V%8B!L4M4(JR3@2UFLIA'"LM/C\]O>/?Z]N]E"K M6<3ZHW-T-!S7:0)U%IKS-.NWC]4!8]6"G$@ EWRR. "RNWV^^UJMG 1".(:# $0Z,BT5@$!5[7Z4R21<[-(LH-(0R MK$(63*T!"@/#H!("60?#M%!8&7=@FV-[RP@RXVSEP/R>UL(S4YNGABVKQY(8 M"&Z@YFMB<>8SSK">KP>ZG5AM>^)X\F^'^N,EDKXG4[.X>6:N*4CP!$Z=%C)L M67QPCG*_X^W^/IF@G 7?E"C@PPH@$(^:MTFM97J$.QX',$H9:WU(4B3%%"F@ M%5)6!D"*,RU8Z5<&CL^;JZ>'RH]%]&WNK=OQ.BQA8IM:7^5-=X-<[9AP!XYR MQZ-,1_[_\9['VQ,WJ4?OI G,O*.:.\R=CZX\IZZ6/6[Y88"@[I:KS?Q?];59 MKC=ZMIZO+ZW2@F#H)'6<*"J]C/N76XU@C-#+3;QYG+9JEMVXXIPP"@""QE)( MH.3*:<>UQH8Y!_-6S_8XD]5@CZB*D/*6RH8G.FW)[*PC_+!BV:N81 X &?>8&:"(]!JW'4IOV MUMF##UI/L%<*2(X@1X^#"*,.=(A(#0^<,0IUX@B M31'V6"$3L!;6BP9;=0!71729.XHC=J5$0'4PHWJV!R^JSXTM53!F M4O%6&O_=@["!^W<:FCRRS7GA6A'&2\\*;\/O#MBXM18(:J#W0BI/J,#N(#T" M72YB3>;P7Q55H(>8K(+2 !FK-UGJD!),.&$P)H C#IA-4B"Y5:!C^-UGAH@O M][#)2/U3=FHHT#%GFAJB)7^]J>$!_P6FAF[]^]>>&CK:/-#4T(?QKE/# ==# ME)?2846 YA0@QIVCD+B]NC@FDO8LLQO5'"MCJ-+ (JJ1"R"\)00 9)'C3A8. M^]7NG8&Z.I2$Z:?LW>GM)MZC,#NX/I]7<%_B+$-3>],^3=GL;]8KRC@0;SEK MFVIQ_7C7:F-FJ]6/^>*FU&0$2Y]7<36LSM(0L M]2@^;TR]4IK%A5R-0O;/O*$^QST[5=EMMO?C!O#C??[Q5PY?9>N5I<7AV)Z& M5PYLTS.+DT,S-G0P8NY7JX#JTM@0"7'()1-66^4,EVWE3A:2H*1:N5W;]I9" M*ZFGC&$*C)8&*JN$Y4HCS?(2G"['IKXN5YN?PG]XM[M+W9RZ.<"&@QI-))K8O7DWF[7-S\Y7SZ0-\ ;MVA+_Y:GMW%P([. MW9G+I'/0<:Q^"D/U,%*/3E_/-O&G'Q_JU7QY?8DDX-QAR^)%'XA1T)GV\"7G MFJCDX\X9;6(6VA&"0$AX/%.FH$&,>DT9( Z.XLE5X\EW!T\^')P,?[I%6WUK MX&:D/&])H6'[TXNZ6;5 JP_G9#OCB/&96.]VDO@P:R6-];Z' MAM.Y>>EL< %V)W $N(15R[)C,N?:3F'E+&3\OE]=_ MS&]OU>+Z31BHBYMYP!!?$MNL[7Q]=;M*A"E70&T]59A)&:9>9QU62G,D"AXH;G$V^P4'I-46 M:G7 6OW>HAVY.D@6DR>6,-2P/A.H#'2.&4=4X))UKHTARZKFFV7]IW1Q!N)O/*>"AWO ML'IH&+(4<$NY*QU>'MT6?>+A>4UVW6@@>;Z5Y MQ)BR "B-,:8RN':\#/S:,YGY'RSGI0V.ZMOLIDY.,&+SZ];I0L+R]YOE]_\1 M;-KZ6_CAL9L]L?<9Y^G.R7E=H@?N9=_1D#Y\[2Y%C2]H7&H/C+12"VXUDL:$ MUN3N\UHQA%)B@>R/%I[@6RP9#W7E\_*Z5Q>C),^IT]@8PJV/#7[!JSMQ%8P1!C4H.-;EOR&K*D2+_/ M]\=R]#VN:@LLW^FSF4OW_Y*D=92"9+Z&E(5'/+RB$%U9FXY8=+;@&=WHQT:. MA&R7'MWBVLXV]:5GWGDN #4<<2\LI@JU[7!KDVY/=__Z6/*Q154%6%7$E:\> MF:2E:TD8UNA$U'-#KB?T8R^C"1E4:L9HOU/&YW[;3) M,A/^CTJIJ%=!HR#%NFU*,9CT#G"O!D9++_; .H<=^>1EY!TE>>N:@R13-FA" M\HB)UY*3KL1-1T:ZF_!+-XFKW!EZ(1CYN0F9CEO>+S>J'65[7EPX;X111!#H>GP8VU.^3'.A$THVK MH=H:1T(>8+RH&I1AW%0[I%6$FJLK/3E.E9GQZ.VD.KV8'4Z*3K)T4IF&X7]B*Z*Q4YY98ARQE&*I[#ZV4LXG MG?;OW\HXTA7050_A=4R(.I.9JE1C\-A)H_(I'$Z87B#EI"3U)7(J8M3;CBB$Q_1K(% MQH0?WZ\^+?]87 JHB<" HG#3X@Q:D3;$@NZUDE>,KX_LKA$9#%?B-@Z"DL. M>9FR4HBW?J*21-G@@G*@(D5..A W,3'I8L%+4M*9C6PA:5*S]ZL/J^7W>;#W M4D$!G5:02$\<09( 3?;-62HZJ4EN(R-+RGX-H@7845>RN)R8XG4O.'QG@L[O]-VA+P<8(.G.OROE\P.BSY_FF]L0- "II:2*(4*) M11)8OM<7!V7RD93L#Q=V_@9$K.8 T=\^_UM;*^Q'N@+D,_6Z A0E*4\!F_^"#'1FZ?PRT!WZ?4U#("Z.?#*',68"PB@A5(ZPPDY7(D!)#E[[_3QPJ[> M8JI:4)G'U;L1EC[=%^,J3P R:1IRQC]FX)59OQ-9YY>%?O"?F?U[\)"^@[![ MDV1[;2YJTF:VN5]?"DL)=P CQZ%$3FH,]GNECJ85X.O=R#B["#MPU1Y=M867 MNXO0E+YY>98M'^7=A MNC&9*CLCD-A)=K+Y&_+&RW.4G)2=GBQ.17;ZFO',Y98!>,F[OK\RLTU]LUS] MB%7.(" (W!A,>BFIZ[?'$9D&4]6"ZG*//X.M5$4I1U0G(4GD M:-@+_7O[3ZI&-Z:F(A8=T3][L[\K"^G2\/%N=GNK[]?S1;U>7WHA/%$.<\HX M,XP"Z-5^34:2S*/@>=\>1QH:3%4+*E<:,ME*E89R1'62AD2.AI.&!_:?E(9N M3$U%&CJB?R(-?5A(EP9W5Z]N0D[T\VKYQ^:K6=Y]FRU^7!IMB",$>1X:$L8; MYP]G.I7-S%6ZM3&.5+38JBVX:H49[*0AN>0-)R;/$G)25/I1 M.!5QZ6G%$Y$9@I6,..1K?7O;-J(L(\QRK(A3%A/B(#YL#7F=N0R;]>F1HI ( MJ:N@Y%&5'(.48JE;"))$T( 1R)'UIP.0+C1-12*Z@7\:?G3G(&.'9GEW%PM_ M+*_^\?'K+(R8]_>;]6:VB#O(E]@*2SCG"CI#H"$2"+Y7(6$R:Y#U:FJDW9H& M8M5@O*BV**LCF-F[-KW83=Z[&8O8;CLX73D=<"?G!$&G]W.&8'8JLC2,,4_W M=H;C*$6VU%V]N(Y56?WM[.828L"-$4 +XK$C5@J\6\K5F%N3O)*2]]7"8K0' M4T4TZ9J32ZTTE[3DY=&"?'5;$4VF:L ET(=H'ZZ21@DBOJ')>$D:5I'2_N,+3JV9T;J"P;+07.X[#\_P' M*+O3][IZC,)" R]+KV_(+E!>DQU]7L+]O\[&^O7NPRA^<\FROX#C-UZX2KV MPI?8"[=-+\P/D/^>.GM$$IH) D@,FNDAFY9GYHQRU)YW(BEHU[+TH,R8W]=7[]9_!)PW*\:<.^_-*#>SF>?Y[?SS;Q>[T%A MXIVVQ%B+-6>0(FIPZZ*2JJ2W-P:"XJ"T##.N'0&442&IA !PSA@D6A1_':B1 MRF_!@BIT737;VA!<=6M$^*':?*VKNX,ILX:6CM!["=/:M#HN M,RR/?1;!5P%]M8-?M?C##]61!=7[+[M9\,B(;K/@"#V7,35.JP>[S9>O>]]K MGE?-=M;TG5)[T_G2/#M>/TU@\AW1V.59?"%MFKY?_W0SFWV[;*.#]]_J^.3? MXD;%V]%-RV_K];JN]^TSP*%04'NDC'$."D[V03/4(*EH6WZKQC,(0S3"@PI1 MB(S4!%*IM82*QX,#8TR^]^NMIR];M-5L#S=Q7BU ]^DI]+Q,=Y@M(\B+:@^S M.N"\J+9(4Z;$9Y:VVI6M+[/UYP;FCIKM\E9]NUFW?_)XG2N;PV<$MEP_G%=+ M"]JU+#V"\Q1RWVZCS!]F/Z).KR\14@(KK(E5TH2K-K\OVBC0-_7"*C M!/.*6RLX4L1KH>S.;W"($K+D)K%)PITC2,?M!T0YE!JJX+W$"6F4I*[THOP6 M95?Y&8K6-#DZ Z-Y\K0#V(I3B[%5J6JYV"\^9!T^Z*]8:=2=4+"!N9^&H@UM MU++H>.V64\S#/3##E?)7#A)1SN'Z8 MAC86L.N%E'-HYKK$A!]6\P#AV^QV'X="(IBCC'*E(-4(.P-EZZ8:NLZAX-.6 M -&:(1=F LI(5X0 JAPW% $B,*E3X0-%P%V(#$_\"O+7Z]X;P_M3&GI29H2 M8[ON]$Y#M@:RY40DUY>AI*W]7^?-;+Z(VQAM 7F_ M7#5PWG^^G=\TNVV'30S$*$186L<1<)XR;0%IW4XPE%3%; 8BE)MPB]64TXA MIU)I)JCRE$@J&2R]J_#K^]^J60.[6NYPQV"O;I])B%N-VWW$Y0%\S@Y^X4Y* MV+V?3O_D"6>#.^[(!^35%GK58H_[]ONG+.+&_G;7_LB ;KOVA7LK8\=^.KW6 M;;=^VWO++S%_RO>PP7;J>]'XTB[].'TS@1WZD0Q=CC[N\Y* 1YB>A?1PI?JP M< -#7(L14# H@J2&"XK$3A.(,&EWWX? 8:D(_W-.&ZDI,4! A#0B\5TY3'3Q M8AK]=K"*=D!:>C$5[CO,H3\MO_RTGT,/4^C\: J-(OQHW^Q-#NHBI8!X2%N8THHPC3JH?K"E-6:B?);FG3/?KN+^. M2/>TLX-$#\%LJD"KJY!5WM_.-O7U^\W7>A6+Z:[JK_5B/?]>OUE<+>_JM\OU M^M/L2\P\0=:UM\2D8(XD7;CNU# *8U]9!1U @#KC- '6 B>) MI9;9X@5ACK!6#=CJ =IJ"[?Z6P3\;]7O#>;$Y8XR_9 FSV?K@CQ%'I;](AJ< MP^0)V2W2(=-0VC*F+4<8T)WU].>@[+&Y=_6FW3[]C_KZIOXPBQ?=?ZGO/M>K M2ZL!H$1K*J#$"C)#U"XMEM()8R^_UZO/RPZBFM0Z 9H"#RS"-$PO&"IH+48J M9.9"&BQ)CE,? TWV[=\6JWIV._]7<.T(>+WUXCKX\7)Q="6Z03[R#ETFEVEN M/6BO3,ZSA[7N9>KV)Z_,MN!V,D#YI"SE0###*O :: MV];!-02D8\R4V#BFP51DO726&AH2.0%[)CN*&K]3,B.I]^;-174<3T5HN\CIXC']%X$!8LQ'9"8<4<< H8 MP;4EI;/5!DK&9OL0["6U2SE?UK@RO&2<51N:WVW&$ M8YYOFKGGMLG:HX!5RPBU[TF#UVEXZ3C!@ 1.X,S D-8LRPRSP584HXQ"QW!R.[]DK&LRTMY+4MJ"3$> M<20%-4&?C.(HWD>@/*ZV\=+[!P>PS;YA@%L=\%8/ 6=FOS;R,Z.Z M'-ZKWR/:L1/:'"9/26B1'IF(C):Q[;&4%F0P54X_A;_]_HNZ7C8O ^V4VVBD M0A"%)*80A!8Y%;SU6>)84MV_DPT02D)0%$!KJV*DI($75A&D&8>:2%E8'".F M>$"Y196G?]TH2Y.YXFSEJ=ECHJK?[?(NA. C2]9SK)Q0IEXD3D. ^IFP''!0 M96=,.P7[&!\;G:VNU[]]NP[!8NA9 5#;-@(:8B6H1B%%$\C[T/+.63P"2?6M M\UHT%C/BM&4VB"B S$]#P@:VZ6D:.CAC Q]@>SM?U&\V]5W( M@0!AVAGJ@*9<&L>;M^*W_@DXX@4.L1T:EPX0* Q@5E,J,5(.40:M-U0(8_.6 MB,H?9(NXJP9XF=-L&9V2O1<[?G]TWW$8J"O.>;1M3VG_XVWYO3,9C2UD7K=C M;EUY3%;>]^:-VFQ6\\_WFWA(X--R>S;@7;UY_^73[,]?E[>W(97^(TP'E]I[ MZ4)FS!'QG!@$25M(1VH.@H!5AH*QSSWA!/!;"ZM-X& MJ-4QUFJSW)V@N*@"WIC.!<35[Q%SM0.=J[5#=D.BS)ZI!_)/NPQ(?AEU36?R ME+ 6Z(^):&H)RQ[+:3'VDNN_;>4\J+?[\J6^"LT^6G]LJICPV7A"[5 QRK(CE5&NFB71$[9V?:6,N MOS4P0U*^VIR6@,0& >?>: HEE8A*(90CQ)NXG?T=(AT!B+SHJ)C;-467-6B.P^A.4_+C4ILQ_?DC@FN&Y 7U:QE M^/,69^_'Y%XCXJ5#;L,Q.($S;@,:LRPRRC+?5;B:Z_K+N:YNGJP@C;?K:!M3YA^;N!7J\=F9;[A4*J+TA+O M*?1.WG33W#C9W,K'#U*,PFIR ME9M'(.*!:+6\FN_>M-XF"Z>!8%9;S6%/ZWQ]<$#CH=@BBFML"<=DFLQ[."-V4IN,3 MZZ$\27\,_M =%]7.@&IKP?3TO3_Q)Z1^Q%Z=ANJ/:?#C.CIC6KZ&4#P$G*!C,<4*(VUT5!:[O91HB7@CTPXZS/ZNZ683+#-!+TI\8I)^;]VZ!^FMG M$"ZV*KZ#/PDU[\'TJ8A]A/Z;AGZ/8NGCR'TT=H=0['8/\ 2L2X.XQYYC%: 8 M [#A"+:R 3#!EYMX+:^_9J=@H?)EXXQPG 6U 9QB#P4"6@D*C56((EUZ246OYHOZ?C7+V-O+)R=A;[0H M+WE2N(-2!2Q=ZGODTY.QTUF4IFX;FRU=Z_F??;S;^N<(PX=Z$G7P4+,=!/""*:'$N8PE"^%A9CJIX4T M^X[;:44\&/F*)'9@8SJ:V 7\,Z+8F8,<5?P4NJUMQ0E&&:3&6JL4-$QAOQ_5 M1+FD-RE>^C87FD-.D**>4:R=I!X:$BN76LLY,(5U\7_>?Y\E7KWOS$ZZ*I8B MIILL-FAZZ&(62?G"6(JL?LJ(!U;&(RM?D<8N?$Q'&SNA?T8WL7S_N.H2,&>QD:&,18CHJXQ_+/KJ83D\'52Q"4S]-S*^(\(HFMC:^ MIHC97$Q(#_.Q/Z>&'1G(6D2LO]=M01=M %+ .\LHM1 K9(#93_,6IK_J_,RW M@; ^'E^#@F$*/5.(0XRADRYH.?6E]?##[/;'XE_S?W98*)YV&,NY#Z^'9D6;?S]=7M6>T9EEY*!I3->G,QI3W-L/7&>1'C9,&5])QJ9)2U !*M M2F]3OWGW2;W[^8U^ZRKU\:/[]#'O>- @C)Y6UW.1F2>Y!W3;1VS7U0%?]7M$ M6#401ZYWDD#:B6,Z0U(^C:,X@UJT+#= \W3-S5;Q?O[Z0[WZ^'5VW![P*O@< M%XR$7RVGF!O5^!Z72@";=57UY5:,#5H-%-4<4@J)UX(HR!&2F@#(;.F*QN_< MI^KM^X\?JP_NU\J\_^67]^^JC_^A?G5Y6M:#Q30%&X? /-UJ,<4;1%6#ZHQJ M]2)!)S2J/ZG34*8![%@./=PR4LXGC35OOE+CA(7,>62 Q49J+#GT&!.&2(@) MTC=PG_^\,E9X((%#(7\.7Q=>RZ8\@.<8*U1:=Y[UG8RWJ/L0EY"1EN=L *D9 MB:Z,]+0\;=U2U#U]WP)]ZXBL[ZG 9RU]*4_M1\L$!BP'&R(9JFJ6B^_U M:A-CRH_U8KYP9H)$AS!.6+CC1V$=CY E0/I M9PAS&F4(,"F=L5S$QR6%P- @JR!E@.,0TQ96X".H58.RNKZ/Y= 1Z.D:&1R\ MY# E:)R &Q4Q:UEX^ WC> 4)1SP!>HZ."' M?4F=MCOVMB[1*X=AL5.6\79?RY\?IO[8$!?%CND'64([)]ZC,Y=CQRD M#(=#Y2'5[9[*H5.2MR>>.1B(J0F(^ !&G$I/NG*2NOQLZ\^;-XOU9M6,IJ.9 M8OOC.HRN#ZOY50TOF<,42:XA=A@SX)VV9N9[I!?5U0%K^YN(-I;-O@I_?HE;SYHNN3-49>8XRXY *T:I.,N@B?S=V)1?/@^F,8B M>0&[EJ5';Q\M?;,(>E.O-[_.-O7'3:SJ%#3]*D[9-_6E]-!Q18B1#C/*",10 MMOX*.$=YSZYG-*PDL5(RPQ@D%%BI,0H).+0 (:'#+SE^V^G=]2>*.M_!K58! MZD6U;A!'R=Q!WHKJ;+&X3SPH5J([NLCG:/W04S];G-6O30=LH58'K.>4T%,< M)FOH(!TQ11$=QK"3*CH@=ZDRZF?SU7_-;N]W1S'4XOKM?/9Y?CO?S.OU+_4L MGLJX?K_XM8[5DT*L'/["N^5BU?Y6S];S]795'TA L76 2VL]4$9JV522-H : MQ5#6@R\#HHH/XP#E%.2.4JP5ED1[#D2(VCATKG!(&PVI&DLNJCW:H*_7U3'> MO.V],W1=FB)/L]?R!'N@#BNBUH/Q>T+,Q^_#:6C]&>Q>GMM[.LX4^L<.39RR M_*K^YWV]N/JA_IRO+X5P'+*X:&*,UAY!#G K).'G;G/ B?8(\H@0:3CQ.!A* MA>:",1]42SNB<>G:!$>XJCVPCB+>A]5,>1Z)T#SA?9;+ZO>(ZEPR^S)/*0(Z M ,L3D\8A+'I)] 9C*UO.GFO7+N]F\\6EH1PYK*P-":L5C%NTO>88'0\$B>TD M9R?:L\82;; #SD"JF0C*S16FG&(BG-.E'^$^CGV&E+8^#&=*VTCD#B)M6USG M$K>7F4H1MP%XGIBX#6'12^(V&%M]Q&V]CQS;JI <. "85]S*D/EA0 5L?<\) MDW02(*M!X.*I4R $UYRZ$,I0!#!#CA-M.6!CYN+',(\2O?X"E\]R=X4K2O 0 M:7/N%=%R$O>8JDR-Z\ST=$6NNTD)*M>3KPXI:9,TF_CR2A,S H2"JUD(!&<0 M0$"X$#NOLXK@K%>K7F[%\%CC&1-*?:Q9!:1G&'GH%8+:!"TO+&@-FJJ!TSGI MS.4M.]4L2%F>1!VQ=>ZT\B$G:S%3,=]DF?6XYH%N-\6 MR\_K>O4]KL.]67R[WX1_'2B:W\Z;LV/'8''CS.429[ M;)L,!U)(AHD%V*M *V<^B#B6 &-J+=<&35_H1N^U3CLFT^RP'C)[WA1W8%+3 M=TW&[\>)R?S9:#B]IW*N?DDZLO]NN?CG_>RV>4C4UE_J50 :WR2I%^L&Q8?@ M9JT9V](O7H,@.5Q)0T)T[8T5KM4@:ECZ;9KLEBW$V!A+.864.@TTPY)98!WG M,):U+CP=O/M/:ZH(JIHUJ#).I0]/\FFA/S^_>>I]#+5JL5;'8+?$[TJW="B9 M-7P/9%P7.&M/=+M%\*!'KML>N3KND6\'5^A[K2"7H&?FQ+)$3^ 20CG;EF,, MU8PIZ==ZO5G-KS;U]9O%]_!SL[2S:TY00 B7',7"+I08%5K?N:6C@B?E+:\V M0I&1X=M><$JHD4Q![IW&2D/,L%6E)YH#M.H(6X;8]2(P8689B[N\2>1YVKI, M%KWXRY@7QN*QVQ1PQ.?\ *^OU)^P^255'X*F"0CX(&8L!QX^&;+\<1-/[]_, MKYZVAN/+;EP(!H3V2F*L*6V= AN;KLHGVH#26DRE B%B<9Y091"@@ FK1$& ME#ZEL$?649/[L)<@R2,1EZ?(SW+619#[D)>AQR.1V$V.#V0.J,8O6_R2& _ MT02T> @KEL..G(X; \W"T?IM_;V^A>W>OW!,0RZ1=8 *3('G?A^B8,KS+IZ= M:DEZIH/'61=R8VI@M =HR@2ER@.25\^UTTVS_[Q?-A>9XI6_X!>5NMK$-_M^ MF:W^$1<*_')5O;D.G3&_FMVVJP=_:TRHX,L7=HC;D(P=0@!)GU7 H.C6K/W'B)3>:%SU,M:6)E^#;&(-B&E1-* M6X:8Q.?O=Q?K.8?PE>M=A4VQ?4W^^7LJLMX-;/T 3\#'7RLURV MI^MGV98D^%DW=OKX&6Y3<*-02&8058QP@K Q@K1^9@*$3GO7S[2#$?',$8%1 ML(QYI8.2^&A2,-$)X4MG'$<^=KQ5],B_<&;!B5[,9NXO%R8U+QLY/BRX!791 M[2@\]Y'!ISQE2E4NN].5JFQ+$J2J&SN#;9^V%^K:JHC">TL9QL):9QUCPJO= MQ2H&B%'IM="Z-.XXA Q I)QF%!DA-5624*5@MVD02_$<6=3>Y+RN@MZ=*-C3V-6AEO&9.CQS>6=R?=U]06BT;IYLB::W M)THYG[?G)[98-:[M!V!/F4 _GN^^?KDOL/ZX86'A[7L=G<4NXHF;8=!_[("97LM<[:98H=UGW".J[/\$D=LEX0NQL>A(9CB:X6^N%=\DNNL,*0 M<&.18%H!!*7>J0[4R">>Y,QHT/R?\KZMMXTD2_-]?D6^+% -N&;C?IF' >): M;< E&;:J9[#](-!2RN:VQ/22E,ON7[\1R4R2DD@J(V],3U>C79)*9ISS19SO M7#+R'.J88BC>^G!4(*DI5<1S(IGC@9N37N!O=;&L#)&^1:FRXBXKRJME-QMY MTU^[[0GD!C7Z\=%-BSPW=_2J(D%BL&.7CM/<1$@.+ZV9C"$IPQ2*!6S M!!JD3&UH3#O5SEF<7A,SYB&G4D@$J 1$"\ AT1XZRS652;?Y>O,7BV+Q:Q\^ MHR/<:6YC/)P[>(Z=D'TZCXXXM_,?X^'=@PM9[' ?VHN@YL-?K8CV[;U;H.+X*"I^N MI!-8,4M"CZ/NPI4:X>_7#$_$U] Y(+1FE5&/J M4?AB:TN*6)<:XS9;53$")'#> V(I!C@DL!(C"X#WA&F8=$6A]ZK(_4Z%U/"K M)\R;!KKC@]TFU-TO9/=:*>D)[=1P=WS4NP2\>Z=YA,))(VQ.!KW]HCN5L+=G MK5X$OD.@ULK5G(Z]G68H[*:Q7W@FIXI1'01@7G@GI)0?(D#/59?8LLE5QIBO S2HT(V*;YEWV M[HAN;J[OD'VWC^P$RCBG,3Q1R^D)_&D4=/I2IACD@";$V^_RU2K/+[^6+T>5 MM]&KL[CX_"Z?K?+5;OFK_/M:!Q#^<1V;D$ N);8F1/S&:BF09UAZH;PT"#5^ M][35ZCB.]]1:8B?BJUI0<8L!TA0);"0(K<^.;AH) M;L3-MO)F0>!L*W&V$7F/][*_1ZFS4NR45UF'V8^$H/OL^](N]J[VI]CN3_15 M=]O]N=_L3W^1=QN8C@7@@T(^@3A\6/V*L0YO6E1NBH>'^::59Q!C^[KOS?RP M$(('GZE";L"\E4(1I1@L39@+1#F&*3?$$Y04 (]L$0Y M)<' +LM<_O[[VZO?W<75QTQ=V,Q<7ER]O?C-79BW33W94)@W"]S/"'>:#]L3 MM*3')Z(F^ZY! O@T+$\$] -MRC0"_*&4*T8YV&D\:O/E_-LL]N5]NUBMEX^U M.'_-;S]'BH\M>\NW?U-7;O[GL[<7'JP]_[.CVK\[^%N@V M"S]55^ZW9,X==G^:,?!DMB:-CW=B9WMRE]1<29[M1)\&/W=!^@1;C[*!T^#N M<50MSF @:;S^\>9+?OMXGU_>^6*9SS\OW/>;+\$Z\NAGEK.;]>IC2 '+5[#" MK]05Q_?%:A[SPJOX*M9> JR9X"%DYYY#"SCB@N&*1Q3'+&ER=J^"06@#K0&J M47FCG\?Y/PH'[) 0EN&D5MMMF@ _/CS,EC]B.7QW! *5Y*N@URSVOI^MMERS MST&7C^O5.A!1^'F:.QAW6YNYA\GN:)J[J-6(NUDIDM6:9%M5WF1;9'V&#LWU(]L 4&(#'#2:DZ%PE)8*@G2$"'BG:4#>Z*] MAX-FMES^*(/;A^)QPU)[SJFMNQEI!U,]SO0VK[W3.9*OS!>ON9PGSX:GXWYZ MV9M&'FC<4S U)S2R]D?]T#EVH2=7]-MLOGA7K(Y)FR_OBN5#^&:?RHQ%!@(E MJ #(>"FXJ&LKVEN3]$2A?^DPM#[(IA5E@"J/)9!">L6-]AP[/6)B]/;A:PA& MXE=1C:J)8U FY$GQ4*;][J/*]J;<[>R7J,9?INZ3TO%N M[Y4&W-N?PB\-J7^:9QI\)YKZIK>+F^(AOYI]/U0=1!8&UV7,@38YS%3 G"*;98$JB(H(YCSHV2:2_]IGN,MQ?F\G>77:G_ M3GU"T@V^9H0]&G)IW+L1*PMR3>/QQ2F83E!F+^A.@_WZ4:48X/2UC9?=;+D( M4=@J$.+'+[-E'ENPW:C%K9W?/X9 [7DA"7@D.::6>F6E4<01;KU& //PO4R: M_M=6!JEZ&TCV)ZW(35. M/=\.M*^GO 3_3=F9]Z;,02K))Q2;)F'<* (=9M>FP;2#:WDTFAP2U71^5HOU M_#:N'*+;C[%/9OF@V7V_N7^\S6]]P"V.KWKJ$0,HHA1SC2Q5#O MF+1>>F0 DM2WK*[W)A[D6CBKO/>644N08@I0"RTF!"! ABZP;XGE\BZ+.OUJ M*Z7BZ+Z'(M9H@Y19K5@6-E^RK MD^WTV>WWW8']?NF )N1M^MJ@1HYH]-,P-1\U/@!'W=>9]J)9!XA%_KZ8+]8^ MR/9_\F41%KW)%^N/^6)>+#\^?@H[-B_KPZ98?,N7ZWDPIHMBG:]L'"E\>;,N M/N7+JS_#7_FQ^;,>^&459AC:0&[A2R*Q]&6#>.VU=$HUNJ@ZJ(#&(!4"!< P M@90:*XA0'E@48G8>OI0#>S?X[Q3\KVRC1;:O1K:G1U8JD@5-XC/)2I<,A;U. M:7=PKAT^[8\K/;/P\W>>5B4Y^'VJ?6O-P=A M\Z_.[3:&P?U A#*);9[ JX-GAZ"8D-DEQ"FE>+6L%_-%^?\T>=7CY\?5^NK/ MXNI+\;B:+6XW,OM@NI7K"*VBH/+D[(5!BWAH MRC]:Q4+5R5F'D[.N3TX5%]T%$;I&16-LRK$0:5('8@+QTK3P**9JNJFO(']: M[^[EO%T$[Y^OUA^"G.7%G-M*B]GG_-I*"#1V5!$E)=!4.>NW9,=DTJ"_A&4Q MQ$H9J0 C84U(!6:60\^X<89Z.W1UQKQ@GE4I8;8,?X[]@FI3T$[4A0= ?AKU MWB$4>_&JZ4#8M;/6^F63S;LFUXYS:YCW"% L6%@%"5/9IP*!+=K;Y[.%A%2< M>H-EG.*$ -;0 0TL!\2(.*%T1(LL"?2<5O@4FL9VUQ+1*5I:6U5.VE8G?-I9 MTQ^+V4,1CM4_\]MXU:M<5WO(@@%[![ 4 $DK6!W?*TLUO%[DGZ/AMS&J0^LI M934)N@EC,/6422T),M1R2[UDH%F?7[FQK'W16MG6;1#W3?:X$[-L,1;E3.VB MT1GF9@_ 1\*WY4W]3^N]._IOLCWQ,OL:KB,0V0&X&K-9%ZBG2&F=]#G):]V1 M:DYN=_ERF=]>WH5_!R8UQ6J]NC; 6N - 5XS+V-3."1J2V/.DE1".[0&@2$* MD=Y1(3&EUDHK.>=44Z"T +!9C:%?$MLWMMM*Z*RHI,YNHMBIG-8*W:8\-ABL M+;FK0JP6*#,G$1N(K0Z -%CL!]D6AK= MM4*>0PXLM<[0^/8D)">(Z@J0XC_)%7[FZRG7)RN@"@P4E%L0E1 MPSXH JA3G(NDU+Q%47%#*'?/IJQ\K^K\+YBF$\FTP[L5\0P.=3@#^!!.,N:W38(I1-2[.9T2C,9V*"N /48ZZ%-T P4+R6S#^R'\0CI6_O3NX06*O?G$]KBW=0I MJ-4J+Z78&S6X&>FT]49$>ZL%X!P#BP#"SD&T&;8)%$<:I%!^@^6,5Q@ 'E@+ M6AH'1#&.C$#>P1#F)CX,;S/.+PZMRLS];+6:W\UOREO$:23>!Z3-*'ID--,( M>"/&-J*S!,@PYKL)"#AI&$7(A!7<:6F X M==)2.S"%;:3YCZ01F)U0.\U6(P.6QE(;NB\%BVU<@FA915P-"*IW().&AHX% M:-OIH!'890EL?, FCQ M:\@IQ-))+#QBP5"PPK*VDY#/-GK+M=E*F F&K>=:,D01($IRQ# EV&@II4$# M,_56N+0(LR-ZS8++\8!+8^S=/.A2L#<;\OZUN/MU2][C1I0G@3H13/8#\#3B MR)YT*88X@FG,M.GVG!]>D5,AJ1%2"1L2MD!_%-26Y1AB*;QT:AU&*=>6,P6] MHAI*Z8W#(?G7'L0VKGY@5MH.<$YCI4[(->.DL4!+8Z1*JJGPT0F03K!1']!. M@XMZT:3H_^"E]#Q[,4[]\-+>R4""1$O'.>#!W5NG*K,R7CO2Y"I=TH)<,0\< MQ19(3Y$+@04V"FO* 1):JK3,MNW]N@^7?U2Y1$J3J;X@;9#LG@/-MD%4$#%[ M0F 'DN%SP)S2F^L,<+?LM;6%/99%[RK8[X^DRIU[9S7#Y5C.W#>L$\B>>U>I M&/ 8IE8]]^JLV^Q=8P\U- 9*YJU5#$.X-3,C7?,FET=7(!HHYR3W,L3>(>P6 M!# )@2&4:43,T&]=[XF47/!L!5C36N?06+4I<^[)U*&\V0JVU,KFT/!U*6K> M[V3KI9AY0->3=MT?IGJ#!EL'!(&Q77KL"4,^PP'>V9 M<7L2ZXQFAVAK("#["KC.15^O8)4:=K5 >1K4U9LV38*OUBAU>K2\7?X::T-C M)TN'D0KK"FH(K>S,(N!AYX?*NZ7" I!S@ (;<^JMTY)"9#U@X1^H$[LKM'V< M?/^\J#O08[>MVJD/W-+QFD"5MT=EFCQD:XM1^G#5MXMOP32+99TDO9CMJ@UD M7&J.J&1<$V_LYNU+IA5)>UNJ\:(@Q/+(6F<==M3IL!8D&&OME $.\*&OL>Y/ MQ=Q*VG9^:5=\FT4!9X$V+1PXB.JV^#*AL:&G$3P1)/2^"=.(%OI7Z^C@SEYQ M:S%H>O/&ZNK][$=<.'!R^,GR,=]_Y^N92!HA[@,W*\D]@!0;J'QMOXBPI,)S M)T&H!Y($[E"$,@H\$QI8$F_M*:@=\F)$SJRESRKQR]M!E0+[#^U;CX0>8)M2 M:?;,.]2>>IMNSH0(.1WK1B0]X!9.C;B'5/7X%.:A\4TG^!!BS]A_^UH_,&RQ*/$'1"$TZ# M3PN\%')DZR D7#H^]%/%?7[8R/IK*6RVDW;[&FDI<,-+5D-L0"I1CXI]>UKN M"/O #/P:B(WXMK>=F!J[]J?842[M&;O7F'.U7%]_R,L17/%6H?H^7UUS9T7L M(6Z,8B:^_,2%KRT3.=;H[NVASX4@B(X-H091REV05D 78C/CB;8A2!N8^_;$ MR?X>!6K(;:T@.DU>0Z.3QDX)P#1AGZ#<'O.$[YZSS@'M#]!*%XS.RQN=)"^Z MGY!6EF^+A]E\<2TYE19Y:GQPQU#&-?#F8'M@5+.AA(<_62B--&8$>>6H%UQR M1K0P'EK)1:"O,:U_(U([^V\*5!(##(!1!PYX#9XA6&"SYNL\D(C4I)@@5?;# M7- *@=0XX/;_/J[6\:OMW'EB-+:<""^I0$ #*NKC+KVE;6*"YVMP) #$1@5? MZJA61BGK3: YQJ$%SJ?-0.C&$#O9VL4(R?"EQ0M#(M>>-W9BO3Y@?)! XADL M#8**MD!.BE;::W$DV.B&2L(EI&.9SKOY(G\;A%E=.QEB;&&HAY0JBYWP:.MF M"4\;PMIH00Z,P1)J*;&ET%@M4>Q=Z3A@F#+/A[^.=+(Z$ 7-2DD3*S/]H-VL M)C,ZT&FA6WTU>7^H-]&J67?E5Z>8FI;[R:/M?/'YMZ*X_7-^?[]]81<9CT(RQH44"ANI,46J M,E+HK&N4&[5:F BG.=,,62EC"AC2/TH)5I '2<*7 UOJV^>6V;"1P3 @-PM- MSH9O6HCR(BIYDP5)LU^VLF:UL'\Y6T/J%"A/T.,@.S(-CAQ&M6*$$]U;)O?; M,G#XM<#"248E=$Y#CY@AL@YCXA77OK*XS6+((.Z9M1XH7L[_%H ;:&1\'U\[ M.?3]J"J[N"^SB^;!RT# =D[8^L>TSV3M35;*-YDTK92F78J6!O0T"*X_=9JG M9FUP:A[VW>9WQY=^P:O7P?2XI0 R3B&@/%BC]MNH)%AD6NB7N+B52@@N! F9 M(!60!2*P1DEBI$!8R:'KY3MY^R&[_L%O&A*>$??4L/ 9Y"^K5X="Q+'CPC0\ M3\:& VW--.AS./5>Q(B#XM@VJRZI_.7B.$0UC!$@I;/",HHMAK5=!ZYOU!PV M<4EJB54\:"VMIHH!#9!VQF'"('8FD4K3W^4F1U<_/X\'@_6^>WZJ%8KN?_W/2: M#)9I0ABCD0FI.C20R!#R5G:J*!/7B_QS_$N=T^9C A -G!,H$ 0*$7;@?Q@R M2D*-=T;'T+N1Z[+VMB"X]2M_\CVQ,MF>_+UEDJWWH#.R?6@R ^2;N]O MAFJR&6-GX$<@;9>3=]V?:?#JD HVS]O[P;+/!SAA:28)HY Y$PQ:* VDK0P< MQ:>M70+-@PLJ"R!5FBC#("5:*"$%B*_ZE%D\&$O%J:GX?\F_YXC'W06'W?9TO%[-[\[A:%P_Y MSKU_F-VJ9SYZ_&HBM95(: Y0KA\@K8K%GCB"#*1+ IM34NL@A M*#" \J\-I1IIB6 ED@94&%$#]X =/^=L6I\R$:951;/45;KDVT5V@P'+^X# M $7L-?(MS][/ENM%_$^??F0[;<,G?4X.H ;=TF:1U%1V,RVDJJ0^NFM/MZ:4 M_>RO9'= ^@2!C[%_T^#U430MQK>.MJ]CN\5ZOO[Q7_/;_.WBKE@^E*'?:8'? M+XO;QYMR$//'?/EM?K,_4UXJ12$''EDD0HZFE0-T2RC8)/59'4Y*Y)57P@!' MB*,:$&T9!1Q#)# 65@_=Z7[?@\30KY)UYT<"\U0_:_N6]^C[VLQ1_!Q;VKL; MJ24O X%:]K/[DL$VXX2G.?\!F(8?F@ .1]]T/^_.-/5A=KZ:??Z\C.7+\@)J M)>#S?E6(($ X+E^9(,1"@7S-6Q;;I.90S5:T1GF #">$"8H#;QH"J< $,AO; M!I+1LY.#'D;/5OEMO,W]/B@37PQ[%PTB.??H:1.:.8_Q\4]S!$_EBQM0NX9S M,WTCY$ZP=K_(3X.!>]:I&/*LMHON5Y=W)F*Q6"]K*>:K?^@?\4\_NPG@[YFH MUP SB;@PD(<_F.?;0@"TN%77I93UN?= &TEL2&ZH%TI+CX+'@#3P1MC=H9N- MOQ*19T_T6&5JO5[./SW&9RWK(GLW6W[.5^M=R-%L W"!X'F*[ID'*@VIX). =#LW&H6S^=9G? MS#>/W0S&DALI@) 0&B69<0QZC(F@R J9U.[YR0=3;)!4QE 1O(L*'XU#7.XA M8M)J /6H2&W)WS_>"<.?SX5[NWG0A[SDB?.>W3XN MXYV1]9<\6^9?X^V=\-W7?#DO;KM.DDX [H#C& S["4PB&42M8N SFQ:2/HF( M8R2\Z7%*@PTJ2 3W-AJH98 ZZZ6VUGH2LM&4X/3($L8KZ*S6C'-+,40::!8; M>5(G@?=ZZ##U:5Y9YI*M&BZW!;!9V#H"=FE^HP5L@X2SAX$Y$=AV1'(:(6Y7 M)8I>3U+5CW.,$,$!+EO+(6P]9SJA0/ M,7V<3BL%@\Q@[3S2GI*A^W;4XF4OK2F1?+IBVI"%1H0SD8Z.(]E/"\1T8CJ- MU2F&Z@GEB5!57]H\YZQ>46J4L]=+7B[R:I$0@?'@TKTGTA'D)!'>5W9%J&"- MPJ,C'\T5<(!JC"'607X@":>>$1:[G ,FAK[TNC4HU3&K>*'9L=RA/003R! Z M"%_T<@Q:'..K/XMJ$:^"1S?6Q)T3!'HJ0Z1:'6/@4*.^64<^6DIF;0@C/+&6 MDG@O1&)I0[:"J#$:R+&.L>[I&&\U>^T8IT,PH6/<0OA#Q[@M!FG'..Q;;2V: M81>2X'!N.>-:40&W<0ZQ@K4XR'L?[D+F)@ !G$M+(8!*!@TX9=P1!C# HP6+ M?1WEG6ZO'N86,$SI.+<1_^"!;HU#TI'VX0S4_.\]$"A6>)PU+&PF=+H^T8:K M]!.]]]F .VT\#^F XQ19((2%(3KB2#B !KM0-N$JG(;B!H4ZP=&IV4R$Z5Y M/7WI!Z2$"OO 8+4KI&]!(SW1XTZ[U]BQ!0X3(LV@ ]5 - M_?1S>YA=&ZM/@"B%&H=!IRTUQI4HT,E@I),/I]F%%BK0QR2RY^V@N M#0HY'>7("8J T$$5:WE8@Q/C\>!/[K;'NH7])P"4P)'#8-.2(H,P71@R :$6 M!#D,4AWYL1%B:?2XU?,U=DP'9$+DV$+X0]S8%H/6EQS>;:>+,, U4=X8A;$( MYQQ))ZO\B#HNDF[AGEB&B-A\03M4AAH221;6\ YC!1E3>NA.L8>>CKUK.\BH M"YH-GS>. V0BO[;$<)SK#^\:C"?J =:)/%OL09'7KD*TQ:91N/9Q_GDQOYO? MS!9K=7-3/"[B=;[WQ?W\9IY74Z8!D3CFT4@)SPG'(3CT/J8H4F.)9:.._4W7 M@I)(%2C6!T]/.0D^#2GG%$'>28:5'9B=]B3,=B)FM8QI][)ZP[=!^#&P@AP@#C#7%'J/')'(U.:$"$F:/M=P16\ M]!;JV-3?\N#>+.-%",TA4(AJ MH]W680&G&_7.:[@4U5X1Z8)'C \5+5,NQ)@:&$8(5<8.G5YNC.B^$B?0V4!6 MM%4XU7[2D9JPY;10IHG-M,6H^>2*F^(A#[E2<',A#MJ.[J7:20.MMP() X/_ M\21..X0J^#SI+&L\MNOPQS/AG6$T^E =$BXAJ*2(4F>!%%SP06==1XFRK4AG M'&A]$)H3U8"N8$XC_^^LQ8NY$WV@TLB[?"A^S.[7/X*)7JZ_Y/5%4$=8,#\J M%&:*AVA->,HWIB(A,@@V]BB'/YX#+,NNLD!;&E:2L75Z(&8EJ31J\)>+*J'* M)L]%%"M;5NU6$Y+)EL U2,^'QRR-7FJX@D!9*5&;VTDMX4I(M8>'K5UF_>*T M=P,\)(H M*3SB$''#06T%UN.DA\9'%PG)$#%&:14O W/IM.38$XH IRZ^938P8UR^=Q_4 MU=N+WS+WW^_=Q<=D[FB/7C,.&06X-"XI12K#B%JHL['*,71.7E[L".@T6*:[ M&B\N+O:"2PKK;+O<7RM&..068JDE4 !A4TXR+XV%8IY,-;M/AIHRATCX>(2H M52B^ED4L(=9X'W09_L+T:AV;C:]F]TVSNI8(-:>38H M(AVLZ?!#"]D/D$);!)IG**L\_.Z7P#TV+'1??(VY;45#UX1R0STW2'H$34C- M'4;5N<>$N21F.+V2YB($^R&6,B*P&W.:*0J$\\)094/H-73N4@E7.M;;G7BI MJ4PG,)OF-6/AF)KD[$&X)UD=IXR=\9Q Z63ZTP>ZTV"AGG1YD1CUAU#C&3GY M_7VH9^&HS7MU+/9] ,@5FC!W3/9M"KA]@[ M_I_E(X@@ABG*VUV!AL-7J_EMOGD![IIA"20D@E&HA+6:$*AJ*W44-0K?.BQO M-;+&,:FT0U0(+"DB"@#&O6"3G.XJ8J*%_>=R[_ M?JG5EZ!,'L6*W]W-YLOLV^S^L1P\>(P\AASRT>IP'7LH/.Q)G*L;A>Q\G#[1XE77LFA324"1K"'.^D0,Q; MBXT*1UKHMQ!&)+$BQAT.?[QW6+#;H1!I0 M'B\V(>(A@\003#5-N]B6;A)O+\SE[R[[Y=WEQX]_R?R'R]^SZD'KY<7'<>WB M #HG3*,+EM.PCDX:%/V=K#97I>,"/FCD_M_C?/WC]WS]I;B-A2??1@IXN 3Y 6U4%I(W,#Y MXT:L.OB[#\+&L$_/B]]G(<#[W[_EBW_^>,BS=^^.M_0>$NYF%;;QD4[-"LM; MZ[]$"?^R";PKW#=29GMBGN,:^RO(G6"S?I&?!K_UK-/!"^_](M:< ^L5-E*$ M@#X/QW9]#4B(S*D(83.E"$DND:YK \08S=)H[\@BW"-KE87" D4QP4)8Y(%W M""),K1GZZ6RPKXW%04:N%V5A[K8IT3S] M=*RA$S"^&NHXE81*!9'B@&(M*26RV7O/)SW X21[M$)L*9[24_@55=$&A<>4BOIWR+ FL5KS(U]=>($"PBENJ M*=468,!J&Q#![Z;$):\L%1L*21)6HS;6"XW67C#,,2; >Z'?HZW>=ML7CG: M19YX*:LKCLVX9$0(TZAE@]Y6LJQ.N"KA_O(FNSB!Z#!5H9-8G2H0]0/R--BH M+V6>EXWZQ*A=!6GSN.,Q+%_)42Q6.K\KEOGF]ZYFW_.5^[Y>S@+(\\5L^:/L M17,1< M_,V!X7TI>Q5^,A2@+"P:X!2&_(\1X71LH5QZG5&N'E),ZIP&EQB,, MJ8,A.?7A_*/@$Z14G*4-G>E:]=7.7WYP6?7#*_7?[GCE=WH[VJ:T-=W-[%P0 MVZF6[73+/I7*U7Q>JA>X_(DZ9\M*!]N8QO6V\QR':7B622!QLK9WSMU)\VE! MDLI[ZLWEDFNML" AUM=,A9@?AG33UF4M2@QO-)+GM34L$<1S!Y!#A I-A;!: M&^.0DAXJ,?23#[U_CV83>&?KN"5M?$@+!%/X?UCP6G%W$*E.Y+-?*JG^<@X* M?H'-J_39'LTI45\'+0[25E=4FE)."-#WKRF0>'W8N5CDHIA2P:2LS01(IE(" MWZ>?C)3!$%IF*/,4,J$E5-PI#C@R"K&TA#X]5+UP5]F3<'5Q%'ZO9:GYS[90.5D6UIV$]''8H^SU\W>[+S M^\=U?GO-A=!(4"@H)0!" (6LZYP4.\JZ652]"N;2260=(=13SYD"2D"J UD0 MAP!.Z@S:OTW9M^_^N')VDE95(9A@5ZF83].RDK5XQ;;:H=+4NOXKCZU^\UL5 M#N?LK.)LAB%-9.'*.$LXDQ] ZB#BPKK8Y+PU-L[FT MM1D5EGN#%0C>&@N@(/8$!-6YU=AP-+@EUN)FLXV\60@D'HK%QMA66;$3^$WV M*8I\%QNOB.6%*-?*(^P%=I(Z!"%C MUK.Z?67Y*+@7*S^^.E A$>6>,2\I*Y]"&V:PL]H[#4A2+C>XG=]NM)BK^;>J AU2W\N[J]GW:V:=,DPC M8#F.@[25@[4/9QQ!F]8(+S^@!^&OS6BR8OWFCK"YUF<]ENON2WC_?Y MY=VS^VC5Q$L>WV*7@ $@$%26>1AO1UJIO8:$LN;-'UY;B%"CO"5&8.4I=5H# M9;AR,1C"3E ^,'/5XF67=]GS>Y2MYN-VQ?4TB8T.:1J+30[-E#%K(Z+:ZF4\*3*]&KK/0(G6>LG0;A +OWBMT$7OOO395B@+.5%IB^*Q:?PVH/-O^T MO@I_4WV?KZX1"I$3H@YC$+X40FF":I.11C::M'ER 8:X(DQ*C)BATB%M#*+6 M.1DR;6(5&9C0HTR_1J&R*-6;+,J5%H.V@ZU9\#DX8FE\?0BL[.]1J)&;01_" MY40HV0G&:<20W50H>CQ6W4C%%@^S^>*:08D],E( [9R0CD) :_O0&OHNM%(M M05APZ1(QR3FF+/P;*N0 ,Y9;:9P:^EI3_\32%+IVU#( :GV0RT:L,]/+1H@$ M@DD$GRPV4$WL "PGJV%=8)P&P734X44%K#LB'6M?[[:3 MK9TQ"A*-C &>6!>^='5E 0%I&]W3;KP800X)2:Q1TE!+E&3<*!Q6A-S$%FOG MK8%%.;-2T'Y*-PD@=RJ-OKP6Q,T+;2V5L&(@'J(X-5Q?;0I!>&TM';]+U ML1;J-*N1M<6I93>-Z'S<]YO[Q_C,>+\7Y[7AS&GDI?$F!+J:0N5];53>(YGV M\D[#12F+(ZX;DW>%-ER5LYGW2X/FM+CZ/PG0AO>]^!:42\_:MUNCM(7[@UI<+])2[O M_'PQ6]R$EHE\)-+*6^ED10KY"C5P$M. MN%.4"X\Y!"BI+W"K>VE/VLN'B.(V9I;SU>HQ2+GI5YZ8DW=#MAGMC09I&M4] MQ[+,TM_66)J36 [";Z=P.L%IO< [#1[K1Y5B@..7D,>KFYMEOEDL'BD[7]T4 MCXOUM8-A&4$88( *@JBD'M;6Q+@VS7CJY!)<"H()T1!)2"T50D(5&['#S8#- MX=_^V@I6DE,E5A:^O=DKARV:EPZ[ =H@3Q\#R41:VD)X67%2+=08D"7DWV- MUR[G?GH*(X3U4>R:CPRW=I14FRT0)(RZICA%H:$ MG56''VN>UB+_^6<#02 BWD./. 4,*^P!%KV>+&5;.*_E;/1 MBB7W6C ;K"YX&HDMY\AXEE24&D->Z)4"#F! D*<(>8&9YH1*YI4S3 []A+66 M*ONV%2MQQN44]K19/OBS;6?BLY4H^J^?HNS9OG[9GH+9IQ_9_N]52F:EEF^R MJ&=6*IKM:?HFVQZ2G;)9U';D*9W#;]\)/S&EPS,-WS,I1)X/%YV2;%/SD;_/ M%_.'QX=K$H)0RRDF4BF,"/#4HRVMDK3F:R.*S12@7@,-O-,AHM:2>,0,MI + MY]G@3X .>,PWV<-&MLFYSL9;/1D/.L0N3]Z1OLE^?^4 _:P>M=+KO(XU]4S] MR_C79&#&=[/M]FY*WG;VO50 :0@PE- 9Z2BWP$CM*@H.R;5#4_.VE=C"$" D MQ88K21%60F,2>W/$>U-8I,WQZ,W;;F2;GK=MNM73\;8#[/+/X&U?.4 _K;?= MZ'5F;YMXIOYUO&TJ,&?PMJWV[JS>ULZ_S6_SQ6V9DUN)() ,0^&LII+;V".N M8EY$G3Z[DWTJ+:5(:"$8-9!B'-R&9UPK3)!T@L.TV<;IOK66)?LQS^]O)^!- MT[;RC$YTL%VY/ M*7)?Y(TA4,A!IZPR1!MNA)(U=3+ D]X+'5!,31!B !&DM(_W=Q7DBH&8 MSG-#45JWQ2ZIY?W\+B^[*/[(9\L3310GMXT)'G#Z.S@]UQ=U/(/'&V2K7G-U MYST?$_)Q9P;BD'.;PMZ<)<7[,%_]PR_S[?CHTALK8GB\B>2\(PH"AK3=Y@54 MNG3G-JBT"!@(#)!:8DJIM))"*(@+]!VR&^22.H>W\'%1IE_O@E"[.WK+4W'\ M5/?T#+G>X-LY&8<7-=FHQ; MK!^3VWUF9SD%&[U=-KJB3C-(79YZK[S?\*%GA-[>4Y?FGJ<_D5<:C(L8WO6=OLV M'0=;/1G5A(1 &,%*-*&.:-A?9.2"$7@M!QL);3#4@D@D1384BB\UBPD6#8D M_P)Z!Y,FR?7J8,]^D:?35D_%P0ZPRS^!@_WI[_";[^;5D\?ITO/E_EW]9;/%;?9N/OL4KUG-4[O7]@=\,W=U%LS3W,T.[C?1JU1B9J6< M62UH-5\EBP)GI<0CM\!M"N0)KN]]+Z;!U?VK50Q\AEMRY9[1_Y[/5H_+_/9R M\2&_>5PNJ[F;JS\6Q:=5OOP6S^K;Q=?'=?C/ <7PMTK_L!.5:.)5S'(J).:"S0'#,69UO/QJ/H9BMOOC[XL^_YK>?\]]F M\T69W\_SVO^;K+_/%U9_Y_;?\]V*Q_K*ZEA C0I$@RB@N MF -:Z;*2(H2S7"6]:=Y:!D^4Y@H ;S%U<:@8840X+K5% O.A+]NKA[(EW7)/ MR"P>S$Q=FK=QES%D4NII. M&[?L4Y[MBY[]6;83/-M*//(VC'<0GG,C0FS8-/S&XEL]G?HR"ZH[M]T_A MN_#5?_Y;_9/P1RS3_N>__7]02P,$% @ ASQD3SB?Z _RIP RRL( !4 M !B;7)N+3(P,3DP.3,P7W!R92YX;6SLO6MW6S>R)OQ]?D7>S.=T<"M<9DW/ M+%R[O<:)_-K.Z9GYLA=-;4D\H4@?DG+L\^NG0.IF220WB;TW*2;=22Q3 A4 M/2A4 77Y[__SZ_7XAR_U;#Z:3O[^(_T;^?&'>C*O_TA3(__"OZ>SWT9?!3S^M.OVP_&$\FOS^W_)_/@WF]0]?YZ/_-A]>U=>#M]/A M8+'\[JO%XO-_^_GG/_[XXV]?/\W&?YO.+G]FA/"?[WNM;9'_]M-=LY_R1S]1 M]A.G?_LZ/__Q!USA9+[\[@9?SR=^& MT^N?\R]_MD.D^C5K+[X^X^Y M.Q*"&F(XR63XKSL,L?CVN?[[C_/1]>#>8CI/.[63U'TBY)M6V:&[IT,R%[?C[*?P[&;R87 MT]GU\L-F2-QOM&Z6\6XZ'@U'VV'0H&L+$T1P78\6^0#/V\5/)PO<87CD-YA@ M@Z[=3K $&6CMK*LR3GNZ#I_]QS9>OY(X'VXJNM% _(W':&7Z;X;9*%\52]0 MTC8@_U[#=;60#[B]ZB48\" :S*_2>/K'?O3?.%(OTW_Y*"Q?S.9Q^UC:A\5T M^/O5='R.YDG\CYO1XEOQJM8/V]_1YY+38#3[M\'XIO:#V>P;_FIESY]=/(PP;YD"NW]EGP2YW^+?S68^ MNISD@]#.;SL\&@7-XWPOE-T9&5T1M?6I]$KCIB;K7<"TLY%Y4_E(/YC>SE0J^;;H; M.W4UJ?L/SR[2:((VZ6@PMHB$):'>C@:?1F,\]IJ>)2U^15<+?O2%MQ^?V\7# M%"?OZ^'-;(;P6-Y)_3;'G][67^HQ?S/Y?--T.W;_S5V1I]G.:M"UC0G>H>71 M]MTZLPU].II2@?:YYW =+20_UYW?C.O5=4[^-]\3?!F,;^6F_8)SR$Q.T]D' M_/1#!NP2S^[;!SPGEB\/D\4;M*CFR_M&G^7K=/9M?V+T-*6."-IP,VWMV<+T M[MY2OFZ?SPM-VYW BO:[S.-)CU:F@UKB93;[5T?1]LF\W+Z#J33;+9M[=3"M M9F#>W*N%:;W%$V?[-+YOU=K7%HCZQ@.T-MD'V;G\NY_.&]Z8->S>P41_&2QN MQ??MM^ZL@>X_8A?+&4U&US?7RX_?#;ZMM.'I+-W@G.K_4P]F^RYJQW$[6-KR MM7[/3=!TE ZF_7YZ\V!ZM *PYB-VL)P/-Y]QL,S_P?CN":Z8*3L-VMJBFATO M+[5M80J_9BF1\?BYGJU\9[9-9'V/-J93+_)US+NE/\SU=/+A:C#;^K*VL5-7 MDRHX$/<=KZNEO/CAPZZ(@]D$+?+\^^5O&BJQ'7Q55P1XF("=+$9A-+[)5V>W M#?+C.F<7R[;U^<.HCZ:]%X&ZG4I7!&PFPAIT;6&" M[V93E$R+;^_&:/[BT93-YL]9IF^;WM:.74ZN0)R4C-GEDAZ@O+8)(J)PC?M\ M29>+;K83&G9O8:+OZV%&PG"8'RQ1M.(W3_#'8;.+^6:]6YGFEWIR4_M9C9#U MTTG^VEOM LGSCWIZ.1M\OAH-'P%Y^]SW'O(P"RH0 =U\VV'($$;SP>7EK+X< M+++IBKL747=^,USSE8/Q>#SX-)TM'U[?#6:+"7[N MOCV,_[Z^[)OFG?SF^OE1PWW3 M#=[; 9B*Q2=\VIGCG8/7H^?F1Z= P(&JW M45J9]L.E[^/@E!U,C1V&Z&?"CVZ15J2;OQM\R_S.C@/#X>RFWMW#J>.O[9LP MV3%BLFCLHM'&V/TLL:%,V'6@O2;_.-S>K%8P6:JGYV\'G^HG1'^IWW@V^ZY; MCO,W.\!C,7S:39$P>='8=EO\8/;]GG< M=A)WK+ZY1L-\#I\:9'+!5X,YI^6J[R9_W0Y&'S^.]?-L:9&G__$;^R>KEAQ9532L@0 M B&@B'*>&$C).)5(E#)\OZ!QOLF9SFYIV>V*7J#NK]-%_1&)ZO ;?]^PQFU= M*^Y]"#02%XP'9;U1)DJBM?-> $VZR:H?8\C.AC],9^?U[.\_TA]_P-]!EW_-+P:C<_O M>N<$@XHZ M4LT.M_F?9GYIRHBE;KN! $7C5L$$H4T,/&D#/'B;B.*>"FZC!ZOIGTAL-$7. M]'#T?Y IQXE5^W4T[P"J>=C*)C L!&M5$" 8WCAW787H]&$TZ0/9JX,HG[BCUEB%]@%-G&&C"I674<^N]_0O;A2AK"=I[ ML>O8P?U+??VIGG4 [M7 %1."@D@\@500K+3X=Y0] R5():CHX1\1 JI]28 !_#<$)I-(!>!D M)PK.,JVB37;T!;TG4]VJ#;S8OE+,> G,>FH(4DC8)$'(!#KZ?(R=L@+;$M.G M[9.Y+P@]VED_LS6>+1[C#OSW%''Y4W?I G^QIEO+3&<>58-+A-N2M #3]R8=7ON=@2!WK 4O:[NYW@ M?.T1N+%])7PTG((BVBBP3FGA)"C^:_[[%JMO4 MK2*4,\L4BV )2&ZU1#O:,3^LVBOM[E?;;@6RH9.5>HSG+.#0!C#DUB M0ICT5J$6PQHY8JP!+1PY:(_CN;8_YO6W"98!7:MT$BMI\*_1XNHN?FN5;B*G MO,Y)#8)?%!X/4, MXEVSK"\HWV8DFES>1IEMDLK/VE9&1V^4"S0P#6C%.0_4"J68)E$:\'^B1ZM# MP+"4(;V#['EYG$TP>VA=,4L44L@Z%Q)$I;6P%&PP)K(099%!\]IN@0\*M+U9 M<@Q.R,=54O$5^# ;9J442?$@$E ?K&;:@P'E*/%2-'+E[_P5^N%C_BMDVN5^W\T\,:%P9$I,, HPB MFIAHM(Q M;-PTIYIW6!B)U^?W:C_NGQ]O.64ZRA<5"0;&J@#*AFM9X9*&C0_ M862UQ/1&OCZ[D?GT?7T$<4 2"8Q# ,.II2'DJWX7;#8:*A*<\"%LY!,#)"O+EFD M2@5E(7B&Q#_A6XK.H-@%Y;=C\7E.COS)2ULD7\TM]8FU<&K8LT*[5GG)@8&6 M()RVW,I(HB5>*Q>*KEJ/_>JA'?1T0^@#"*Z]XU::1SR(Y"10H9GG!"VKZ'20 M/$8?A$15A<@^'49.Y]QLE>B] >_^GB]7Z_BU_F-=2N$MEN=.XU0&@A ^,94C M?3QN26\58U%$4%K$4/+$?^QG92^6:)?3Y=Y^[9*OY>:5P($ M5PF7X((%S84C20WSH*;D)G\U$J$(0%L(HD&@$(UR[H*%/R M(H$FH23"Z@CC\KJ#R5,\=L:"_MZZIL/?KZ9C9.5\99MM?.!ZVKBBA!BO(Q,! M#7I)J0O49K\GJ:5(T?<*K,_/DEGV(?>Z@,"SIZU"NO>%)K_:=KC+XL5%/5SD M&B'?J;ZCR7#T>8Q[\-;9XEYAV8"Z_0>MA ::.(G6!0'4>2T9Q4WM%8\*<-.? MLJ7; RY[X\S>M\;/=\[*,KOW!5IW:;RU8Y6SDW@'U(!A8+2V48CD\]62Q+7P M$FSMK.N=G.3KA >]N4(.1ZZ^F,[J9\YBJX^1-B_1;9.[Y'XCXBG!N#'<6\L\ M)&$T#Z""$XE1;XPK>:(]]MC$/N1?/VPY5-A/?KO)CHW?N4?NB^#RP2MN#;,N M@F720K1&$]SZ:$22Q*.$5)*W[MB#?/H <^\?]1*Z:8BDP++E4"HZA.048GP*)*Q("7(%DV1O*+=2=.!,O],><80'Q'N0W+ MVA/(#4:N(,:E&M243MKSK05N3]NE[R&V:.-ZU*]X]Z)EX;GWC* A -8R&Y@FW%D2 M&)B@&F4&:?J.MZGH\;H(\(8]*VJ$L=RJ%!. $OC=S,9H!4O12&Y/65=L@[O3 M+JE]VI[X/'!'% =F00,J&#;'3P61K,R^1[SD[NQ8D=J'X/SO2QTOK_O7]GD"4V! M.IHK^2CK;% YV,^:8$"($N?G8T=<&19V<+[?E]K[.U!MDM1O-_C0[]"["E$P M+[2./AH@Q!H79 I.>\ZE\ZHD@<6QWGET=0QV1_:](72?6,Q.SM-HDAVWWM:# M>?U^='FU.+OX;5[G%(HOV2"[=*^HY;@<*YQ4(E_<&* T$J[ .5PD[[4F=6]A MM9VP>]HY]5O'TMO1X--H_/(S8K..%;ADA8E$1=QJ(D@;49RZG.M*@/6AY/AZ MO4*H(_3L2_5#W.3)DKFW0D/=*1]")>* )E5VM&0]4R^!C#(TJGO1TZ;J< M^[?5?YL\OC0;H')62N]I%"+D.!_G+%BCO)*> E!WTK91"[C8=CW;!M'[,HW> MYMS-*Z$T;XZS#;TJ[Y0&J2EUS(.$H*,U5AFP))I@18G/];&>(QV"JSU*]X6H MARH2.P!J?:?*:(>6HP@&]PL(R5T.M Z"1$B!*5=R1_@*8HK;QE-KA.X+3ANN MKW8]'7<=JF+&^QS9C[I] B63DRQ:K1VE,@OQDA"GHO"15X.VCBG>N3KLI]?7 MH]5-*FKPN0P"KJ.>'%0=WC"G,)H/Q]/YS:QNH"'O-$ZE @<>N5Z&-N")HY,6 M47 CN=0LQ$;Y!0](CR;B8;>!*B$U4B)0A*@!B7-+5("@B01A\2 N$0['KD1W M!)VGT;5=\N.0HN,8?2,.(U6(33X_" @3/%B>G J):!)1Z+LA\>0TXG;AO^:5LBPO%UKY5DCHQ:Y3F/('6U'"-LDX3*PC/BMH)0JYE,#P[ M:MHE^8%AUJBXZM:^5=*&.Q=#2B8!LPY5?N5% M3TG9&7Q<+^ISM,O^O=Y0-WQ#ZXK2%(-T1*/*!5$B#;B7WC)PA**)>,JN@RTR M%V,E%K*4!9\$*Q MB(+[%#,5=7NDM4/H0P(I_SBKMQ]D6_M6UB0GO Q4@J+[ MA*54,0P:P*J$V'L?7Q^O1K/S=X/9XMOF@^MIN\ISIFT,(0AXT'M2=H.CAK/>ZX4U9<2KD[[9K:)8;W.EGZ=IM#>9.^E;(J>BK)\M!& M(:P38=I1B>F*"&>/G+"#]83"?U!ASV/)%* V5,Y=KOT0%3R>G$0K(L"(J.JLC9T$F#=R*V"SQ01=6\"L% M8G>D[Q=DMYER6\7:[9A5P.V4DG-&1 ^H[VO)-5.X^"1B-+KD+?)XBT8>(P+W M8TA?=S3O;F;#J\&\?B#:^SK;CW+P'9GOR;=JT"C\UQDEVX*,3D;-45A MP5GDEG.S5Y:DE@(+<^1NHV#"[QI6+@)P@5#R5J)%@T+0RFS/T*2U=B>9M:8; MCC]-_%!"YMYRB2PG>7L*-L;.D_:50]LW5U^V7"D05&L"N>":H$J"#/&4(;0O MEU\$2QE=>W/3&\RO\L&(?^0([]VV!\\Y(#\D[]*X][ M3C*M4[2YG HWCB%I54Z&PH@[:2^'0C \=='K@-R]B:447ZD^+A[^MM]7V'*D*P@?E5+*.)T"2:#1):02"9FGV5>LU[K%IS>3+SBYZ>S;KR\F2WJI6<5#E"H_^&4W-Q*M%2)XKL%('FDT MO5X;O6J\%%"U5_^<[U:]S3?GN\95$M)H876@3D#@2DLKM21?6R Q5\:O<, M*B!KOQ#Y=3H9[FCQ/^]2H;2D2D>A0!N(RFKIK,5]0"U!;:VH:-.Q/N9V8O07 MD_;8C+&'!;5@CST,5E$?T1P51&AFP9&$NRL9I([T1.)!)5H*5/:VR MO1G0VR/9;/JYGBV^O1L/E@X]^9)CZ=RS6;'>U*TR,7F"QSH)*9>C )VB8<$Z M2PSSBI4H3Z]#MK4(M!8)W9]MMAA,+D>X.6ZI42_BU^'XYGPTN?S'='K^QV@\ MW@"M)MTK0VPN:VX8,QY8XJAN@%).IY#K(K&2X_-UV/XM0JP#@O<%M09PNE]! M N>C9N <$:AP**L(419U4RJ\AJ(Z1*_#_&\1,GL2M;^T@RM>W!7A^WH/[ U M6=^I\@*70R&)A*A/+&IPTG"2"+&*,E5RG5UT&_!*T-(:90]P>]1('7^Q?14# MT]XMG3\5&$J,3QZ_D'N6#%@H\0#:_6[@E0N<-BC<[S7!UDL!Q+XW8$R47D@P M$5","I3.5#90*$4^Q:$@O7D@=,> $&SNI+2^4\64 =3WJ1>X M8YU66G!" Z&)>M#6EKRX'KM72?M(6 ^U,K+W_:3_;O M7X0A598.X\B^9RMI M\,+?8)1*>Z2!(VAK1 9@D_&YB!23)!)"D>I_#OCMC8XUK_[M4[[O1$%^>OT) M17]FZ9I$7/YYT-SKJ"60_(!@A'.1.Q-D,JG??#/]V@L=P*N8P > S4Y/SQO[ M5=03[3Q3@H" D/.K1!!1@#/$.Y].,9CX$*I<,>5[B*HE"Q(+[3C*C"NI./>\).^)ND&EGVRH]?+_Q?)M>T%X,5.E;%@O#$@ MI17 O7=,*ZL,&E(YSMZ>\E-U-Z!KC=8'T.":Z6L5C8GB#DB$!PE&$1<]=U;+ M1!W^(I0497Q%JG[GVMF.=.X++WN]%6R@E--(I8"&DA(&(J.& .7*.+#CI93GMKJ.F3IA57(E(:\PT@ :#,(4>HEI%QG@LA MGV*MD3;Y_$)-JP+R]G;/?U^AZMU@=/YFX@>?1W@B/)K]INO]K9TK(@C!%7-# M%:[:!NUQ\SFA+!6,)U+RJ'3L2GD'H&J=X >02V_F\YOZ/%Y_'D^_U?7RHX^S MF_FV4F-;>E>!A&"B5T(+!Y)1ZX5T(@GNI8V)E12U;ZY4F170)O5ESOSRJJ'6 M/LU[?+J\N<[Y_.KSN]3"R+ZKG-[J2[WR4GL[G6<'M;.+CX.OFY\O=QFIBDY% M*H7SFA-@(>K@(E,.HL\E5.G!JLB^3@1V2_V^T/@^5WN&1HVE TBKE63D?FI&4ZF;)T><<>R]H!YEHG^.&LRIVL MR0H$ :<,_LL"\"@UFLDNT""\D4BX$O_Y8P]U[0!&Q00^%C?& O?%BDB)!DXT MTCL#WN;:O#@)EU0.]J5%R=-VETRG>\W5!O$?X':PS(COEH2]JA>Y?,/WLSNQ M-(G)>TT5)SY)!XXZS3S1(MC(D6%4-;)4.K?2D!UGL^5RSI?7%^_JV8; ^,6^U@65ALJBTM3)1P8)V)?>8QW_EU _&"FE^ M,&RM;C)VP=6J1Y62YL"9XEI:""DY[[AR3G#<5$2Q$I>78W_F[1=3>]'[8'@Z MNUG,%X-)CJ7>!52/NE4^)R]B?Z M8;3C>^K,SRYR@M(TGOYQ%/G#[R>SFT+\K%OEC#-)4LJM<*!LU%X$R;WE)FC) MFF5)ZF:U.4,B3O?=;/IEA/1UWWZ;YP#GL\]+?Z?)Y4,YI 8TV'VPRMJ@$B29 M80_21N6=#7"80+>;CYWHRYAW85H2$HZPFUUH(A MWCHO/>,VZ:@XB[U&]O6>':I+WC^'V=Y4[^_!_]]OYJL*'A^G[^OA%(_=94K8 MAYE_G+8G_+KXN@H9(2-PQY-WX&4P1%!&I8)$C!5PRDX%/:+Y"%C77TH99#JJ MGQD,^/.X7J)B9/N5:1@170H DS$GYBUG#H;J#8!C!&G M'#5Q6"0]RU?3.K-ZD]V/IGAO,TTN_72^+,<41O-5T.\F>=QPB$I8%L%[M)&( M V#&)G"6*D(8]]2:4XZF."JX=L2P'IUQ9JL=]MTZ[J>="W7/ZNO1S?4\)QZ_ M)?MFGYP]!JR &Q4H)U+Q %'B$2@XU9KJ7)E6V--V#SLN0/?!P-[<+O+5DALL MKVZN/]>3^395X>4.59*&)*9CS.GV. ''*?-6.<'0SG6F) ?=L=\"'A4X6V%/ M7^#[QV TR>0YF^#F^7Q[<7IV\33CYP8T-ARALD(*K7Q0R@)P+XQRG ANLE9$ M0BJ)6&KNRO&]]/S8?:;$8P)F-YSJS[YZDB,R?LV;JW;UI+[8Z &YI6>EO62! M,9^\!#"$:*L),]Z#8L1P5X+,HT_#>$SX;)=/?>$R36?UZ'*R2A$R_/9Q-D") M/\PXN-MOOTUF]6"\Q1MAEV&J@%N1<:>%"AKP7R,BQ,0@$JJ%D"6(57]IHKM@ MMD.V'5\F!CO#Y5VN'A3]5?[QS6153OGL8EM4/]V _9YF4'%#@M'4HW%KP6IA MN/ A.8'2@S+%2_S<]5^"OOFF.4Y^]YH^(JM0K_Y\1)7;F- & M;W/-!ZE2!,NH!IF$!)=?CWA @GIJ="0@2Y": [/^$K]-@=H9SPZ'W.<%2G?" M[//N%:,BVU0_NWJG MF_/W;.R7RS(3&HF7$4F*%H)S(:&%&U566KSIQ^7\3P6X_:E_P"-Z&<5\FR=K MV]5LD^Z5B$8K3GWB1 +!M1(5C>6!F>B0D?TDC?U3X:Z8"0>&WZ-,;7LB\.D( ME864C"166F>$L@V1(&_#"&F6X0+J[&(!X7:(3'GN>A(-JA"TRY<"B\YYH^^)T[2@5H3DP MF_"@;0(#6D.@,G 0V@@IPBD7$SN< &V!$SVZ_3>\8&@E#J4BSI@8N Y&"W!2 M&A)5M,9+R&]XK"1UP[%G*.TW7* ;AAP8EBNWK9;"I#8,5B4"EK/\HFP]Y'3H MFL9 ;62>.B)4B?ES[#ZJ?89)M<>"OH")2L?M?:T=_L?-:%:O+;2] 9#-!ZER MG6ZA&+',X]:/T7'/E,0C*2?]8:(D\=OQ7SAVB9JG]=*[8DEOP)Q-AW5]/D]( MQ0^#FL[RT#_4P+PVIEFN7[")/-X]4J403 M(=0[1CDP,!JH 6*U ( M3342P80@I524E3SQ%'GHOW[XM4W[@TG&70"WK6_E4%MGP'+B/@^*X#9C$EA@ M5G(C@99<"1VOR_TAI5XA!_I&':/U IT:8+#A2%4,DGE%DJ.@0!)N M(2D9O-2<&DM925'!YI>4?Z+SN!N^'-_=4"MW0FCO$0+*^, A7]PZK5.0-B*M M'>;8;'R3D]PM4]^=?5Y>-#0T?5K_WLH(&F.BT46E@""3=30<52K!4PCX MRUXN1H_JMJD59&XPH0[-P[[UX/?ULCK#Q^G'P==_C197.0TZKB!?7>P:F[_O MD)5UB9LH"/6: LF%(*1,5H-R"8*PI^W^V2?.^V%0SQ#&:6\+AWJ!F-MQO-^X ME: J49V"4@7$BAE"D_!Y[ 9P>L=D90_J"9;RXJ(=H%,>OPV64]'L\ M\LXF>4WYM1C_R$X-7P;C+*N,\GCZ)!==H,HR MA>8BE;3D6O;8'?![!&([U#\J))8BL$J,)9TXU]Q9(,QH1BEN/\V93H!G0Y\W MI)^7@@(!,5OTA[^.H+(/('=DQFD!40:TSF0R^:H7)(M6&^\-IXGQX+PN24&Z MLV/H"HAQTN,UYC'!<#=6] 7##S>?/X^7)\5@?'=2O)E<3&?7@Z;E,9N-4 GJ M(5?YX@X-M !,4X;'32)$6I6H*S&<=W_+/X'3N!NZ]QB.N4HI6<_?#4:;\C ^ M:5D!&OPDHF8K0X0DHV6)")X,,T@LXTM$VK&_/K;.\NG OKNY850XEN*+'9PQ2$B3I1A21QQAL'HBBIP;&'270/G1)2]ZETY97? M)X6[\W":G+]PM9BSUX^G\YM94].T9.@*HN>.\D1-(B"8U<^Q@BB:97([9G0/:'G>GA./: V(-50)U>X\A7V&;TI7Y> K'W>JBK M*=S/L%FVS9=Z5%*GZ"7(%!P>=T)K,, 8B!&*ZT:^5MT9/#=S?7CEJ2,WS>L MI(T<>+3)&0L*&/Y5)"$L31!H(*0\@8O)46.7.7:M"GAFG[)C MZ+X\G;9*TA[ D4LYW4YP'J;7@]%+SI<;VU?6Q!Q7ZFT*$AC% S&FJ+EEGH$5 M97F'CQ0FY?Q]#I1BRO;H2);G^TM]_:F>;783>VA7R62C=((DF01P(QVN21$! M7GI0TI380Z\ )27,?>[GM3=9][9JWD^_#<;+U A+?[*UO%_?N%*$&\HTY\0% MD#X83U3^$INOZ2TIJ9=^K+.2&Z(%)J@-S'$G%K7&1\1('J&-%3$OZ1VM$[0LJ[^LO]>2F44#?TZ:5PT-6 M6321<]YRP44VS4.*,B7IK#_IHLTE_)VV2M:>@9*=G+-K?IYICB[Q-_,%&G6S M^/4V.BKG!\!_SC\.OF['TBZC5=%[875.496SJB2EM:+44DA&)Y=B2>S%SG#[ M4L\^3?L$W/XH>1EN'5*^MT>(VRK/M\5HFHBP=5TJ-!F$]]99 @R4B?$XYB7_Z@G]6PPSL]2Y]>CR2A3(H>B M;X=7LP$JQ3V+TG+OF %!O!,0D*[&*ANTX26N&L>>4J-UG'5"\KUOAIZDY++7 MT]EB])\K)N5$FB^&SZZ[.=IKL"HX%GR4QJ)6 %ISDQ."$2)5TE*)HE)BQQXH MU1JX>B-_7Y*M83'V#:*M:3EWYK5"W2"DA#:(\M)I@A\AM0GGBIJ2\.;CS0+8 MNE3KAMJ',@)W,/ZJ)(TV'J0&%-$IYA2&*>3H0Y2T6MH2_.P>U]1O@%TGFGP! M,B\@YH7658K<'!0\IIR[-4_6KPI M**=LOP[V>8+YRBS'I2R^_5(OKG+,:),T](WZ5UQH;ZBFB64CV!NM58PLY0([ M)E!1\I1_[)I4BZCJ@M;]X>QNAJM5W#F";X36RUTJE5@(-B#=B 4NN$8")I(B MRS'UP?>;6^,5HZD5\O8=SK']ZN!)RXH[&C753M&HP C(B7&M(L"= 1!%!7J/ M/W=QJX IH6MO*M!WY=U6T+Z=\>8HH,T=*YI0?@J"9W7@P+EW#LU0KC@7)!*5 M2BX#7DU<8@N*49M$/HR.M+JNN,'IWZYC.IF[^F(ZJQ_%Q<6O:&\@>T>3P>S; MDF0Y1B _2$Z7EVR-CK_.OK6"&%$)!9\8IQ I*@H)U\YP(QMCE2Q)F+U[$-&K MU?*/AT.]A^/>[EE73^J+T784/^M1!:%%4I&PR 1H!ZAD..=]9-8D:G6)16#^ M/.*T'>KVA1Z4\(WN);YK5S'K.:5!>I )J-3.4*LB*AJ*>;%]I7W$E=& :T&EU("5RA%EI;6X*80OJ55" M"SVICAXE;5#T4&@)H_$-VE8[X.6V1\65B8:%* 2D7$#%$JLI.-P6(C+"90EB M=G97>.6(V8^F?6'F7_7H\@JG9Y'*@\OZUYOLYGZ7+O_L9C%?#";9/7";Y-EI MG$J"#BIY;@E*6ZZ)I?E="%<6H['RKWKMO9XM@ZY+L!X;@[;YYMI3= M0;ANI JW("J%*N>_-R"7-S=>>AZ#2VALB")-:N=K^%J;Z?88^9&AYEC'D^JR9)ZYKTK_"[/7 M7[E:=)9-TTG>VVL2/33J5PD#T1 2<7D&M$EH!R3O0@2CC?.IY!GNU6!J1ZZO M T\+].W-2/]^JFM306QL7\D4M:!).14D*&,U\=9YD[B2U."9^&? 3AG3GUKM M+9"Y1Z7U>CI9"N.MN2&>M:V4DR091D-D%*P"FT@0/%*AM)*1G++8*63RGR]]? ?CG&3RS<0//H\6@_%6Z&SL5^D(-%@K/(T4HHW.6:4"#0*X M#>0DLTQT Z,VR=P7I,(M=Q[7%7RH-GA7%&LKPG89IH*7VCP I=?G]\]\6S%V,L=JA0M MI\*9;#,#@- > $FJF&=.)UUR=A[[%6&[@&J%OJ\E2Y,/W%A)P>0X4XC7[@GV)VJ-;V7<9BM],GE^]O9^.QVDZ^V,PVU(%8I>1*J.3 MRG5_..4, N76.9/OVQ5QVJ9TL.R!O3U8- ;$<\^S#@G=FXS:X;7U^1N?MT:I MZ(%[JR'E- PD>E0;I4A.V=1KQJ:#E._J# 1/!5DAZ?=.0K!0.* YW(GQ_%L Z1X 7+8"GC2LM?E82O-/@_GW-]3O:Z3N?+2H M;Y-[KXCROAY.+R?+4;85?NWZJRN5_=&L5)H9 Y1$%R6XH" 9Y;6*)=+YV,MF M]R67CXR'>TOYQNN8_[,>G[MOOTXG_W$S&(\N1B@37GB^>3<>K$WUUL5W52: M-9Y%[6R6+JA<"4:4!LX%8[RGHK1]I^+J1?H? ;LZA?5M@;83!<-)F_ MOQI,+M<6[.OV6RO&+2.2)<,T!^J1A 1)ETMS$DYD+*F;6U1?\L0QWAO'>O/: M6CU]YL2A%Q?U<'%V@(\579]/9A3V??EZ3Q+-\T"K[S-,D MM39!0*+Y\41RM(]30+.9Q!)_BIT#SGL/P>I+8>F-/[UFDUE3?[)!Y$R3[I6D MD47%G.%"@W?>*D*C(0&5, =4%E4JWSW _30UZ0X8<>19$X3W*6@G")& R[#< MI1!)$D0&<*[H;>K8_5[[ E4)Q5_+'2SUCG&5'R1(?EYSFFH@V5TEY&1PLJA6 MY\YO2J=\IU]*^A[B_E!M>3=X,$QVC.:;WX%Y7@__=CG]\O-Y/5KA&']X"E_\ MJ%I^X88@O6=MJN"T5E[&F)B4V5_8.LXYF"BMM3XTTO%:F7J8#F^6_COX16MF M_KA)Y1+Q)ABG57#,>(_K,+<3=U:R4RQB6<"]:2M4;":!]V;]_W\SF"$IQ]_> MUY^GLW7X7=.Z(D%33KSBELHDP7/O[I:24#$N>70H>LD_9@R4T;!C.+R[.[K" M8+%-)'S7MDHRQ:0T :^82CIPL.QN&2J$?C-ROT;94$+.CE'Q<3:8K"H2-)(2 M3YM707K\'QAC(5F$.@7N[A9C)2U)\5_DJG_,<"@D8D>(B),%[J4T&M^F%EF# MA*?-JA@IM02("(:E$ (W2=Y-WOO83Y&05X* 0N)UROGW]>6RTM)D\>O@>MT! M\5+3"A4>*IQ+DN0+-..\\/?'G->Z))?KL;[#M@F'(FIV"HE\MS!#";6*6,NN MVS[?H\Z^^>GY9H1L[%E%[G6TP@H:52YWXR'=GX TZI*KH:),UL>+D3;IV2ED M/@Z^OCE'HHPN1L/E9!L<)FOZ5,+EPN R"!]% .#&AGOA:&,JN?DYHH? -F'2 M#B4[!8@]/T>6S&__>#N:U'0C.%YH7P7*J)%$1FT(&MG4\^#OEA.#+/$R+TK= M?+S **=B'Z#P^./9[./TCY=>8#>TKC1U0G/4HPS'GY XX/7=4B2"_6 /6$>/ MB+V)V <>E@?=V>S=;/IE-!ENUCA>[E)9JFETE@J31!3,".+$_:("%"5?.:+X MN@Z044;)/N#Q;CI?#,;_=_1YJSKZ4H>*,]!",ILX,TX+KR)Y4+1=+(D5V?UA MZ55!HX2.'0$CRS$[JP<;H/"X"6I$P2L04EN:@TZE8NGA:M;0(KE0=*EYC,PO MH%Q'['Z+#!F_NYI.-E]6/6U6)2%Y"$SH""2_:5H7[Q5AM*Z+TKB=W'UE(?4Z M8OV'>GB3;W4H^_1QM'@QI^A+S2I.C%M6#F "1&"&!'6/VTA-D3_*R5U4%E*O M(]9_G URL.&';]>?IN,U?/^N3642))&L@:#0N@DN,D/OIDVL)B5,/^V[R1(Z M=KSSX]?ATN]XPSWU2TTK&8%SI2FA@1H3O1+BX9F%B*(S_^3N'5N@8*R,4A5?2$[UG;(62'3]= M("5QD:,O=1@L!K<3WO)F\5*72B1MB"*,LRSXI%92W2_**UKD?WBBMXVM4++S M9^Z9'RSJR^GL)7_4-2VS@QLD;.0*I)(^NUTG>Z\8&5%R\\Q.VW&RG)J= M B)>U[-+/-K^,9O^L;C*@1N#R69)\6*/RCLOHA L*5R-]LG']'!M:D/)\<&. M-252FP!I@ZK=2HZK>CQN@H_'#2L;I)!H3%D1;>!"1,H?#*KDBMQK3^[^L9A^ MW5HB#VGIFR2O:M:QXD$'H92R-'I!O3!$JWN$:U_B5,6.-0ERJR9*>\3M"#WV MNIZ<9W_0-!ZL \IW;2K*B?)>$Z=%XE$$H_FM NVX"D5U9=FQ9@)J!Q,E=.R: M_:&>#V>C=8'GZYI6.AKN<-I"1^KQ- R*9%TI!"&)AJ+T_*SH:O.H^;\_!3MV MQ$^C^7 P_C_U8);PDW4FR)K65'QJ'TE@0:TL[GC,J:HG2>2WRU')RCQTF=%EYRO#"#[T[1; M'10G.!N,WTS.ZZ__J]YLASQI6QD)PH:D L,S$?10Z,- M>G;E#[.Z'0S(:(R##^" M1C*LFQ6^G4XN/]:SZSSQCTA9AU_S^X8%OMB^"E$*KE!^* \0(5JM+'@0G!+" MF"@YOH_UEKDMCD_;IV\O>_(A3=N;R<5T=KT<(N3Z.^-7OUU=3)H+9U"O=F"Y MPG\@9Y^77 @E6*.(\NY6^&:"T[QI4K3ZA=85]5HFD@*Q1$%(3EM%'8 *(6H9 M8I'+T>OLFO5UK+4Z[I4R4D1C#3:H.'!O+'>4#P6-3%! M,)>*W)=>%79VX_=&Z.Q-WNT 6E>&H)X@N7Z;S+/;77W^OOXR'7\9H:KRQ_3C MU?1F/IB*1#,._/95?^%'U/GN#KCGBOOM]Q9 FTCGC M#![XR1N3I;C7^>$-? JG7#^QC5.MA)B= V"MV'G2HM)&AF0\%4P&P)F[()F0 M.M][0(KF%(^G/1GWE.U[$;!+QO\RFHRN;ZXWLOZ[-E6N ALM4XFXY:6H8^"- MTB*@59T$E#Q+'3WS=V7?M!TB=@J P=?M 'C#Q;KU(%U32N.T(5D/2KH$2PS5@C' M.(M.>!E3*(G$.=:,@EW8NX5T/012MMJYSQM7)L>7Z^0<1 (V1>T];BK/(V.6 MJW3*MR/[3N=G$\GRPB23X/)[V<7R!RTEW#:;]^XL_=KSYZ= M^E<4CU,.W'AK'&AC3;"1)' DHIX63E(K;0,)S]]26J=U7SAS@_F2!%L!]7U# ME-4$137Q7'$\C#FNASMKI"(N28M'_ EJ-!T@IXBHA[FE?7M7L;[Q)>U]CRK1 MY"'7\0"60#IJG.2HTWM'!9')E&17/U9?[N[O]_SV;?1Y-)>Y\2- MC3'T?;?*&ERF8218;P %J<8/=(R",,,E<269[W8^MWJO(57,_HUP*J)T;]H1 M+OKLXLD-\H M#8GAJ9!XY*=89J ?R59*ZL- "U7$T?P#LFUP?C9YK'J^E"]VUR$JP2-UE$F% M/X 35 N?%"A&*0F!J1(U_G5I9&V#K36:'_)(_6URD\M9WTKB'$HX6E9/376N M8SW,3'^Q/&[QF!52FDE)M'=&@5!@*,3$(D\R)T20)5G*CC7"K\_#M@LF'$8\ M_C)8+/,SK7'JW]ZIBJA.^,2=,8E \LZ9R+Q*W-OD@SSQ6 TN:U*.EFY M&L__.?A2_SI=N+J>_%*_9*1V]EU5(II12;A%X@!SR4K42:@S(II$"2^YD3W6 M ,:VT7@LS-D;Q(\WSE/)_>:B!++E(U?&LD"$X#G> %+DVD?BE;8V6 #N2T(P MCC6 LA. ]LZ*_L[G%0?3:#*8#&L_G2_F_YAM+IF\MD_%4@"M@IG4(+>QEZ,UI!(>AD95H!!!4 M42 V&FN,M,(1FB37S=+T'FMPF%7$J'S1)IF'X)R+V@5'.<=%*AU.T2&R+6XW M" [;C;JO)3@,18[6 9C @PF<-P8T"3X 1*4%M7^>&(P=F;P].&PWRK[&X#": ME#?42"Z# *9=ONF/3$9A0B#:GGHPZK[\;AHC:]O:ISS=CNX[LKU%VT5II)Q1Q09IQCJ-%8/+!4 ME,:+/XW'1"G0CY!;K\_YD#NG(>)_A4S+]5'D@([,<"V)U"7!%J\+C6WJC_N2 M]_!N.LNZCN>-GK&;#U)QRJWUQA(I'%@*&O>Y0A-.^>@AA8.=[?W>.#7&0F-_ MG4)"OV9?5VUL#ICE!ND(C'!'(W$D*")\CGX_Q=C!?O!51.?#(.JWR> ZEQKZ MS_H\WR'M!*L7^E;6!B=PG=I[#@FD<4;DXT %2$:2DM?FYKZ&9H6M27V9]_BI MH*N?+Z\NMT,EQ;96QKG\J")XY+3<"[['"6$Q!F/\DD(T%Y7*) M[>[X-UT,QJ\71&T1^4! :@Z?R@.1AE$I)6J"4EM-N58J631G(D,;ME<7OI," MS8ZD/1!4TF T^[?!^*9^>%C;=( UZ%W9G,K<,"!H8P#WTB5 YEA!(%JE])_1 M#Z\E2+5 [G[="^[LT/CU3T_0WB,18[DUB-H;\*F0Y9]Z[7-Z6!6T; M!>'IM#,R]Y@PXW)QE] :OWF+@\%+S2O)E!72&,ZD!Q.9\YY!B-%X%$7! MEM@PQPJ@=CG^0I+Q0B(?"CY;?0U>[E )*="N9Q(M,PX2_Z2612(]VOC&1WO* M&57*N+T%.GN1]T#JZ-9<*B^VKYP..HG$G?4>%--:*Y=XXM8HQA,K\EU]9=#9 ME=N;-3+?#//X=3B^.5\]:.2+Y\&:4HJ[#E&!1'%-T10+DD,B7AL [8'E M0CW#K8U*W"[6N\ 8XR'L"19)10T8+2 MB2M*6%%MOJ--ZM,YT%HD^=Y'HAT.9_5J G>&ZIJGRTW-*V6TX$*XG&8> FB- M^H"Q+E*C>!)0$@NV M2U7R0K![GI-^7@CZ/L)VI'$O=[A+U7#^_1>_PJM9;<$'04+*-^Z!@P&9;(B. M>]*]%)/;$@AZ.E=GH"_;Y4C^\DXX]&T]Z@5X9HZH%(%1X %;@QRE%,B4,HX&0\:RKSSJIK(FY)A M*XD4(98QRY0$%:-CQ@>B.?-.!@JG^ K5*\B>^=KUQJOC$4['657WV.16H!:8 M%\"]EH"80M4H6.>!*NV5/60*!C^87Z7Q](^\BOH?@]'D[70^_SAU]?MZ.![, MYZ.+47V>\UJ-)A__J,=?ZE^FD\751J>H_4:L3!+6*4M(0F4@YGMW(86.RKC M-%>G'*O2]L.EX!-6]M]CWT1KYNNINA/E?UM_J<=;W,":#5 10O,=IB8L5T&0 MQ"CIJ$;[5U(B0SH8^+K&VXZ\G_9 W-ZA]4L]R#MJN>F>+V.KG]A.XU26)"0" MZ@+)40!%K90!*)/:"&LM.5B-MVZ UC9 UN&O ]+W#L,WD\\WB_F2*&RK@]F& M7I5PN"*O4!.T$FCD6JHD6+ J^$1%.-CU0L<0:Q<#ZY!63.^^<'6K.X1Z/KJ< MK/BX^:1\N4-%68HN$F **4;Q8+"$:QN]])$9T"4GX_%?D+=S3+9"V.A6>F8-OT[@MGOTXG MY_>3WXJK%UI7SE)C>#!>\0B!)MYNEV]6A=ETH38XC4SEHNE7BU'G\YMW84I)9H M>TCT;%62UG>JM-!4",Z230YM$Z%117 !/R+9*3.55,T]]K.LG/,-H+07F?L" MTZH"R"IOAYW/Z\5\ZSFVKDL5))+)1=0M@P%J0:-RZ6)B)$;F\,<_&9!VY?NT M$S+W"J2''#"[8.GE7A6#&(%$8U5T@/]8I*(&Y\%#CMDKT;&/73?J"DZM4+JW M&*#A,E9@_F[P+1_O=G*>HPEND&.CP:=$/Y! VP5TV[I6*9C $DG2<8_+S3EHB([<.L^] M3T55IXZ]+&[WHJV4W/W=4MV9+V\;I9U^UKJ2A$JJ1,2%,;!,6R>#4EI8AEHJ MDO&$8=26[5=.UO[A*5D MR?O,L2OX/:)M7WH?CX_F?::\[WPR-SP:S!\5W_W+>?.)QQY0XSA/'@$F(6B: MM6TNC$/+3P".2.E1//\YXJ5V9'0S%Y3=*/L:75!"5+GD M4<@UCT!%L'C>!B8,C\R:X$X9.Z4\;^J"LAN)3\<%13M.E5(T\N"!"V:C)DSE M:HN.4F$/YLI[2->!QEC8PP5E-WKOB;/Y;/$(8_BWI_C"CZK5H]#PVYKC[&F3 MBD9O\7_*21#@\V5K!..D"1H'3]!KXJM7=H 5TK(9"N9W,)C7P[]=3K_\/+S] MQA44[O[V% IWGU=V/+Z=8U;SUIU5FYI77C"DBDL!_P6(W$JD#9..NF@5?GB" MPF1_UDY;)VA/./DM;,3%;Z'RBAD5EAZA!*CSAC(B)$V44!DL.T4*@4L:J#0,0#-G6712$@6>> FDQ!_H6(^+;C"P.S%[PL#9 MNXT8.'M7<6X45SXQ3P,X2)8$!#+E*@;AG2RQ6X[U+;PC#.Q,S'XP$'][OPD# M^.O*O5S::\; [L3L_\7OP>1]/YK_ON6R=%.W MRE&KF*)"*L/!A.1$DBZ?>=8ER42)&GFLQT?;5Z8MTK=_)/GI9/G"T*C2R:9N M%0'B:*!1I\B!6V.TX6BB>>C!OY MCYM5(7$"D$1$MZQWH2T;=(6T+-O9&PU6K]O6-%$ MA*+))$^RXX$TT6GM/"@:@V;LE/U\]N/J&FCL1H3 M9998+4!$:@/Q7@>0@:?\"?5^R]@677V\REL\N;J_0[IR2'D6[_+-^H-A+F:4:#5#1 %2I:(P. M&EA0-H!@E!GIM*72E3SH'OMI5 2&IWFFNJ!V_Z+IU^FJ0,ZDMZ[7\ZBL63UT0^[AC07$/_14.NG8PCM]DL(2YD5.),0E&*L( M'M@049^7I%E"CU=ZH5QZ(!72\M6$=THG _,6C4GB $ECN)"YN#8:>[BT<(HZ MR_ZL;1+>N1M!CR:L*P;G$TC4Z*D"&:5+@7L3$FZ2Z-Q)EJUHAXTOA77M1LRC M">N2*O%(H]6*,DB16'!:6A]H+GE&BV3!L1X7W6!@=V+V@X%_N(UR ']=X2J3 MRB:^(@*(57@X.FZLB%H13HK*CASK56LW&-B=F/U@X/UO;A,&\->5L41ZKJQ MS1D$849%5)Z]I0)M,-VLB.\K IY5RYX)DYQ6OR/1FW M)KYA-P(>67R#2@;!#I'@?PBQ)B67(D,*<) MM7"4:PF >BLJ+"G0J 0Q>)(5>0,=JQW0"@ *B/B:0_JCHEHZ$C4X!])R[?"< M9#Y):C03_I1+5K3U[-4B?5]S2+_$(U=QS6-T"6)05O*DM7:"2N,8.^67C'80 ML$M(_V[$?MTA_2$E38*2DCL++.!1K".5-BKB\?]PBO&Z[6)@IY#^W:A]S*%] M/L6 JC_:_LF!0TDN$AK]5$@!P"TO$4BO+;1OWZ.M@)[''MH7A=1&X6ZQ5@!C M7%.%\/;2!&X9/VE_G_VXNCFT;S=R'FL05]0L0'0V,2Y!1(_J?["$D\AIE-*= MLB//OOQ<'\2U&S&/-]J3(R&(9E0%- 5Y=#J(Q(!K3Z2Q&DI,I&.UJ%L&Q?[4 M?#VA?4P:[@WGQDH&)A$KG?3:,QHIC:(HJ\QK"^TK-Z3W)>OIA?:YI;#DS$DP MPFDT($7 ;1B-!F).,5M-*V#8-[1O%VJ_QM ^PY%F6@KN3'X)M?^/O3=M;B-' MUH7_T7FQ)9:/2"QS'>%I.VS/G;B?*MA2V>9IB?20DKL]O_Y-4)(E2R)99*VB M>KI/'UDNH J9#Q*9R,TY[\E6]&0S.L[X*2>I=XFGCNA[8GE^$BR+WH %"3DE MRR$2&=%(S4UZ)<5AVV.K#V)/,,_OS>6WV=G5N\__(+VR//EVN5[7ZTRD;=P- M\N^RR:4'6H2"R1U3$XQ5RA@/7N6[VBKUQ\27]]JQ?K[0'_NP=401B,G'&!)H!1 MTN:H%03G.1,CBV]'4!;V)(B=0*W%Q=,B\LR7/-V.NX MSIWLL=D)TUYBJ1T7(FU9+J6-!KR++N=D33;"*> AM$EQG;IP:\OSIJ5V#B/Q M<&[0';Z O4=E@]%5\MPXQ\B8"J1I@/566XC&0+#,F&;7YR<#K4.Q\.1&MFMZ MOYR23DD2T9S"C%%!SA(E;44F8R#50 K>)@%WZ@9GYSAJ3]_!X@KOCO[TGVLB M?ELN-KZ/W>K7SG&5,:7 M =4 &"T<\((XU,2RB3.19L H)>3GC59+:Q+ MW@V%TT>?NE<3>_;YJO1&CCH99RP'F[3W2OK '3IESOW: N.D4E4J! M(T32FZ,#+9B+2.HRR(!:)*+U"4O/KC&R'(0%0X'P0_V]7ES7)?KR+AOXW_.K MK^%Z?44;>97^.KNX+ET6?(G17-?GGW;B\8C9*N-YE#Q:G@0'0=1W@-PP281" MS+UZ];5>%?UY57^E[]Q0H^@IA0B_*+YWE/E0 MGUW,UNOYY_FM_E)_7J[JW;*ONY=4,43U MHJ]^V@-V-"8-;Q<]IYB0-M+()-HRMFSO[$#&*$I&=Q*ES93Q6>:D5:W6 M4'M@=DW[Z>3];"R\]:]?]ZIS=5A,V>D@@\\6<4 MAR11F@PFH(N161FT*/73XTF&!8=5Y MTZ"APTA\.D%#(0B&&('EXO;+T@D;M#/)"F693:=8;[D[+!P1-'08O5].T)"0 MGH@$C.9W$)VS3D7');,N6"[Y*;9OZ0U'[>G[AQJ-AY/AD?WL];TF\6N%>;9?/5_9Q?7!P*\DS<5>G(1R&:/:,!ZZ6P$IP1R M(51.L4U8TLL1PEUB? RV3 3F=S>_6U9;KSXO5Y?TARZ ?OB[*LEC9F0N^M(A ML>C?C%2I[.FXS:94\QS2D7JZ4.^=,;U[!GYNQW_6LW+;N5G6:/?_/[_F_OIU MW>""?]>P*B!#D0/]8S-@L$X :$U'* K!,37:"<.MMHFTV#FN(H6!"TG+U$9 MD-P:PSV1 '0(+/(V09!35^2ZP<'C-@P=4GN<[?SSEP]D4PDCVG@^WLYGO\\O M;GP>XQ;JZV/SHTI&&XE1*9+[H?275-()DWE(&7BC>**>5_L<)VZY=_YN\:$N MC2Z+:VIQ_MMRL;K[(\[6\_4^QU]G[ZA8Z:K)?$D%3 224E3=& QFQ,:GEZM M4&F,KVU"96#.#*4\_UP?_G@@B?*J_L_U74?X)KC=/KI2(@NE7# J2UHV6#16 MZPS!8U(H3_E"?P3P;(-O9PP:')C/??=>SV6#T54,46&0B:7 35I^M)X"0:D MLBGA*5<(ZA06VR#7&>G'A-SZY^;;9D^D4 MB)XG?',ZJ=.V%5L&A]X-Q9ZAT88H_UHL?U_7J^^%-F\6WZZOZ*^79)Q>S&_3 M$.\7V_Q@[OB5E75:JLAD]JKDB6?:XM(Q*2%&@T&<:.H[ ;ACB$5B.! A6P-E$J)FDXL.J.D1RZUC+X-WE[8<3\RWKICTM'0NDL. M.6N,K.TC*NYBE. L$X*V0\I6>2^L8MK%4%H+GK!;__^N-M_;V^:&[<[)B@LEHG;0$#DI(N-5J'3 ")<<=5#JV.VA>&T'$MG>YX M-.H]S]-E''7)N'6>2KHD@D:P)F4 QLLM!!KI&3.:_&/"3!P%L]M1%:KH/%=2,EJG],EZC%IH3Q3US+M!"\V\(I@=1_XQ82:/ M@IF\ZW(N5-9)62EHG3I[I&V5RP)IP[J]($06;CG \2A$MTNF3@/"NIK#/QE'O?= 3&;1"?",MZ];'\_+[V M;I9'4U7)<*X9%SZA!A'(5@3O-* )W&3)3KEOR80@=*C+I1T7C\9JR>DCBA!M MZ:?U_'S3?FJYV(W*G8,J6WQ%NG /^*8!0_+6@DK /#@O^&OPO$P+?UWR:Z0( MC*-4KK<-,MT[?4^E%&/)I4![-X/2S!%!!;A(5@8J;=I@?^H%ZR:D(X_ RC%O MZ$N1W2?29/VK./E5]FP(M)GFP$O\-J^JO#%,J&B)K1X\,@S,!15"S)(G)D=3 M3*:['XY 8P,/P(!,G/JV6']X1._;([>OO;'S?94!9#QS&U$@*"D^(5^@CREAXT]3O;9I\8T&5P&2]EI8I38%/,@, M :^R4:ZT@@EJT.:LXWDQ1H%H;USJ F^TSK,VD-LYOI*ZU#4&9YU@X)A"RPPG M)9"G:!#,95@QGB7K/0Z 5?.JLA<9-9$)1)X M,ZA1M[R:7;P6*';-FG9R[\'*CSQL&\U0>:V88REGIB)()ATJ)T5D+&>ED;>Y M0]!_R[Z&LJ\/5G4&O^//WJ:35%$:6H!2""9"DLHB1JFB4)!\Z?K= H3F;Q > M#L(NN374*?S@\P\[BG0G$P:F.SMBX[PT1HTV')_GT>-SB/ M.^7/. 6%GB&;O]]:3WPU:_KI)O#GYB[@!.L,"43AR7:4:#SI\]IA\,9GD$++ MV%#MF'P<2>-R0QV]JK+))L--#A(])&LQ<.:"#?82SK(#CJ_>S'SCXNNQZO&)(Q]@5LFS"[.KB]N@F*6%Q=YN?ISMCH? M9O\\_^XJH I>9N^9XP"289)6^" -Z@3YOX=8'506(YB M"4,R)I)F*Y*QQF2+6EBC6>#-:FEWM7&^U73TG'^\FJVN7LKV:8O884*O#N+Q MU/?/EJ7>=^TXN[@^+Z65TFRUH,<:*79]?T/%1.:<"_!@=:E:X1T89"ASU,&; M5@=4R]3WO_?8-'A^M$W>D=#XY_RB7E\M%_6M ;C^M/2E*\9J=EZZR?^/_Y]M M5OY@'U AD#K/6?2)(2 C9<5P(+4_NI!B\&TR3%ME]K^6/31I=D]P WW\2HS^ MNKP@A#UW# WX]LIGDU,&%6/V8+BR,F8;HV=&F^QL;D]]L[Y M4,\NYO^MS\M9NEQ\K*^N+C93+3]OR=/L>2\=_#U54&0D6V^C@@ HF4LQ216X M)7IEI=I4 FF5Y?CWWIH>]\?>;8]ZV'Z@>7Y.U_/&VO7J2FOT"1UXG30(Z]"( MF'@@LS66A+H1HWS_WD6CLGKJ-Q(3N]$3 I)7)FO,D)BQ!G/Q H3#OX*DH3MT+']NBW+@G_ MW*!\&TP]=5SD-T%K/+'B$D]-&7LIB.E_[=UK6I M?OQB(C%Z@?1X3.K_T+OKN?R@O,SII+K\M5[/5CS>7 MW^C\*LLJ;MVRL@<+^DY<*T<5&88?9SOSIMI-7)G@F$0)F?8*0')>>A$=,F.B M]RG#W^+E(%PM1V3.*%+GX]G7^OSZHG[W.7XV6US=\R*4SE++U8]7)KF\,#I*+7T4G/BMK5).*^=$M%B*5QTC MN;;U9#N:9=MR.+N8MC+<"4;Z/L/(@$EFF0!..%>;'@'RE*MZ]X&3Y6BL.?)* M8+VZ>K ]Z4^/MR;]JOI0[OBW9&+^\O<5@.:9*XR"-+;H@H^&9 SX%+50FK?I<#AU8ZEKM+1JW'H8'P;'9&>- M6[-C'!GSM(\].+#>&09T,D!&6BAKDT3^8O#6+2 .:-MZ&/''!%F[MJV,.6M\ MY$G* $;2Z@QI('20(+=6M$H=F.JY.S[(CB/^4""[OQG[1._=H]X]?;C28*60 M1"@>+7"O2EJ<4PF#\=:$5@6DI]JB=515KC4+Q@'6K=-A_M_=+=B:#ZZLD5:@ MC*AM "^M"T8JLI]\\LZS=,H'9AL,[(13!X0>"EYEQ^V%T?U#582 9*KGG%P M<-$J7M)YN00,D0SP5P.7=CQ>=D3@H6#RS^6B_O'/V>J/^BI?+\[7>R'S_("* M@\C )2(7$AP"H@,FN%8:0@RF39VSJ6M./<*G$V(/)G&6JQ)A<%7_&E.P7PCM M&E>5&N8^2.4L6='69\LYZ0$I99.TU&&T1/B7#:PN:3XT M]43^X].5;S) 'WS4XGP3>-<05H=/4I$Q'!244KP.( ;F)0N:>VM+>BGML1; M.CB%^.4#JW<&' VMXZ]1WNXH]]K5U)7W9+MD$NT.) C/T L?73;<&XU6M_$" M3?4T'>5V:R2JD/_[R1U')E\O55:E3$9;KJTTNU8ZC^="I2E-CLIL8V4\A M B=-Q?B$R2#*H%,:MB[D0!V%AD?3XZ9^_3)IR#NV/;=K5"#+;=;+9 M:E2073[*_CQ5^S^2LIC4 B<\A$,0,&!0@$(;/T(GC1)B=GJI:L-L1G M]>C0[(,W4Q.;M]VY.Y">MS-5F:S+Z""#UA)80!>XC]Y&XU&@;J4"'%Q2[F\A MV@6/IH;9^V;>'<#V?K(*L;@WA) ,+$1I/0N91\G!)8?8*G[G\,;8?R.W&S8= M[39XNRP%U5:7-[$CY1,?.#!F5^6G'^\W)2NW>0>:SU!)+058JSA7II#/\R T M9 3-5.*MH.>FD^,V&MKZ9D=K;T2#!D: MY9RRP;71(CG[&V5],V24TC CEV8=NH(+B\1>825CFH.7 7-V7FFFK>>)S,TF M6Z1WM_2&)[O*TW4Z?^6B 1^EO.PPY'=9T.99' MO4N2-POZL5PJCBHZ;K_AOA1@(UFQ=50EO%562!4D>%"&=%".@<2T*)2.N5&D MQF!K;5*^P*JL04I2:%FU 1ND4]XK.JU)I)'AW(J55.N7[D\27SL@[Y(Z] M*=IV2AN7*:]<""9GLAEEEJ@82\YJ$#PZ:4[+?U(E_?6M7JQKK!?UY_FNW;1G)$DOYS-9*D9" HO@:>$I1A&Y-.CXH%G> M0[3?Z1-7W=!X@!/B:K;X,B>U\V87C'8^_&.Y//]S?G%!^O'C;SKHQ#AHGDHQ M,#+0SI:)@Y81G<9@79"9"]+P&V7G]75>;OOX9CK@WM$5TGIS*"6XG09+"E V M@"+X&!E7Z$\YL;4GD#S1%+MFPN#B8.12O^,(!6U0E[P%X@P#$OY>9!F,$4Q) M$-*,:!'>WRSD^6)^5;^=?Z^?K&A;*>##)ZE0J2P$3Q;)G.%*NNQ"QIC*#;I+ M9K1./U.0"HU1LAR(_$?JG\WJM]9KXN"F]LVN$K^_/E5Q1@N004$0 ";1-UN> MLI8A*XPYGQA\^F#LLBOB#@2.K;7TGGVNLB4R06HELD\E\]49K= 6QZ\SELAQ M&@!IQ;WG$7 4_882$.?_>WUSO;Z[X//V$941EG$9O+$Y ?I 9C@I2:0B&1Y9 MRJ.IIKWBXE">;I$-[6@Y6(FZ[2+R[8[\S$.&5X:%(!U'YV0$'DAO%_2;G S3 M$G0>+=MUQ_/V1#-9JBD3TE& MS079BJ"C0L9T0+ NI MT<0%TGR:2MF$1J,6T;ER>-#! :"DY\993S^.)?*&J-/9)Q)[9,($3MQ- M%Q MI^UF:"6",%E'LH2]*?''SC(3>'!).,3D3KGF=3_(:'[P'L. X23@>?UY^Z<_ MH=-.*7C85%5TWEICK8K<@.7::8C!.Q6<%=*?=$??02#9,T/&.J0WV^DP8#:9 MH(*HHC=$ Q>+SX\A$YA"DJJX_T(K.!Z>.#Y,,8V!X=@#&R9P-#](\[VM_K%A M_W&']9;)*E*84[("9!1T=M"NY#$+!:07!2R'2@MP3C>_>RH'>#=,F9)1T]*8 MJ7QD'#PJ'S0'A=9;4F=R),H[I4RSP*[.$K9?@:SL@ F#.Z9'SF 8QS%MDE=6 M<Y;O2+2+KX0HF[3QQ9?;CZJ61C:T7-5$I-" M1">3]> \)V5=LE*HRS[ -CZ6Z\MA:3[0+O7GYYOK_I*W^'FYNMQ, M,G(XVK$;&+4AS4D"^N0!LG"EEBD+TCF=,J81,Q5^(N7FBS\0MV[CE4DIW+' MG>,J'9(M3D4-7 D.F&\#U:5(&1.VH.Y#F<&^H;/Y<:B6_ M4+TAUHJ)G;CXWUNNSU?Q;X=2^R/,= MHRI-*BA7F(74)'Z<( U72636YDRG6K.@^]/0&1IS?=D7=8>[3"XY M&5)[>[SO'%?)LBA&NT]$6F2*3H;@E4^@I!;HVF@14X=5)Q!H!JNCB#T4L'Y: M9+=VV-Y66,\/J)AWUGLB4V((I1HSQ%+^5BFA-=# MUZW)T]3:>/ALY8(/CG,F5/;@^1]!UP(BU4B%G M\YD?YE^^7KW[_*_UC0^X>9A:DQFJTKTY,),Y#QJWWE#&@+LT:C**6!$1I]H3X%UUBD5N(P@D7O'Q?@ MOH+;(L[S>GWK-W@[G_T^O[@M6O\BW0?,!(32[(EG "ZWXA/^Z6\:$NMYC$ZA(ANSZ;7?R_>K;K@OCX22MEE(DQ"1-" M!FL3HA/E9@*Y-MRTNNJ;*DK[1=.S=W\#L&92 ";*E25\^G/9%K7W,U4RQAA( MZQTZ0F2$U.1YS9=; ^_C7CE&#V"(9.$Z/Q[5W*T3%59:[RTV2J%')CP3I/> M(TU4]%O4K6RGJ39:GBY$#V?(U"#J/Q,3.\3I+_-52%J/!IX,: 8,!5J4BG9P M=AZY4VWB30]NOOR:P=J&*U-#; <@K;1QCJ4@6# *G"EE'P03$%*,V9B +7!Y M>*/E8;T.D\+E@8R8!!3_M3B?K\^6UXNK^CS]=4:/^LORIV-QN6V^BO2>X)D3 M+H,"SQA:6PQ(%;*V6:HVE56;]U0>JV#,^##MB"_CWN/_./C*_D?E,G=1)>Z$ MMB"C068,1\Y4$I)SW28[O%5#Y5-!73=T'R,NY&CO4/-)JNR%R"8[Y;DG0R]B M=A(=8G%L:RM.,2&U;]]0;]0?$X-'>X0.GZQ27G$RYYP2QD!RRJ$AFC.?'7C) M["DG//6!G0;P[)0ADX!I([]/PQFJH%0N%<$A>14 M 'DT%R:%PCW>G<9S5+3?T#BC(B@##K@#G1U&!L!E:?A[PEZ=J2#Q"#Y,"8M[ M?#A-IZA0H@85+&G,'$0R3B =$UF8:&E/YF'JJ[YJ)![!ADD!-,IJL@C MBQE9M$F!RQX%SQYX](QH;Z&-2)RZAV8J0#R<#5,!8E-_S$'S5$%&PQG$$HP" M"H/S1@:O+'-2&-%*-D[=#S,!2+;AQ51PV0**5= >+?.0& _@G;>NG 9.Q91< M#JVLE:E[6R: O@/)/RK@CO"M'#1/97*47-)Y$&,":PQ&Q:0)P45A2M[,2?M4 MQ@)C1]P8%9F'(K "89T3EAFD!4;2/Y3VH7@[HW%,:WG"7I2Q<'8@S??C:4L> MUM/*OT>Z1UK,5NF<@K;1(A@/V7MG9ZL5+7WZ2X=C0&^0. M]H9T,&NE18(DA;5).$C T$2ADI&,Y1 9C-98NF\(]@V50V#9*8OZA^=.+\BQ M4U6@(BU&H+9:0]!D4@GDB!*]X(;+-N%<4W6'3!>(1_-E./1M\7X-((/((S@V%PB]?CZ+DJ2::\$#IGGP) M8#:0OJ."5\ D2?Y33%V9/ */8,QP 'S^?OGHN:H4'">MF_$H)0C!$'@F(]X: M[56P\A3='M,'X.&,&02 ^[P<[2:L8D@)2NE G2U$YBT3@GO.;<@F"-4F@G6J M[HY)0[$-=P;!8Q<0K"037%IK8LP*N-A<0J%BTGH;0HIM!.!4W1R31MV!#.D/ M: =X-=I-6!GK.6F[FK0-#Y950 M*3O'X,] FDN!@M\9@E=6GA[ #^3!\H;_Y8GYY?;GY]1U5 M\G*5KZ^N5QO-]*66^[.:D>8BLB!MA78P0Q]\\J1-)^$2VD9NER$2P-8WI+[E MP[&Y$D?/6<64I>+"$? M$!Y=#I:.8BZEU R@S4DT5=] 6\3L[D[8&^W'25!\ M?CTD.-\L/OVYW$B(EKC\9:XJ(I<0O?<\. A:HW(B(2)CBFO -GB]9$*V<=]/U7DP#N8.I/3@-V?OKFA3O%E\7JXN-S.] MT'LR"3EXF0R&9$%*X;/(5AE4*)2 T"C1HNEM]R.*_7I3NC?\NM'HBM[IA&$J M,Q=)90/O$A,A9Q1:1N-?47N,QIQ=]DWEH_TC_ZY+>Z[ZW'\GD?&EOKE%NY,< MG^K5Y3[0-)Z@\DH*7?KX6-1@M/;!$9TL9](1\:!-8.!4<=,+PY<#4'\DT'(%%;N<"%-CR(*"V=B(-V1AX2CSU@9J?^T3DKQLA^ M:P7-PR:JC!1,)V<1H-3_U-99KYQAF7-B@3_%"_J!@-DK([HZ@^-MP,2'V=7> MC+D&0RNR&5S)^BNACZ P(492]J4(+'FT\10[H@Q][G9 ]TFG=4[ M\\T/G:HR/*5@=0B1!+Y6@"CH%]&)I *+)]E&JGNT''+6MF?"!,[:PT!YV$05 M!LV$(1EOC03!M0,OC")1X#%RY]L$<4U:./8)R5Y9,!0@GRN(_=ORZO_55V%Y M>5G3^LYCO3Y;S;]MV-[D5NB8"2LOA)20;#:6=K H\6XVB5.N;]GR MMF50PA^M_#U;>/WV$W\\^,2] :L'3U3ES&BS:08: D20KKBY+!@6I.893O$X M'@H3RP$9,_B]_(?EM:IHM%0I MZ49WVOVLZ)[2]T2^052#5>X?7(7L)6-&DU%+2$O6:R."%;D4WU>:G>(M6%L, M+'LF*X2=@TK5#..=CHD'#4(DET5"'EDHQ<8C MG+*SITN^+GLB^#BW!H\^OO$5P:-QE=16RY@-.BU ,.6=$5J"D@&=4 M[CR#;S]<#AE>&:\S2R CPZ%I%-1P>B3Y@RG*WN.F1Y.VT MHF>*X^U4B)XKIJ>0^92+L M6$%U/[:*(B(X9:V7#I1PZ*5@T=%)[GB, RM*+QE979-Z5''5"%Q[1M)Z;4Y, MBI!I.R&S"%I)+TN(CTRR546-J6;@#2BTCB;T%(NO")^Y(4.!=H2!'!,ZX")F MINE_'&T;C>GP#+FAS;4NH-(+G0=W17V\_O;MHBX)+;.+,%M_S1?+/U]^QHC+ M/,2D([<"()$US)/12N@4'&?P7S(')7))7S2 RE+ M&E)2R+VSS$C"J^093]FA<"R7E\/0^F@Q7[[C_6Q^GI>KF^)>ZS>+LXMKVF-O M%O^D;[M>;3YX>YN";Z/QK.K^??#W.Z-YZA"UIP3K0V9D72PDO6H.#@D&](;+V6;^B>3 MQN> Z%D.PYMQC/N[;-[&%OW=@$H'8Q 9BL0R1*^=#3QS 4'$R$T\Y>"O'B"P MT[0_DN9CV/-O%L2+>GUU^\GO%H=V_=H^0:4,G2T"2X*. ,,='3-">)6L"]Y! M:J/Y3?5*\&4-"OE_-:0G?9A<-CMZ=XRJF$+5(M!M+]UN5K2*JVF3")CQ'MG'1 MO)03N$- [)"';4E_M&'\.*SBW>]7L_FB[+?TU]G7V>)+37MQ\XGO?K^8?]EP M<:]1W&K2R@-@H/]$! /<@/.H+?@,BC:SYFT,CDD+O_X-XB'Y,I3@>[2F9Y>T MQ8VU0RRVF+6*8.F?E) T(U"!62X$"J6% JD03E%H#HFNY5BA4SGD 2K,U>:6*1\2,J=;)3&=-'\MCPJPR"YI(P5SJTBAB<-.#Z(_!PDHX^/2S75P=(LV=' M5%HGAC()1_8W.!4]K55K,L6!6^5]&XDUU;C SL57%Y3MJLC%HVBS]>-*7+\6X&_-FFQA<1[OWR8GZV.]!O_Z"*N^R3,$(K M2) -\5GGG)WUB:4$OE$07S\KW4[T9U;X].&*1S))N8'$2E*^$YYS-)RP5-;G MLGOK-0!?\7G9,X/XW:7WU=KE>OZ]7I>K3P<8F2>6-5.GAEEEDY-ZZY@J1"'HK %"$0!7 M&4E-YD8(AXIQ'=LT)YGZCFW/^V4_5!YGV_KS\WF99G8QG823+G>T%-EEB8+S M("! 1A&E08!4JD%8WZCP9$/S\ D0BJ:US>Q[]N'*AV@S%Y7=_S7?I7X]?;A*1C)%4BMKJ<$K MX[E63CI=*CPRJ]O< 4P5-%WP>-DQ8<>!RV^SRSHN2]'_QJ"Y'U+)'"$ZH04* M!QZ4%U8I#3HY,D0Y/V7-O0V_=T+G:/(>G[FV7'RO5U=S@O_'>D&4^VUY56_: M\?U)W_/CYK__K"]_?[:MXJ%35%J4!JU<6J\1Q5%MX*Z0(F()$;HY6H M,VD"249N+6_3LV"JYUQ7J-BI('5'\W%P=Y>85KI_?"36UN>W/4!F7W8U#FX^ M2>6=BL[I4#*2@$6'4M"YSR,3PB+]9TC11OSY?7DRV.N0[./=$Z_(J#R3+46=MLA,@E4491711IN2C]Z917:V^7>Y^<34_GU]<7\V_ MD^IU5L*.. $1DED)I@0U0A M<0T.N;$PFOD_\ UC8V!M]<"/P(VASKZ62\,?ST^PYYJSQ[=6#LC R1PD& /& M6U32*59.%B&\"6T,APFB?BR0/FXO,AF&CKMQ&MW7[AM**T8#$35FYT!#)D,= MA(*D.'IA]&@M)WH*LI@"=AKA^6@6]7IA=W.1F)?7J_97=H_GJB+(H)(+HOCD M0DBV=+Q&Q1B'A)P/6H'G5UME2# >P_A#;^Q:DGXHN9^H\G M$2Q%)!$LC'!FM!R>%P*P[DG\0JY6=OE.NWY%I4C0@^,V&9/!6N$"HK4LNVP] MD7$T;^O?ER;=4$86>-L/3]K MX#LX[W>+!W=,Q2E. MRWOW^=/LKQUXW#NVXD:HK%G6J$EI2V"-#-S3_D\J$MG]::D%0R.P:_I/3R+& M<@S5YYW(Q-NY*JG0HZ5-Z$! S.BY]"EQX9.3&4*;P[Q5#]S3P&3?_!@*H_^N M-P&PYY[VU>Q+_=MU,13??=YH..MWUU?KJ]GBG-2>VU7$^?KL8EFJ2V]4GP:Z M:#]7M]. :C5SE1AM>,4"DRJ UP*3!&X"\8.T-6W;F%<3 M%)U= .>)!34D T8^QV^/E">R_O"3?-M,E2FU:XRP6M&Q9*RWT5BKP&3GR8I0 M;<(Q7HPS='QMM"/V#!81]#@@;X]Z^>SS5? A.&0L*3(C)4,'D:7@/,D$7?K[ MO@8WZ8#0ZX()8P%L_ZW2EA%53,YGZ[0U,0-WPH;HBNH=I.,^FC:V2JNRA*\$ M9,>Q89Q,K%]]Q'>ZRX-KL*UTO%WE_:P/4K5.(E,K"6%C--G:Z" [Z2/36H#" MF#/I<8W4UK\SM1Y&$!@GG(D0?/$M$4&=$P%HIVDZWP7WI]@PJ#N4]9NV=1AK M7DALT033MK2S":SW'C(#3!DS#Z*4]]8B1-.JR]#4M\!8B!TPA^LP[IY"#A?( MY))6R?"<($KC W*=:-$A91"MZI=,'<^3 -*A"5V'\>ME9MOPR*.A,]4)#N!] M)J/.(LL^2Y(8*@Z:5SA8X8GN$= X^>8P>K_,JEY,,FEE< 9 0=" H'QB0COE M98JMTJVG6\RD-TP-PX674HJ0:R?!"V 2 W OD0>2^]9;KIEVNHU.>+!G[_2Q MU9+\+S?'V2%&P11S43@((EG4V7D947CN_8-.R@-X/4X?9EWQX67EJG+EM,PR M$?@#:,8]&E,RH5)6Z#AK$\M]L'OCY6.L2UJ_W-15!M:53*/ @H*L1"EGA-I+ MX)RT@%;A U-OLM27U.J="R\WC]4);Z0D(FHF0)E >R$PD85'SY)K52_3O#:T M=4_O%W+Q_';(I%:?;"("JLBU 2.3=VZ36IXB9L_-:,5%_KY2[IF5+V0S^,O2 M7*R_G7 S?^6TE<"<%^@]H,S>8DC.^9Q*T'$:+4![^C?11^"OVPUP% ?'B9?8 M"(K3J$0K0D(>!<\9 @A#E(XA@U,L%GLT-LHPZSN^X=GX+;\XOPT^.:+=ZT$S M5@D-0Q^EB#E =LH'K9G*T5FIA831W+4#!RDTALK6((4^R3Z8L=&9MG$08KMZ M6<4-VA1+N\VH(9()ISV#R*-4B@FFVES.3%U1[!'9([&G]^/O_6KYK5Y=_2BV MVA7MU/2?Z_FWDH0PVN&W]8L:G()[QU91^* LZ_V*RD4MP@B:+"2@1($!!1:NR240Q2JD2.MIYS3FIA[-M^P8,<2'SY6@0S" M^1# Z@B>!T^&5\Y<:!?1\I..X.J0U4_ZM1Q-X:,=-0_?F?XJ=ZUUF'V;7\TN MYO^MS]\LKI9O%M]I<.@%4D!9JSE$FQ2V>4TA7N6 MK:MHGB&R>XHJ!ILXS\D'F<"2.I.YSF"=-U9I%^2K/F8:0V2K%=HI]8>Z4-GZ MT?CC$WW(GC2-!J,KE5%Y3BJZM@+0,<^MU%)I[HS-1I^R4Z![;#2U9HZF_^BX M*]^]-R>BP>@*DS=.FH A>I")(>127MZ:; 32T7W"N.L4%DTA=S3IAX(<7A/1 MYHLO]-%W/[ZY_+9:?M_4]5CO#5EI-+["7,IV1D-6!D!,$8,1QC@GO W2Z#8Z M^8N%W3'06/9/_,%2:^[HL#^AYMDZK55:ZC&VRD:>> MOM"KH.J"VD-BJ1%^[B1M]-IG$K7,66"T(Y#V2#G59=3!\#8R:.I)"'UCYB@* M#Z=U+]97J^NSPK,W"R+%%V+B?LFS:U@EM2!+(B=MG(<8O4LVT-(MRY%^\FWT M;_N*L=0AS4>_]GS;(%UE_^#*NE*GTVJ6D@7OZ6<>#"F-"1Q(J]I4J)[ZA<%X ME^W'DG]TT/UCM5P?!;C-P$H8)YC0&A()<&[0YR 1(DJ5[%7G$5AH M"K-CB#Y8?M+9V?7E]<6L-")X$$)!/U_4&]8NSOWED5E@@$;Z*")1@)@M"'R%(2@XP: E)%!9*2[@>VB_E(6=!+ '8E!HTO1W^JC M@E-H6.6DTEHXIR33 -Y9YIW*,G+:X9[A:!VF7C80.R3Y>%%;(V>Y]1N/A4"G MF%+,\> @TND5,V-!>;0Z^ZRG&.C?*KS_/J1_AP6#2.23B2[KUO^P_U65GXV5G)NITOOM *%O3CV++_7ZS>+A,_/%V9P.^":=E3J8O3(Y>ILL1V:!C#=7J@+$R(R5I/Q& M-6+&;(O5-9$M74Q/FI6*@860-6VOY),U61BK8T8N(QV,)RQ]!@7?DU:7@_-N M GVO5YV5^Z02L=-5&G+K"7;)#C# 9-S&%/,X%-I'V5YHUR=%JO\6'\IN/E0?RN6 M5.G^UR3_L,UTE0$">0F,=E)#YL)'TL1%B*A<2+R5-W:J0J-O;"P'9\L4Y4&W M:8O3$Q7"A2"--49+"\;2EZ6H,!FCN"-UM-%E?->KW)9,MF!HC(1]@J$S;@SH3OUU$8WR2G:,JJ1A!HU#SY"# MY J]CBI8;1$<6G&*64R]PN&I4[4CTH\&L48I)#M&53QK:YR/ALYO8+3B%+E@ MF51\9]&>=,I2)^S?!ZFC23T8I)YJ,>6[]T>![!I7&1,TJ8;TK^20-^VFN+4E M\L'K%%VC+-13@=4Q$'@,JPZ)/>)QB/7B[.OE;/7'X6?B+T.K()7SM$ACHP7. MK!?"6AT1.5DC4K1)>)MJ[,?(!V,;^H^'N+N//OR(?#2TTCS'4J,U&Z?)&C6T M>,9-="$R732*QNX\\KQ1W$Y$A-5 H,@L=LA"(*9(C0KK#L5+,BA]"7VA"Y=V!L M%2>/GJAZI!H3>T^,5-: M[KS[_,LG;K67=SY?61*CX'EBB3:#5<$&$Z(R5DD7E($V*3E3%B9MN+OLGJY' ME_2\>^N[Q7;EX?D'*Z.RX32AIHT @:0>CX"Q=$H-AF-H$]T]W2;('3%MV2%E M6_/^TY_+9KS_^6!%MA3S1N1HLX?DC-4R9JM)3"H1+0[:$>H4>'\L9=OSGIYJ MN/,?/%J1,9R]3LS73M^=[/_=8 MI7*R/G@G.&D]S(-/T43O&90W8#K%0C@]\OTXJA[/\Z::[ML=*=I'SE0QP3&F MQ%22'+0'%[-6 :2B7P1HE:\]U4HW0Y@7P[!CJ%OQWZ[+?GCW^=VWNBQF\>4V M/'27MWCKF"HD0"=E2*Y8]L*YJ)4+#F0P*=+&.DFMM'= /([X[XC\HWF)W]>K M\HO9EYKO0-FN894@C4P'Y53@"@Q33F2.D+GVT0=MVERA3M4!,S3,.J3_>"Z^ MW^JK<+TJ9#W(S7<_K,K"10:*]E7BP,M50BF-X(Q1V@@.;=S&+97M$\):AQR8 M8C)"G*]G7[ZL-O48UN\^T]K>KY;GUV=7MW.M\(07A M,T8$G22&38Y;DXW34SS)?=O*Q15MH'_/S^L'*[AE2FGMEXCTJ\7LXJ?Y\)-1 MZTTFS>K[_*Q>-V^BT>'[*D%25R9!N\MPR-J@,$98U%EC%+)9WY$7=O?;-Q*W MMS<=C6]]^B%N/_'=ZO8#=WBOGGNT4I9YF5&ARA) .2Q]\Y@.DAL>@SKE+@@C M0V/9*6<&P-C#M>[T=6U]OG+21\A&:,4MD'YAM0E&<9.$L#&UNO6<*MK:\_[/M?O]@)744.026N;,@I7+@DTD\(WV=(27N!(,G^V/\T71MR_D&SLVG M3U;&HN%&"4_Z#TA,#C(/*H*3,1K#VA2$F+*[JQ_>'T_8ULS?%]7P^+E*E7!Q MGP0/ACXQ>Z<]"FM1)<2L;)N.Y%/U5O7(^"/)VOJ0+W9/LV/^_LF*V9@]63VT M1 D\:R\,EY(GEPB8D-NP?JHM%'H\Z(\F;.NC?GF]:G;4_WRPP@)' =)&E."Y M1*Z8<)%'1Q\:6U6OGVHGA!Z/^F/I.I1_YO8[]^9=_?)<%;A CMY9*30"[6W#;H;'#UGY7C@DG,@VP@! M%-#1R8.7/ ( [%-G.U4C=!IW7$.S<*A8/[@T\-RL7%4_'M^]?7N\]-?9Q?7 MFZ:DZW5-_YY_FOVU ^!'S%9%5!9+Q@QM>]K^R>F@),1D)!T1-IQB\L" 8%H. MS: 7X/C^5,K /^/]GM&"WRW>TQ":\FT!VFD5ZU,QI\ MBAP#,,L\2R@4G;[, MT?^P4NDLX @9)M[ MVZG*E;YQL>R-_ ,& 3X1>IOJ$:5"\:*^V%^@:._P"DU(EC$>5(K@LO)*R\B] M16]4E'C*%:B[0<33","NB3X5N#6I3]1@@LK$;%-,2J'F((,CG4 ;I3.W'K0_ M2==D/^@X$'I'D7_0>D5W'SI?U6=7%S\^+4M'P6M:1K/R17N&5[2!#:V3=$[# M 6X"%E)87.P@J5PBM$0?6'CN9I&W9)_#.!]^KI:7G_Y^F9!W+DDC7VV^G$0 M\K:.KY".DI2#,B%HD%G;+&/FFFL7)3.M,M*F?B4R(/2ZHO^4 PB%-"*"U*", M!#36!V>-U!A\:881VQ3YGCJ2.E78.B+PRX@#M-8P!:STIS2@L_/2(T\& *4+ M &V\A5,]^=KSMU$LN7/^\\SHP,'#[P"H)J]'D))1%\ J0.ZYCEKQ4 M[&6^S='T K#1AJ7/N!,[H_/P$:. 6F4EG"CNSZB9$TC'KPTF)^$P.!ZB]I:W.4:FF]?7+4BZ(&R?.L='XLRF M$]K]+>QLVT7CSN>KDNU*M# QZ% (A$2>4I"4-@-DHP8%RTM75+NB8O/(0 M@A6Y^/N-;I.[.V7]M#L4M*1HGUAX6VJR^,MZ112=S63RC4U73 M6AB)1YDBF?;1V3:N\ZGJ&=WCHC5=C[97/]3KJW>?_[U<79SO-EB?/%B52"(A MHS !2.%F%E%K30CF)@@F4YMS8AA.%4F]1D%T3/#7$U\JI""3WVHC/6SHHF+R*")F M%H#'4XXO[0XS'821'L:'EQ)&>A<\^FS\.4T4EA>$XV69^7O]?K:Z6FSBTN_G M_U!_.;4H4YD2"(U9*#"&HP&;G=51>JO!-!+\/<4EG$3!)>\D,.UB LS (:$G M(U,X4B>#UB&1DWV0RD),JP'$N\6TE $9'Q$HK$?2 #[00AUQ&3&]UD'T;> M"=QD6ZZMB2"$2AG0&E?JI]LHG?=9D(EUJGAHS\&G-]F'T7)*-]E,N,F.^ML-,\N*PG ,5AD"ERRZ'VDSVPC$:9Z_]@MYSNAZ^NLUJ 4 M)B&XEF@2>,>L9>!$BMFK&,"=8EN :9E%0[/P]=RF1V](+\PR88@0T"/$I%6. M421-BN*@?6,'BU<<$$Y=U&LXB$53O&C?;/KUK]_Y0F_#'3-" T]&:0W>9BN8 M]I(3+P(ZJT:LN;!;%-^ORJ_JV8T8_D0\0/J8/YK)E$-GK2RPP$P)B< &C4Z MQJ-R3AFK%9YD4%K?J-HN3GKFSF"YIEWK&PTPWML[*Y%]]C:PI!2I.DQAU,", MY,+*4D/O% /R!MX!4^'=R"$^C>5YH_%5W(2Z!J.4ME"N"X/B8*7B.@(7K9L8H*E>!HTD5_OCRB0-E6W6UFO]^?47&V?+M;/6E M7E_]/%).*.PGIRQR0*F"R, S"2(/9(6:[% B-XV.@'[$SY.U[(O;>7Y %;+G M*2)J8R+(4AX-2R"GA>18SMCF5N_$S)/&6-C7Z_,8P@]8V^O7C\4?G^@#]E>0 MVS:J4LA2M$+2\1W!LE#:OX=@T LL2QWT;FWXBC:M.+\/2$=3>30TE>]M4AYN MVZB*196%%L$%GD&4%N+@+ (&H[W!V,;U^>+0= S[]\JF8TD]&*1NM8PG7[ZW M1,&>D966,1OPWO#@03-2##7702*)?\?S#>G'V]7*V M^N/P0_"7H162K1J E]2 ",EK2P:",[H4:^33_4>;+B3L VIQP/7W4K(QGB0%*R262IL^<,I"UTCHX8-J>*N<[8-FR0[JVYOS> MMJ-/'JRIXTG=>W3;QZOEV1^;%J=A>?FM7JPWXX\(/>LL+OGL8KF^ M7M4E8/#^@S[4%[.K\HWKJ_7'K\38W\LGOY_]*%FMZQUA:]U,3/:"]B&*XKZU M!(5@+>,!(\L2$;QMI(Z-3#%\N+"&,=YM9JY(LT;2M'STP"#19G)1(":)3GLZ MFMMD+4Q=J R%MJ?1X -R;"39Y,_/Y^7_SRX>UN [-F+VM,56M@(4G5:"&P,Z M)DRD"G'.G?$2HV]T<=QW@M8]('_A\FHU6WS9E#9:XX\GH/5_SE;GS0OMM7Q' ME514/#A'-HJ%P!2ZJ!E#YE(4B853K"XU- *W)F0-R[NAM/B;#]P?&/S+5QCJG?>'8W33W\N/WU=7J]GB_-/?Q()?M ORG<]^NI_ M+>8WU%F7[W]?KS86R^*L;HK@KM]3,9E=#F"(([%TQK1)D2Y&YY_Q$8-O(UU; M112<.IQ'9F070/]MOJBOZGK1,\Z[>$T%8+,.QC$(!FPT:'B.6?I RAXWKDUJ M]U1#)R:-^1&8.BCD_SE;_5%?]8GVY]]0T2$722'D(CH.Z)P5M*#,L+A-LVMV M,_U"/8$O&^B=\+//R.4/A8P[XME__GWE=28URY>,;@="6]0NOJ2,8] M9OM1!.PU$6:^F%]>7^YD_2_/5-X*A1F]1(Q@F$E#,Z_H5"?+K]= M+'_4]>U-Y99U7FS@=%NP[VSY93'_+RVS)L[?^%/#[-O\:G91?NLO2Q^6'5NA MIS=6C@O)@O-11@X1K W_?WO7MMM&CD3?]VMX*UY>%B"+Q8&!9!)D9FX M-@^!SN^9Z4$*.HMV",WJ'[%R4ZM12'KW6T7\V&1I7 M\]5ZN=GZRV_6M^6FZ63>VQ)U8!I^,\)$3 T0NVFQ\7OR! MP0CUK%OQGIN"#;+@G;J/E;39/!HJD6 "A>KM97M_F62I'J\^&\8Y[8R69 MXU(RJESUP_>I'6RU^1?EW,[^I55O!?-_MX M _OJ0\4]:5!<4% ,$E)PU@,$<$D93] FH]5<-*;_%:6=?$>O8]L?[^H\"ZOI M^N]@Z+VY>>Z.>R??JRS&0E-IG)()DM6!:9Z,DT'(4@^ES6IC+[ISY #^;HN&63?" 2>RBCL[HOE5K#UI#1%$A "*P2KW#.!(1L7 MQ]JL'>Z"_T?S"45-*XY5^[5A\7V]FZ^GG65T(V5:WB]G- M[Z7^T7H_R%N]M$I2.!VU(^0:;/9#M[G$0%YP+GEH=:+)+D!^%,A]2JQ3K&(] MG96"RGF>\R_*])P&KL^]MR)&I&+B3GH'2,IYY3%R#MHS%F6;O%I^.80_'K$G M%%JO+L9N-/=ZMAM$^7TW[L7^KU59(E&Y*)C5$4AH*PT1MV =4I+0JG;:Y23] M=+[%R45Y-.SO.[+M8%DRZN6[>KU9SG>:.2WLSO[]:C';K,L IJO]T#[^C94P M+*+,NBY]!,N%AXA,8B2>ERQL5_#H(WEKP 4*P4;)O484*7DX M9XZ-OA#8&:'18;+K*]9[-<^&K?XMPV$[AE>[#-4]]$;/M*JDP@/ D$FL'JJ,GNCW!YM= .MTT]Z;R?M]:S$9'ZIY_5R,LO] M]S>?IO/I:DM"?E?OAK#??AWTGDIQ*Y4Q7(-+D*?!)B%E=C" M_N@&@%U._^B3/E[U<_%7E:+9R1$"R+Q:N" UQ$+KGR=1<=&&=&#L5G/X;47O M\NN-S_?^3F9]\_@(=YK[#+*;O:#2BJ25B;*S(X 9X4HV9221*(_=LEX#-W?U M\OWBA<6<&Z/G>_+?+L0S4(AY^[_WB83EI/-^$E>KS:?[W,)+Z/G1P)^)*J.% MR'*;%W&3G3VAHDO.,)^AA(W2H"ZAY[H2MERQU3KK7(3L,SM,63\D@43CHSI' MTI^^$=A9Z/DPV?6V]A[%I<]2%#P&QX@AE$B6DSQ$J34E(I_L&>-P $ \RZ5_ MF"A&LY%Y 5SZTJHHJ+#%:P)GC'56@B;DDL?DXCE''X^$6!]<^H=)I7?NHF_N MX=YXT9-M*H$*;)Y?;B0'%LB15 XCUX&89;9-Y?*Q(V]8S#S%*-120N-@FB66 MT'!&2$Z#4C9XQS"PZ)2(*'2;A,&?)WASZ*+=1@3C89I-UD?/R/.@0BEOYP$, M*84L:0VA7:[I2*%SI.">8)H]; +'Q30+X%(D1=XS!URR8#0Z$6/$J,&U"OJ. M7OB'BN])IMG#)G%<3+,^+W2,K,@]SJ/59"$$'DCS9(-5O$WEM+$N'" #)PG2D-196;+:N,AL7G15Y(DEJY3Q9UV*9/! 0^_R&SWJOUYP>A#R M+\<7I4S%'XM9?LTL@^+=9-T)5U+SKU<\Y86&F&1*I&TI9*E#R2[3R1-J-UCL M8K1G6XV!>BH=Z4R89Z1$.Q=J6%W:=:+2GD$*++!$ 4@'IU)>S&7DQE+2XJRW MSV>M7\<)^)S4[-Y1'5C-[CM1653,NJUKXD#(DH>J@ 0/@CEI79NCI=%[?.>M M9D<)^$6K69S>36_J^E5"WDVJLNO=\_[O>'C/OW>OEI+W]9)Q^M@A)",Z&$#PDT.<^-UZPX!09! MJ NE;'?:,P:!OL@EZ-UT]3$MZ_IJGA%3K]9]+D&/?;L2##G+$ A. F0<..#< M*M+,",X$M6%"^PEX9T>Q!)U KF>C2SV')I[I0N4I1#(!4 8'(3O7D6->_(-' MDT(,%W[:EZE9QXGW?!2LWZ#$,UTHM!7>,B>DBL0B@G]1'5OU!VNWJLPG@8-KQ@ "['[YWWSZ-%G^E0;3T$9O.9Y_+F'FCSF[7!''T.F.;TC.EC)($Q@V7 M&AN=)W?JZCT0\;9XVH]RQLVR:.9^![#QJRJ0*NL=CWF#FA=HY[SF%$)@(BK- M0+=)]?\Y#%AC6'W/)]"MI/J^@KW;BAX$UKUMJY -M+=:HS$>/#!B%7NU>?U9/FQ+AN2;6BDD=E\LEEE!5=!H[!:0792 MP*:(UI31*Y+993GCW-C!3>2II-(S_MXM_IK,&J_8C[6HN,HZA4$DAPF=/[ ?>GI:5EAQ- M$,XB,4"G D@70T*,3AO&SCG_7!]XS)GXH=M9> GTM?&\W[V?3ZW^M=X;O:]?W M4&H_UZR2"C5WR086(Z1LGE/)G8\Z:8S!Q\$*.':#M9;27G0VL4-#J/#9[F6_ MWM^XU-80//N&UBL)#GUP>=77",;PE!W(P6K6=@.GTP"@(:J.GN6CXQ'9^KZ: M;.;7MW],2_?5 ZM=D*OB#4'"/@1??3W9=I^CH/KQI0/O[X<.5-'HQ6S@AF(.6UWPF5 MDF.*!2Y$;+-):W5R_A)6LM;3V3M(WDW^^SH[@;0"D_5D41&4G.LH_@ "W:_ ]O-5D>\A]LDQ-[>.I-OP'N+C!S^)2.(1P] M, _ RX@]>Z\E(6K!! (:[;4VP)')($@GT^@XO:.\J!]/$Q[N#0Z[O_S\*RK& M\@8U1HHD"2@DI[F2,@3RR(B9RR6@D\'HR0O*)Y50_S?QFYSL'8';PU];06). M84Q>@0:6= G8*61YY\P#B58U)L?ND8\%RYU+K<'RNOM%^5$X!?[YC_\!4$L# M!!0 ( (<\9$\W%:LX4!D# &4J*@ 6 8FUR;BTS,'-E<#$Y>#$P<7AA M+FAT;>R]:7?C-K8N_/G<7\'7YYZ[DK7*59Q I7$=X%3VJ>K;)?MZCY]OV31 M%&PQ)9$*27GH7_]ND!HHF=1DR2(EI#N.)( @L(=G#YA^_;_/_9[TR)(TC*/? M3I2/\HG$HB#NA-'#;R??;[U3?/)_S_[7K__?Z>G_6-=?)"<.AGT699*=,#]C M'>DIS+K2/SLL_2'=)W%?^F><_ @?_=/3XJ'!9UW6,/S/E2U/1\A1*7&)Z[J> M9YJ:8V/OP_-GG6B&?Z>8NJ)B73&9WR'W!B*J$\ZX\:F;P]&;Q^FT,_1 MZZ5)-3L>O"3A0S>35%DAXRX5Y=T,Q@MCCM+?3KI9-OC\Z=/3T]/')^UCG#Q\ M4@@AGYYYG9.BTNLTX49VSRT+V?WN6/=,+TTURE3_RUI[)RJBGC M9N[3TS#*6,+2K+J)4H6*Q]/[P6EX%[]^-,WZGT:%-8^EBQY+JQ\+@],TZTP> M>[Y+>A]3%GQ\B!\_C0KY8\K<8]D@6?#9'>]ZOJ\I.*!AZ&?5#_ 2RH>2(;5U9-A%?DYI?Q>;P$= MH73\;P4=891I[?C3&CD)>@E;("EY<<6CH1^'U>_B)57O CT)HXK^Y6\J"JMX M% ^C+%DF&K.5>#-F93,+'Z]X+-?.M$:H1H45G8[\,$BKWY47574PJ,$8**@B M?_180_WHL:Y#BVDX4Z6B@VDR^_"4?TF=.N8BRUM<+-2C&@L$>U)M,597:KM[*2X M0H>2&AU/JE20=P:X6>0*V*AORDA@904%&=/0?=ZG?QDHH'XF!P7V.>\Z(% M8UL\IEJ\7X+U]3A?"1NC@DH;W0GO0U 2B"5.!WY2X>J^JE(M\)5OK82,L58J M"W2X1H&!"J=UFEB4U;HO51V@]T(!T.!D%]__+BJG?] M-0RSEYJWY655NO]<1T %@#/JA1'C >"T>W7]JI(+P-"[&H/ BZK&T*E#(EY2 M\4!=:%89C7%#LM#*5,LW.'IW%19QY />5:$2X"9$=/4OFY;GE)Y]N%M'@VXE M"7@?ZJ/+NRJQ!!>@WH>I=6!J8I].5>3#ZM"45:)IV8.O-R>SE:K :^2]Q7'P MM-B_XS5J')EZ%Z;*W YJ) ,**KVKXO7IL-^->S6/SE5:X&^IB]TMM MZ->HY:BP!O_80[\>_Z!PT7B[<9*M,.)QM>H>U+Z]2EK#;IVS#265X%"G1;QD MP=B6#ZMF1-&P7PV^G2SYQ/V[3U"#)6$PARJU=GU:7H$JSX#E/^J37[QT/GR8 M#[E>A1#UJ9B[&@-V5V6Y>&YI<9PXK5"1@.(.U^+PL%RC'JT7=F&V3@5]DZ!F MR%!0!1QUN%$I^_>#TV&P,%&3%U M&4?[M.2&J)4IM3&1*E.JQ4EG3"IL#33)WEY%4*F\?U]#4CR MHIJ8]J M,+4HJW1UTGA0 W)%666>Z)YQG&"U3!H%T).*DS[6!OFUH?W(7ZAU)&K27S4Q MRJ1H02"Q=*Z@.OL1L6P9/:#**_U?HOY5Y.]%=1%27E05ZM:P.*NBP]A#6^B^ M52/H="9@29*S/@X#F:DEH\$E:L8:+:)?-?6X"5AH'VI&5@-_427\@E-1:H*I_ZI-3%4$ M@-.T5%4 F!NDQ7[Y(I]\D2]>X8/7^5_5?E>7!74A)2^J8FTA\G_3Q3S-M!IS*>Z494W>N@J%X362Y+=M2+GPG5K M6XK"2DBMR:>.(X.J],FBY$EU /[ ZB S+UL49];.IY9K5#E:[&')_/K(E7XH M3\RQNDQ5E2G.%2.KU!I4:$UVVWDXP]9Y^*I8"?\@>S,.NQL_$:Q%\_%=^AZ4^CMG^]BSLO M4IJ]]( []]#.Z;W?#WLOGV_#/DNE"_8D7<=]/_HE+TO#?[//BCS(?H'^_=H) M'\=/PE '/?^%1YGLY.S7\/DS;Y\EQ<>PTV%1_A'*+XKXLNCT0Z*[';E@P3,(L9.E7/^.?7J[@;3'P*026>GZ0G=HFEFTP\J[M(41- MCU#LF+;E4,LAGN[HIT\_3E>J>')VA?[UZZ>98;UAE&&TS5$J#D::XB*$+0.I MCHY75[JBJG:EFH 8RQ$#(504]YB.BDT* H@U YB$7>*YKJ.8P"4=619XE>-A+JOX7B*[V3!- MXFFZ+3L>E6TDVQJV=:K*)L&FIB,9RY-A+JOXAF&.A]%AX6<*IJ'#S8/#TB ) M!SP4*'.%R*IK8E,U3-G3#,-2D*L!X3750(I'IRJVK.+)V>1-4A9+"7L,4R9U M$O\^XROB69+$B11'D@?QB*3(WR0(3*1!3CT)GF,=Z88-LIP+DB9_R!?*;W'T M7L]_* W;TUR9$F1KU#"1ATVB> A[@/R.B2DVIL->5O%$*@*LWTX@(OM\%X/S MX(-;/00[R?^^?01V/FF2>6$:^+U_,3]QHXX#ODEI,!96L6I9IJS;&.F&:]DV M=-FR%97HLFDZ'>A)1[\EI;Z+5NZAER3 ICI M"!L>U4#?J84-1W9=XEB3?B^K>'+V3=MVESFIYSNL6HKK&HY%+0LC0]>(BVS+ M5K&F::Z"3'?2X6453\ZV(]YN!"[?B\T#.;]W#EKT_'?V4NJPX<)C5,.:*5-$ M+),@U=(%'1J/;!2??K;C?C^.;K(X^''E)Y?)3<9] M\G_XO2&;-C09*\&:;=@RU33L(HQ!5QT'QF1HND6H)Y/)6)=5A+%^A,&.ASD> MUY;&"4Q\VSBY.&%+-PW3=)#GVA:Q%8>N8*HKBFHJ"'-.@CJL0 RNZAAV;F%.G?5G%G0YO%>Z=I^EP9FA M%4TCAJG8!D6J[8 G0VW7=L!74%633H%F6<63,\7$*E()TO?#N5=#LU7D4D\E M%$0-H-N!V,*Q%1L 6:.V;7O3@'))13XT8LC Q#WIW.4PXU/;?"=E.GX4TUZ#4,FR+(LNDQ$2.YC@F M16#:L&I/O:,E%;?!OVA8A!E5_/MC-+ _'':7G4BK^S0<^8KK.O/Q_M ;V&A@O#-'JM_U"V2J9L 8KIJT@#>F*@UV5 MVKJ."8$8P76G4K2L8FZ5%+0?"N=4'9/X(HSR?]!1B9]DH.3M+*A9. ")D^P0'E6VU M2"/%(IIGV[)NRLA!AH4,4U<-"A&OK2C&-&&QK.+.1'H5"K=&I#V,%9Z)U5U% M1;I#B6KQ)(-G:+(I@[LW#Y3R;!#K7+/'N/<(1J=$ M(9=O]FD_7_X2>OC@B]QU(FCG&YW?O3C\IZO M<^KP:E_.K3[IC M(/6LSSH\9P1?\M(\,S1,!G'*4BF^E_A+.(!+!36E,3E_?D,DND2;/#],\@#, M>IE\_%O($C\)NB]?V"/KS3!L4N<\&H 3DE=0JMDTJ?J5^2F(#V?6/\.L^SV* M[U*6/'*!*%JY9M!%/M)\^IY_'28)B)GEIV'Z!20G)T+>UHPGKNF*@EW+4 R$ M-$I-V[$]&5PSRW"(I98\\<4508W60*Q3M )]U2+_"F()PC+1J?G?.G\"VO!/ M-00,X37L"Z!9!X3Q*GZ4QRDSL:,IA !+9/5:AEVPKQ; ,\ M=*SJ=BFYN;CBR1E@N?ZV@*N:**MX)6_$FWD"?@$#<'E?U"S'.9;G4DNFFHD( M4@QJ:9YLZ" 9LJK9A$P3U\LJ+A"<5=+S]FB5>#[^\9+Q/^CWI:^AOK/ "E'99"W5P/9QH9_\XZ M-!U5G;YRKJFK. U?-9#/,52S:3S#<'D_ZNJ8,-/AI4HYSE&):K@Z_,.SC9J- M#8A:"'44B- ,U9CR;UG%(CGYED3P^GPLSZ@=.1^IY5C@2#HR(1C9)L"Q K$V M\0P5V4AVIOF&917'?)1WP4<(*H0^+N2CIKHVGY.V(;Q%R%"P1L&"Z CB,$!, M/)W=6%:1\U&53V5RJLGOQ4>ACU.[B'7;\1RJ(=4&Q4*6*NL6-EWPB!79*GG+ MRRKN5A\OKX0^+N0C\A1+U17/@N 4>^"1R=YG<4 MVR8>]SRI@CS9I):GVZZF8\\BBD*FZ;1E%?>!HWOFXS[U#\NFH9MF[EC$U M;&N[%[,]-BJ.;-FF;B@><1%V%.Q03S<51"P509 W73>ZK.(^C&';V;A%%%5D M17%<8BH>^"8*T8E'3-DR/>28INIHRI2/2RH>(1_WB*(.=G6;ZHJK:1A15\%$ M!O=2TPAV+ -[4[8MJ[ASMK6 +=O,=>JJ;A#3!)-E(FH;X/%;LHH=5S4,8B"#- "QW:H02V+R(ZGRQB";'5FHG]1 MQ9VJ2TO8LD5U4:FC(-=2B:R!(2$J-5U; V_=D3%VB3N=JEM6<:=\N;C\>P-] M^"9Y$2Z6'8 NV3"IC%Q5)[:G4:H08)FNHE)J(/3U*3LJ 0" M94<&"-1=&]L6N'V4II-]B2BCO5Q^OO5@/U<9\XZMJ&2U10*,_!;YQK=_Z+)K>#+ H0(<(8:I8D\E MFD>P9T_MW[**&^I;P3;UOX<1XY\F0Z1/?M+AARY,UUZ5UECQA;-\C97EIXRO M5X-6@73Y_H/O49CE#Z=\*5^Q7QC8TLFIF%83+=^SP-OJV'%_P**TX%&2<)YR MOELOTRI7_DN^)HR_(_]SS8^* "ZQ&Y8\A@$K=EC.)'SYM#/!MNZ"G7%DDQ+P M)3P;Q!\A*BO3]0?+*IZ<76GK;$3>,75AI/F6VRA@^R:QZCH6-A7--32$;-<$ M*^_JGF9I,I)5RT-3/VY)Q44DWFQY>+&U?V8Y\RS]Q[^Z_4$O?F$LI_1EOCU\ MR\263+RGD:0AT^YZY!?(@\Y%*( MW35DZK:B*(@:T\50RRKR1>$:WGQC4BV12?N)K-G4\PQ-Q8I*D8)MPG/-R#1L M&^DVD:=PO*QB3F1S!T1NGR07UKWLJYB.;JJJXQJRBDS;HE1SJ&=ZU#%L%3Y, M?94E%7,B&UA(%G%@L3JVGM*\$I'/FV5PG?+*7RWCKWC._=FUB(;NF(3[H!1 M \F:AQ7/H0Y5",8 WA*TV45\P/1\%=%==8_+VR54]%:1549V:I)7=/0-8RP M;'$;Q=-$%O_9*47*RRH"5?5_F5^-M8FZVNEDK2*J95M\?Q&U;4C6A#B=?<;:*,^2[6(ML2G%PQPR-KX9)T 4:7?7\ MJ+R9T_ 1JB?3L M5WZE3GX+2-^'44KY?52?N_E% CR)=:J.;LKX^,QW>!;%_+X-H%$( ^,GIGZ: M;:-X7?D=^=6WIIF?9/Q4NK/Q<;C\7*GYLM(# MK#C$;E2]6((X6U+JP.1]XQ]&E%E"J"W.1+T;S2<$90_\[?E/Q6\=>//SH!<& MX:A/4B>$*FG(CYT?:UGU2$_.QN4K#/773Y5O*SKWZ57OCD5(*J9+#D4H*H9V M#$)0'$F@7]JW"LZZ3435XB:J;#+'I>!)DZ.23>5_?&)8LP>-QPLBMC=H?HQ8 MLP<])^1O'?0T9&OBN&?0 *^'!G@G)N%;"PB5KX_R%QIU+OE]6NWP+F!(GZN&='*6'YY>.:9C<"OF MDV25;)\LM"D*V\[QL2?&@7.GY @+[,0QCGI?S,^=-;]:\@OTHG[@SB" MK^F,PM-.L<\LOU!F/F]=HC#= )VP5"G:+!PK$U/+FT&E4$P[ ][?,(Y]T)XM81UN<3Q MG8]!W&<'J1LKC_LH('3^T@5A9AMB9G<^'?U-6,WF6,T]IETV0P"'+YQ,9M?9 MOMJ]D!ZDF*PS]#;BP\B-6E,@KEGFAQ'KN'X2A='#8;*^>I#OPN0MNXV$&[J$(*!L04.[&;11XTFX\:<1^89&5:*"7V3"SLWZ*6L2G+4Q6 MB\5)C0."V9BD$8N3A$?9C%V.+5V6)"S#8;N5FX6I(HW5@K!S0R]!V(L&9""V M[#ULN)I=B$(#1&$GL8/(2[91%+:\;G7CZ6QA_@]P$KNP$7RMJ[SN8E<1).S< M!&QQ&>OFBYH%GUNU7'GSA8S"VC-(( M/-G_U.3Z>")BC18@PV:+(86I:)*IV,'J6+$,H7'Q12/FI 6?#WNV>3/M%Y:^ M!3J_V4R2L/3-L?2-6(LF!*(Y K$#A,"-/UAR-ZZ06%_52%>H==N A%2T;J75 M^DP6-K Y-G G2^_$V1#-7J"_3997KIZ@G3^':9;+LA_S(DH@7CZ_?=-A==L."80(:R5IF<%:CWU2P%A!PD3BMT:/7 MY!]=>KH6_5L(@3N4;2&-1RX B\!M7/05_(R7KW[R@V7>,.H((-L!D(W+JFDM M9'9=F?U^4S('#RP*P (<_Q>4KPJ]857:]M/N\4FN\FZ2.Z6OD,UU M,9?/P[(D"'GJ ;I]?&+Z?@!;26HAL>M+;#*($S]CPC5X/\E=0/*V2G#YD@KA MYQZ/,#?*S]W)16WO+=N"G=MBY]H;WV:2;+ME9QBUFYWE_A\-.^O!5K"SA6!+OJG?;ITF M;DZ:)Y2^'J&,'5PBD L].%*C%=T3T2__-EG?VR)%F!U2H0X+QO1>?N+V]^E. M8YBK)(;GLY>KGI_G2?GJ_ 'OL?7R*@*QAB&,-GJ :N./Y_U!$C^R%NY(66'@ MT]A@I9&W,6R8G[]>1QSL&%Z># .^7>,\@BLA0L&G!;IWXW9?X7/^H< M,*NGPVLK8S<%^4G9 7-W;HS'!MS"CN_?CC=(X_E6S&'&DF/0_)JQ'AL",(G";)@PJ.>%S_S3 M(3.]?KAMM=\;.VS,3UDW[AV-NM>/MZVLWQCD!>N/%>Y%9-Y:;=^4YV5:J;7?(=0$D8/[9*LYJT77X$3%=U9P(JVVKH=GW$@)+XI6[F$Q"^6 M>)JF++-[?II.+?Q-QK=F/H3!='M)6B_@PDIL36=FF3%R/NJYL7T5$6:J%4J[ MJQH4)Y!) =;IK9"Q_:E M8T*B&Y7N%G;H@-+=P@SM6VE7R=WDSPG;M)K>K4M0(?N-SH0M,#8\&U@8-:\1+I0VW?T.H4N'[HC*Q1<*+A8$"D47"R3W*^"BQ5> M.U%*L9ZJ=9JPQQ!46+5#"D&% 6M#\G>#5<\B^=M:U1')WP-4X0U6,@NW]EC6 M-PM'NZGJWK2'\LJ#6'/FZKN^ULO+*9[#VB] ML)C8;9?2"@W;DX8)>18YVW>[Y7'#;II?('6OW'NNH42LLN9X::BP@X$0&1*6R.X(E/:=#?^ M_=1=S'PV7L_%S*=0\/>WYV(E4VOLN5C))-1]#^HN\MB'I]@BL[Y_%1;Z)N:- M#E>Z16"X?[LB(K!]IUC$<:R;IS[$<:S[ENAC%4<&L] ^&3'Z * MB\7N+J9%&@3#_K#'F_S=#Z,O<9I>@$3[:=?KQ4_\'>S*3UA;=KD! MV3]7D7TJ>S-TWY+P5W-M^LX5V+:EGBQD^K1#:W)]=[HXO_'/W-_&OXK=H%O4 MQO,HB/MLPIXOW=OR4(+ M)1=*+I3\P"VY<,.%&R[<\,.VT!=QU)EPMAWZL:K$5@SM*!#\'4XK?CO$MT7( MFI\*WGLY!D](K9#:AD[%S$NMY??\*& W7<9J M\C)9ER4P>#X)!3U_KS-\#E?TZRA>RI_4D_Q@YTF%^JVD?N/USB';OPX>4"BP MMDZ^XL/1*F938I)]*RH-@G@89>F5_^+?]1B-.O!+,F2=)JGL09O-U3EPM,IZ MH%94V+ZC"L6$R6F1R3D@31$F2"COJCEL$=BU1&5%8-=P1=UQVGXU1;5%]O-= M%;*"WD>KB <:M+5TYN&8C:-0QP;9Q8:I9Y,ND ML),-LI,[7JPHLK2MTU:1I17**YS<1JNH<'(;YN2*+.QQVTR1E6VHA131Y[$; M1Z&.AV47#R^Z/&AM%-&D4$[AM#92-873VE"G52CF<=E(H8B':Q%Y&H:/GR%5IO7)V9C8GX'86Y+?1:PJZ=$B7C53D]9X M4P];4E/O%!Z*MPB86^KK<4X7#S-$U-2KP[ %]_M]H P(<1X@"Q M!0*+$*>-('3*TG0IKK=*]+O33!D_ M!K\2B"_,TCN;I8/W,VTJ-'I_DV%4:+30Z(.8SA8:?;33VT*C12[H<#5:)(.$ M1F]=HR\N_RXT>E\:#<07&BTT>N^WA3==A5J1#6W07:5SMTW7(S\OO>90D!?Q M;U_]Y[ _[,]AL+ ,K;,,O/$):T_.^-<9W@K#@]CA]H M&P35I*5%1J@)&+2;M+3(" D_J&$@5+U*J.U^T(& T$Y6"0E'2(!0LT#H0-=+ MBV!,.$)-Q" 1C%6?X-H\"!(GO K,V0[F'.0!L@<",GL.M@3(B.!*@,S!@(RX M#$1-T-$06MO48(_R8UL8JA^&G MB&!%.!)[*>JHI6T;C\GG\YU$0]]E-!LUR(?@2!Z^1\!)> M K]&#^[S "20M0/CQMJP8(13E:D>XOMI3S/.WQ="T2BAV!^DCA#U,LB@$_!7 M4]:( >^RJ4'.*]_UD^B/&Q:%X]PBTO7V*;[OQ,/6CCAL^ M=#/&(AO*P\SS@[ '))MK_Q]^$OIW/78-PYN/\#IQ= Z#2.[\Z,?E_3WC[X%J M7\ZMR^MVR.>[Q6?S3#HYXUSZ_$8N;:E[\SR>"9^6,_F=-!2,L[R>+9>W9\O/ M)QH*NKECW6NZTNQ3JM\F3Z6KE^;$XXU7+[41P"T_S7]LA] )I%Z,U+/Z D?E0A'IR _J1BVI[96EG5VDW+Y_3="$ZX/S,0>$=2/524;V,V%4<1ID7 M/K+_QY+XBB4!5"A(?#.\BY-.F"^NL./HD259"+[W19RQU!FR\PC4)0;2W3[! M(R_%WW:(\%(9VQ%=WBO?K6XOW[VR*.5D&M/L(HSR?]>C&QT^#-.LI,<%[;QX MF!R(7+T'D=HJ9*OX9T+(CDG(MNOIK2QDPB@>GE''F[!*)J9-/$:^70CF9]'Q9"L&\AP.L) =Z)$/Q+",&^A6"]Y=^[ M7NDKA& OYF"/FR56#90//#W8WOS=[L+;"GP0"Y/:*F0'MW)H_WO,YD*IR>X1 M]Z\AC,2.^X,X@J_IC"#3(!CVAST><%ZP['N4,+\7_IMUSL$ I1E__'<_C+[$ M:=HNF5XX^JD$K3O\HPC)YE,\:TO2F&9 4MM/NUXO?N*;4-F5G["H98[:^H*T MRN@/)%TC)*-%DM$@A%E;E'*OKH*27A+W+[,N:]FLPQ+1R9VOY:,]"E$IC)$J M(*>-D#-KC(RM3T.]02R$M[M/;[:."E\M3%[_*#?X^N0G\\>Q7;.@ MYZE\B>DYKS)F%=SD'^1G[^R\R;-FUDKB]'Z3[SU=55$C!% MPAD1V%+>>J,3X&8D:$L=>8O\33OZ-@'5H#1S:-[6M[]B M<4Y"6P%F5C"VN6%^&\9'0$9#_)B6FQZ!,:1'PL:_36_8:M0BV[Y'MV]9VLW3X/^W\.2Q\H=2+DPOV!,.. MA]##Z.$JB2/X&.2$>F441I6 DE''3SKI]T$'2,4[+*OM$H:U2#!C&I;3X%U$ MQ-S^)0!S6ZT$.#0('!JT[NL=T>0X97%?V'1 ZM(@H!0Q5:-BJ@8!Z39$2:3X MFC1/*:SR\0!?^ZUTX[!Y=U9[7CL$SK8*9YLB& <6:!RO%_]F/#@D2R;,1*N< MJ(,R10?I11VTM<0"-EL/FUN^07@]L1!.U/ZF%7=]<;3@?(,XW[ M&6N)RJ'[ M/:US*@Y,F(0CTI IF/V*TIL=6@%*#8ET=N#;@&",=U5_]?^,$QLBU;C/DI(S M,_[I]BF>"^OM&"+7*$OR':1\,ZSU8K$HZ/;]Y$=5MB"]9@$+'_V[WOQ&YHJ6 M;E\&LWNF[81UPNQ5S7:(']^T_)K (P?J%86W%-4OX\^K7,,K!NVN(V/V3ONP MD+]-G=^<4<@M'W.P3"$OHQ742"CD&Q1R0F&AD'M2R,9XX2M9R&["A$KNV$9. M:2R4\BB5.H8T*#BL/I)??<)BK@"OQG-,[%YX*O,,N^-A M2^;Z5V3W9#SOQ^[]WX6R,KMOV".+#HG?I0&]GTN\__NY5]=O >=M9_=:UEO M>=NM]SK:74HS'P:_5\R;'Y1^+[O+;,9^A\^'Q.[)<)J:SMJK;RZ8?42>^21/ M&9M]M16X?98H+D,!@N9L2."<[7<=8FBPH/@]TKK9$\*%=MG4!,,+O]89BP MW4?&<#%!(J!.6"V2WWR-=AMG#2VL]LX9&+Y(J8YSY([5[+21,, M/PA'32Q(/$(XGQPZ]CN+'Q)_T T#OY=S/-_(E[S\\?VF#6RN'&^9FEV>?_/&,AR$(S/S?>K01VCLR;L]U%#NK#?1P+CPGX?*8P+QA\D MO O'[?T=MT8P?KE=%XP_2!LO8O2]V/CFK'81GORA.W0K:;F(RP]SQ ^R?X99=WP$[XW? M8ZG=]:.(]69.'RX7.&'"@JSWKYS$+'Z M/HBWJ]=M-XF'#]USZ$W29YW03UX.2;^:XRK6$OIHHJ5UEH:+:*EQ%J7U&-^H M:5OA@AV\P@@7K&63ZQMM114NF'#!A %:OOQ$F*'FFJ'UUM4(8]0T8R145:CJ M,:OJ_JVJF 03JBHFP9JOJNMDV855/0I5%5:UF=,%&QW5*[(Q(AO3FBG?=\G& M"+^Q3<9(^(W-S,:\B]\H5%6H:MM5M1%^HYAD%THJ)MD;JYZ[3Y9.MTX*Q6RF M8JZV)_1(5'+_<:A02:&20B6;,T^QI=20T#2Q5KJE&9=W6_\BPK@&*(P(XUIF MH+:491'Z)@Q42Q,9[S)[)Z*FO:N*B)I:XS.^VQ$'8G576]13K.YJ9L[Q76;I MA/5LNGH*Z]E.AU8LN!0++MOG'Y8D_*O_9YR,Z9=.Y7O\4Z6 !XS3/@-^7(?I M#^O%8E'0[?O)C]?"?631D%RQ;WLSMRX#-M##NQ*NZ[5&,U_0=J<4K F]/ M+Q:R9TXGYOFSNUZ,N3OMP!+V'I,Z_DNHHU!'H8Z-2.FO81U+-UL+A=R-0JYX M>;A0R0.WD%PEA8JMJV)"YELK\Z,DOI!Y(?/'F U?ZGH]Q<+QVJGC-2:P<+OV MIH[[WZ.RJCIZX:,(A':JCU,*"X44"KE<(>-A(A1RIPHYH;!0R"-6R%53]S?A ML]#'7>KCA,!"'8\U?B0B9R)R)L(1B]EC,'A^^2C;" M*Q2S"DU12#&KL'<+V8R);:&.0AV%.N[?.JZACF).0SC0^X3J3?,(("2-T^ K9 MHDD^L4QTY]-\8IGHOE6R56E,H9)")0]?)5OEMHJ3,7>LD.)DS/VKX_Z7BHIS MHX4Z"G5LAG5<9V9!+(01"V$.7"$;-[- G_RD\TH9W/Z@%[\P=I/%P8_+ 2=5 M.]1@S.V984V%H'9QFBGFO)N)B87K3GJ<9J-[N3BM.W\ XK# MZ.&0Q&BS$1^#6:K&)1XO7OO10R$T>?081F%_V)^+[(X:MWC,-R%2<7WJ#)6V M%%X)6-S%_2 "%EL B_N+U=_%7;MBR7V<]/TH8($1AR8[@L(6 MV_*#,+8[!D6-#A^&:::<%O]=.32Y?8*^O\ /0H"V0XOWPRB\'D;A[6'4>5GD MA*@=GJC-@A4^, ^NQ>+5,C>N$3BY_S1S>?;M/ KB/KO)H%D^MB]QD"]\FIGO M!YHRKAH47L\>62\>\*KN\P#XQ-HAJ&-)6C#/5Z(Y&%+! CO8@Q_XW6FR '#>LUPNCA]]9Q!*_!T2DG7X8A6F^&O>1 MC>AXB*BRULB/"7&^">/3 ..S_W7)&XB"0),FH^^5.)8 "=L#?D M$?T-"X8).,,L=9^#WK##.EX2]^VX/QAF>7[@\M[UDRB,'E+PH&^Z?L*LE^H& MYC-N95^\'7(Z$:3=$6@F1_>:0DQ0)(M#,./HD259>->#XBB,DXLX M8ZDS9*]6\4\/<13B.CG@<@/J'4V"^1U%N?6>P+LB[+X-__Y%\QT-OT#90T;9 MHW(8)M. '#=X,R *>3M7/5_@[&N<74"G8T):X<^V06A;@+3[7^?[SDY#OQ]' M.8B9 MP&I$6"4F9)LDL@WR19NU$UHDI)HCG/M/2.T_5'K_62R1D#K4A-3Q^+/""6B3 M$[!___3]U[X*E#U(E-U_(FL/*"L264U.9.T?7?<0_8L0JT4AUO[]TL8M%'3# MARX_1$&([/I9UEG:'8WA;]#. I9?O<+_"OE=67[GB78T*:X&S7,)P6V/X.[? MKVV0X K'H<6.P_&$9T*,#U6,]Q_&-4B,A1O1'C>B$8(KW(CVR^_>\7?_89S MWQ;+[_["N#TFSD87+4^DUF%WV7F49LF0C^N@A>WU4)LD([,7))=9_L8+DG.6 MX[>QO.5FS[*)Z851&.2G[E_%:58< MB@Z(>\.2QS!HVW4#5>,<,WZE@;91VROR=-8P#2.6IC3X:QBFX>2NB>),]VZ8 M=*[ !HT0KG3]4<0I H.!3RDP)LFML/4R>R8\-] ]EK'.51+_R8*L72)20YKQ M(>]SM%DD#VN\="EEI\M^*DA[-&FZMTCQ\.FQD73QGEK]2U??[<6M0S%:[;,ALFB!MWOUYMVU;Z\ M6M0R%&_:LG7]95'+4+QFR\.TLZC![S?.F@T^W T6-?B[M>[84QXPIE5MCJ0\ M+U^ST6@X#S:SC0[@X]H\XJKO@,8\YO<=536>@\.TRJ920+\[BV@,Q1M++EW8 M,A2O+U_CH+_<<"=\!#@NXQ)_X@+IQU\ARQ:FV+(4JBC(PQKQ;-LS/4J1 M81%#M4ZD+"X:N 7S=RKG MKQ@-8&GU/WIWO9.S7S_-$:RI%)0-,J4@(M3P;!7G!.5G*6\0366*BHPI!;'G($WV9%M7$*6:I2%= ^%U3(,@ MF>AU%)2Q2UU'5VS/IH@H,B:ZJ2-;ERU;QU2FI1+'T! %.=)M#MFQ9)R:@!'$\PS9JE?]8*5C MIT*FEE\#_#0UAY@FMA%&MN50P]8US:*>0W6G5@:/%3Y')ER;XJ"F6[H)42:V M- .9CF$ICN%@ VF&Q2V0+2A8I<4FGCI!FJ&;FDTUG7@(03QI62!^"C$U6;%E M4QT[( M;I7L8G6J_;KN& 9RP?VQP U%)K7 &=(H]9 ARZ#^QRV[:@T%24G[=619"E 0 MK) %AMS$!C%5H"6 C(L9$IEQU\S5GY.R&[3*'\<,E_G=6FEF$O'IFTBQS8, MG2#%UJAM>!IQ+(6H%K5<(;O5%J^4-46JHYB4J!#Z>Q !&);L8'#X5=/0+<4E M:LGBJ5@U5WY.4+Y2=A&:4M#P5,TSD&5H%D)4PZXE:RJ804]S%"1PMP9W2YD3 MA$U#M1S7(+:'",3]"K( Z!25J!![D2/W&6ID4)/-Z6P5@M 4N;)*#:(C!?16 MTUU#MR&&L+GC*N9,*F50(W*)@HZJ .[))L@"M14>O-JN@F4'?%C=*&R_J6F$ M\'2KOO)S0G8KYUKTD@6RB>OJ-M)T10;XI):&3,OD\WTFYI-6@H*5VH]*VN^" MJ9%55]85J?]IF(9GFH:I(1DCVU% I:]LV5@RLZ4AH<04% =^F M!'1U0\/@2Q(=O$O=M$ F#*1A6[,U2\-$$+""@*JL3D,@4\:86)9C4\=&KBI; MNJ-8CHZ)Z6"JF(*"U4&D6:*@(AN&K.NV2SQD&!HQ%4!#0_$<#21V3BA12I1:KI27C5*'$-A4'! XC!^L4O"+=I;;K4,,R/8&# ME2OO2GD,0#T5(U'" M>/7G!,,J0<,L4="4D>Y04%[90:IN4!UA[)JJCA3-= VQUJ=ZK;XYS9M02^'+ M]!"F'GBKBD(T%^M$LPS=,73DB@7/U4$K,4H4=&S5@O]I!"-#T\'DFQ;$H]3! MX(02HQ2T:DA!*S\G*%^YUL>8:K\EZR"U6#=4UT J=;%%-$TS )M-U3+%+K-J M"B(\E4$+88-"?"]3JB%'QM0 M]\P=-DE#D*>6#->/?>A37T&RR*.A52NR!JR M'9NX1#9=BQ*/4.JJM4F_8]7BT?J%D@6R; PND&=:!K(0^$'$U2U3 ZFD!K5- M3R1.JBB(S9(2\XEW9!BF[>D(1)'*KJ[K"C1(90^98KM=%0%):?;-!O75/>I0 M0ET$XR.F8UK$=%V=4-D@M8'341,0>C\E("BMY^DV]\V1K#G4<3R#$$I,Q5)5 M6\3N5888!C E($8R=0V*P2 BTT$\E+>PIQ!BF*;FB-"]T@XK\I2"#L:4&I8% M)L1$GJY8F+I4UPS09<56ZY/ 1RV"N!1*.P[H+P&:.9:'L,FW$NJZ+1.LJQI$ MTDYI 9*)\):L(14,.:*61<$/,BW'HJI#(=[>^_1Y M\4L:#Y. I<77+O-A>/"Y$SZ>_9K_\8L#N!2/RC;194=S31B%3747RX:I$L,Q M9 0A+3SDSSP(?Z0T>^&$!=*QTR[C9[%^AA#DOWZYCZ/L- W_S3Z30?;+"7_+ MJ&I>PI-0-12Z(46IO_'B/W6>?Y?'S8<2/,?]!*+..!%4X2[C^ ?&S#O^33$I'W2]>"'[@?_VR MH%9^='#@]T8ONHNS+.Z/^U1\^ZP-GJ5./.2D^T\Y_^>7&8:H0-PRM_W$__E/Q9!_ MF.5?&]%GLGB'E=I8?[MJ7C?7=SKP//?+\YO74>ZN:6W[LWL M,!9U=/<=NW'M[]?GM^?NC40O',G]'_MO].)W5[(OOWX]O[DYO[QH4F__Z0/J M1P]9''V0G(_V1TF5D4[&/5Q=JDBM4&TZOHTE^X^5_EF]DVMA-5Z/*WG]"K9X M@-E2F0NY9Q/%47Y\81CDUI<[&(C_RXQ2C. HBFPI2'&HA\$ N@2Y!D2\MNU2 MS985\T2*?'XZ;H>%GYTXR(]/YX<4 ^X7)[A>DB_B@I/Q^8*DQ?L*:M- M]9-+P+2TSM3V5(_HFJ7KCHX4@V*5NK9J8.J=,\E+OOM)(31IBP K8A[=WZO%V=W\3,'.&+JQB]U>/G:=6L9GY9[)]^^ MT^M;]_K+OZ1K]^KR^E:Z^GY]\YU>W$JWEQ(X6K?@34F*)EU>2PKZJ?.S=.E) MMW]SI9(/-O&_J'W+BQ6BZ>WU>L$OD+(ND_X:RYA4G,,N@=EA'6F9*5WQ+;^^ M;N6I&V;LE*,= UE\2OS!R1(M*DU\JPZF)K8=Q->K8(C//9[Q54S=LC5#PY5: M=)6/RRT.GE]-ASYWH&H?*G8[_LL+\Q,6@3O.!EEQ5+\F?Y#X@\OT:2LDE';C MEVQ'BBX386Z%N9WR[7W-JS&=B;.P[&K$05CGITZ[B&C$4&39-<'40IE7&:LD M?E3Y%14&=L; 9A,I&UM8GMC?CH'-1]%A05S<$?1Y M" "9\+%/@MKW_[LMLY?%@D;+:/2QR;Y!?K=:RF\TDKP0K/!%?AW*YW624:5M M"Q[AQPS;KHIM#R#>()JIVHI,L>)0!4"^#/!N?J41?VGQSFTDI&H&*<7RQ M(W=B!00WU2F">Z:C(%-Q'(0H7[]!$<$*\A37L!3;L.')8SW_R^5UO;PX/#YZ#Y>.L;>IHGJE0 MF6 DFRXQ9=E"1-%-Y!B&IK[FX*W_?#ZZ?S/(N;C4_3/PJ:P1$ZORZLQ93^?> M(:#?E8'-=4"",#;F5R5+?PZ3,.V$^1HRL+BUIF+W/0O+FIIW,'GPH_#?^?>? M6Z!/6V+0^<1&4L>-%4&*H M8JBM'NI>E;893@DIW?-";%GF9VY9KH)4CV+J88/OH\"R[KFD(C% .YV$W^%= M_.<+!#[* H?$-&4)ZG3\))9NLH2Q3'B-*S!H>C""JVHJW\7&3Y!#JNT1B[HZ M15@GNJ)@?K1$#8-L^'B9W,9/T0+VW,!0KOU[G_4$6Y:R!9=.J[$,8EB:BBW" MY^>(0JBLNPIG$[$LS?1JV9([H9?)%<13X/:]*0ZS@2!0*0I]P;P5F%>ZG%:W M0*.H21T(P!P9XC)^NY6&'55U+5FIB,1&S+N*@0F]_Q<.%H?09T0GLB(BL%<. M_HB,/+\Y2$#\PX'?D]@S"X;\9G?X&3QNEJX5\;28&B!'$A>DVM!B=E*X2;,0 MVU';GU:?.L/:=*,\OU=24:GLN9J&5,VD2-<4JJJ&8QNRZQAE]>56D";,7Z*P M;QV)KJ#=3IC]_#IAOXQ@TU5FQ-2(YGG8,PV,',VT/%/3;1W1?'.=JI4)]B4& MW;KJQM'NYQH10+)ARG(KIAJWI//3:;7_\Y]85BG.(2 &-O MR%51\D%RI> U1+1^MF7+V'(RWE[X)JP;S>?H>"8"W:@[-V#2@) A2T<3>2QA M'6DP3-(AG]'+(!@J-J]*BOK3W<_<(/*U-33(/F]Y:KQ%LUCK[(TT%%G1#(B( M5%TQU;=->Z&ETUZ:NF!JJ[YHX6Q9?9&NO'DCIC)XEM*X%W9VN@]S]WAY&V;% M%F/F!UTIZ/EIVI"@9CY[M<_LW('R/O%S(WCSTH=??EHO+!"<;S'G+T9K8'*E M9\]!UX\>X(=(>NJ&\,O4HFZ4WNT#VWIL2Z09,2 WCZ^HO],TR&I9C]*EZ! I MF1YQ=82A1+8A"G ,#1."+0]1FU_I/8T"1O[+BZ+>Y1"\( K@RR*!-3=9'/SX M( W\1'KT>T,F_6_YH[Q.$N1H57FK\KA_D2/R5.20IQ+3YC&GZB*-\-/%J.-B MEQ!DNQZ5RR(W@OL"[1?(F_7U^D)(U=%)E5(Z+8W*BJ.9#K95#YD>I1HQ#-=$ MCBYKBJ7J54#FCJS(XL6LKW+NW/B,T^VW$*!=T!N'?I-^[\5W?D\JCB"2^%;M M=>:U-MKPT?JP?N-.-BRT/X\Z?%D(D^Y>I*#+@A]2GV_5?^JR?%41#^-+:W=_ M4D:9NZZ?2O=ACW4DO]>#&GR#%D\._#4,>6H@BZ4[-JH #8^R \6CBL;7!!6[ MC$:)@E)^82S9/'G B_DN(ZD#I> Z\ZJ#A 4L=Z055B+J4#L&= M2KLQ7TH\WLV3=?UL?A1/_FQ7>3^+AT<#^?F#Y$<=Z2>U--H[T!JH=/+*2$.: M 2AA**9J(V1YGH4-X_6,CSU,$NA=L9..VZ7,SX;IMK*A)V?_8ND6\YZS6W]6 M:F'19L7)_OJW]J3\]R+>?A_UM\YO[ T8N(: ) ;& M_$4ZYP@*TLNGQAP_\XMM1W.0,6VCG%V\'D)-748<$*[9P[ XQDZZ.;V5?N+T M-W^15$W].*J1=<-\1\& [RC8-784'9Z@ 4M_WH:NE^[ATF75,6U#1Y9N(^H2 M2T.*JZK$)8JF>&[%DI82H3F=1ZHO=%WH^G9T';3+EWI^ D;:#P+0]<3G"LNE M/^&&L_)7"<3DM+(@[0-(P%N2L6T"0>U#]U\^<#\!F@.[RA/G#])#$C]EW7'Q M1W ;6-ZW#KL/HWP/;SX7SZ>B5/F7NA[FQY&, M%?IWP/I7.A[.H Z23II?Y^QY+/?>_)?4C[YTDW$'7CO M.7M]OV"6^(,45D]NA_=5:UCRE2L024=QOO!DF!8SS-#CXN*%BN.BXR1_5^^% MO_PIA%?#:Z6(/?'IZX0]AFD^LQSY4<#M',3K_-PZ7CG-?'Z42">5^#D(8:=N M3YWVD__S@LEBL2IALBHA[;)>;\QZZ2=@:+XVH#AH=,G,^\]UJS_^Q=+-EO$H MBCJ]D9:H_"I54[8A5$ 0&V"JVAKR/'X2HH&)4Q$4\,&\V1=Y3?0%/-_V<&ZAM7C='F;5"4M.LG M+)7B89;C%0>N\6:FD1H50YGL ,_W-;)\*4Y0[*9)B]TT?CI^H@>O23. /;Y, MK: 0O]/E\T9GRL\%"%[>*+QU7AFU:82N.UA7+,5$+N@BM@Q+MCR(#!RJ>9KE M6!7GW13[@O)M036WTXXV)<%/(S,DJ:2P0+P])ET"/D"LUN-SJ0 7 M/_.X(AMYKD4P5WSF=8<#[K3P( 2"N'"TR0!L9@PM!_$#BZ L?O;!DCX"N@0\ MRGM(_#[8^6'4D?*;;L;KAC<^'2BO^SG,@"$!$.\KR-1#OA%IXHXY81H,BXM> M^$)E"H-[2EX?D)RV"/KQ8-\ MN],I5[LP&@)-W?X 0FC>!3]0__9(+]5H\/2( GO^)Z\.Y"W#U(42\784JGK/[)B M"UO?AWAJI"ESPE[L>JL:;B>&-GA.I!]WPON7#P5Q\@7Z(R4(HSSM 8;H0_YA M-+)IWF-R4'D8%7XN%[81!8OXO*)''Z7;1;T!FY)O607YXCOO\OTZ??^E&&T< M!'SG2X=OT4G97T-6,*/H5;YM+^_XJ*.O7KPY(.X7CK?@K*S9@YV]\>W^SPK> MAO!_]N+_6.>77^GU^85T]3=Z_97:[O?;[--36U=0/D.=_3@C;;!X 5GE35EBXR8P!/CV];XFG9RUG; ]@HL M?=-6+6WN!+P:(*!@G'P>LVC^)M0HYI>@3AP'"R%"";450S60IZO8-G2LRHZ* M-,U6-.VMU%ZE,V=7]/I6.O]8X6(()6R\N+V?+)V<>><7],(^SQTZ[Q(Q?>%:@HI9:)#9/H M,D6:I6!'=K%I6+)GJ8:,[*8!U:'KSJ&/;QO8L%QFU\0&/F7"(KZX#S[E[D2^ M!\_R>P 93+KI,I:EHX42-VP Z,%GFS1Y/-OT/?*'G1 >^7DT21*,:BAY#2QP M1N!,P_3PT,>W#9Q1-%NS7$(-QU60Z7E4)Y[LFIAB;)NFC;:%,U.'I$C^]P<) MZT(]?KP>ORN[SZ2?OL1I^O,,THP/I\R@NRS'G2B,V/@PO&*-1X#B:N M;EL$Y-@PB>.L[PKQQ=M\B;!4@T!5*>0R^@@<68$GN%$X\DYDL6W+-!1'L5U= M0S:1J4$,1U=L:ED6A)O*SN:]5#'OU09AVIFD['0;08-$:U]XMYQ=:K,B M"\;8<'67(I?J2,4VUFU%,6W7D4UL*[J\,\#3!."U09AV)BDG9]_X7IT0'#2> M/N?8!3_TQM\Y]/7B=,CW2?MW\7!\1YIT':8_&B0Y^\*SY=S0R#'B&;\4DE"B M&ZIC($=QB>?)EJ%RNE!*;+PS/-,%GK5!F'8F*7DZ+$OB7IICV542!ZS#X:M! M8K$WYVLIJ1L&5GLZF$ ,50RUU4-MJ8>1?]MXEXBG**YJN#)$EN"*40>;CFUI MCHHU67<W]A.GD[/+V;^YU8[:(-,-!64YU76Z4@_)>"Z], M9)@V44W9\A"?8:2*HKE8P8IM>)3N+IH2VT!:(4P[DY23LR_LP>\5851^?["( MHU8A\G'"E*H:,E:H:VNJC5R"B6S*"K(-Q]0M77;TW<$4%3C5!FG:F:B-KZ>W$ Y,CM$H"V"CL,[1@!S=!TS5(- M1],4%V&D4)5H#D8F42CU*-G="0%BX4 KA&EGDG)RYK![/U_D]'T01X!@41@G M)2!KD'CL;77G4I(?)VA13U9DI'F*030D\Y,K5-,S/4/35,!T3ZP.$*"U&TDY M.?O*-[K<^/<,G*[2XJ8&B<7>3AQ82NKC!"N3RL@AB"*-*DBQ*58T!6#=TBV" M()RF.P,K),"J#<*T,TDY.;O,3PT_GYX:WB"!V!=,+2?R<<*4I;NNH3NNILLV MT@R'V%C67 H$LFU--G<'4X: J38(T\XDA5_HT@WO0G$\W$JT-9I];M/XU'9C M<#2K\<18Q5C?O,QR^1MTS3 M,M7C&QU=/SO^Y5>_K.<< MJ'.*T]GX1AM5UEVDZIZBNCI29(7HCJXA2FT;81=;W&\1-]HLN2DFQ\3R?2K& M[/V>&['X>]3C=Z/QAP;M&9:-KHB=%HY^?V/POPW3R"Y]C'?T:#Y/Q MKWD'^5O'KY.NNCY$W@$;YN###Q?\R)_E5Y,Q?BW98)#$ Z!)!L,#!QA^CGLP MF/@I&EV^%79":(BE&U[LLQ-VC4<'=LW4?_D@6?"9#1-__-T+DPZ_Q&;\_>_# M1W]2^<)_Z/G_?NE/2J_\WDOT[_"OXGM.V7^$_?#?87_\"Q *B"R59K^SQ.\P M?J-Y^E&BO0Z\>]IB<9MY566N%^.^?_J=1?P9ZLJ2QS!@^?7IZ8?2B_/2XIG\Q_$S@P'C[3],1#0I!)./@@L=9SC8HO$M;R$? M5SK@M]SQ>]> [\FFO%;UP7O0GG=,O83A==]/PGD,6OT^O[4E9J00J@\W<, MS!!\"^]#:.'N)1>'X>BF3I;TPPC,_<,+J#V_M'#2KSO6"]DC2^?1B#USJ7GU M<\AQO_/J9[Y%.P@'_.[P^2)^F>JK'_O^:T ,>[WYWX)XV.M,?GR:^39N/HG_ MK.HHIS^__/+UP-(L[%=V-.8F#=@]7Q /.'OY9>$OXY+QL63LH=B'#OY?FE\N M.>$.)WE9BU, G9Z?2$!7T,B\\D?I$G#'#[(A8'/K=$4DX J1/> MW^=-/$3Y/991!D)WG\3]XLK$6LGZ.%YQ6-R_6#06^+E0)+F$)N'=,!M?.@D_ M%V\:&\&@-^0W4G;CO"0_9*2X#W)$F/*BQ@G1N%D"Q9#.SS](/ $WNNR3CF^, M7:(W()E/#/#23V>NHP0V/X;\W#?62UEAW58STCD'@,PTBCB97U?Y^^20N1?& M^9.?+C<^\GMT+^CHW._QE9]/T+GBLMJG,.O.7UO*WSBYNI1?3A\69[/DE]C> MN/;/^=O970+]?I'4T2WK'Z5_Q4,I[8YX!+9^R$TU, F,='XW*G"P3)$[!I^A MT_!4W__!CT: 8E#D+#_EDU]/S]_:),->&B"_(A2 20L\GM+>?OUS>:V M],Y/B[N(>5LY1MX7G/73=-@?9"5EET8>WN0\GO[DB)YI,S-7J_++3W,=]A]] M 7N4X,&EA[+78."4G=L(@.%[L&WJ+BUMI"^_&Y7$#T K_PFUP2D?,'@QB09 M]SJ_E14D=,C&%[W>#[,A=QZGBE@@& '?RL7VIGVIDUU_;2XQ);WG[?+!?.C M-+T'-V%_#<.D,$]@TC[,/#VY.S:W?EDATV#O[L#=* @'1 )!84!3:3"$GP-. M0JB2W_Z<#J;PKQ16W/9^W-[KHEN-J MF 3#/KPP1]$1MHRNO,U%_!Y&.#68G=&C3=)4?M%W9WJJ5(V<3V\0#F8.ETJF MATO%D\.E2O(,T?18DO\<1B51KGK).F?W%7S3;LY9M_R.Y5FV+<:GFAOA8^* M 9;\P-'=Z*__+KS0:4-(;,X]R1.FK7#9S?I,>Y\+ENW+"\>]N'$=?L/RS>67 MPA>+?@&I=:6;O[GNAIB;O;89D7Z2H\U:JG"CJ>Q5Y[1/Q6ZFT0#&1F^/H2 M@M6Q[%V%95\@I[ZG=&SUAO+U1&'CE6RU!-AL,#7N]=K,'>58FG4F8/TX-^*9 M723X^5P!R]+/;S37!Z"UASZ^H^'EMAT6N9GZRR\CX]F=@'_@/OC^X#.7$1IU M^'_DWP B^EB3_:9AV3O*Y^K[? M2W\[.>7X 41F.9(4,\:_G83/V>=HV._$V:CFR9FN:A]45?[UT^SXIH9U>YS< MFT=PS&ZN@)2V0@HB$TBA*E$Q V6%R?\V+/I2CZ'W673;Z.@;FH9(TW%CFHJBDD0412*D"G;Q* 46YYKRMM7J.T8 M-$3D#YIJ'()"'4?838,@G_^7$A8P<'] A#Y($J(%;C1/VKYI8F:HF L-F M68:+'%M#NJ-8IDL&TK"MV1I/(;U1$;=C$#5=_6!HVD$KXD%% M>.<1WQD0)R]'Z8-B--6O_Y^]=VUJ(\G6A?]*1>^]W],34>[.V\I+=YR)R.LT M9]O@,?3,F4\3,A2-S@B)+0E?YM>_F1)0AJY=4]$2T?F&$5EO,A=0,M^F&/+[HZG]W(9GJL! M/I!YN&L:HJHQZ8,!I(T/$8O@ RC!HIY(<0@(21#P)287JZ\7B[YN PT37@*3 M7>J%J^YS;P5@-N#V#[X*U^D!5D;T>JXE#1B$ XVU,C)@I;@0U,F5X-N-8%6R M9*A3JV[KT+N:U4=Y+^7NR62>2JHW*7>W+"?V4>"E-7B#,E93RY%P 0(0'4U& MRD*T)D,PAH66=V8S8K>4H$H*71J0#T*WE[F_V?K<;ZBR.FI3'N-> MV%3Y:#RKCF ;'&6O)^ERK#!JF,S>"9=R()^%7S MAFIV7E_* HW*.6*[X*O.NO7V@XK4^K%4WDME,0O8@'%$ZV 84(FT=\[KMG[< M!:@Z4J(IE)+O!*CV(P#T]J:7=)E:==YTI4S%<%=)P.7,O*\ %6KIIXB+5JOB M@4>@4A$T2A,4',-<8Z> ? G4V\5^FY9:C\_\[4*O,X-!<552E%/S=MX*V3LD M\EID(E":!^LE& 74*&4I(@0\&,:HMRWO[Q.1V%$0A\F2Y^JK[3'Z#L;SP?B/ M8>H$M_01=2$0MQ5MLD8;%U91Y+ ,7(**NBI02AEG(2A%I=?MW*/;=5RZYE\FD[,T%F!]=AXGIB;1]0MU-VF4M#$A=S^0:?NDF>VU98\1I6B 9CM17, M<@%82)6&:5B)F(ZB#--63XS;13P8GTXNJY/!ISNE4@VQ;8? M/)+?@4*P=>XN1M!&LHXM(C2[]75+6!+))H3Y:<==F 9OLJ M,[)%ER'BU\^^.;V9X%_ZOOQ^<_&-KZJ2^ M&F:W([-&P\'[X6A1DI+G9NW\_>W-7NY'5..N@??5X/-B1G:J&!J8-IH_>DU-1KA;"A&D/PV@C"I2,.28^8":W\[]LS\W9Y9/3X3"\/ MS.OZO*R]0[FDI6"=-O?HG1MWGQ7)S"Q;RRRJ]L2"=@1S1Y# %K2-#,/!>BR1 M Z$9;^4&/H]9.O*04%$2M=L%ECN5/M@8JI6.1/SF9)7$A[-AM $':?-ZV."K M!TAEJ([I,LXM=T8S2P@(D)+3(%)*KY*.(]3J/VVN9\-Q-9O9R>7[X7BQR/9N M\6US[6^A^WGMS?E0B;HMC'Y@VWNK&.R _-][;))Z/!Y"1FII#-8XZN>2JF!M M$$%KX$9Q8M:*S6Z$JH1209>9PKW%9L=N@UXG99RV/8!]*I3I>YB0L1KC)&!N MA9:>60%!40-(4(J9%\@1@EMID9LTM=7&3.U^!@KWV0[/R/TJ\[ MZ=VYI:XPX'7UH-5&D6"%--B#]LAPHYE@3!(NP$K\I;)MZV5,S7,W4$$H&2TY MWHD1]GU0J/IBWFXK=F0=XC$@N39,(*TI."0U]XYRSI!7#B"@YV"G(R\Q127# M8A>PLQ_98_?DU5HBKSM61LL;(5=!#+?:Q[^D!B*9(0YS(STBW&$L6R[?%<(Z MFYB[($M%=SM;(AL8^XC41@"6:P5&64+2!&"%G0E,:&]M5#BYI&SM2.VJXTPI M9:=#1WN'U)TR!I<-9T9W(K;#*.MNYDSP1CQ5:;"!8*,"L4!41&\P1"W[52 5 MOMYFIA&:V8#D5*)DM-/V\7W-BM<1.5$T#YX03TX)Z3F KCU M"H1,;>Z_D^VPQJGX^^#OJ,NWV4TQ4LL>]'IK9^@WZ5F \?SR>F_+B:CN,RS MVR8E:;#A_',_>@[T=&CS/EE>>[W16Q)ONO>R11V M^/A%$6_XE^0@@75X-I\6$PNJY^*0 MZL32_\7L8C"M9L7@>GXQF<:/ M./NUP$*5'+&22KSHA8"%+ F04@&[??MP-DO=$=*KD^OY;!X?Q'LJB_C:515E MT(=J]/FG[$Z_KTXT_ ,R6&:IB[);"XC;H7D0@? TB9P%_K5 =-K1A03X6]K# M]1D2,@>RLA6P:\B3M2)/.1/4:LI4 "EC:%&8R4HPA8)UIJ0]0CD=:3-BT[U M^-XA;Z<"4SI^6]JAP2C*U>%9E-[%Z>!J.!\\=SC=EB),-DQEK3B.1C%57ACP MP)3&!!@G. C"F6WW'KY;R[=Q*0_&=KF0#>"ML2]QI(92Y5S%79-@VPHC4K>D M8LQQ#AYC;30P$-HH4%3K !PA95I%=2O!J*N.NIRK4I&=@%$V(QMF9'S_YWAJ M:G.RN*A&9\7[S\7A9/P_U_%ZSH?1#KP;7Y=^I1K/%HD]11I%7_PXOZB*P[\Z M^Z=]4TI_? CLK :[B+!."1H(A(*@A28:2^^-ML9)":TN40U4'RQ,<7]Y-9I\ MKJK%4R?3Z]D:DS;**. WH:JV(?&U"[?O&&#NR,FD9+=V,WMVT2D]/KR^O1X-YE,231>ID%-U7 MT^HBBN3AAZH8+F8[[JEJW? !F<"-%YX;9$RT3(T*0( H)2F*CU&KA*ZQKHM$ M+=M7 S->369J5>71^,OBT-LE+18E0ERD>V5;M@6S<4D I5$M D((3XSR/ M*BRDC @,1GB+2;0)+5-M6_79@.HH![(D8B>&-V^)T=JA?#NKSH>GP^?6@^_< M#,N']%9%&F*08>.M4-1Z#8!!I>I8C) 6@4C$U9>H?5?-!\-Q5%<'TW&\M5EC M.]QR-YXG^69Q+>)S#^0\"0KQ_UXD.FZ'BIL-U$P$7R$"1AK3#SP-3AH3F 4V(S4I$\ 2)_3@BX(J5F+),!.NU=7M=[C#[9DYD#VN4^I[O MK!H)2LAK0P@$I;F"$(CV1ECA@]7&8R):"4K-Y%2_V(#U6<$E$JQDJ--VK \A MOY?9S=F*WG/ -GQ:#$RTNCT6U!F(")5<":*!<2: FW8$Z5& [<;*)J7BHE1L MDX,)^@G8/:U$7.0)/U54/V'[NYHBO=;:EOZ,EW[.=*6>4R)!2-Q18F"**4"2 MQV?!.ZX-)I_& =\\O M_EX\59Q6H]'-;2VB><$QOLP5OKNED>!G5ML/J8_%N M#:_^$7<4.7-MCQ:ZXW7<'\U1\-Q]>JVHSI!__4% NY3 M&EM^Z=,@]"-^DJ\\7F'ZCG@FSR>3^7@RKQ9P.XF[?ER-JL41?24E8L);T-)C MD,PK'540&0C0@"V$\&HY%O+F QY\^S]'[T<)+,NWOYNDR[J8SZ]^^?GGCQ\_ M_O3I_73TTV3ZQ\]1O:$_3^/+/]^^]X?BT^7HE]$@[7@U?O7[\9-6]\EKZ:K3 MZO)]-5W*,(K+(O%!\7X0K^ TGJ./U32U<)X./U1GQ?ET$X_D[\DN)X'I^XK-)@YN'X='1]%E\=CA>_>9.8>F-%S H]'E_' MWWA774VF\R(R88@$4V#TZK\3U2Q^Y7,UF!;5^&R1K/JUJRV+\^$HOOIQ.+]8 M_,:QMXN/JMY/KP?3SP61BS>J+\L:&T?B:_C\WK*W(-@@D=-XY]7TV:986N?3 MT^5ZQ:\JTF5&>VR:IES'Y9Q7?TP7-2QIW<[3?<_2\J8DXMECMN:+Q5C\M62M MVY^_PH\WM[;>,\F^V*;%WQ?3FOW^J%Z]GU:#?[T:G,>K^64P^CCX/$O<=3&] MN9'! N(S3"TU$9S<19B*$#13 7DAM916" OI=P;W5N!)MS5X]#T5%],D6O]C M)K3GQI-@"5@P2&GJ%6;*"J X$,^??DP6@B,>@-2C,>WKW>(-[B_@=S:X=:<= M'^;%3Q^7G_\^ZB+Q]\W!T1O][N"P>/N;?O=&6__[R8'5KXN#0]L^F(]"H>P> MA%^Y;GMTZ/SAL7=%?'1\]/K Z9/XP_%)_.>-/SPY+HY"?.G-VW?^M_B^@[_Y M=$M';WSQX^NCX^,_/?[>UG\O)_%05@L'SV'\\MLK>^:'%F_BSPB\(NZ,/ M/:ZNYDWB1TL^[^J2TQ)T]%E)'G5U67TZ*S\>)/D]N9[%M9J51?7I-&Y)<55- MEVT%BL'E8O1UK\[WC]?C&T5EMT MU'^?I/U_3]G_XFJ7JCU&\;YN[*%H)(T&5[/JE]L'K1NN[8.[ [F/WS;'EA^ M!XC_:E@/]U_#WWY)KO1;J[VTW]_UL"5W.3P[&U5K<;IU[$]Z5-11]*F5Z5HE M>%/B+C2\.W%91$FYY\'G?3@&27U[^BG8.T9X<,K8&H["$]:A=3CDTU9"?E,C M57O. 7N[\3)O_'YN?$;\GF[\UQ"_!V-GO[(8[_S?_.'O_CA/GLV39U?8_1O= M=WLAD7<^XS[O?M[]7>Z:<5C-BZOIY.SZ=%Y,JP_5^/I;LU,ZUWQ[ES#WG&O> M0&8;*(&ADD+>);9AJ[GP(# A9#%_)?[QFJ 6@+3K3JE=\L-#M/)98IUIR_X M^W!^8:]G\?ZJJ?^4,DWB'>O9K(I_SMK=!]PR[?>O)^Z?L^G\GV^7)^=H>EQ- M/PQ/*_UI./OGS;?=OOAFX4'K(CL.4*E0EW44O@"EX2PDD&7N?>9,#)A[#IA4-[0 M+S35RAID&$!D#$T!(6&T]]Q)T>XLV)E^\4*$@0DM2:>=&%ZVJF;G6ZB]FWP> MC.:?EY.;%BU"O^_RV-\&2@^ 'NKNAYQ;@=,@)V$P!.ITFBQC.#?(4VFI?QD? MQ/O+Z?B?-]NMQ\L^B]TA'Y58;7)X=/_FV60/>&:%%BL(5#=58QPY@N-+JBT(5@K5BR[._?XV99Y)(L*"- M#,ACJ:*)#1SHFK1KV1VH,16E4NOK@KDMH'YT?X'MK;%:_'2_[/#HK7^G3PX. M_U+X__LV=0KK>P'B$PY/GY*D]L+QFH]&/AKY:.2CD8_&\U=HIPH?[62VZ/H[ MBQKIN M>*F8VH4$>G ,CK&:!8V.%=):WPM8/(:8S/[>0 MI>PTN)P1DQ&S,F)([9?R2,8_RGFB)!#F-&/6>N*,E!9P:,UA>82,Z<;C1#@M M@7<9S\V0R9!9&3*LAHP6"AQR(<)$ +5<4PY&.A55-:IL>TK](X1,1Y!AJ"0L MUSYM3^U3-:L&T].+1?'363P@H\E5FF+RW%C+CB4FDD9PE 3LA'51:AD/@0B% MN?#,*2$XQX*%=AQEN<1Z?.;J!?:?KM(\F77:2%BD*;.=YA/V+E\P^Z7V$8VR MKBY.T4OL &D<96!4'Z7#B@9C%$96^Z"?B\;.["_,<**C!28M5I@E!&8T9C#]!(:C1J M:C38*!EI:NBEC %GK-<S^70P'WZH]M-+0UD-/R"$8HF$ @' .-,.I,$1.5QZ9MK" M\&91_[)#LA$^ 4N-4P=E[9EG'%'7 M2O=XCESJ"$LLZGAR)W2\_0C1'8SG@_$?PS3(>#";5?,T$CK>Y+\'B[.9#*]T M6.(%15L]/9P-SZKIXL7L&KF/6U+CEE$$C'JCN>" )38,&QZ$]]IA@>U=8F/J M]_%+O0.IUFFN&^L?$6SO5M\V%W^]=EJ)/72\4,)P2Y & P2$>, MDDX3K#&3FJ]+AG84^DR206O!A@[!FGG+*$"B6&LD*X:V@ M8(10M-63;G6:W)\R2 6.>A4,C1H_C:HVC_^N OX. MV\,30DLJ.LWHV"WPKQAL[J&UO_CI?GOX@T-[],87/[X^.C[^4Q'>';TI;CK& M'QT>[V?@F?,:NMIY@@5S:2A3A*XT*,KN168(%@)8JQ;UZ-:/%#+G(N&B-*N92<IHI/(OW'Y][**(E&.X07BOYO3L1BCF&9#-.&11LA!X%(%8-$J M",BJ0*5MF>^U,9"&%R^7^DTUOYB<'8P_5+-YZFKZ?'?V8^P$@!=WNV6#?<1\0%9Y!WH"$8 .2,"(1)AJUTJR?(?LZ]I&)3OO?9/1E]&T(?;)N.VR M>*J=!<$ "-=2&T0%$(>T4 ):\V^?(?LZ1A^@+G.@MP-]_?1 =]\.LIK&HQ1M MQW36;>^!5C6$T"F'-%94.208\:.,TUU@P233FEG\%O+<07<+X=J77F?@$ M*6=YIUO<] J+?965.P=#TFC=+Y#AA#-#HP;+/#'>"$\1"]PZP5BK1?(38-A9 MU1 OZ8Z/G\DPW$<8-MPX@&5J^V:1=!(X85H%%J1%05EJL/J*$_4ITK"C)'Y1 M NVT=B_C,..P!SAL.'1"8 I"-,^L)1 X,2",EPXP$"6C;'R>..P,A[C3A.'^ MX7"7@HEW)N%-SXL]==RHQHP;SA#R/EJ R%H(:22'Q,QQJSS!B,E6B?KM$FY@ MR!HI5:HCA3)A@?WQ21)@ 0M&:+/@RP M[GKODQ+3''?/"-M"A#6R7A2Q5FM+.>8<,$-&&Q'AQ7&(* OA*Y&_1XBPCO1# M'NVT'-W+"-M"A+':,^DTUL)0[4-$& *MD2/$,ALDPYJY5C?N1\FP;A!&H51X M_[)7]B*"=S2/P+P)WY7%N)IO4[^2E_>F$,3K&!^50'E@8)&7X"TH!9Q*PB1C MDLMV2Y+%VG]1-78#Y\-JK9$^6BK>B\Y$V?799[FZ=V!N9-MH:U"4O98*H2 B M6R*'/6-&&*25].U^"D\%.6LW;W;GOYZPOYSQ>QUN\@>]D/#-5!%RU M?-_)X%,U\Y_FTT$$QG \F'X^F%>7L\/).&%Z.AF-%H!??^:L*B4AN67@;LG8 MOL+O(:\RYO5@# J.::Z%DC+BSTL9#%46.8$)QEI\)3*Z2?RMH;N@*AFF>^>J MSK#= =@VYMD$+CD1 AM A3%F@@>2)2DWC$9VCT"-RXVNV]AAG(,-\-V"V%+ M&FXF+H.,ZJVEF@-XJG1PF*84OY2/I-MCZC8N;;MN$:I*JKILD.:E4%W:T1G\&?S[!W[>$/V.:"&%8X): ,L-\=HI MX@T+3%+_ERJU$_$E2H2%@ &V5 5"!&>FY(@3"DAY0P2NN!3I(:$,3J^ H#AZP& M#]IW*=I^I=H*(H#%9CF.""'/& M*0I>1LT(M"-:8TM\0 2OH!UU; -264K1949CYIG,,YEG-L$S C?2R"BXR#!, M*0_,"RFIYYP8(KR+;"-64'BZ[LM/2^ OWAZG7SRS!^DECW$T%6_]N^+X-_W. MEX71QP??&#[5/65]:U4;I^0KBG3OR.S!T_$X0#SE5C?H:U*-F4 *&7PRFE1G,AJ>/]#G=_DZ3]<@=Z:'O MRU)?DVR/>"QSPG &1NR]Q&&"6-[I 0M!72 M.@1@C)2!&.:EXI9+QF%E;ON:7ZLC;NNT7#=S6^:VS&T[Q&W0Z#:BO76<1VLR M];K57$KAH^ZF-)*4$]LJV7B"WK8N;F.9VW+JU@,>-7?P^O<3[WJ8.;$5]-=M MZD0_?6Q,U-GK1%EGM9!@L 0 %;4]8RT@I((7#+4J6[]D03<<7<^KL\UXV3:: M0+&EWK9=5\XR2^T*2SVHK#5" 2+:H"S:H!*H!2>\1@@R/QGZ-AUBCD4@?P&+,/54L/DT#,UI;8G T BW"WK7<4K<[HY<;9T<&2,I<0(!XMP( MY@QHH3EAECK:-;A;+IYG@5N43.9TSPSN#.X:W%+>@1N"8\'9X!SU0&G4][E/ M($06D%&FU9B\ \G]C^[ G:KC.NV0DL&=P;W=X.:H 6X/@7#GG;,X56C?@>3N$-R\%'PCF<\]!??N),4\S10_6[J0.FUS]K+NRPVBG]3H M=U$Y#Q(A'$ "MF!4E/$:!>.4\MZTZK&^@?X;CUZ+!-9MEDLH%5E?W^.<0K*5 MLGP_4H[KD]GE&=4;V=J.:\UM3! M(4<5<"X=.&653,A&\;V<6:,>:X8_35;WV1#/J,ZHWDY42][L+V48TDXY$U*F MD!)1]EFG$';!"?18^_MILKK/%OB6HKJ?T?(O<7^QK#K!(KYS4QQ -^E[Z_&" MY$7(IR*?BGPJ\JG(IV*%!=D=5__BI_OUK_;HS=MW_C=_>'SP-]_/(08[F7C< M V-(-&K"%./8:H\]1C15KBK),"%.@>8!(=9R7-K)Y=6TNJC&L^&':MD.\[": M'YV?##ZMM9B!/XY(US!.@)8>-1CU6*E+(-5:9@3(#?9N!&JW67+"*8"PU 0\J M$"6(\AX[SWVP3+>*0)^LS73=X+O$K/\#33(!90+*!/1M FKT0\-!(*>BPH,5 M!^6U$3;RCL,&&0VN Q6H8P("4F*QT72N[6"@A>OGY_D@7OGM\X^'O_HF^ALW M,1J.JU>WGBR"_NO>,F >;[IQFZ=5/ G3Y][HR455#$[C&8N_]3E^53&>S*M9 M,9C&I^.ICE_QQW0P*JX&TWDQ.2_F%]6L*NQD?)9FK)ZE1XO9#X.4,1J&X\'X M-'Y+<3R/3US&"YS]U+K96R/WRYMOW]H/WU^<9]XY?+'%B[\OIK+-[B_@-_9X-:==GR8O^+0- =';_2[@\/B[6_ZW1MM_>\G M!U:_3J[-]L%\% IE]R#\JB/VT/G#8^^*^.CXZ/6!TR?QA^.3^,\;?WA2'(7X MPY'][]^.7CO_[OC_^P])L/BU\'_]_>#D'X^_L_7?R4D\DHE*SHK#^.6W5_;, M#RW>Q.SN%:S/_7JRJ['@^NS811RJUW6-_S#C=^^I[VC6Y(9)CF[_+GY M\>.DO(WN:P=HJ1(MU)/BM!J-;EY=-.=(/\?+/KW]^2LK<3*\C'+_L/I8O)M< M#EJVSL?AV?PB/HSW=:/.G4Y&H\'5K/KE]D'KAG^XBY3=Q1!Q$CW?"J0MOP/H M?_WZ0TNSO/G^;[^D5OJMU5[:[^]ZT1#H2Z50BB>E4+9GHG5JG;=83CZ-Y>3W M9/4]V7HG%(LH#_?3*[-71R I:4\[ 3U-B%AA.;I*@UG#,6BOPVH#&-=T:IIZ M\IZ20SX5WS53\JG(IR)S13X53^2*?I9S=!QK.+[IK)"F_^IV, M^X3#TZL@ZCYTV,1;7#&D40/@O,Y(>JF<_6"1"DG_> MO/^?=^D?_G^NA_//*:%I,DY9 _K3<';WKJ6VNU!VWRQ.RW>+X0\.PQ/:1#/: M98^+7/?1@R856PH[54]LL%3Y$)@E1&! U&GG E=**X$-(;;5YNTQL),]@ITH M =:DR!BG@S+&BGE?: ;5#"":.$]TQIQ%5KY,'C8,=Z SM9$LC2 M+L.N#["C->R\E$B"L!KI ,@)C8VVTGELL)$ MP+U1Y:(X]D"Y=>B2 !W<+]_>5T_,L"CVE'JC-W/8WW]38> MV2/S1N:-)F\H7/NP01IJ'$7>. ")## G!8U6AG14:K]9?>,? MO>$-7-(U]B_)S)&98QN9 R.,&WYX$[P1 A%A :Q47%JC(HT8Z9G49K,J1W^H M@Y0(.IVNNG74L6(Q@^REQ\,OO&BW() 4Z$)HPY"JXO0XT+FM"?(3R%SCM;7\^,KV%]I[U]:=<@:PHXCOC$I MG7JL@B3:>\> .F0HBX#7V%E,":)BM;!A?Q O2H76-P@F(SXC?BL0WQB?GF5\ M1GQ&_,XC7JHLX_<*\?VL(OS&! MYE2=Z;'@]\AKD,Y'/1#X3^4SD,Y&K Y]6 M'3@YC[\=%=>+R2AJ?K/_=9M7N8:JP13%2M:F M73I U"DAI 4)UCC-+:/4Z. T<[1EVC5.\=):^WJ18P>#JTBI."H5[$3V^!ZX M4S*\^P%O@L4=O",8-3"A$#@$RDB#E*0:6X:M,E2XE> M.X*WE%#B3EVM&=X9 MWCL/;\KOX,W & P^27 #F C)E2 1\)P)X ;:CMG'P9MU)+U%J3J=T93AG>&] M\_"&&MY(!@<4!13E-6A-#05&@PA.< 5(M3LA/ ;>HB-X2R1+SG>BHKJ?D8^. M(7/3-7'AAOAEF[U6>^N^S#[+O/MY]_/NY]WO39"B2U%_$X%0ZX@_Y$Z"F]?D M*=2M!($'0@,'PZD!T%1Z@RAAC@?J,*QHJ'?;2W!52P"++HNALHG?@WS';06< MJ)L(&BL]%4&8B#D H,HS(Z@V3'-M12"K.KY[ ;C 4W5C(R:%%> L MYTP!ME3;*-N4,U@1HXU?V16= 9U6[F?]?./ZQA8%N-JGM+@YH-/N2?'TT#?Z!;*';+( M$Z&]CDIM(,JR:$8"8AP0<5QWWY-C$XT#5^:)O>["D?V5F2S:9 &D01;$>AL$ M8=X#!VE F*B;]TPDY&Z SV0)P+4! M0ADE@3FBK0V@F3&!6*8BCW 9U0K;'BGTN*AWEXU#5G8]R"X3V[>S84@.*.PY MU!N-/[6'0(7C*F@%E 85*'BOL?>@,1%HQ?!?+Z#>:?@O0SU#O9?J/32;>F;! MW0V:,V!W%+"]E\T"9=F\'[)Y+ZK7=/RVM+N#47$U&)Z]&HZ+T\'5<#X8];R6 M[0EG)A>[[%>Q2SX:^6CDHY&/QDX*.<1QL2>&#$.P$:(VE $4J$$(%K@_R&*NK6#T$0HJ0H]ZW*$.P#!$4CGK[(X/5& M6D4 +/&28P)86R,Q$E^;P[&>&KOU0S#>>ZE(EH(9@KV (&U D%++B51*00!F ML10,HD9JI$2:8+E:7?G3J^[6#T$F:4G(3DC!7(>WGCJ\;4-<,)*1_A;:=4(-L[CT\;GOQ]Y*HCJ=D_?0>:J!])P# MU076_I1]HWO"&0]1AJ@I0TL6*'!%M"<@.%4T..:BD6PY0QAMAC)6*K=;MS8! M)89.:W5[EP.?P;^+X']086A4Q$C!"3+:,)]Z,YN@A;,XV@:>Z"!#/4BE?^5S MFU,85(EEIW,VL\:02:-OI/$ 9\B&/R\8KAT25GANP&EOA!2!>"T1I@XYV]\J MNG5K# 27C.^VRK!BP+R?SH?%X7SU?C"K$K0OKZKQ;)!V;#\=AK+A,(3 O #D MP&,*2G+#J)%6*T0]8ECP+QV&^NS_7<_F"8"SD\DW8+:8K[U8;-M8ZW?)XS,; MSJOC:OIA>%HM^>%==3KY8[SXE 55],K-\#T/)"HQR[.A=DR:;RN@H:'H>^M= MH(PRI"'%XAQ1%&,OJ#7(R%80[@4 W4LG )4EY3FDEP'="T WRF,PEM(:CQR/ M@AJCH#'WAACDO7=>MW/+7D9"]T]'QX24!'?9^R(C.B-Z942K&M%@! DT""J, M!X6X"MQZZ925BB/?SI-Y&1'=0T1C7F*Z$S)Z/V+^S9ENQ44U.BO>?R[F%U5Q M^%=G]\WQ]I"W7N&:(01E0 CG1"( K)0T7J* @41V4%BS>YZW1]/#[+>X!>;S MX63\/]?Q]LZ'U9FKSJOI]#YIO!T-QMMBAA/HM%P^.^QW7G_8.MYXB#9H31O, M22,]]MPY (VU-M1IQR2Q1D8>$2]!&_TP]M?:;+=WOOM,!+M(! \J$$S5O;6) MTI)3Q(37X+G4($%*C;$" $Y?2H'HGTW!5:?=,;,"L?6\D4>,[D+$5Y^>QBV: MQV\LAI=7$=@IJ3R9G45BI^+T8C#^HRI^/*ZB,3J95X7Z!A[VO>V::N20<<

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�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•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

?^ YA,D?ZR3.*RDZO&X2;XE40&=<<_8I#R-XM@N>' "*QEQ?,,](%*5DO MMEI^C'R UM.F#6LOFVHMKBD9LRTD=/,7Y:E7GLO $/'F' MB]GOO.?Q\22Q2H)S\[B%QU][-,8):/M&]=N>RV!&O025=DS/ZW@$P!NZ[(8/ M1<^\39\OPQN06P7&&T6K"[FX%J*I(W\?/_+V9C% M* M%E\4I&GH(%O<(])]:/(1]FP'%Y-F]>B[+R^>/]9!3WM9PH)JJD$(2"B KWSU MH!8_5D=D#K["1FL [KB6>B/@>$%!Z/II&.[ M5'3%SA%J./AUY'/1P0B'2 FI6![ MT0AR;/P9^ZH^'6;"]FN'"7X[GC+^/U& MP\6%F,*KNQ!WQT5BQM3>=KJ"#EIG]OZD\34L# $L>:O,41"BKKXJPQ2M!Z(F M (OUG!8[-@-106R84)GKDI($Q%@E/2PBV_WH 3!.))O8%E?-&W(L\-_!3(XV MD/CYL 1=K6P,W/M6:A=3#OS9Y1\K07]@Y5RY2__&(VSMLJ\T.C"F1XA,S*,& M2GF$+V@_:X=391 -B!!^+Y5X*H=UQES[,JAI TA:022,N^$ M#^4.U\KY8GRM$81KY"\X0E). GTN+]+V"BE*0%\_[OKN7[YN(K,W%=B[*+$O M<_=T4!1>;[FKT+:&HQM#Y_$<,YM[NCB@@G:=:-< ,O#S&8W0YGK M/WR Z,_V*J7N2IC$11@2DE"*H=%DWQ3%?K%LFC=JO5'#*Y5507!*+Z5@R+;( ML6PJ553@D53.-Z$!7A=7I40=](9?>'9C)MK2@DMP3PN,F;%$C#1&T$[#-B,\ M";+E#/-<@+)16D_;DA1<7E&:71E-1R&+2TCEC.]&C%HGW=-='3>GN>F"(/ZE MT]')WA9+^O&-*PY6Q1J5CNN"\CFND:PUL*1HAZ MW[F%MQAP^*8-C%L5ZKCP6(JC1KP&B2BW/.P!KHV]#>&7;(DBNG=$QX/V0/,8 M,1R6C3BUR,.$4U*3)9[,-H-BD#<0()#?CQ,\)DGL7 M_LE*7*\\Y2UR[6PGNE[;]YC&,)E^%!4]0_WH#8]OX0%CKV34="2A623E65GA M;!KT)DOU=ELG.V9T!I_QH!8G"2#*IE! M0D-'VH#8VX(6C,UT$H8]#C6)HG*MMX?N=Q;UT[E9DNYSGJ6YJ"])JZUCUUMA M2@XK?(;(3D.WK+1N-=KIA$/9=:2S/I7A_MZ5PTYP(&=[;F8W_BU;DDT=L^K^ MCEI1=Z98/:*-&"2'H@^#(253BG3MTWDM#SY$RA ,7]5'R42$UJ1BF#96&;0) MM&)-2>+(K:TGH;[W00L4K7U!+A&^AV=N7FKC)!,GFZ[<9(R:GV&MU+O#^E5%_M$%51VH ^;.FER_ M&O8@5\4!:Q2O3$Y.$"NQ2ZE/20XWR3AZGV.4SEF,S&+ MY[&R=#,PG:[Z&%]^<<&F+V5GXZT\0YP[VMGN.26_L-$B;A&H$19H7GA/LUS6ST6@2@\MB;D_)KH[PJC+ANYK; MJK@K4*EY2XUI!_WQ9-7%1!>5EABWDXZM3FI$,*&)@YD.9Q+E>?#@.9^]^/K; M+SKNNSN;@V<+_4B26*Q5EEGI\QUT&<.YB(V5^GWS$8_5+3;W4<EF<]/A M4?E+D1$B;+,!%'HN#29RK#M@IDNH901/=LJ3,S9*6+4?/$G =V0R.ICGAW]9K E/[AH3 MUHLOBA4CZZF5Q[,G3S\Y7WS!&*+<%B)S2)<8-)/YIA@6:'L#Z&(IV@J^_O1P M=V$OZ2(6WC,3-Y@4@+6@!'T]=RDP%KASZ-84?SN_73<>>\5,<8;!YAGD7KID M31S'=ZDR/!E1G[F]O[N):A4!7\.YHFK-IUYGTP93% @M<%U0C($HK4]F,<;T MP#1,JNL#ABXR[;K:,(&%1F9OAW8&5"^FT](EI=GG %QDL'Y!CB#VKKM4)H-2N6S]O\EY+B.XOO"P)/S@ D7Q$U._\%!,#T MY2^:"HSB*"YF&F#)1[AW3M@OXQ\%-W9E9/I09T,COH]=]T HPULS?@C06[H!M*V;4C]UMBZ+!W&==)T%^[&@J( MN=OP;UT->]SIJ(6[[/+(2EL6JWR0MKPQK(*TP,Y\7F;_YQR_V\'T_!RK*DAP MS6[[71H]GCF]A*4[WK@KHK.KYN*A%I@$2J43QMCZ;R?.4ZB_R= MK2 ?<.23=1.,P%57\7M<@0[WBI/Y$LT%^LHWP<%"YH]"6J"J:QR&B"S+V< MEISCR[K+X2N7-35K/)PO7DU^Z)?%.ND8B%U;'2N&3-8^,D%H,@RP5NICDG@4 MR[GPV$,'T0 ,#14^> )=(RT:WLA?K$TC=#9"#,;:FBT\C1\- MOR(P:_ &.=W7:U!58EA8TJ*GXF_I?)P^?-S+A[+G\01J!-_"%=3*Y92 V3\P M>6C'-2J'(SP4#/A'O0 MNL9J+JM#?*N9!>3_CCJ$SKS!/Y3W"2-EJ$>G0%)H MZEZQ$LBD)R2_H>O0K+?<<=Z4TJ^70WC( KV'9'E]-Y2T^:]O!T;BA#=^_/W9YW__B*FQ3*>W*4#:% :(2[^KT^:S9G85A]X?1/; 0>D49^$Y !DF+G MEB(M73\]"B>D# C:=@U()_9,$*U1K>:F8A4+XPBT9,H)A,N,+MD/ZLA(P!P6H4:.:)6HD*#5S:R2)[?5/*:RG MPD/C*'" M!7U]*9NKH/J+V ?1GLT?904$BA(7 IF10'>R@CXP#?Y!Y/95^IX M\+VY0\273#PS$XNW^Y(ZJ26Y*.?-^$LT6H?R,Q*A;YLKR2,]>?JI0!S 1?4@ M3?=-FIX[ S9P,AS$ L;(W:&VKCI0Y>(<@+97:ZG M0X2?X,8I883@%5#*5%*J_&9O3?8:/@4<*:])3VN9Q"2T,?].,C.Z/CF25-UZ MR;FJ/OK)='K#AK< #'*KZEB)%B=Z'9Q+&D;3EEMNIJN?U.$D Q-#'S3+*RI- MSK@LD!4#XMZQM"O#:W3,&J^+:P2S.+E@#'$<;KL2#!LQ1:YF3&9)3?, MTP)5#&.\.)$P"HO)\P16AW<_:*/[IHV^(M^V7/G"'3DX%'5Q%8BNOAGD*45> M=Y$.(F6 V,I#?5 D\=>#I)&RHQ29T>.RWG$QNAG+ZT'^[IO\O9@$>4"0O\%@5@YNF MZ S+PS+VJT) BX-0AN]]$-A[)K#?4X>.O="VB8K2Y(EBSW?#ZA)(@[P^9&JJ M<$1+XX*IJ\ -Z[GY1Q&?RT5$BSIO099-L7>XO/5".7J(E"CO2N;=3;#5<'#I MO#A>#;K(Q<\5FZO0%./#_7X_Q94R M\4^>7A[/6.I$FZBJ.\BK3M!1>;!;?S MJ>H\V-IDUVL.1J31UW(3?B)CMZ,M0$@G0 YBO8BID6\;"_^#&NV2C"+JM@9&R3 MH3(#9<*T94O;]F U[%I)XZ+1W'*%S1ONZ;:_EGMYO;X $**)- FP ME*SY]6_E596%@Y(LN4W)W(WHD242J",K,RN/Y]'%[I2+GV58M7L=0D]YTYAU MQPB.Y"Y0HH+P 7% E03UHDS2ADK]EKB _IOIC*OMH4,+4;2$<:STX&KX;IRZ MA^?7L_=+D(>K=2))FF97DO A'I)5$&X$X7RX!VT!#-0$=V4 M!Q>':02H94N8B4?Y'U(7B]\&)'$=<;%X)$F."7Z;H%\=A?B-U7H^%H- 1Y/A MX15JO;+?2E"C>!NY>-*6>:S,RC6UBBK):$.ML#1 O%AHM*=87]F\:A4%1B=/ MIR NI,MCS/B73HVZ=GAI^S(G.#.^[R@#\>ODV=?0;..56;11X'C$8)/#.1;K M46=A$2_:G&HQ8IJ(%-(UW!DUZUUP\.*#Q;IN72(HZZ31YA^JO5%M=56K4MTGGC(Z"0> MR%>QQ6?FY"H/#*@W$42 M0&O6@#K%;2]QRWLT4 &"GXCJT;6%1N$LO*Q!D*XEZLE+5*TR4 JQ$Q?WHLB# M?T=L$9# RB<5FC-$Y,*#@ P0PAE_$$ ?P74.&#J;B]%=2%"D6W$$^@:=*ZN] M/Z&W23$!_\,)58UH@%7T1Q#N3A[%91L"0@Q16NG1P1;^QN8=JG!GIQTC1% " M0M5D0)_[ 'O+U).-D'*:Z5SK*PL,RE":!P=#&,(DS,2*A;/!XC2=#U))EB+A2: M#V?S4I7M<-&/%H95G%H5U0'[1U7NN>K9#NZ."Y\JII?^HS%01- MJ1$("2N>BHJ28KX0X+8P1]QPX2>ZBWBX,+4O&%P2STN06W@K!;LL^02(0@!! M-L95[7@P1#[DF&/3K.!1X+JT80-(OL$"V?E-D*LBMPV9@G.*/O^BF0T#('87 M-#ZS-!OS<#VZU]^ MN7"_>F4Q;&2/L#6NK;T(V_#-=9K@$1NZ9AD+*5-C3CB]S'@DX*4"*")]T!M, MP!WV0AH'L5C++7A$UEY)'8G%XA $B+P8YA^ M ?3T$6$ $I8@#G')R'RZ(E$4CB!^^;<%_#@I/!47ZYWE8T /J3VAFCZH"05. MHR(9W@,61&OK81:UO6\'25D\&2-TQA M6V-:>0U:6E8#S=YVI8/#U@]8=+AE6R8-]HC&$=BEE$^HQ73HC@3E2T4^\5=0 M[(5M3H(D%0AW@'@6"XM2VZD]\8%KC'P2;?M*.3-03S1."!:XZ)+ M_37PJ=D=:!R!?-)X)>BC1%C+5VH&<#MKQS_& ^6!R?K+R(2WLGD34(46(Z#1 M =;%#,'*9")\4RK)P5$S2@H!LH(I\6E"7B#@JDRB", >+*\;5L3$D?W.W)CT M-OL$(=P1,-(X;@QTH\Q3,!GDV0Y!LJA:WP=8%S2?!N4'9 M< J%IXP&HTZ/?C "U^$WI$>K393M56YZ(-#J6 MNG.C1!4+Y#*"W:"@'MS ,X@LHC)KO*&KZSW7]-$E%+]7)>^];;J:*PFAX&IW MA; F+U/B]+,=^-6HQR,Z:K_%^A!JUJR&B)!J:ZQ6\,'O]/D\9WRNB7E7G(+; M@]&O="J'7L>Q+)JMP[$=+B@N8M0W0+GE<$&Y=NCO3P904L1$HC[<(K04O,[V MW<5^,*/*'1:._E@D#,(7='[/S-YWD"@8.;5T9$IJF;5JS#!6O$B94: 21=% MI,;R5JA/.O-D'L,26^!8 .DNZS6!UK\ S%D(>*[,CA'*.I?:MXR>='0'&]9R MBYW:%FMJW&(J8R>DW=MH'RODO0*;@D0?KB$ M>D3S#O0) ,8A*;ZP4T%=00438C0/UE6;HA@Z5$PINH?RT>J(&6!=T4\X-$9M M(OWN#*U=K(T%I;ARH5(2);_NEXXOGEAN/"BQ)F228]A+#]('GO^6Q[OX MO#S?33/SY@02K.;MJIRUT1?PR( P)W$4%B93$E+^0G',,E8OUMBM*J\ )SCP MZ NYPV*2S*EYS_QU!!V:R<@='#\EIE0-JPQR/$G!!*)A@@850]TTXQO=#^NI M;CKT%5V$10F@!3+)O_'2JGUTCHJIA M=3R(7W61!=X+J+F3K@C)%80=&FPV'N=5@&P)K.0VMU\V[7^U6YG TWZTO&V'&PERO/RO&)*=^U[%&'\L\ M4K%[@X^AH^EQ\2RAS;"WX&H/Z4K=A^$2> +Z_R-&6Z0O5*#:&)#D,V3=(=IJ M0ZS4(-@[V-\.$)LA%>ZY?X3E:++Q6_@5X.S-QP(&0[',='@@F-PQ' X! 0"# M6""U:(D\C-R7A^]/#HM7K5LR-*8"7$/X)JD,XWC$.;/[%A;\DD<'3Y/?<3Q9 M_<8.U4-2%//I!$5Q46J1"6G\-K6%L?$Z\#V@WD 9H)ZRHV-!L(JQC5#]8]-B]+(4X##H[ ^.,8I:R'# M6YW3\1'N&J$;:5VXG7A@H)P$B#-J@"/D+:*[_H/I0N*Y5C6#5L+OU=^#)9@$-WFV=? MTYQ>&^H^Y)YLT1Y"Z0+?_:SZC$]ENXVTG0*PMAQL>. '=/0Z1UGVY14=Q^H* M.[R;ND!"0$[V*(+5B#9XK>S"9MAX3"E% MAG)U@['-NZY_3>&L)JE%6;5=QD/74!M)-E 9MH#LE[G-A5.;?4(% P+D6(XU MN*YE6G?@+R\QQ6KNX.%\TCG_)T^!OT!$'9PG73@B>^]#M4=0Z9#9L%_GQ">N MD>QJGPL:3PYB, M5JC5*2D]>L?U81! L!6#[H;1JV:-S$70N+<1,<.R!(!Z$,O*'?*0OT*Z6[:R MR@38XZNDQN;JE:.4%%()BX[F.+S*O>*WOQ3RD:A%T"39,&&V, TODP<&4:CME0+ M%3BB@-X>;OJN;/H.:#HO:&,%J##",I5G^@%>>#::=_CAPGU.%2#+'N''X(?F MC^'>6D54NK97K:H4?B)!IDF91B$:JVT<>*T6W Y<$2R$<^4&-MR0+=DMO ?"8CGF2S\:^-;Y\8#H77O@:&!"4I-:8HUE[:P$BJ@%AC. MZ.UW-XSCT4$<4_*";.4,1(C('K^I[JMZ_L.??4<162GC")GT4;G$ N!5#N8] MC"%9KN*&>JC+X>'!27]06CAP2XW**Q MF$O-E496A7H%JB5PMP100W3/0)]0C&,"E_0%!4Y]E&L(N!9%G"LU%' IEL D M-OF*%N2HP>JK@*0^4:H _E9BWUN#D9N=7[(\SI!FKW%\Z-HIW\D?L+/UM8)P M3\ >/LZ54@R89$$8*TL'V[*[HL:;2*9!Y',.J7%=(S4%R=VD'A#S8I*D1P^A M.]MHG%X7W5QS="BNV.]V>UO[@ZW38X<'2Z4';15+"HT/VSCMR#$7:(?K<':O M8]XA'+>YH,,=&6[^[(M)^[53]DJDP3 6A"5G91O/XM#<[#09K.2!O&=62ACU M^7"+?@7Y'VX?A,&S*J(?A??45MXR#IXH<5HC\W)(!AAY@@0":='<"'S$"X'7 M"WZD+8_XAJ'ZF0IH511(\"C@^$)@JWSPUNOJDI&^R=';RG#NHGZ^\QE=F7J( M_74]Q/>IA_B3ZF:Y71Z:UXP42H+R=\R9>4GCRPR".ZSP('PSSL-93(3B:9HM M,"Y'A'KQB.$2&TL+6QB4.=4J;<+BGHT@A>-4AD\9(U^JI_O@^P&E?>A$!56W MBS/LJU7>_.(M(#O-IR%=3.:+'$(EE(N."[/JTG1:0@OUI:UL'R'D<5),)+\/ MG'/9HC"*/L&RMF3DX+,#KT3= 14T@!W@I@?.*#EP>IOR,VMLI@-YRM05P+C? M, (]U0!:F3#"PF 8 LDM=T8[7IM1\W"]&:=9I,//RFD;F !( B!E8UTK\]TF^K]39PC;A;%4:3VVUOW(HI:Z9 MG 3T^2PQQ\K,M:W8OZ$8%^^*4+?FU?S+=39JF'K \PY86BAID)54M(4'P2X( MGJ\IH-RQBBR #V!$5?=P0&:Q8.2B#,5IDGE2:&-(:AP3N#WCD:+E5XV2ZIMN M%Y?@F:NG$AQK[!,%@ G@6KY\5B$O8Q=QA39="G]EK:ECP?P]T@J=JEVPU'XPRA2ZA+7%@\KU&SEIWJWW2.JR[ > M/BDVD1OH= >IR-PP65 XX%EHF )DI#179!HT*OH9'C./9KO9W0K.? M4?;E\@ER"LQOM?*;12C=3'5K:OY>PS0IDFKDP4F;.^P\LTK%,94*)]SL7,2U MB(24%DH%K7JT#8!8M49H22@."N7=/5T/5-/NQ?H'35>D.L4>ULC("FN29I$DFCWVM(-N( M,AUQRF9N3!_*3C:W.1]\8>@'M,T;T:E AH$4+;TM ZD_X5J/E(KH42=E>427 M&WM M:2E'QA#]C H\EC9%CL(Y21Q&2V<:Y H_BPH!8)-"0/2D3Q6(=N6O@O\C]N;@,:8:18HL@KWUDNI]D0VZ_:M > X.J\QBD&8*MWQ1D1-E>@6=Q.*[,R>J-!%1XSGR08?^:> M@Q,%W;-B7[COQ<*(FE,&!W(&LQ4R#:_VON9Q2]_[RBS$B[>G3!C2$@W#UAZK M0\SGHHQH%F.HW6& =/:X[5I1F$;!N%+4Q6?_0G\!@/]1J5P_?$UK'"M(AU-B M/>H-YV]!4B/X\J(@HKO0W^)J(Q7YX7RE8)P*[4+PTYN[5&U'*CE;_S0>UK^2 M&4C8+Q\OU"NLQXZ]VEC[#>(63+2&[("+M8P(R ^46*N/(;JV;Y'! M*,JVSE4.^4'73$H%Y?/)39&8%T"O"QLZYJ5$QK,1>?LWH".RR@:Y+O=4RN # MJ\!JDBGCD.L21/^ \)*KU-E3I$STAD-S05T?CHW'K\Z[DP Z^4) @G=)6YZ; M@ *'04B J?3HXL3/M]-H]E&AT\'V*[$Z-=K\4AK]Q62XICLX01'F_#CB9J\. M76+;0)\=P0%"D<6544O-60(1@FDBSJFK M>ZLFUX;89>[2^@O71V74$;J]KC9!'KA*)HJRT'E,]M[5Y;C;6'TYR.@+[(+- MD4!8%NI!ZEZ5YSU.%E!_7$%RP")#YYO"91I5D%E4H^R2_/F(I M=R2XA@3!:' S)W!2Q^AATSJRTDTSP,OO'+QX5.RM]""TZ"HS5%_>L/#R!WI[ M2-WR0'7\0%'-,C,9M:^DL>I>\9A;59Y&21\;]#MP$*J&"Z*9E.6S\]!-I>+2 M*Z@IS]<.K[(D\NJ>W-HF'MA)72BP *.FU:KXGXK!+]2-D?7'*D[K^"O#,$ZX MQ=1&IQOF:]V0)0K5F)W\TE[%VZ//YBX(^46IH- =;[-98KTR:$5KB! '')C M41'LA"Y[MC$S+9L<3C3WU9;%1@U!J^W?B>GR M #APXNUS'(:NC%(P+7D?*-N>&2,VHG*=;%Q>AR!&#,"!JX* G,:;61A',\>L M:DA1A!(QR,) ;>0,D;%KL"HF)$JIR;]M:5]@I>0DZV^*Q+),R7HTV8;-HG_&1Q\ETJE)\&((C7 6HK; 50LV5]0EW3V,Y-6V@;/@"LKL5:6%F ME$R/"4DG6;0;3E@@_CT!$[I?Q -@XXQ8FW,\:52[AY18DZ=\?RR*C[ ME5QQ;+:45G!0 )8^"E(JEV99*!&SF$-52P'+/\P(0P)KJTK> -1 ]N/8[&[^ M&I)A,CY"$BVP8U=!+DCAX#B.*!2(<,\2(L#R>CR&CM Z(-PDYOE0ENRZL)6& M-JURN8 X,!Q,29-!$R_>H\]%^1#0$A:4A*0!+%(E*9.1/8K67@0N24Y"9]FP M6G(B-< @K3.,26\X64&CA'C:HJH"<=''Q(Y2A,,, ?.;WJQPE9ST\,5):5!/ M?IQ'X&"DU!4*P<%HZ:W[S,(J'7K".F5\ A @/+;=2<9PY+ CM MTS@11(J*[Z;*R2B>I>[8<: #015M:Q9*E@W0C,P)FA+Y/)1PZI"-U,S2[*7^ M'Z;_F NQ*DY_<]PXI!(O$$5S+(J24/+!'S8GJ"B]A6-PWAL)_FLQ8PW-)\7X MD!PSEE"__@VI!3SI&\+:X^%683$B:!V4[:9@$=;!+DN%(6JXDP).A 64!Q # M-@OSRR0E,SW$L,B( VZVNR24F,?*["->WG34V;GL.L%V9&YHL?F7EVK[&$YO MTG\E?Y!GW$'S0SZ@2L"%E5L>;QT@L8\8DS&P:;[!GJ*6M62409'>#]W77Q??2G"RQK2-L*(S3KQ*(7P>IL$+2"3?3 MOYLU2SHG0$MI=RNP\F-D[#W@8QNW[1A*V;(\3VIA$CT*)GC(%7D7^G39=ER53DEK21J&>'NK!8 7G=AQ.<,(N6 M2-,Y,KK\T/AMMZL1VZ1XM9A"SIMU?X/9P2Y']Q#T/I@#IU4)H(=W/3%?1-2B MU-598LUJLW[ #I;PVFH&JS"DCF/&U6SH^!J'%+>C\@T+">O/2\^%G>&;.=E+ M48H>O> X02_)N%7&V-%-;SS-L@@\I\S/W2&;J5HYFOM+G8;T2JK*2(\2HUI>9;ZS!P.<$T+K&2 M3P@;7-%%/54BG+/D"5*S:/TUCOL!BY9=#DDJ,T=A+LVK[M[N$&/YBB_#0#=Z MYGQ?"''X6*ZJDH[ [^!K(!FQOA81HXE(F3/--D"C8Z0K[=/BJC*,PYA[@$>D M9.< 41 1*@5&W^()\T*4X5=HEC,WL,X0"GHRI$9"&'3-S7"??F&[& ME5E#8[%3!:'8#QCOR )X?#1B0D$;..L">#0U.@T*=@!3J9CR;==#//UL%O5X M84[$?X2S^9O.?V?#@K A26/ZP6& .R78[+AS+A&J3WR,CK,H9EC576HN([(K M.D-F%(B]'V*@DF,BH">A+1!VU@PU (P-R+A+D"&]Y-LT)(O]"S,7/^&!R>=$ M&FX>TW"A5Q5/%/I0'^_@#WBN0O.L.5\VT!I0(<%@YR]T%QY/ [CRHA0[F 1,P<885_T4E2&;-?H%"I816JD"TQ"];'=.(<[3(G M*LMD(QPBEY^9%W7%12Z2@1UK@,V'F M@?JT"40-!)83!0[,,;9)H'B^?65C$ MJ0_Y'&KM$934',)7FT"6#&4W$."R#7BP''* ^.1PX\=H"K(D1==L7(!9D3I1 MD L9SUL")"/OLQ+<*ZP<%[ 4-T@;*93CHLYJCG0MY![/C20FZ!P)5F6K2G$ MU@11Q$F].;3,T*]H*9(RN$NPJTUI!](H.1%M;RV\F(-JOU3IFQ&L9,$8PS55 MER!6A@1T4>XQF,MMF!!8S'++>M:LZGBG-O_CWWN[W3?TWU6Q+BV--Q6;6V0RQ.GC=5[C@9+>[+CAY"@4G+][^DP^9+V-CCJ;?52LX5!E[ MB:ETI33J#549X(JKDW0\M6X%$T*2[=2I'(Z@(78.$;VZSV#AF=$3#4<&_VX5 M#X71W2@(Z+IR 4"MS+X#CH!:7=0S675S[X^;*17+N_10_EB@.E7V9VP^E_#M&9Q[!AB0)V"_'E]&7=%")"V9L862 M&MY(E;BJQ"><8>["-3LQ&T(S1T.XF6O@7?YODSQ8NYO!82O%[X71AL*L]B:R,0L6EYN$\YJYOM)<6 MX)\64#GJ\DS-" ,)3;LUTG 18>&_1'U<2$0*;(MBP?=@A)-BCE[NPZ;DO)Z7 M2'(44_@J$ZH-)HCE<97UN#)W]7@;B'$KMTK-K3THU&$Q@9C/]>K MMXH8OU8P$Y3@K^A2K2&K!T<_H%JA8&8,N 7#!=HGM9*!W2B\/ZLJ(/N-N+*' M%Q1TY:8' .Q9YG>TCTTBTUYX%!C(7'BZ/9_%J7[J2O'*K5R1EQ=+S>F[MM;> M6'0NK )6>JLA9^K!H=&OK$V-LY'Z,UH2MWTLZE+/V7_LR\HG;!OZQ#BR9@8? MKJ%B!>LBQY@9NJ#*$W,,5^7%WL+)>&> K$6@!\O %Z-0" &&V+4 MXHLL1_&L-/RM!>6Y"@J6KG'^I446A'*2#(Y'USHD M'K9B]GS%3,;$_;L$D=<*< #!2.-9C/PHYMUM51!O*EZ7SHN"H0/KM@& M_@J43URDQ &^M?@]-_%3%;H%N^[0#%=(%$WQU&5>YQ'S:JPEXKE)!.-Z2?"G MDLB58(^M1\)LF/&],9&E4+PKR#C\M"(>KO3^)+ 6HG[ 7.GV#FZL 7W%660I-&B*/.;M2P\-UE0146(=.5P2\85>$GT M>!E88"T'STX.6N R- V&"Z5@\[@D^M;*X;D*!=I_\00]1U)Y"E1?=?HKU4X+ MW528N^+PZRR?KMV(9R<=3'"%I2VN+;0J)HWL-KI\3\HJ+4\6\09A,6%1*W&R M6,F,QV3^]0X>W3F<04@NA"8AJ&G2E7N(+"UT1,BK;-Q>]?S&5NNUO#XW>56N M#J'9(GAL7!0VEN)J3QTZK3%ZA2W4,0(23HT+M': GIUT(%M)P1?A;*P4CA2_ MQ86CDJ5BGN(-:(RU*#PS4:#Z&.$$,S=A76V%3C!S$ZKF3_SC))M&U'2>,P6= M?8P/$W>4 2V*Y9W.\FHM8UV*?FPU+9/L%&6@F,S)EA;.9E/=&=?X62>1H@RU MVK10M#"G/ JE9P.M5/G"L'K?=K(DW6568+%VLBZ(*:J$A]_UNPJQ2QLED#$N@J^B^ M)Y6!=7Y1Q\Y1@9%L:_&AS#Q'GLH<<3Y90H9)IN!B*>0LEP>*4]X$B$$AG"JZ M"] YE]=&I:Y,02G^J\*& W6<5HA@G* M+#%A-HR\525*7V.?+8'OG1>Y:%UE:?OBIMMK)+T%A2#6 8E>_8&HIB < !7H MTE@(WYV03:AB@(AT9)^P-8T[ES.%+@Q;)T.:0Y\)#\S\NAA-XF@QA1TV.D2Z MEJ5Y>)3DH\6,FNM8Z9"1:U31%I5 %0Y#8Q/Z,3A5//IJOBT]D""!(7(U>]J_ M:)0J7V'17]X$;X\Z;D2,C,3ED8.U2,;_@-@D7,:+X>=%;S [$; MTCFI]>N'34M(-=O SM:;.825 3^O&3HU87.MMI%722$HK-UUTEJOD*=(9 M&BI=UN_VNV*'C4%!+240.:V+4P67W2'8%I:$%.1K"H UB[2LOX?Y!-DD0"MK M+$VJ0B786;HU#"R!T,P:2@6;X$)$B2Z3#;2QZ A'OR^X+Y?T>7AY"= NQ@"G M"^'G=M+N23J:K^D-'-#[S5&0WR!O@4XL5T=,;ZCQ#)MF726?':PER]&#J%OU MRMN0)UQ!;S>.4!E+&)#[.IJ\JJP81\3HU:28,/Q)DO/-9DI;9E_5MDVTUDW; MVWF9"2.R.6'&+D. ZY4O>@(H8I8?F-?)5U\B@;5%@S(DBTX(G\86L2VH1>*6 MR*C^)528Z#>4TK -FDU1'>E5^WR_^2&P8/(E)A% \)P;<:;P*591@S' U:"V MV-;&=D*D+'+W?X45U"Z2= L&(*0X M8K N.Z*( :RJ6A'U/*(_A'FV8,Z6.,RA/U4?2_Q^[AHMPZ5G]M4*F8K/EE8P M8*:JP+\Z%!4)PYURL)S,%GEKUQ\7=7BFP+)/2D*E@V0&325D3%4//=\%FP^( MLI0<1$$4*V2_T.-6PVRY'=2P)_28?3S=-H>@HOAO>:(L,<:%[%?MC4JZ35#M M(Y//$C%:&2EJ\*\.P0R7X1=D42 \DD*GXX!(#) IHFRDX#7H&)^8"1D(38[QQ;(L659(8ZKE\TZJ/5UUM"]B;!^JW5FD!_*46&X/6$NH'9A(6#:NOQ L(3N,1"K0"0Z/'%N"2WX",$M M2DR4OC6\ ?8(QLDA Q/Z 70I@@>P=D3NPR@5H!PC@>QT2L%)&,OQ)$SR6<@1 M V2V =D Q0;&*N+XNJC 6?A[EJM>UWH@GA4)1U^\*) ")6X5>2S 0*0>2!$ MH95MPD./E>@A9S!!/!6._P)1[RT?ST4\ MRJG*'-Z-V [P=L+X8S\!="B@0<)?HZO00KMSZQ\/HXIATC+U"6.%,F4'=1@B M^HZZ4AA_8QSGX-M:_XO =BC.3K=[BI>A@@?$E6J^!^:3L7$3F!>W]]4%(^>4 M*NVQA([7L8"#:QNFM7O"(R0D1A M/?&4"J&4=!R1"N.D$#5(6#L[9E4L3N-5YH*FFQ5M"#D+(S639)@@PHI#7&+X M[?22_$D4&P7<-1M*+@0%&M9 +4EOYR\59)LDMXA7[7AE3 MWA)I C"RD-F5! 8OMD!'XSB4L6'4]\MOE?BT5/0+T39;;Y5KY"\)?T?&[U3=3^+G'&::NQ^!O09N9C2-< ME.S\626#5\LA;\-7XT,B4+I1LXN9[3^"T&!D$8S'-B@IS6S^[0]!K6M+WT!U M0A3*(*7A54;T"/@>V#PW -LQAU;%-8>+KP@:'DRB5')8%JV5V5("*_I>&YB0 M!0.<, (MJV_BZS4RT+.J>$)2#Q?59/^6^D>!Q1P394R3+C0%\22,EUFEBK^;6$_502)K5[) R*$ZG!.M=%"C"7$\RJ:-93CHW0[4KL MWM^Y:_I8A:S>F>MJFUD,[A'Z8C%>8J#7A<-KR;ZG9!.Y?,&=+:1IL;! 2&_" M\3A, *<\&Y5 1[?96>6:8KRS6==R@UQ+=TKI)@;1UA!!ZA _#.)'XH:87S#Y M*\"*+H@:VS*T$JN*6R2'M0JT'Q@^.A@,-"40M[$)4CY^BK<)-X(V$>X/=#6Q MC?)"I@'E165!5U#G,O]N7EN8*X@C 9$@(KOHO+$J^$O@Z'BEP;]0 *[ C]B" M4,C^^H5"7N1++F%1#'2]EM@,J*\.NW< %/8:YMC(8_J@$/-A<,*<9Y;1)+3-1 M= *52SK\S>T?19&-J+-$$FO9]$HJ8W@!7>NS%NE*(,N1.0*\AM\)TJ"0PTX2 M_>U%L;.WVST[/MS9.3SM[^P?[1[LG)YM;_$;(U_VF?JP?YEDV#/77- ?^1*KP/3CJ[YX,!KW3G?V=WF'_8'"R MO[-WT#L\/#L\.%N?A<<_"X-5/PLG1)Y3='Z%RJV+.(6Z1W<&GK*\'YYU>]V= MP5EO]V"PT]T^.]CI[YWMG>T.!GUC L[VU_+^^/*^O>KR_@N4KER$8V#,.C%. MUS3#M/QJBWFITKM+!'[OL+MSX.>4?E'VT<'.R=[VX=K M@7]\@=]9=8'_@([U.3*:A@TCS?IT5), ME=%*0LG,:XA(6QO N!C.B_BU_%";L!-B\Q%8Q[^]Z+]H%UE^Q?9?E(#[?]O? M=7^[7>:'65EF,U^4^V:5]++I?]/GO5]A^2[^YD6;CJ]L[6,((#X]BD>R?"MOLB_>-O?K ).W&H3O\>LVEVV MZB%,C4_\QJCU+'_][UW\OS>>TQ.3GK*NW*0LYZ^WMJZOKS?-QS8OLZNMPWPT M2:[B8BN.+L-\*PK+<*O7W=[?WMO;,L_K]0X&O?Y.;W>[/]C>V]V*>KV]@^U> M%'_M]S8GY>R>:^R/M7$Z+]X>J@*/3U+@\5EA.,$?/D,G /7-'5[F,1;O!]BT M&G5";AX;(5A8IS\(.OUN;R?H#./R&D"M;'W41Q^0^SP=$>7'(:2 S2LPRW:Q M>;@9:-R?<3*5K 4FT$Z/H7SOO\-T 45;>_BV71B%V DC6)*C.ZZ@6G M>)Y1M^@9- #M;_S?SLNS!&NV-SMFL3;ZNWO]O5>2^4@*O[4.T#D3[)W!UA2 M=]GL?#1/E"0B9W=H/"^A]7HDF?P0XMW J_J*TMF(^Y5Q=Y)7\8-UXY G'R,3 M=SI&.&,LXH;" ");_R#?E+>[A]+"%?$\A%%S)[NLX6;#)6!M/WZ"N3XC^U&M MLEC;CW;[T?]>]D.;BA;;\&%49F :>C_>,O37EF%M&=:6X;E;AFI\>&T9VBW# MX,^P#'>[1*R0H1BL#<7:4*P-Q7,W%-MK0U$Q%#N[VSL'W=Y>M]O?WA]L#6=Y M:A[?W_U_VP?;W\M2G"6YT5$8B5H26>KU25$'HIJ_5^B*.H:)!1]%6UW!_L[ W.-&3P@P-4?P?^W&2=K68[]=MESOUUVO-00W.4ZLDAC ML7&>NA_\D*C56GVNU><35Y]//#_P_=3G?G^_-]CM;T6[_=W>/JK/!^27EZO/ M1B?]B!!^'JXT+^)YR<[[-FK.?5]S_HA,\%ISKC7GBFG.5IWC"LONH7CXW[UN M;V/0-=>OWL'77O>/;U @+][VNIN]O[8HQE<]=FOB+3 M^.H'!E?3L<%/"^@&[PW"C=[VR_#55F\GHI\LCH9K#_?Q;A 59UNCXJP=LK62 M^TF47/\QE%S_IU-R#U^V%B5W9@EDUTINK>362NXQ3FO_$3RYOO'D_O,GTW*/ ML&YW=N4@V'<7#=C;1_S!XTU0=?C0WF"G2WH->!PJ&6/YT$%WUZK(,!^&:5QL M?/@ZC6]$._:[W3Y#ZOMC#D?$I9X@9F$"! (8_X,!%Q/@?$LS8";Z.HKG%NF- M*9,9QM_A,;:^.E"PA12W'!-WX#PK".0(CO/>&S/]M:9?:_JGK^GO&_3K;9Z_ MOUB%[,PCS^Q_CSZ]ZYRG1%+>.6'.M,X&@]SR[X5+S?Q@SCOCP\9A+MP;YP"A M$5+QT4E8AAU,2 B;,T 2XGO*\+(@GMC9,(XBSH[89X"=H _*^UH11]9:X_G. M]5EIC8OC?SQ#K:'/ZN?P:Y9FLQOC!ABG [% +T:3>!9:;;(^Q.M#_&1%'0[Q M\>&[YWN(6T_Q<3@=+:9T"UD?Y?51?O("#T?YY/3L^1[EMI-\$H^3E#H*WB7I MEV%8Q.N#O#[(3U;^C75D#6/X;&$,VZS%[D]D&;_W7&_?X)D9T#1^"B8$C./'3Z!1:5_?)75S7IWKM[S8@:_Q_[I#_H4QUJYG%M-X,NMMT8ZU22GN^. _3,3YEA_ M:%8CF1D8.2PZ6.YT9^K3)#?NRIPQ.X#:V[SCD@F2?6KCJ9G- G3BR A,F / M+7+I,=4BO7ZEZ3D.ZV)LU#4W.ZJJIMP5&Z!1F(6(I6%FB^KX)?MZH,^.F,2/ M9=V,OO..U^G5Z\[+Y!5)B+EFFUD4T YOSE,V30A)Y2B<8FG#Q22.D6Y0\[/> M;V[6MO#!9 /S;0]#T?RVKPHL# ^#<%_VO^U9@5G 6U80B4%IHS":,9OG\00V MQTCSNZQP-OW;1E!.\CC&U4C--G_C8L[,+R8%^P!/>W^E,U[GP$/L#&#+;OHRI'= M?JXPS]7.H_%<'0[ZN[N[^[N[9V?;.]NG^_M'1X?'1WLGIT=[>R>[>\>&BG&2Y&7QT#VKT9Y#1.3C8W._N='?-16_7S&E_YV'YG9U;\SO; MN^WYG4'[GY9DA99]:WM%$T;//9S\G>=GY6WPXL^?ZR,K\Q=OC\X__'+XZ?Q] MY^,_#C_]B MUYWW9B'=%7#;OP&NF&P_M[/[R#MZ=+,B\UJE?6.GF$??FW_M8#B@(YCD3\+1 MV+K8ZIPY^'A^^O?3=[\_#\'L\Y8,6&$8>: M5OO.^N@$(!2FG8MY$E_&TUF8!JVQET=_MX.;^&_DA ME=@51\I4$ P3Y45GGB=F=',SO+$=:$8#??54B\]W&T+5_^>_MH99=//VW_YK M:U+.IF__/U!+ P04 " "'/&1/B(P=:B@' !$5 &@ &5X:&EB:70Q M,#$M,S!S97 Q.7@Q,'$N:'1M[5Q9;]LX$'YN?P7KM$4+V):4V$E\U$"N[A;H M$>1 L8^T1%O<4*)*47:\OWYGJ*-RXNPV;;IUUD00VZ)(SL&9CR/)_H;/CC\= M7?QQ>D)"'0ER>GGX_MT1:;0,<7QR3WR\^O">=MNN1"T7CE&LN8RH< MY^1C@S1"K9.^X\SG\_9\IRW5U+DXDL\!2Z^(1UJMJN>13!:*3T--MEVO1SY+ M=<5GM.RAN19L='(=\C'70R<_!&%.(6TXEL&"I'HAV)O&1,:Z-:$1%XO^!8]8 M2CZR.3F3$8T'YES*_V)]STWT !4/^&PTI"2F$8Q-CSL]S]ONGAR^/=GO=GMN MKW>XU]E^NWMP<-QYV]T_;HR&#H5_,PI>2J&"QZP5,K2@[VV[+P::7>L6%7P: M]XU=MT4/L665TCP.F>*W1IC#>2YB+$4 4Q0>(9[;]H8.=KBG:CXL#E,_1;=# M+C]0Q6-R&E(549]EFOM4D'>QWUXW7<^S**)J0>0$U M8PN %YCSFBOE:*HC. M"-I2BIGQ[;HG- @@W%MCJ;6,^OO)==6D96*.:^8)-GF ((&8F$Q :3YCA*9H MT#E+-(O&3!&OUS39U20Z9.104A5@A]+*E+S"]I=;^]O;[L"<-I^]P6OL]D_K MN302G47C1366)HF2,TA^Q68\A7>_YDTR ??B8%[S>U!I!'+Q9#%EFQP(<4=/ MJAB!%D2&@&@)PGQFG(#BQCS.I<%\-(XS4-NG:0B=-(55P^$QZI=JQ7W$J51+ M_XID,>36J\*LL_/+RJ0IX*1.T<&IB1QP?T#&3,@YMJVRCRN2,C7C/B/06+,) MY_3V!FFQ'JA'_@EFB;C6C*5MLMXQ=RNAC(2 ^5(9'_0S6"R%JL+D1^CWQY1/ M%[!6$RE@;7'KTG0L(%AA[8NE7Y0Q6H^KI0A(Z,(,@J!<&;IM_>B\&8ZD@Z%H^K!Q-4M8O/]P*$51.P3]F'"H3OVET<9?7 ;ZHZFRA6RYP M?^?%H.QT\]SNW:>V[SZU]TVC5B@T8\H <6%3GARE^46J>,DU2:7@ =ERO>Y. MCRU'P?:-3*H?%S/4FTP]8UI6QTIMR$UG+XG=7QE\/[Z;5]OVJ7D*'U< M+?=.X['Y\N=5E \!RIV'*Y9,]S[7(,I'G/YZ<7&2 M7UR8R^[ZQM]?VR!;0U2V]EO[-\#^1XJC#U3*3VOV< MUS9\UK%\V]BZ=>-+4XN:OP8UWS,:K'[ 9@'3 J8%3!OV%C"7[Z%F<&V.E^+Y MDV#RP3S(MV&RF2"QL>CH[32[%AU_&CJ.J7\U53*+ WQ<+E5_:\+P[W\#F_D5 M^JM$L8AG$>%?OU&!7\JHOFA#(@.O:PS\VN9 MCS(RO^Z)I[8LM=BYV=BYW]SK6NBTT/DCT&F+50NX%G!ML6H1]_O=F&?*/3AGQA33=$F4HJG*[<&.%"8PQ;8)$2&E(%4L+]J'J'$FS\9]@ M 6[&J$]].0F8HW''GF1"E I+6$GT!'H.[%5IC4K,4(>I)6D&FMN2F-TF<#: MFX W/&P*?^XC>:SQ!^=-B,X8+%M%CT7F'.*F8G.KYT413"F-8,V9B@PAV\WX M:V* M)1AGS2)&,D,QF*I6<9"$2\QP]C6Y$M&%4Q7,=-I#O.;X$$=E_7"D&.8 M--AW*>S*]?B.[&AI8FET,S$Q M+3,PU:;T_;2!-_W7Z*O:!#5$IP'/X<)"E22E(]5%?: M[FQQWC%VNONKA/R?/J;6=O!@0")+E+A#B0@:\_.S*Y_O_FS]4\\;7@[9_RX__\[V=]L^N]0\-<(*E7+I M>:/S!FO$UF9=SYM.I[O3O5VEK[S+"X]4[7M2*0.[H0T;)V_[=.GD[9M^##S$ M_V_ZO[1:;*B"/('4LD #MQ"RW(CTBGT/P5PSG[5:<\E3E@F%F-A^UXQ1&->::T_5N&,&3N3\+X1J=2V(IX(.>M>B@0, M.XW!P?. ?=0Z.]X;' M'T>CCT>'G:/.;_NC8;O3..E[''_=K.I/95F*%%HQT#*Z?J?]ZWUS?;JRS%&1 MQJ"%73)CK-$<7:ZLUFR[>T]Z8>'&MK@45VG7;7'-R/'C7@VTX/*.N!M-"_5C M)4.<7SX8MN?O^HN^/N96QL,0T="R*NOZA]E-W<\ 00-ZXXZ>CBXNSSZ>G0XN MS[Z<;\93"=$_W-#&R5F3?0*>MC[QX$>.>/T@(.4BV=[J[.WUFBP ;44T8S;F MMKOHM>5C"2@@9>GC^T:[X<8FXT$U+AVI+^,(5_$84=A](%H$FPTK95,1VKCK M^_NHB$AA0[I;?O"<[(+\A!81<%EN&_K06)4[M$F5[[3=W<-V872]7?9W[_"H M;C^4VRCT@GSVZUO MWH"I"-&A/G,M4O8UYCKA >3.;W:6!KN])4MT#\-S2'D%S#H/J//, /.!&X0) M B*9L>M4326$5] L<*,+M(0*'TJJ,.'B7(X8X>F,Y:G5.: =3,$N&R.(.$MP M1&98Q .\I)E*,(1;5A*"9M-8!#$S.?VYG3\%#:426D BC,3D3N7"5-@8%V@R")R#I#=# MUU2(R\2G@)LRGM6WX94%&V3!WDMA ;!(I(@S@NPMKII( 13'V[IV7Z01!E5. ME2Y^#F0>HD[$;@U$3<2]H$"<(?2(-<0F*6]I42+2W#&-S M="=TDB5RB ')! M(6"=.>/\";B)6235U%1$T7 EC,7ZVS).%PN_T^FMZ^0WR#D]Y\9 MY"\7\+&]==3Q?^N9$M1E=4B!4D61P.&.>>? <\:X!@=3A)V@QX]P8F ("L+$ M-(/$$LP3E"MH' H32&5RG$<91"M9X#73*H 0+QNV@_ , ?%>8'!T$\0\O0(V MP.!\D4N4\/=XRS_8@<(+_R L1L504&&?%CPA_8PB>(T^!9S)EY4-10N&(C1$ MZ[Q+*I2@>JO[[(ER>/03B#*GYWK(W.'O-DR5#;=60S"H"A'DRHVGX=VD2BC@ MN5E]"I4D8T"HEI:*(D?E&A5@V)X(XY(!2D'J]% ?=YM&ZJE(@^0.^V6528DJ;<4'WDHH5QQ91+'R,:K%E M9HGOC@P.YP55%T1K;8Q+L3?E@K)<9\@SXVK'(% Z= ZXAN8*4BP))=(-[T!& M/"81;-8*2B'?1899[I54&R55\,Q)-9IPF;NH3HB#*,(60TP0*V9)JS O!5?( M4L5P>??@.(03,<.8HD<9J]P^[,$J>93/I8$:L.CIMIV-J];.A04H=@+]Z9'R M5QILD@;A,Z?!L$#8?:32@5;9"+@[2^FP1D:A6DP%0:X)C[7"9XG61!F+U^F[ M"=1EZ,SU1W%F!(AL3#6WY$N'0\0[NXLCH[ITGSNU[O"JYB;>95(6<(1 M$4*7/MU^E*EMQJ2X!ED>S-V1;_[C+7H9Y'M!IPL'_Y;3!??U15@1M7D;OBF; MU,ER&\D)[FL4BO?:H+EW'%LAJ[29UV;N JI,$F$MP".Y$]^[U$.$_=8@PD%CBHS*!!*"S)#J5 M"@0@7,NZ:M[,3X%?4Z%4E/RN5'+-BOM^I3H"7HL$9=]=G.0MB?@\Q(D&Y@'_ M0<*4+0Y.0=1C)](LJC6#I9K)DX1K7*];3)EHEQZ6OXQD\*+ _]R[_ $67)'& M\-I$*()+"@AF]Q5=B?IF4:^(=*+D!*AH2?E5^4VC+O,())E4,\"[TU@5F8,O M< HYL)&*;EER74#GSWS1XQR]3L:@M[?\PW9OO^E>=JH<7D_5]M9>I[?Z*RQ/ M+J0V>0'6[6H71!KB$W7CNO:40H-QF6-,9"!;@5* M2IX9Z%8?[JWW-E2@")I/WS?\QL.!H6;B$:D[W!PK:U52^52,NGYVP]Q)+=MJ MNY_%J-'!K:KO77U<:JA?M3X/3;W^._F ?SD;G M@[//VUL(V S3QYVW?OC)[\#5!+ P04 " "'/&1/2=FX+1 ( 2+0 M&@ &5X:&EB:70S,3(M,S!S97 Q.7@Q,'$N:'1M[5IM4]NX%O[<_@IM.KM# M9Q*#4AL$TFN_GWV:7A.:HT@^'IP'@07HPORK]'G M3^1PO]DB(TU3(ZQ0*95!,+BLD5IL;=8-@MELMC\[V%=Z$HRN YSJ,)!*&;[/ M+*N=ON[AK=/7KWHQIPS^O^K]U&B0"Q7F"4\M"36GEC.2&Y%.R%?&S0UID49C M(7FNLKD6D]B2=K/UGGQ5^D9,:2EAA97\=' ;B[&PO< W05E0:.N-%9L38^>2 M?ZA%*K6-B"9"SKLCD7!#+OF,7*N$IB>NSXC_\6ZKF=D3-)R)Z6F/DI0F,-9T MSCJ=SL?SX_?]PU:G_Z[][OCHN'_6&72.CMOG1Q=GM=->0.'7C2K_E)JE2'DC MYKB,;JO=_'E=70_O;#)4I#'7PFX8,=:@#F^76BNZ7=^#5F24,=CVAE59MW64 MW9Y8?FL;5(I)VG5[OH6=?2VHO"OOFC.O<:PD@PF*9T4.6OOM5?/_JJ4AX(CK M[V#J^>!Z-/PX/.^/AE\N=V.KY-'?WM3:Z;!.+F@JN"2_9X)/N 0$UTG(M171 MG-B8VNZJN9:.)0>:/O M-_'D 1MW#P 2TRDGFD\%GX'WM+$PY+><:B""G)-KGBEMB4K)1Z43TFHV?@OZ M1$7D3*C/5(N47,54)S3DN5L)&:;A_LF&1;L'%#CTO(!HNT?4?O(@.J,&H ,@ M2>;D)E4SR=F$USV6M$<04_"<4@5A&@93P U-YR1/K;DT@Y2$WANHYBB3TAH/>RIP&[C$P!E1*%_Q!!PJ$0D/B M &(I# =+&-=D%HLP)B;'/\OQ,ZYY,0DN(!%&0DJ 2<9,V!@6:#(>.@-QW@Q, M4PR6"<\%-F4\KV[#"S-VRHR#Y\L,3B*1 O80QDNLU8$6( [=NM(OT@B<+\6< M&:Y#F3.8$_!< 58=N"#086< 1V02,DS*)54*E)H[JH&-S"7C=93()0@ /Q2 MV*DSSIZ0FIA$4LU,21[-)\)8R.0MH7C3VPU6UBL<,*4Q:]:^T&"G-#A\\C08 MK6#FES?OVJWC$U, O<@VT:&J*!+0W#-O':"&A&KNH M0% @)@!CA!N$A3(PC M4"R!>((Q!=M,F% JD\,XC#1:28_A3*N0,[AMR!Y EG'@@,?EX#:,:3KAI ]. M_#J7(-$ZH(U69X][*UH=YEN^*;!&2#UW<'Z"GKY"*0]QM.71BJ(511$HPG7> M)1I(8*[6??+D>7_T(\A34G9+:-*W3YT\%]S 9( AEY@\#/ ZYDPASNGFP,EP&EVJ TEQ2A_XB'UHBN%X$+^P4 M$&C %J.D8.[4QN1C(YB D@(7('S6YD)FBC/E!C,IYR^,2[M<0%&&@T$6 A@. MRB@^JEQ2C(.P+&?$,B.#$3Z_JZ:E<#7F* BA"L9S]O1#T[-BU_B9L>O1SGV- M9(\/"X_F&O!S*AA2B!J5.MQ1 _3#D@5Y134K,0ZL$W0LI+!SS-$VJ47&.SHX MI'NRKHA62AX79F^+!66YSH!IQN648:@TGB&3$81*.P\ MJ8#Q(H-(]T*KG=(J?/*T&DRIS)UG1\SQ*(+B0TP!+69#$;%("!\1J7QSJIB:1:Z(D<)1D3,70MU^ M%.%M3J2XX;(XR+LC7__;6_0\Z/>L3AXZ_[\G#^ZU""O)6U\Z=8PQ50(M_3M2 M8(L$T P"EL& M"/^Q5"M] _\C%V"^\P-Y&KHCO[:I2ZS^(,I' F3Q*J8<%N,47XW7B\_CQ"Q+."_],_ >A#(A9I<+%U "-W M@0'@[%[U%;BO^SQ&I%,EIQR3F91.BC>6NH@E/,FDFG/HG<7*1P^ZPBI@P4XR MO4TA=P6?/_:+DDNP.QES_<-]).7O>)*WFK ;8W!D7#=")27- M#.^6%VN/;>DI0 0L3#_4VK7['8-7<7C\<\6-K/9U#I9]#WN6L;)6):6YOM5M M9;?$'?"2-TWWL^I/VK#1U9VOMHL9JK?\!K7]TZD\\)T#.# !N>A?#@>?R.]7 MP\&O@T^?^Y?;^+!B,[['8M$GX(O8;BP8('H7'_]YGM[G4Q[SU)_%4UW[RNU> ME[3[H[!;'N9X].2W^C]09_BK*PW)$SHFWX34PU^I/^I3V5>] #\//GW=<]\MG_X)4$L#!!0 ( (<\9$]B**>GAP4 M *(9 : 97AH:6)I=#,R,2TS,'-E<#$Y>#$P<2YH=&WM66USVC@0_MS^ MBBV9R[0S&-LX;P7*C /.E4P":2"7ZT=A"ZPY67)E$<+]^EO9."$E:9HFZ?6N MS4S LE:[SZY6N]JE]:H[Z(P^G@00ZX3#R=G^4:\#%6WNU:2:VJ-3V[#:LKF4&:U%.JJT M7[;,J_;+%ZV8D@B_7[1>619T93A+J- 0*DHTC6"6,3&%\XAF?X$+EG5%V9'I M0K%IK*'NN&_A7*J_V 4I*333G+:#RYB-F6[9Q1"%V4MIK;&,%I#I!:?O*A,I MM#4A">.+QH@E-(,^G<.I3(AHYG,9^YLV7"?530,\8A?M%@%!$ER;U5VWVW%V MW;T]9V?[8-_9\SUO:\?;]?W=O0.OZU3:+9O@?[ZJ_"@EU%H>JDMPME4-'(3/P"6KQCAG]/G MPWDA8"QYA R66P->O>;>1/LE8"F)(O0'2\NTX>ZDEZM(0W0;JIX!:BAU_U!OT\3R<#L_\_@A&@Z_'_3U@NGMP5AO6.C48!IT48X"K H81 M.EY 2)5FDT45TIG*9@0%:PG7/K6YX>[L-G./ I(!B61JPO,J<4%BK"8GH&,* M0Z+&1-#,&EQRN@ _U&;&6*V*\T0C/GE,%!-P$A.5D)#.- L)AYX(:YL;>W5W MMYG!AQE1N-%\ :;3OP=IV1E=7G&#&7#*<\80Y<0Q7B5O3!V MXC?/I:%!EIJ,.<4CP?ER]EW%J>3C+"5A.7[X]6'.(AWC(^HUEBJBR@HEYR3- M:*-\6%/8P,&LK2.TNQ$OWE7JYE*A(_.AKF:7: H1VRBA)/K2W"T,+DP@P'U: M8AA+K652PBU>]A$QR%L&&D_\U;UB^CE9<->OJ>,EA]55^Q\C?W-S-)P^0 M=F;#8>#WK4._\^$L&!;G;;\7]/W>,49)QVU^=G.Z:;_;3?,%RWHA9 MA,[[%/?"0ME;]/MJ'_A/[/'="?#.F//D&#HQHQ,,TQBR-;N@,)A,&.;7G]6W M[#RO2&]%'GZ[2^]:BLOKGAU>_VI5_YZU?^>K:X4KBOR6)=O]\+ MCF!XT@M^#XZ._?[/&EO^-WEKK3+[?NGJ*E$5IOX#V9B3S'$VW[Q MD.>WXO&@K J*X:],]_-FNN=O<(QBEBT;%>A 104:FNK:G)TLKU+OZQ9H"?.8 M827,-%:N'$M=4_AF(*2&B&)%'F&AR_'SJE9?*;Q-N7M5?'=DDK L*\O@)0_D M/S9%>"@5BL];V.,%2II0145H9I""B(618CK;]]3),,/T4W)LF[ M'E60:Z2W]0I6U\#K>4QQC<*R/Z*(?2(5-7S(1"\%1ZA%V86XQ[QOT)9JV38P M%U]<972=4D$5:G1M%F,UCKAF!*&MMRD*XSR@2_!HUUKOFJ_WR_^MUOV+EFU^ MKFB_;.6_H[3_ 5!+ 0(4 Q0 ( (<\9$]\FV82PA@ ,81 0 1 M " 0 !B;7)N+3(P,3DP.3,P+GAS9%!+ 0(4 Q0 ( (<\9$_C M(3U[Q2D %[* 0 5 " ?$8 !B;7)N+3(P,3DP.3,P7V-A M;"YX;6Q02P$"% ,4 " "'/&1/5 [5Z?1W #A704 %0 M@ 'I0@ 8FUR;BTR,#$Y,#DS,%]D968N>&UL4$L! A0#% @ ASQD3]WV MJ\ZA,P$ ,% - !4 ( !$+L &)M3N 0!B;7)N+3(P,3DP.3,P7W!R92YX;6Q02P$"% ,4 " "'/&1/-Q6K M.% 9 P!E*BH %@ @ $)EP( 8FUR;BTS,'-E<#$Y>#$P<7AA M+FAT;5!+ 0(4 Q0 ( (<\9$^(C!UJ* < $14 : " M 8VP!0!E>&AI8FET,3 Q+3,PVW!0!E>&AI8FET,S$Q+3,P M&AI8FET,S$R+3,PGAP4 *(9 : " 5G(!0!E>&AI L8FET,S(Q+3,P XML 70 R12.htm IDEA: XBRL DOCUMENT v3.19.3
INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS INTANGIBLE ASSETS
Intangible assets consisted of the following:
 
September 30,
2019
 
December 31,
2018
Intangible assets:
 
 
 
Finite-lived intangible assets
$
642,677

 
$
307,995

Indefinite-lived intangible assets
—

 
326,359

Gross intangible assets:
642,677

 
634,354

Less: Accumulated amortization
(179,828
)
 
(142,546
)
Net carrying value
$
462,849

 
$
491,808


During the second quarter of 2019, $326.4 million of indefinite-lived intangible assets were reclassified to definite-lived as the underlying in-process research and development (IPR&D) was placed into service upon receiving European regulatory approval for Palynziq. The Company will straight-line the amortization expense for the underlying IPR&D over its estimated useful life through August 2028.
During the second quarter of 2019, the Company recorded a $15.0 million gain on sale of intangible assets in the Condensed Consolidated Statements of Comprehensive Income (Loss) due to a third party's achievement of a commercial sales milestone related to a previously sold intangible asset.

XML 71 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost $ 1,147,834 $ 1,322,661    
Gross Unrealized Gains 4,928 497    
Gross Unrealized Losses (165) (2,986)    
Aggregate Fair Value 1,152,596 1,320,172    
Cash and Cash Equivalents 423,220 493,982 [1] $ 882,184 $ 598,028
Short-term Marketable Securities 297,572 590,326 [1]    
Long-term Marketable Securities 431,804 235,864 [1]    
Level 1: | Cash        
Schedule of Available-for-sale Securities [Line Items]        
Cash 294,543 228,809    
Gross Unrealized Gains 0 0    
Gross Unrealized Losses 0 0    
Aggregate Fair Value 294,543 228,809    
Cash and Cash Equivalents 294,543 228,809    
Short-term Marketable Securities 0 0    
Long-term Marketable Securities 0 0    
Level 2:        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost 853,291 1,093,852    
Gross Unrealized Gains 4,928 497    
Gross Unrealized Losses (165) (2,986)    
Aggregate Fair Value 858,054 1,091,363    
Cash and Cash Equivalents 128,678 265,173    
Short-term Marketable Securities 297,572 590,326    
Long-term Marketable Securities 431,804 235,864    
Level 2: | Money market instruments        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost 128,678 205,736    
Gross Unrealized Gains 0 0    
Gross Unrealized Losses 0 0    
Aggregate Fair Value 128,678 205,736    
Cash and Cash Equivalents 128,678 205,736    
Short-term Marketable Securities 0 0    
Long-term Marketable Securities 0 0    
Level 2: | Corporate debt securities        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost 519,693 564,852    
Gross Unrealized Gains 3,713 214    
Gross Unrealized Losses (67) (2,288)    
Aggregate Fair Value 523,339 562,778    
Cash and Cash Equivalents 0 2,000    
Short-term Marketable Securities 206,782 376,545    
Long-term Marketable Securities 316,557 184,233    
Level 2: | Commercial paper        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost   77,702    
Gross Unrealized Gains   0    
Gross Unrealized Losses   0    
Aggregate Fair Value   77,702    
Cash and Cash Equivalents   21,964    
Short-term Marketable Securities   55,738    
Level 2: | U.S. government agency securities        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost 204,371 240,436    
Gross Unrealized Gains 1,073 144    
Gross Unrealized Losses (97) (697)    
Aggregate Fair Value 205,347 239,883    
Cash and Cash Equivalents 0 31,474    
Short-term Marketable Securities 90,790 156,967    
Long-term Marketable Securities 114,557 51,442    
Level 2: | Foreign and other        
Schedule of Available-for-sale Securities [Line Items]        
Amortized Cost 549 5,126    
Gross Unrealized Gains 142 139    
Gross Unrealized Losses (1) (1)    
Aggregate Fair Value 690 5,264    
Cash and Cash Equivalents 0 3,999    
Short-term Marketable Securities 0 1,076    
Long-term Marketable Securities $ 690 $ 189    
Minimum        
Schedule of Available-for-sale Securities [Line Items]        
Long term marketable securities maturity period 1 year 1 year    
Maximum        
Schedule of Available-for-sale Securities [Line Items]        
Long term marketable securities maturity period 5 years 5 years    
Short term marketable securities maturity period 1 year 1 year    
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 72 R31.htm IDEA: XBRL DOCUMENT v3.19.3
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)
 9 Months Ended
Sep. 30, 2019
Derivative [Line Items]  
Fair Value Carrying Amount of Derivatives
The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows:
Balance Sheet Location
September 30, 2019
 
December 31, 2018
Derivatives designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
29,900

 
$
12,686

Other assets
22,892

 
10,324

Subtotal
$
52,792

 
$
23,010

 
 
 
 
Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
7,875

 
$
4,036

Other long-term liabilities
7,641

 
3,653

Subtotal
$
15,516

 
$
7,689

 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
Asset Derivatives - Level 2 (1)
 
 
 
Other current assets
$
71

 
$
168

Other assets
—

 
—

Subtotal
$
71

 
$
168

Liability Derivatives - Level 2 (1)
 
 
 
Accounts payable and accrued liabilities
$
858

 
$
142

Other long-term liabilities
—

 
—

Subtotal
$
858

 
$
142

 
 
 
 
Total Derivatives Assets
$
52,863

 
$
23,178

Total Derivatives Liabilities
$
16,374

 
$
7,831

(1)  
For additional discussion of fair value measurements, see Note 3 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments
The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Financial Statements for the period presented.
 
Three Months Ended
 
Nine Months Ended
Derivatives Designated as Cash Flow Hedging Instruments
September 30, 2019
 
September 30, 2019
Amount of Gain (Loss) Recognized in Other Comprehensive Income
$
23,973

 
$
35,431

 
Three Months Ended
 
Nine Months Ended
 
September 30, 2019
 
September 30, 2019
Derivatives Designated as Cash Flow Hedging Instruments
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
Cash Flow Hedging Gains (Losses)
Reclassified into Earnings
 
 
 
 
 
 
 
 
Net product revenues as reported
$
450,900

 
$
6,196

 
$
1,224,458

 
$
11,171

Operating expenses as reported
$
457,087

 
$
(1,388
)
 
$
1,340,900

 
$
(1,885
)
 
 
 
 
 
 
 
 
Derivatives Not Designated as Hedging Instruments
 
 
Gains (Losses) Recognized in Earnings
 
 
 
Gains (Losses) Recognized in Earnings
Operating Expenses
 
 
$
(1,286
)
 
 
 
$
(5,182
)
Derivatives Designated As Hedging Instruments  
Derivative [Line Items]  
Summary of Derivatives Designated as Hedging Instruments Outstanding
The following table summarizes the Company’s derivatives designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Australian Dollars – Sell
 
6

 
2.8

 
Oct 2019 - Dec 2019
Canadian Dollars – Sell
 
24

 
28.1

 
Oct 2019 - Sept 2020
Colombian Pesos – Sell
 
12

 
89,400.0

 
Oct 2019 - Sept 2020
Euros – Purchase
 
150

 
189.4

 
Oct 2019 - Sept 2022
Euros – Sell
 
453

 
624.2

 
Oct 2019 - Sept 2022
Norwegian Krone – Sell
 
3

 
11.7

 
Oct 2019 - Dec 2019
Total
 
648

 
 
 
 
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Summary of Derivatives Designated as Hedging Instruments Outstanding
The following table summarizes the Company’s derivatives not designated as hedging instruments outstanding as of September 30, 2019 (notional amounts in millions):
Foreign Exchange Contracts
 
Number of
Contracts
 
Aggregate Notional
Amount in
Foreign Currency
 
Maturity
Colombian Pesos – Sell
 
2

 
96,000.0

 
Oct 2019 - Nov 2019
Euros – Purchase
 
2

 
44.1

 
Oct 2019 - Nov 2019
Great British Pounds - Purchase
 
1

 
4.9

 
Oct 2019
Great British Pounds - Sell
 
1

 
2.0

 
Oct 2019
Rubles – Sell
 
2

 
1,420.0

 
Oct 2019 - Nov 2019
Total
 
8

 
 
 
 
XML 73 R35.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2019
Concentration Risk And Geographic Information [Abstract]  
Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues by geographic region:
 
 
 
 
 
 
 
United States
$
201,874

 
$
174,722

 
$
562,217

 
$
528,082

Europe
125,485

 
111,069

 
369,585

 
323,940

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
49,939

 
30,515

 
153,671

 
134,021

Total revenues
$
461,097

 
$
391,706

 
$
1,249,605

 
$
1,137,998
Schedule of Net Product Revenues by Product
The following table disaggregates Net Product Revenues by product. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net product revenues by product:
 
 
 
 
 
 
 
Aldurazyme
$
22,852

 
$
27,593

 
$
73,945

 
$
117,652

Brineura
19,840

 
9,936

 
46,815

 
27,743

Firdapse
5,668

 
4,977

 
16,262

 
15,080

Kuvan
120,524

 
113,254

 
340,771

 
321,414

Naglazyme
94,408

 
103,089

 
279,462

 
269,171

Palynziq
24,142

 
4,129

 
55,250

 
4,129

Vimizim
163,466

 
123,342

 
411,953

 
368,016

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205
Schedule of Total Net Product Revenues Based on Patient Location
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
United States
$
175,127

 
$
146,742

 
$
480,330

 
$
409,294

Europe
121,363

 
107,851

 
358,041

 
315,270

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
47,759

 
28,734

 
148,010

 
129,034

Total net product revenues marketed by the Company
428,048

 
358,727

 
1,150,513

 
1,005,553

Aldurazyme net product revenues marketed by Genzyme
22,852

 
27,593

 
73,945

 
117,652

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Customer A
16
%
 
16
%
 
17
%
 
17
%
Customer B
13
%
 
12
%
 
12
%
 
12
%
Customer C
10
%
 
10
%
 
11
%
 
10
%
Customer D
5
%
 
7
%
 
6
%
 
11
%
Customer E
12
%
 
—
%
 
6
%
 
—
%
Customer F
—
%
 
13
%
 
—
%
 
6
%
Total
56
%
 
58
%
 
52
%
 
56
%
 
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Additional Information (Detail)
$ in Millions
 12 Months Ended
Dec. 31, 2018
USD ($)
Leases [Abstract]  
Rent expense $ 12.2
Deferred rent accruals 2.1
Deferred rent accruals, current $ 0.5
XML 75 R55.htm IDEA: XBRL DOCUMENT v3.19.3
Leases - Schedule of Lease Cost (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Lease Cost    
Total lease costs $ 4,277 $ 12,212
Operating Expenses    
Lease Cost    
Operating 3,535 9,946
Amortization 600 1,811
Interest expense $ 142 $ 455
XML 76 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]        
Net product revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
Operating expenses as reported 457,087 407,447 1,340,900 1,223,374
Derivatives Designated As Hedging Instruments        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Gain (Loss) Recognized in Other Comprehensive Income 23,973   35,431  
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (Losses) Recognized in Earnings (1,286)   (5,182)  
Operating Expense | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash Flow Hedging Gains (Losses) Reclassified into Earnings (1,388)   (1,885)  
Net product revenues        
Derivative Instruments, Gain (Loss) [Line Items]        
Net product revenues 450,900 $ 386,320 1,224,458 $ 1,123,205
Net product revenues | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash Flow Hedging Gains (Losses) Reclassified into Earnings $ 6,196   $ 11,171  
XML 77 R72.htm IDEA: XBRL DOCUMENT v3.19.3
Stock-Based Compensation - Stock Option Valuation Assumptions (Detail) - Options to purchase common stock
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility 36.80%    
Expected volatility, minimum   37.10% 36.80%
Expected volatility, maximum   37.40% 38.40%
Dividend yield 0.00% 0.00% 0.00%
Expected life (in years) 5 years 8 months 12 days    
Risk-free interest rate 2.80%    
Risk-free interest rate, minimum   2.20% 2.30%
Risk-free interest rate, maximum   3.00% 2.80%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected life (in years)   4 years 7 months 6 days 4 years 7 months 6 days
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected life (in years)   5 years 9 months 18 days 5 years 8 months 12 days
XML 78 R76.htm IDEA: XBRL DOCUMENT v3.19.3
Net Loss Per Common Share - Additional Information (Detail) - $ / shares
Sep. 30, 2019
Sep. 30, 2018
Convertible Notes due 2020    
Earnings Per Share [Line Items]    
Debt instrument, convertible, conversion price, per share (in dollars per share) $ 94.15  
Convertible Notes due 2018    
Earnings Per Share [Line Items]    
Debt instrument, interest rate, stated percentage, per annum   0.75%
XML 79 R17.htm IDEA: XBRL DOCUMENT v3.19.3
LEASES
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
LEASES LEASES
The following table presents the Company’s right-of-use (ROU) assets and lease liabilities as of September 30, 2019: 
Lease Classification
 
Classification
 
September 30,
2019
Assets:
 
 
 
 
Operating
 
Other Assets
 
$
51,284

Financing
 
Other Assets
 
10,346

Total ROU assets
 
 
 
$
61,630

Liabilities:
 
 
 
 
Current:
 
 
 
 
Operating
 
Accounts payable and accrued liabilities
 
$
7,273

Financing
 
Accounts payable and accrued liabilities
 
2,952

Noncurrent:
 
 
 
 
Operating
 
Other long-term liabilities
 
45,499

Financing
 
Other long-term liabilities
 
9,544

Total lease liabilities
 
 
 
$
65,268


Maturities of lease liabilities as of September 30, 2019 by fiscal year were as follows: 
Maturity of Lease Liabilities
 
Operating
 
Financing
 
Total
Remainder of 2019
 
$
3,115

 
$
3,204

 
$
6,319

2020
 
9,925

 
3,464

 
13,389

2021
 
8,721

 
2,865

 
11,586

2022
 
8,406

 
2,258

 
10,664

2023
 
7,504

 
1,748

 
9,252

Thereafter
 
27,464

 
—

 
27,464

Total lease payments
 
65,135

 
13,539

 
78,674

Less: Interest
 
(12,363
)
 
(1,043
)
 
(13,406
)
Present value of lease liabilities
 
$
52,772

 
$
12,496

 
$
65,268



Lease Cost
 
Classification
 
Three Months Ended
September 30, 2019
 
Nine Months Ended
September 30, 2019
Operating (1)
 
Operating Expenses
 
$
3,535

 
$
9,946

Financing:
 
 
 
 
 
 
Amortization
 
Operating Expenses
 
600

 
1,811

Interest expense
 
Operating Expenses
 
142

 
455

Total lease costs
 
 
 
$
4,277

 
$
12,212

 
(1)
Includes short-term leases and variable lease costs, both of which were not material.
Other Information
 
September 30,
2019
Weighted average remaining lease term (in years):
 
 
Operating leases
 
8.0

Financing leases
 
4.2

 
 
 
Weighted average discount rate:
 
 
Operating leases
 
5.2
%
Financing leases
 
5.4
%
 
As of September 30, 2019, no operating leases are expected to commence in the remainder of 2019.
Supplemental Cash Flow Information
 
Nine Months Ended
September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
 
 
Cash used in operating activities:
 
 
Operating leases
 
$
5,918

Financing leases
 
$
454

Cash used in financing activities:
 
 
Financing leases
 
$
2,027

ROU assets obtained in exchange for lease obligations:
 
 
Operating leases
 
$
9,268

Financing leases
 
$
72

 
Lease Commitments as of December 31, 2018
Minimum lease payments for future years as of December 31, 2018 were as follows: 
2019
$
12,976

2020
12,549

2021
11,198

2022
10,574

2023
9,993

Thereafter
27,701

Total
$
84,991

 
Rent expense for the year ended December 31, 2018 was $12.2 million. Total deferred rent accruals at December 31, 2018 were $2.1 million, of which $0.5 million was short-term.
XML 80 R13.htm IDEA: XBRL DOCUMENT v3.19.3
PROPERTY, PLANT AND EQUIPMENT
 9 Months Ended
Sep. 30, 2019
Property, Plant and Equipment [Abstract]  
PROPERTY, PLANT AND EQUIPMENT
(7) PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment, net consisted of the following: 
 
September 30,
2019
 
December 31,
2018
Building and improvements
$
709,990

 
$
694,447

Manufacturing and laboratory equipment
365,348

 
345,947

Computer hardware and software
165,235

 
157,787

Leasehold improvements
52,379

 
41,188

Furniture and equipment
37,603

 
33,234

Land improvements
7,239

 
6,551

Land
83,094

 
77,993

Construction-in-progress
84,021

 
64,170

 
1,504,909

 
1,421,317

Accumulated depreciation
(535,609
)
 
(472,635
)
Total property, plant and equipment, net
$
969,300

 
$
948,682


The construction-in-progress balance primarily included costs related to significant in-process projects at the Company's facilities in Marin County, California, and Shanbally, Ireland.
Depreciation expense for the three and nine months ended September 30, 2019 was $24.2 million and $67.2 million, respectively, of which $9.8 million and $24.9 million, respectively, was capitalized into inventory. Depreciation expense for the three and nine months ended September 30, 2018 was $26.6 million and $66.7 million, respectively, of which $8.1 million and $18.6 million, respectively, was capitalized into inventory.
XML 81 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
 [1]
Current assets:    
Cash and cash equivalents $ 423,220 $ 493,982
Short-term investments 297,572 590,326
Accounts receivable, net 402,970 342,633
Inventory 609,049 530,871
Other current assets 126,548 98,403
Total current assets 1,859,359 2,056,215
Noncurrent assets:    
Long-term investments 431,804 235,864
Property, plant and equipment, net 969,300 948,682
Intangible assets, net 462,849 491,808
Goodwill 197,039 197,039
Deferred tax assets 525,131 460,952
Other assets 112,646 36,568
Total assets 4,558,128 4,427,128
Current liabilities:    
Accounts payable and accrued liabilities 483,745 437,290
Short-term contingent consideration 10,000 85,951
Total current liabilities 493,745 523,241
Noncurrent liabilities:    
Long-term convertible debt, net 843,616 830,417
Long-term contingent consideration 48,930 46,883
Other long-term liabilities 97,432 58,647
Total liabilities 1,483,723 1,459,188
Stockholders’ equity:    
Common stock, $0.001 par value: 500,000,000 shares authorized; 179,604,381 and 178,252,954 shares issued and outstanding, respectively. 180 178
Additional paid-in capital 4,782,916 4,669,926
Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC) (9,961) (13,301)
Accumulated other comprehensive income 37,003 5,271
Accumulated deficit (1,735,733) (1,694,134)
Total stockholders’ equity 3,074,405 2,967,940 [2]
Total liabilities and stockholders’ equity $ 4,558,128 $ 4,427,128
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
[2]
The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 451 405 1 true 110 0 false 14 false false R1.htm 0002000 - Document - Cover Page Sheet http://www.bmrn.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - NATURE OF OPERATIONS Sheet http://www.bmrn.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 2102100 - Disclosure - BASIS OF PRESENTATION Sheet http://www.bmrn.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 2103100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bmrn.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2104100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.bmrn.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 10 false false R11.htm 2106100 - Disclosure - FINANCIAL INSTRUMENTS Sheet http://www.bmrn.com/role/FinancialInstruments FINANCIAL INSTRUMENTS Notes 11 false false R12.htm 2107100 - Disclosure - INTANGIBLE ASSETS Sheet http://www.bmrn.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 12 false false R13.htm 2109100 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://www.bmrn.com/role/PropertyPlantAndEquipment PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 2110100 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformation SUPPLEMENTAL BALANCE SHEET INFORMATION Notes 14 false false R15.htm 2111100 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.bmrn.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 2119100 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategies DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Notes 16 false false R17.htm 2127100 - Disclosure - LEASES Sheet http://www.bmrn.com/role/Leases LEASES Notes 17 false false R18.htm 2128100 - Disclosure - DEBT Sheet http://www.bmrn.com/role/Debt DEBT Notes 18 false false R19.htm 2129100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncome ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 19 false false R20.htm 2135100 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformation REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Notes 20 false false R21.htm 2140100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.bmrn.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 21 false false R22.htm 2145100 - Disclosure - INCOME TAXES Sheet http://www.bmrn.com/role/IncomeTaxes INCOME TAXES Notes 22 false false R23.htm 2146100 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://www.bmrn.com/role/NetLossPerCommonShare NET LOSS PER COMMON SHARE Notes 23 false false R24.htm 2147100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bmrn.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 2202201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.bmrn.com/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 25 false false R26.htm 2306301 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet http://www.bmrn.com/role/FinancialInstrumentsTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.bmrn.com/role/FinancialInstruments 26 false false R27.htm 2307301 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.bmrn.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://www.bmrn.com/role/IntangibleAssets 27 false false R28.htm 2309301 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://www.bmrn.com/role/PropertyPlantAndEquipmentTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://www.bmrn.com/role/PropertyPlantAndEquipment 28 false false R29.htm 2310301 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformationTables SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables) Tables http://www.bmrn.com/role/SupplementalBalanceSheetInformation 29 false false R30.htm 2311301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.bmrn.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.bmrn.com/role/FairValueMeasurements 30 false false R31.htm 2319301 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Tables http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategies 31 false false R32.htm 2327301 - Disclosure - LEASES (Tables) Sheet http://www.bmrn.com/role/LeasesTables LEASES (Tables) Tables http://www.bmrn.com/role/Leases 32 false false R33.htm 2328301 - Disclosure - DEBT (Tables) Sheet http://www.bmrn.com/role/DebtTables DEBT (Tables) Tables http://www.bmrn.com/role/Debt 33 false false R34.htm 2329301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeTables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncome 34 false false R35.htm 2335301 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Tables http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformation 35 false false R36.htm 2340301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.bmrn.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.bmrn.com/role/StockBasedCompensation 36 false false R37.htm 2346301 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://www.bmrn.com/role/NetLossPerCommonShareTables NET LOSS PER COMMON SHARE (Tables) Tables http://www.bmrn.com/role/NetLossPerCommonShare 37 false false R38.htm 2402402 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail Basis of Presentation - Additional Information (Detail) Details 38 false false R39.htm 2406402 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Sheet http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail) Details 39 false false R40.htm 2406403 - Disclosure - Financial Instruments - Additional Information (Detail) Sheet http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail Financial Instruments - Additional Information (Detail) Details 40 false false R41.htm 2407402 - Disclosure - Intangible Assets (Detail) Sheet http://www.bmrn.com/role/IntangibleAssetsDetail Intangible Assets (Detail) Details 41 false false R42.htm 2409402 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) Sheet http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail) Details 42 false false R43.htm 2409403 - Disclosure - Property Plant and Equipment - Additional Information (Detail) Sheet http://www.bmrn.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail Property Plant and Equipment - Additional Information (Detail) Details 43 false false R44.htm 2410402 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail Supplemental Balance Sheet Information - Schedule of Inventory (Detail) Details 44 false false R45.htm 2410403 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail) Details 45 false false R46.htm 2411402 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) Sheet http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail) Details 46 false false R47.htm 2411403 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) Sheet http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail) Details 47 false false R48.htm 2419402 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) Details 48 false false R49.htm 2419403 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail) Details 49 false false R50.htm 2419404 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail) Details 50 false false R51.htm 2419405 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail) Details 51 false false R52.htm 2419406 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail) Sheet http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesAdditionalInformationDetail Derivative Instruments and Hedging Strategies - Additional Information (Detail) Details 52 false false R53.htm 2427402 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail Leases - Schedule of ROU Assets and Lease Liabilities (Detail) Details 53 false false R54.htm 2427403 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail Leases - Schedule of Maturities of Lease Liabilities (Detail) Details 54 false false R55.htm 2427404 - Disclosure - Leases - Schedule of Lease Cost (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail Leases - Schedule of Lease Cost (Detail) Details 55 false false R56.htm 2427405 - Disclosure - Leases - Schedule of Other Information (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail Leases - Schedule of Other Information (Detail) Details 56 false false R57.htm 2427406 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail Leases - Schedule of Supplemental Cash Flow Information (Detail) Details 57 false false R58.htm 2427407 - Disclosure - Leases - Schedule of Minimum Lease Payments for Future Years (Detail) Sheet http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail Leases - Schedule of Minimum Lease Payments for Future Years (Detail) Details 58 false false R59.htm 2427408 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.bmrn.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 59 false false R60.htm 2428402 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.bmrn.com/role/DebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 60 false false R61.htm 2428403 - Disclosure - Debt - Summary of Convertible Debt (Detail) Sheet http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail Debt - Summary of Convertible Debt (Detail) Details 61 false false R62.htm 2428404 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail) Sheet http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail Debt - Summary of Interest Expense on Convertible Debt (Detail) Details 62 false false R63.htm 2429402 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) Details 63 false false R64.htm 2429403 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Sheet http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail) Details 64 false false R65.htm 2435402 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail) Details 65 false false R66.htm 2435403 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail) Details 66 false false R67.htm 2435404 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) Details 67 false false R68.htm 2435405 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) Details 68 false false R69.htm 2435406 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Sheet http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail) Details 69 false false R70.htm 2440402 - Disclosure - Stock-Based Compensation - Expense (Detail) Sheet http://www.bmrn.com/role/StockBasedCompensationExpenseDetail Stock-Based Compensation - Expense (Detail) Details 70 false false R71.htm 2440403 - Disclosure - Stock Based Compensation - Additional Information (Detail) Sheet http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail Stock Based Compensation - Additional Information (Detail) Details 71 false false R72.htm 2440404 - Disclosure - Stock-Based Compensation - Stock Option Valuation Assumptions (Detail) Sheet http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail Stock-Based Compensation - Stock Option Valuation Assumptions (Detail) Details 72 false false R73.htm 2445401 - Disclosure - Income Taxes (Details) Sheet http://www.bmrn.com/role/IncomeTaxesDetails Income Taxes (Details) Details 73 false false R74.htm 2446402 - Disclosure - NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details) Sheet http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details) Details 74 false false R75.htm 2446403 - Disclosure - Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) Sheet http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail) Details 75 false false R76.htm 2446404 - Disclosure - Net Loss Per Common Share - Additional Information (Detail) Sheet http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail Net Loss Per Common Share - Additional Information (Detail) Details 76 false false R77.htm 2447401 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 77 false false R9999.htm Uncategorized Items - bmrn-30sep19x10qxa.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - bmrn-30sep19x10qxa.htm Cover 78 false false All Reports Book All Reports bmrn-30sep19x10qxa.htm bmrn-20190930.xsd bmrn-20190930_cal.xml bmrn-20190930_def.xml bmrn-20190930_lab.xml bmrn-20190930_pre.xml exhibit101-30sep19x10q.htm exhibit311-30sep19x10q.htm exhibit312-30sep19x10q.htm exhibit321-30sep19x10q.htm http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 83 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (38,872) $ (73,561)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 79,510 70,955
Non-cash interest expense 9,395 26,099
(Accretion of discount) Amortization of premium on investments (1,897) 769
Stock-based compensation 121,763 112,261
Gain on sale of intangible assets (15,000) (20,000)
Deferred income taxes (59,780) (32,735)
Unrealized foreign exchange (gain) loss 784 (11,997)
Non-cash changes in the fair value of contingent consideration 5,646 12,836
Other (18) (459)
Changes in operating assets and liabilities:    
Accounts receivable, net (61,803) (95,884)
Inventory (52,571) (10,232)
Other current assets (13,259) 4,276
Other assets (7,112) (3,148)
Accounts payable and accrued liabilities 21,747 (12,090)
Other long-term liabilities 2,386 3,744
Net cash used in operating activities (9,081) (29,166)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (94,241) (102,541)
Maturities and sales of investments 635,678 857,063
Purchases of available-for-sale securities (528,497) (439,198)
Proceeds from sale of intangible assets 15,000 20,000
Purchase of intangible assets (8,323) 0
Other (1,747) (10)
Net cash provided by investing activities 17,870 335,314
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercises of awards under equity incentive plans 21,768 55,643
Taxes paid related to net share settlement of equity awards (40,951) (34,180)
Payment of contingent acquisition consideration (57,508) (43,108)
Other (2,025) 0
Net cash used in financing activities (78,716) (21,645)
Effect of exchange rate changes on cash (835) (347)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (70,762) 284,156
Cash and cash equivalents:    
Beginning of period 493,982 [1] 598,028
End of period 423,220 882,184
SUPPLEMENTAL CASH FLOW DISCLOSURES:    
Cash paid for income taxes 6,088 15,791
Cash paid for interest 5,777 7,521
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Decrease in accounts payable and accrued liabilities related to fixed assets $ (5,801) $ (7,678)
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
XML 84 R30.htm IDEA: XBRL DOCUMENT v3.19.3
FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities
The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2019 and December 31, 2018. There were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2019.
 
Fair Value Measurements at September 30, 2019
 
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
NQDC Plan assets
 
$
1,135

 
$
—

 
$
1,135

Other assets:
 
 
 
 
 
 
NQDC Plan assets
 
15,039

 
—

 
15,039

Restricted investments (1)
 
3,157

 
—

 
3,157

Total other assets
 
18,196

 
—

 
18,196

Total assets
 
$
19,331

 
$
—

 
$
19,331

Liabilities:
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
$
1,135

 
$
—

 
$
1,135

Contingent consideration
 
—

 
10,000

 
10,000

Total current liabilities
 
1,135

 
10,000

 
11,135

Other long-term liabilities:
 
 
 
 
 
 
NQDC Plan liability (2)
 
15,039

 
—

 
15,039

Contingent consideration
 
—

 
48,930

 
48,930

Total other long-term liabilities
 
15,039

 
48,930

 
63,969

Total liabilities
 
$
16,174

 
$
58,930

 
$
75,104


 
Fair Value Measurements at December 31, 2018
 
Quoted Price in
Active Markets
For Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Other current assets:
 
 
 
 
 
 
 
NQDC Plan assets
$
—

 
$
370

 
$
—

 
$
370

Restricted investments (1)
—

 
9,581

 
—

 
9,581

Total other current assets
—

 
9,951

 
—

 
9,951

Other assets:
 
 
 
 
 
 
 
NQDC Plan assets
—

 
12,828

 
—

 
12,828

Restricted investments (1)
—

 
2,450

 
—

 
2,450

Strategic investments (3)
942

 
—

 
—

 
942

Total other assets
942

 
15,278

 
—

 
16,220

Total assets
$
942

 
$
25,229

 
$
—

 
$
26,171

Liabilities:
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
$
55

 
$
370

 
$
—

 
$
425

Contingent consideration
—

 
—

 
85,951

 
85,951

Total current liabilities
55

 
370

 
85,951

 
86,376

Other long-term liabilities:
 
 
 
 
 
 
 
NQDC Plan liability
17,598

 
12,828

 
—

 
30,426

Contingent consideration
—

 
—

 
46,883

 
46,883

Total other long-term liabilities
17,598

 
12,828

 
46,883

 
77,309

Total liabilities
$
17,653

 
$
13,198

 
$
132,834

 
$
163,685

(1)
The restricted investments at September 30, 2019 and December 31, 2018 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
(2)
The Company’s NQDC Plan was amended during the second quarter of 2019, which resulted in a change to the classification of the obligation associated with the Company's common stock held in the NQDC Plan. The obligation was previously classified as a liability recorded at fair value and has been reclassified into equity and recorded at the shares' respective grant date fair values at June 30, 2019. The change to the NQDC Plan related to the prohibition of participants to diversify investments for deferrals of Company stock contributed into other types of investments. The NQDC Plan liabilities classified as Level 2 represent investments held in plan assets excluding shares of the Company's common stock.
(3)
The Company had investments in marketable equity securities measured using quoted prices in an active market that were considered strategic investments and were included in Other Assets on the Company's Condensed Consolidated Balance Sheets. During the second quarter of 2019, the Company realized an immaterial gain upon the sale of the shares.
Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs
The following table represents a roll-forward of contingent consideration.
Contingent consideration at December 31, 2018
$
132,834

Changes in fair value of other contingent consideration
19,916

Milestone payments to Ares Trading S.A. (Merck Serono)
(83,472
)
Milestone payments to former LEAD Therapeutics, Inc. shareholders
(5,987
)
Realized gain on settlement of contingent consideration
(1,928
)
Foreign exchange remeasurement of Euro denominated contingent consideration
(2,433
)
Contingent consideration at September 30, 2019
$
58,930
XML 85 R34.htm IDEA: XBRL DOCUMENT v3.19.3
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)
 9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income
The following table summarizes amounts reclassified out of AOCI and their effect on the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2019 and 2018. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
Condensed Consolidated
Statement of Comprehensive Income (Loss)
Classification
 
2019
 
2018
 
2019
 
2018
 
Gains (losses) on cash flow hedges:
 
 
 
 
 
 
 
 
 
Forward contracts
$
6,196

 
$
5,025

 
$
11,171

 
$
(6,683
)
 
Net product revenues
Forward contracts
(1,388
)
 
498

 
(1,885
)
 
3,762

 
Operating expenses
Total gain (loss) on cash flow hedges
$
4,808

 
$
5,523

 
$
9,286

 
$
(2,921
)
 
 
Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI
The following tables summarize changes in the accumulated balances for each component of AOCI, including current period other comprehensive income (loss) and reclassifications out of AOCI for the three and nine months ended September 30, 2019 and 2018.
 
Three Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2019
$
14,181

 
$
3,271

 
$
(13
)
 
$
17,439

Other comprehensive income (loss) before
     reclassifications
23,973

 
522

 
(3
)
 
24,492

Less: net gain (loss) reclassified from AOCI
4,808

 
—

 
—

 
4,808

Tax effect
—

 
(120
)
 
—

 
(120
)
Net current-period other comprehensive income (loss)
19,165

 
402

 
(3
)
 
19,564

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003


 
Nine Months Ended September 30, 2019
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2018
$
7,201

 
$
(1,917
)
 
$
(13
)
 
$
5,271

Other comprehensive income (loss) before
     reclassifications
35,431

 
7,256

 
(3
)
 
42,684

Less: gain (loss) reclassified from AOCI
9,286

 
—

 
—

 
9,286

Tax effect
—

 
(1,666
)
 
—

 
(1,666
)
Net current-period other comprehensive income (loss)
26,145

 
5,590

 
(3
)
 
31,732

AOCI balance at September 30, 2019
$
33,346

 
$
3,673

 
$
(16
)
 
$
37,003


 
Three Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at June 30, 2018
$
2,568

 
$
(3,686
)
 
$
(11
)
 
$
(1,129
)
Other comprehensive income (loss) before
     reclassifications
3,355

 
1,475

 
—

 
4,830

Less: gain (loss) reclassified from AOCI
5,523

 
—

 
—

 
5,523

Tax effect
—

 
(338
)
 
—

 
(338
)
Net current-period other comprehensive income (loss)
(2,168
)
 
1,137

 
—

 
(1,031
)
AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)



 
Nine Months Ended September 30, 2018
 
Unrealized Gains
(Losses) on Cash
Flow Hedges
 
Unrealized Gains
(Losses) on
Available for-Sale
Debt Securities
 
Other
 
Total
AOCI balance at December 31, 2017
$
(20,232
)
 
$
(2,722
)
 
$
(7
)
 
$
(22,961
)
Impact of change in accounting principle
—

 
(586
)
 
—

 
(586
)
AOCI balance at January 1, 2018
$
(20,232
)
 
$
(3,308
)
 
$
(7
)
 
$
(23,547
)
Other comprehensive income (loss) before
     reclassifications
17,711

 
985

 
(4
)
 
18,692

Less: gain (loss) reclassified from AOCI
(2,921
)
 
—

 
—

 
(2,921
)
Tax effect
—

 
(226
)
 
—

 
(226
)
Net current-period other comprehensive income (loss)
20,632

 
759

 
(4
)
 
21,387

AOCI balance at September 30, 2018
$
400

 
$
(2,549
)
 
$
(11
)
 
$
(2,160
)
XML 86 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
Significant Accounting Policies [Line Items]    
Lease ROU assets $ 61,630  
Lease liabilities $ 65,268  
ASC Topic 842    
Significant Accounting Policies [Line Items]    
Lease ROU assets   $ 55,900
Lease liabilities   $ 59,000
XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 R29.htm IDEA: XBRL DOCUMENT v3.19.3
SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Inventory
Inventory consisted of the following:
 
September 30,
2019
 
December 31,
2018
Raw materials
$
68,391

 
$
74,616

Work-in-process
321,073

 
231,064

Finished goods
219,585

 
225,191

Total inventory
$
609,049

 
$
530,871
Schedule of Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities consisted of the following:
 
September 30, 2019
 
December 31, 2018
Accounts payable and accrued operating expenses
$
226,769

 
$
207,620

Accrued compensation expense
132,049

 
149,937

Accrued rebates payable
55,957

 
43,116

Accrued royalties payable
27,881

 
19,977

Value added taxes payable
7,556

 
7,785

Forward foreign currency exchange contracts
8,731

 
4,178

Lease liability
10,225

 
—

Other
14,577

 
4,677

Total accounts payable and accrued liabilities
$
483,745

 
$
437,290
JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bmrn-30sep19x10qxa.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 451, "dts": { "calculationLink": { "local": [ "bmrn-20190930_cal.xml" ] }, "definitionLink": { "local": [ "bmrn-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "bmrn-30sep19x10qxa.htm" ] }, "labelLink": { "local": [ "bmrn-20190930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmrn-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmrn-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 617, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 52, "http://www.bmrn.com/20190930": 6, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 64 }, "keyCustom": 47, "keyStandard": 358, "memberCustom": 40, "memberStandard": 67, "nsprefix": "bmrn", "nsuri": "http://www.bmrn.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0002000 - Document - Cover Page", "role": "http://www.bmrn.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://www.bmrn.com/role/RecentAccountingPronouncements", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - FINANCIAL INSTRUMENTS", "role": "http://www.bmrn.com/role/FinancialInstruments", "shortName": "FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - INTANGIBLE ASSETS", "role": "http://www.bmrn.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "role": "http://www.bmrn.com/role/PropertyPlantAndEquipment", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformation", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.bmrn.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategies", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - LEASES", "role": "http://www.bmrn.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - DEBT", "role": "http://www.bmrn.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129100 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncome", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135100 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformation", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.bmrn.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145100 - Disclosure - INCOME TAXES", "role": "http://www.bmrn.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146100 - Disclosure - NET LOSS PER COMMON SHARE", "role": "http://www.bmrn.com/role/NetLossPerCommonShare", "shortName": "NET LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.bmrn.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - BASIS OF PRESENTATION (Policies)", "role": "http://www.bmrn.com/role/BasisOfPresentationPolicies", "shortName": "BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.bmrn.com/role/FinancialInstrumentsTables", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://www.bmrn.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "role": "http://www.bmrn.com/role/PropertyPlantAndEquipmentTables", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformationTables", "shortName": "SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.bmrn.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327301 - Disclosure - LEASES (Tables)", "role": "http://www.bmrn.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328301 - Disclosure - DEBT (Tables)", "role": "http://www.bmrn.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329301 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335301 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340301 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.bmrn.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346301 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "role": "http://www.bmrn.com/role/NetLossPerCommonShareTables", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "bmrn:OperatingAndFinanceLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Basis of Presentation - Additional Information (Detail)", "role": "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail", "shortName": "Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "bmrn:OperatingAndFinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "role": "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail", "shortName": "Financial Instruments - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Financial Instruments - Additional Information (Detail)", "role": "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail", "shortName": "Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Intangible Assets (Detail)", "role": "http://www.bmrn.com/role/IntangibleAssetsDetail", "shortName": "Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail)", "role": "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail", "shortName": "Property Plant and Equipment - Schedule of Property Plant and Equipment Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Property Plant and Equipment - Additional Information (Detail)", "role": "http://www.bmrn.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "shortName": "Property Plant and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Supplemental Balance Sheet Information - Schedule of Inventory (Detail)", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "role": "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Accounts Payable and Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)", "role": "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_bmrn_ContingentPaymentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)", "role": "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail", "shortName": "Fair Value Measurements - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_bmrn_ContingentPaymentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld", "reportCount": 1, "unitRef": "U_bmrnDerivative", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_srt_CurrencyAxis_currency_AUD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_PositionAxis_us-gaap_ShortMember", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217AUD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfForeignCurrencyDerivativesHeld", "reportCount": 1, "unitRef": "U_bmrnDerivative", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Derivatives Not Designated as Hedging Instruments Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_srt_CurrencyAxis_currency_COP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_PositionAxis_us-gaap_ShortMember", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217BRL", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "shortName": "Derivative Instruments and Hedging Strategies - Fair Value Carrying Amount of Derivatives (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419405 - Disclosure - Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "shortName": "Derivative Instruments and Hedging Strategies - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419406 - Disclosure - Derivative Instruments and Hedging Strategies - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesAdditionalInformationDetail", "shortName": "Derivative Instruments and Hedging Strategies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427402 - Disclosure - Leases - Schedule of ROU Assets and Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of ROU Assets and Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bmrn:ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427403 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail", "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427404 - Disclosure - Leases - Schedule of Lease Cost (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail", "shortName": "Leases - Schedule of Lease Cost (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427405 - Disclosure - Leases - Schedule of Other Information (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail", "shortName": "Leases - Schedule of Other Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "bmrn:LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427406 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail", "shortName": "Leases - Schedule of Supplemental Cash Flow Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427407 - Disclosure - Leases - Schedule of Minimum Lease Payments for Future Years (Detail)", "role": "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail", "shortName": "Leases - Schedule of Minimum Lease Payments for Future Years (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427408 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.bmrn.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - Debt - Additional Information (Detail)", "role": "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "I2018Q4Oct31_us-gaap_DebtInstrumentAxis_bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428403 - Disclosure - Debt - Summary of Convertible Debt (Detail)", "role": "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail", "shortName": "Debt - Summary of Convertible Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3", "decimals": "-3", "lang": null, "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428404 - Disclosure - Debt - Summary of Interest Expense on Convertible Debt (Detail)", "role": "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail", "shortName": "Debt - Summary of Interest Expense on Convertible Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429402 - Disclosure - Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "shortName": "Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q2", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429403 - Disclosure - Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "role": "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "shortName": "Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2017Q4", "decimals": "-3", "lang": null, "name": "bmrn:StockholdersEquityAdjustedBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_bmrnSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435402 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_bmrnSegment", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435403 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Revenues from External Customers and Collaborative Partners by Geographic Region (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435404 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_bmrn_ProductSixMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435405 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_bmrn_ProductsExcludingProductOneMember_us-gaap_ContractWithCustomerSalesChannelAxis_us-gaap_SalesChannelDirectlyToConsumerMember", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435406 - Disclosure - Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "role": "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail", "shortName": "Revenue, Credit Concentrations and Geographic Information - Total Net Product Revenue Concentrations Attributed to Largest Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - NATURE OF OPERATIONS", "role": "http://www.bmrn.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440402 - Disclosure - Stock-Based Compensation - Expense (Detail)", "role": "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440403 - Disclosure - Stock Based Compensation - Additional Information (Detail)", "role": "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440404 - Disclosure - Stock-Based Compensation - Stock Option Valuation Assumptions (Detail)", "role": "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail", "shortName": "Stock-Based Compensation - Stock Option Valuation Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445401 - Disclosure - Income Taxes (Details)", "role": "http://www.bmrn.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446402 - Disclosure - NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details)", "role": "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "shortName": "NET LOSS PER COMMON SHARE Net Loss Per Common Share - Schedule of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446403 - Disclosure - Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)", "role": "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Common Share - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_DebtInstrumentAxis_bmrn_ConvertibleSeniorNotesDueTwentyTwentyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446404 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)", "role": "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail", "shortName": "Net Loss Per Common Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FI2019Q3_us-gaap_DebtInstrumentAxis_bmrn_ConvertibleSeniorNotesDueTwentyTwentyMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "bmrn:ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": "-5", "first": true, "lang": null, "name": "bmrn:ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - BASIS OF PRESENTATION", "role": "http://www.bmrn.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.bmrn.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bmrn-30sep19x10qxa.htm", "contextRef": "I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - bmrn-30sep19x10qxa.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - bmrn-30sep19x10qxa.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 110, "tag": { "bmrn_AccretionOfDebtDiscount": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail": { "order": 3.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accretion of debt discount.", "label": "Accretion Of Debt Discount", "verboseLabel": "Accretion of discount on convertible notes" } } }, "localname": "AccretionOfDebtDiscount", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_AccruedLeaseLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued lease liabilities current.", "label": "Accrued Lease Liabilities Current", "terseLabel": "Lease liability" } } }, "localname": "AccruedLeaseLiabilitiesCurrent", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_AccumulatedGainLossFromOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated gain (loss) from other.", "label": "Accumulated Gain Loss From Other [Member]", "terseLabel": "Other" } } }, "localname": "AccumulatedGainLossFromOtherMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "domainItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "label": "Adjustments To Additional Paid In Capital, Accounting Impact, Nonqualified Deferred Compensation Plan Change", "terseLabel": "Accounting impact of NQDC Plan change" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAccountingImpactNonqualifiedDeferredCompensationPlanChange", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "negatedTerseLabel": "Common stock held by the NQDC" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bmrn_AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "label": "Annual Shareholder Return Multiplier On Absolute Basis, Percentage", "terseLabel": "Percentage of Annual TSR multiplier on absolute basis" } } }, "localname": "AnnualShareholderReturnMultiplierOnAbsoluteBasisPercentage", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities abstract.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ClinicalAndPostMarketingServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical and post marketing services.", "label": "Clinical And Post Marketing Services [Member]", "terseLabel": "Clinical and Post Marketing Services" } } }, "localname": "ClinicalAndPostMarketingServicesMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_CommonStockIssuableToEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock issuable for employee Stock Purchase Plan [Member]", "label": "Common Stock Issuable To Employee Stock Purchase Plan [Member]", "terseLabel": "Common stock potentially issuable for ESPP purchases" } } }, "localname": "CommonStockIssuableToEmployeeStockPurchasePlanMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bmrn_CompletedProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Completed Project.", "label": "Completed Project [Member]", "terseLabel": "Completed Programs" } } }, "localname": "CompletedProjectMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Abstract]" } } }, "localname": "ConcentrationRiskAndGeographicInformationAbstract", "nsuri": "http://www.bmrn.com/20190930", "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Line Items]", "terseLabel": "Concentration Risk And Geographic Information [Line Items]" } } }, "localname": "ConcentrationRiskAndGeographicInformationLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndGeographicInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and geographic information.", "label": "Concentration Risk And Geographic Information [Table]", "terseLabel": "Concentration Risk And Geographic Information [Table]" } } }, "localname": "ConcentrationRiskAndGeographicInformationTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Concentration risk and segment reporting disclosure.", "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]", "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION" } } }, "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "bmrn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentLiabilityAccrualSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Liability Accrual Sales And Licensing Milestones", "label": "Contingent Liability Accrual Sales And Licensing Milestones", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilityAccrualSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentLiabilityAccrualSalesAndLicensingMilestonesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Liability Accrual Sales And Licensing Milestones, Current", "label": "Contingent Liability Accrual Sales And Licensing Milestones, Current", "verboseLabel": "Contingent liabilities short-term" } } }, "localname": "ContingentLiabilityAccrualSalesAndLicensingMilestonesCurrent", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Payment", "label": "Contingent Payment [Member]", "terseLabel": "Contingent Payment" } } }, "localname": "ContingentPaymentMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent payments upon achievement of certain regulatory, commercial sales and licensing milestones.", "label": "Contingent Payments Upon Achievement Of Certain Regulatory Commercial Sales And Licensing Milestones", "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones" } } }, "localname": "ContingentPaymentsUponAchievementOfCertainRegulatoryCommercialSalesAndLicensingMilestones", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ConvertibleSeniorNotesDueTwentyTwentyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible senior notes due twenty twenty.", "label": "Convertible Senior Notes Due Twenty Twenty [Member]", "terseLabel": "Convertible Notes due 2020", "verboseLabel": "Common stock issuable under the 2020 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible senior notes due two thousand eighteen.", "label": "Convertible Senior Notes Due Two Thousand Eighteen [Member]", "terseLabel": "Convertible Notes due 2018", "verboseLabel": "Common stock issuable under the 2018 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandEighteenMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bmrn_ConvertibleSeniorNotesDueTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Convertible Senior Notes Due Two Thousand Twenty Four [Member]", "verboseLabel": "Common stock issuable under the 2024 Notes" } } }, "localname": "ConvertibleSeniorNotesDueTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Five [Member]", "label": "Customer Five [Member]", "terseLabel": "Customer E" } } }, "localname": "CustomerFiveMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 4", "label": "Customer Four [Member]", "terseLabel": "Customer D" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 1", "label": "Customer One [Member]", "terseLabel": "Customer A", "verboseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer Six [Member]", "label": "Customer Six [Member]", "terseLabel": "Customer F" } } }, "localname": "CustomerSixMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 3", "label": "Customer Three [Member]", "terseLabel": "Customer C", "verboseLabel": "Customer Three" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer 2", "label": "Customer Two [Member]", "terseLabel": "Customer B", "verboseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "bmrn_CustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customers.", "label": "Customers [Member]", "terseLabel": "Customers" } } }, "localname": "CustomersMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_DepreciationExpenseCapitalizedIntoInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Depreciation expense capitalized into inventory during the reporting period.", "label": "Depreciation Expense Capitalized Into Inventory", "terseLabel": "Depreciation capitalized into inventory" } } }, "localname": "DepreciationExpenseCapitalizedIntoInventory", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share line Items.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_FairValueInputsAnnualRevenueMultipleCeilingAchievementPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Annual Revenue Multiple Ceiling Achievement, Percentage", "label": "Fair Value Inputs, Annual Revenue Multiple Ceiling Achievement, Percentage", "terseLabel": "Percentage of annual ceiling achievement" } } }, "localname": "FairValueInputsAnnualRevenueMultipleCeilingAchievementPercentage", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_FairValueInputsAnnualRevenueMultipleThresholdTargetPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Annual Revenue Multiple Threshold Target, Percentage", "label": "Fair Value Inputs, Annual Revenue Multiple Threshold Target, Percentage", "terseLabel": "Percentage of annual threshold target" } } }, "localname": "FairValueInputsAnnualRevenueMultipleThresholdTargetPercentage", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis foreign exchange remeasurement.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Foreign Exchange Remeasurement", "verboseLabel": "Foreign exchange remeasurement of Euro denominated contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisForeignExchangeRemeasurement", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisMilestonePaymentsToAresTradingS.A.": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Ares Trading S.A.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Ares Trading S.A.", "terseLabel": "Milestone payments to Ares Trading S.A. (Merck Serono)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisMilestonePaymentsToAresTradingS.A.", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisMilestonePaymentsToShareholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis milestone payments to shareholders.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Milestone Payments To Shareholders", "verboseLabel": "Milestone payments to former LEAD Therapeutics, Inc. shareholders" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisMilestonePaymentsToShareholders", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisRealizedGainonSettlementofContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Realized Gain on Settlement of Contingent Consideration", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Realized Gain on Settlement of Contingent Consideration", "terseLabel": "Realized gain on settlement of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisRealizedGainonSettlementofContingentConsideration", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_ForeignGovernmentAndOtherDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign government and other debt securities.", "label": "Foreign Government And Other Debt Securities [Member]", "terseLabel": "Foreign and other" } } }, "localname": "ForeignGovernmentAndOtherDebtSecuritiesMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "bmrn_IntangibleAssetAmortizationAndContingentConsideration": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets and expense charged against earnings resulting from the change in the fair value of contingent consideration during the reporting period.", "label": "Intangible Asset Amortization And Contingent Consideration", "terseLabel": "Intangible asset amortization and contingent consideration" } } }, "localname": "IntangibleAssetAmortizationAndContingentConsideration", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "bmrn_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease liabilities.", "label": "Lease Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LeaseRightOfUseAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease right of use assets.", "label": "Lease Right Of Use Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "LeaseRightOfUseAssetsAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee operating and finance leases other information.", "label": "Lessee Operating And Finance Leases Other Information Table [Text Block]", "terseLabel": "Schedule of Other Information" } } }, "localname": "LesseeOperatingAndFinanceLeasesOtherInformationTableTextBlock", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bmrn_LesseeOperatingAndFinancingLeasesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee operating and financing leases disclosure.", "label": "Lessee Operating And Financing Leases Disclosure [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingAndFinancingLeasesDisclosureTextBlock", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "bmrn_LesseeOperatingLeaseLeaseNotyetCommencedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Liability", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Liability", "terseLabel": "Operating lease liability to commence in the remainder of 2019" } } }, "localname": "LesseeOperatingLeaseLeaseNotyetCommencedLiability", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_LongTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term marketable securities maturity period.", "label": "Long Term Marketable Securities Maturity Period", "terseLabel": "Long term marketable securities maturity period" } } }, "localname": "LongTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_MaturityDateOfCreditFacilityIfCertainOtherConditionsHaveNotBeenMet": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturity date of credit facility if certain other conditions have not been met.", "label": "Maturity Date Of Credit Facility If Certain Other Conditions Have Not Been Met", "terseLabel": "Maturity date of credit facility, if certain other conditions have not been met" } } }, "localname": "MaturityDateOfCreditFacilityIfCertainOtherConditionsHaveNotBeenMet", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "bmrn_MaturityOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturity of lease liabilities.", "label": "Maturity Of Lease Liabilities [Abstract]", "terseLabel": "Maturity of Lease Liabilities" } } }, "localname": "MaturityOfLeaseLiabilitiesAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nonqualified deferred compensation plan assets.", "label": "Nonqualified Deferred Compensation Plan Assets [Member]", "terseLabel": "NQDC Plan assets" } } }, "localname": "NonqualifiedDeferredCompensationPlanAssetsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nonqualified deferred compensation plan liability.", "label": "Nonqualified Deferred Compensation Plan Liability [Member]", "terseLabel": "NQDC Plan liability" } } }, "localname": "NonqualifiedDeferredCompensationPlanLiabilityMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "One point five zero percent senior subordinated convertible notes due in October twenty twenty.", "label": "One Point Five Zero Percent Senior Subordinated Convertible Notes Due In October Twenty Twenty [Member]", "terseLabel": "1.50% Senior Subordinated Convertible Notes Due in October 2020" } } }, "localname": "OnePointFiveZeroPercentSeniorSubordinatedConvertibleNotesDueInOctoberTwentyTwentyMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liabilities payments due.", "label": "Operating And Finance Lease Liabilities Payments Due [Abstract]", "terseLabel": "Total" } } }, "localname": "OperatingAndFinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "bmrn_OperatingAndFinanceLeaseLiability": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability.", "label": "Operating And Finance Lease Liability", "terseLabel": "Lease liabilities", "totalLabel": "Total lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseLiability", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail", "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due.", "label": "Operating And Finance Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDue", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due after year five.", "label": "Operating And Finance Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year five.", "label": "Operating And Finance Lease Liability Payments Due Year Five", "terseLabel": "2023" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year four.", "label": "Operating And Finance Lease Liability Payments Due Year Four", "terseLabel": "2022" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year three.", "label": "Operating And Finance Lease Liability Payments Due Year Three", "terseLabel": "2021" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments due year two.", "label": "Operating And Finance Lease Liability Payments Due Year Two", "terseLabel": "2020" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability payments remainder of fiscal year.", "label": "Operating And Finance Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "Remainder of 2019" } } }, "localname": "OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease liability undiscounted excess amount.", "label": "Operating And Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OperatingAndFinanceLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating and finance lease right of use asset.", "label": "Operating And Finance Lease Right Of Use Asset", "totalLabel": "Total ROU assets", "verboseLabel": "Lease ROU assets" } } }, "localname": "OperatingAndFinanceLeaseRightOfUseAsset", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail", "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherAssetsCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other assets current fair value disclosure.", "label": "Other Assets Current Fair Value Disclosure", "verboseLabel": "Fair value of other current assets" } } }, "localname": "OtherAssetsCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherAssetsNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other assets noncurrent fair value disclosure.", "label": "Other Assets Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current assets" } } }, "localname": "OtherAssetsNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherInformationLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other information lease liability.", "label": "Other Information Lease Liability [Abstract]", "terseLabel": "Other Information" } } }, "localname": "OtherInformationLeaseLiabilityAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other liabilities current fair value disclosure.", "label": "Other Liabilities Current Fair Value Disclosure", "verboseLabel": "Fair value of other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other liabilities noncurrent fair value disclosure.", "label": "Other Liabilities Noncurrent Fair Value Disclosure", "verboseLabel": "Fair value of other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentFairValueDisclosure", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_PreLaunchValoctocogeneRoxaparvovecMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "label": "Pre-Launch Valoctocogene Roxaparvovec [Member]", "terseLabel": "Pre-Launch Valoctocogene Roxaparvovec" } } }, "localname": "PreLaunchValoctocogeneRoxaparvovecMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductFiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 5 [Member]", "label": "Product Five [Member]", "terseLabel": "Firdapse" } } }, "localname": "ProductFiveMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 4 [Member]", "label": "Product Four [Member]", "terseLabel": "Vimizim" } } }, "localname": "ProductFourMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 1 [Member]", "label": "Product One [Member]", "terseLabel": "Aldurazyme" } } }, "localname": "ProductOneMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 7 [Member]", "label": "Product Seven [Member]", "terseLabel": "Palynziq" } } }, "localname": "ProductSevenMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductSixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product six.", "label": "Product Six [Member]", "terseLabel": "Brineura" } } }, "localname": "ProductSixMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 3 [Member]", "label": "Product Three [Member]", "terseLabel": "Kuvan" } } }, "localname": "ProductThreeMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product 2 [Member]", "label": "Product Two [Member]", "terseLabel": "Naglazyme" } } }, "localname": "ProductTwoMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail" ], "xbrltype": "domainItemType" }, "bmrn_ProductsExcludingProductOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Products excluding product one.", "label": "Products Excluding Product One [Member]", "terseLabel": "Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim" } } }, "localname": "ProductsExcludingProductOneMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestOfWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rest of world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of world" } } }, "localname": "RestOfWorldMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestrictedInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted investments.", "label": "Restricted Investments [Member]", "terseLabel": "Restricted Investments" } } }, "localname": "RestrictedInvestmentsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_RestrictedStockWithServiceBasedVestingConditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted stock with service based vesting conditions.", "label": "Restricted Stock With Service Based Vesting Conditions [Member]", "terseLabel": "Restricted Stock With Service Based Vesting Conditions" } } }, "localname": "RestrictedStockWithServiceBasedVestingConditionsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right of use assets obtained in exchange for lease obligations abstract.", "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease obligations:" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_RoyaltyAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty and other.", "label": "Royalty And Other [Member]", "terseLabel": "Royalty and other revenues" } } }, "localname": "RoyaltyAndOtherMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "domainItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]", "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities Table [Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "bmrn_ScheduleOfInterestExpensesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of interest expenses.", "label": "Schedule Of Interest Expenses [Line Items]", "terseLabel": "Schedule Of Interest Expenses [Line Items]" } } }, "localname": "ScheduleOfInterestExpensesLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfInterestExpensesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of interest expenses table.", "label": "Schedule Of Interest Expenses [Table]", "terseLabel": "Schedule Of Interest Expenses [Table]" } } }, "localname": "ScheduleOfInterestExpensesTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "bmrn_ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Lessee lease assets and liabilities.", "label": "Schedule Of Lessee Lease Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of ROU Assets and Lease Liabilities" } } }, "localname": "ScheduleOfLesseeLeaseAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bmrn_SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior unsecured revolving two thousand eighteen credit facility.", "label": "Senior Unsecured Revolving Two Thousand Eighteen Credit Facility [Member]", "terseLabel": "The 2018 Credit Facility" } } }, "localname": "SeniorUnsecuredRevolvingTwoThousandEighteenCreditFacilityMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Performance Metric, Percentage", "terseLabel": "Annual percentage of shares earned, performance metric" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualPerformanceMetricPercentage", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "label": "Share Based Compensation Arrangement By Share Based Payments, Annual Target Ceiling, Base Percentage", "terseLabel": "Base percentage of annual target ceiling" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAnnualTargetCeilingBasePercentage", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term marketable securities maturity period.", "label": "Short Term Marketable Securities Maturity Period", "terseLabel": "Short term marketable securities maturity period" } } }, "localname": "ShortTermMarketableSecuritiesMaturityPeriod", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "durationItemType" }, "bmrn_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency", "terseLabel": "Issuances under equity incentive plans, net of tax" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares.", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares", "terseLabel": "Issuances under equity incentive plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "bmrn_StockholdersEquityAdjustedBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stockholders equity, adjusted balance.", "label": "Stockholders Equity Adjusted Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "StockholdersEquityAdjustedBalance", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_StrategicInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Strategic investments.", "label": "Strategic Investments [Member]", "terseLabel": "Strategic Investments" } } }, "localname": "StrategicInvestmentsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period.", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase Decrease", "terseLabel": "Decrease in accounts payable and accrued liabilities related to fixed assets" } } }, "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecrease", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bmrn_SupplementalCashFlowLeaseInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental cash flow lease information.", "label": "Supplemental Cash Flow Lease Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowLeaseInformationAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ThirdPartyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Third party.", "label": "Third Party [Member]", "terseLabel": "Third Party" } } }, "localname": "ThirdPartyMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_ToRepayEarlyMinimumRequiredAmountOutstandingWithCertainOtherConditionsHaveNotBeenMet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "To repay early minimum required amount outstanding with certain other conditions have not been met.", "label": "To Repay Early Minimum Required Amount Outstanding With Certain Other Conditions Have Not Been Met", "terseLabel": "To repay early, minimum required amount outstanding with certain other conditions have not been met" } } }, "localname": "ToRepayEarlyMinimumRequiredAmountOutstandingWithCertainOtherConditionsHaveNotBeenMet", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand nineteen base restricted stock unit awards with market conditions.", "label": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Market Conditions [Member]", "terseLabel": "March 2019 Base Restricted Stock Unit Awards with Market Conditions" } } }, "localname": "TwoThousandNineteenBaseRestrictedStockUnitAwardsWithMarketConditionsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand nineteen base restricted stock unit awards with performance conditions.", "label": "Two Thousand Nineteen Base Restricted Stock Unit Awards With Performance Conditions [Member]", "terseLabel": "March 2019 Base Restricted Stock Unit Awards with Performance Conditions" } } }, "localname": "TwoThousandNineteenBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member]", "label": "Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member]", "terseLabel": "Two Thousand Twenty Two Base Restricted Stock Unit Awards With Performance Conditions [Member]" } } }, "localname": "TwoThousandTwentyTwoBaseRestrictedStockUnitAwardsWithPerformanceConditionsMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bmrn_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate abstract.", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted average discount rate:" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_WeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term abstract.", "label": "Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted average remaining lease term (in years):" } } }, "localname": "WeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "stringItemType" }, "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four.", "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]", "terseLabel": "0.599% Senior Subordinated Convertible Notes Due in August 2024" } } }, "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember", "nsuri": "http://www.bmrn.com/20190930", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian Dollars" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian Dollars" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_COP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Colombia, Pesos", "terseLabel": "Colombian Pesos" } } }, "localname": "COP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euros" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "Great British Pounds" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_NOK": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Norway, Krone", "terseLabel": "Norwegian Krone" } } }, "localname": "NOK", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "currency_RUB": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Russia, Rubles", "terseLabel": "Rubles" } } }, "localname": "RUB", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r367" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r144", "r192", "r196", "r352" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r141", "r192", "r194", "r349", "r350" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r111", "r112", "r113", "r114" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "Restatement Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r143", "r192", "r195", "r351", "r361", "r362" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASC Topic 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201802Member": { "auth_ref": [ "r68" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.", "label": "Accounting Standards Update 2018-02 [Member]", "terseLabel": "ASU 2018-02" } } }, "localname": "AccountingStandardsUpdate201802Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued operating expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r18", "r145", "r146", "r193" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r100" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "(Accretion of discount) Amortization of premium on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued rebates payable" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r6", "r7", "r38" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r173" ], "calculation": { "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r58", "r67", "r242" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent", "verboseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r52", "r53", "r54", "r58", "r60" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Available for-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r57", "r58" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r55", "r58", "r60", "r243" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r202", "r204", "r225", "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r204", "r219", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r74", "r99", "r291" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r99", "r291" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total number of potentially issuable shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r140", "r326", "r339" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Lease Classification" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r47" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r270" ], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Fair value of financial assets, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r154" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r155" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r152", "r157" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r148", "r153", "r157" ], "calculation": { "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r150", "r157" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Short-term Marketable Securities", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r150", "r157" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Long-term Marketable Securities", "verboseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r205", "r221" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r250", "r255" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r235", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r98", "r239" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Non-cash changes in the fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r237", "r238" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Short-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r237", "r238" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r30", "r355", "r356" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r30", "r101" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Financing Activities, Lessee [Abstract]", "terseLabel": "Cash used in financing activities:" } } }, "localname": "CashFlowFinancingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash used in operating activities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockIssuedEmployeeStockTrust": { "auth_ref": [ "r198" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock.", "label": "Common Stock Issued, Employee Stock Trust", "negatedLabel": "Company common stock held by Nonqualified Deferred Compensation Plan (the NQDC)" } } }, "localname": "CommonStockIssuedEmployeeStockTrust", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r185" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; 179,604,381 and 178,252,954 shares issued and outstanding, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer hardware and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r131", "r132", "r281", "r282" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r131", "r132", "r281", "r282", "r354" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r131", "r132", "r281", "r282", "r354" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r131", "r132", "r281", "r282" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r129", "r131", "r132", "r133", "r281", "r283" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r131", "r132", "r281", "r282" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r14", "r328", "r340" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "totalLabel": "Total convertible debt, net" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Total fair value of fixed rate convertible debt" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Long-term convertible debt, net", "totalLabel": "Convertible Notes, net of unamortized discount and deferred offering costs" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of Convertible Debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r199", "r201", "r353" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r76" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r75" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Operating expenses as reported" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Impact of change in accounting principle", "verboseLabel": "Impact of changes in accounting principle" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r12", "r13", "r14", "r327", "r328", "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail", "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument interest rate percentage" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r182", "r328", "r338" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail": { "order": 1.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Convertible Notes", "verboseLabel": "Carrying value of equity component" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, convertible, conversion price, per share (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Convertible notes stated rate", "verboseLabel": "Debt instrument, interest rate, stated percentage, per annum" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail", "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms", "terseLabel": "Interest rate on deemed loan description" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r41", "r274" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date of convertible debt" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail", "http://www.bmrn.com/role/NetLossPerCommonShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r105", "r186", "r187", "r188", "r189", "r289", "r290", "r292", "r337" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail", "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r289", "r292" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Convertible debt, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.", "label": "Deferred Compensation, Share-based Payments [Member]", "terseLabel": "Company Stock Held By NQDC" } } }, "localname": "DeferredCompensationShareBasedPaymentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r230" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r104", "r231", "r232" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "verboseLabel": "Net tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bmrn.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r46", "r161" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail": { "order": 3.0, "parentTag": "us-gaap_ConvertibleDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "negatedLabel": "Convertible debt, Unamortized deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentAssetNetCurrent": { "auth_ref": [ "r46", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year (or one operating cycle, if longer) of the balance sheet date. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee.", "label": "Deferred Rent Asset, Net, Current", "terseLabel": "Deferred rent accruals, current" } } }, "localname": "DeferredRentAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentReceivablesNet": { "auth_ref": [ "r46", "r294", "r296", "r297" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property, by the lessor or lessee, respectively. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee.", "label": "Deferred Rent Receivables, Net", "terseLabel": "Deferred rent accruals" } } }, "localname": "DeferredRentReceivablesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance against a deferred tax asset" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r99", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r99", "r137" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r48", "r50", "r253", "r323" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative Asset, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r48", "r50", "r253", "r323" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative Liability, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Gains (Losses) Recognized in Earnings" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r251", "r254", "r258", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r248", "r251", "r258", "r261", "r262", "r266", "r267" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Forward foreign currency exchange contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r245", "r247" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Aggregate Notional Amount in Foreign Currency" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r106", "r244", "r246", "r247", "r248", "r249", "r256", "r258", "r263", "r265", "r267" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r103", "r107", "r244", "r246", "r248", "r249", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives and Hedging Activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated As Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Total Net Product Revenues Based on Patient Location" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r111", "r119", "r121", "r122", "r123", "r126", "r335", "r347" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net Income (Loss) per common share, basic (in dollars per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r111", "r119", "r121", "r122", "r123", "r126", "r335", "r347" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Income (Loss) per common share, diluted (in dollars per share)", "verboseLabel": "NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r287" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation expense" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Stock-based compensation expense capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Manufacturing and laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r270", "r271", "r272", "r278" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r270", "r278" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r270", "r280" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r199", "r200", "r201", "r271", "r319" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r277", "r278" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r270", "r271", "r273", "r274", "r279" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r199", "r200", "r201", "r271", "r320" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1:", "verboseLabel": "Quoted Price in Active Markets For Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r199", "r200", "r201", "r271", "r321" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2:", "verboseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r199", "r200", "r201", "r271", "r322" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r275", "r278" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r275", "r278" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Financial assets remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Changes in fair value of other contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Contingent consideration at September 30, 2019", "periodStartLabel": "Contingent consideration at December 31, 2018", "terseLabel": "Liabilities remeasured" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FairValueMeasurementsLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingLevel3InputsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail", "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r277", "r279" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r304", "r310", "r318" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r306", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r303", "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r303" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Financing, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Finance Lease Liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r303" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Financing, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r305", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r302" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Financing" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r304", "r310", "r318" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r315", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r314", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r168" ], "calculation": { "http://www.bmrn.com/role/IntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r168", "r324" ], "calculation": { "http://www.bmrn.com/role/IntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r100", "r284", "r285", "r286" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r199", "r259" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Amount of Gain (Loss) Recognized in Other Comprehensive Income" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Gain (Loss) on Disposition of Intangible Assets", "negatedTerseLabel": "Gain on sale of intangible assets", "terseLabel": "Gain on sale of intangible assets" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r162", "r163" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r248", "r262" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r111", "r325", "r333", "r348" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r71", "r99", "r138", "r156", "r332", "r345" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in the loss of BioMarin/Genzyme LLC" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r139", "r233" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r96", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r120", "r125" ], "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Effect of dilutive securities" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r169" ], "calculation": { "http://www.bmrn.com/role/IntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/IntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Gross intangible assets:" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r164", "r166" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/IntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Net carrying value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r136", "r288", "r291", "r336" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Total interest expense on convertible debt" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r79" ], "calculation": { "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Coupon interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Summary of Interest Expense on Debt" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r118" ], "calculation": { "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The after-tax amount of interest recognized in the period associated with any convertible debt.", "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "Add: Interest on 2024 notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r93", "r95", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r24", "r160" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r45", "r159" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r26", "r160" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r25", "r160" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r78", "r135" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r357", "r358", "r359", "r360" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r357", "r358", "r359", "r360" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r316", "r318" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Remainder of 2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseNotYetCommencedDescriptionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Not yet Commenced, Description [Abstract]", "terseLabel": "Additional leases not yet commenced (undiscounted):" } } }, "localname": "LesseeOperatingLeaseNotYetCommencedDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r330", "r343" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r270" ], "calculation": { "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Fair value of financial liabilities, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FairValueMeasurementsFairValueOfFinancialAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r14", "r328", "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Percentage of commitment fees payable on undrawn amount" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR Rate" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Purchase" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r180" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtSummaryOfInterestExpenseOnConvertibleDebtDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MaturityOfForeignCurrencyDerivatives1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the foreign currency exchange rate derivatives mature or expire, in CCYY-MM-DD format.", "label": "Maturity of Foreign Currency Derivatives", "terseLabel": "Maturity" } } }, "localname": "MaturityOfForeignCurrencyDerivatives1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "dateItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market instruments" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r128", "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r97", "r100" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r61", "r64", "r72", "r100", "r125", "r334", "r346" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r111", "r117" ], "calculation": { "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss), basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r117", "r118" ], "calculation": { "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Income (Loss), diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfForeignCurrencyDerivativesHeld": { "auth_ref": [ "r245", "r247" ], "lang": { "en-US": { "role": { "documentation": "Number of foreign currency exchange rate derivatives held by the entity at the reporting date.", "label": "Number of Foreign Currency Derivatives Held", "terseLabel": "Number of Contracts" } } }, "localname": "NumberOfForeignCurrencyDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "verboseLabel": "Number of operating business segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r58" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating Expense", "verboseLabel": "Operating Expenses" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total gain (loss) on cash flow hedges", "totalLabel": "INCOME (LOSS) FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r311", "r318" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfLeaseCostDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r303" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetailCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r303" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r303" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "bmrn_OperatingAndFinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r307", "r312" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r302" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "bmrn_OperatingAndFinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfRouAssetsAndLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r315", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r314", "r318" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfOtherInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r293", "r299" ], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfMinimumLeasePaymentsForFutureYearsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other Accounts Payable and Accrued Liabilities", "terseLabel": "Other" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r56", "r59", "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Cash Flow Hedging Gains (Losses) Reclassified into Earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r62", "r65", "r67", "r185" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r62", "r65", "r240", "r241", "r242" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Net current-period other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "auth_ref": [ "r240", "r241", "r242" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Tax effect" } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r250", "r266" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesFairValueCarryingAmountOfDerivativesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r151" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale", "terseLabel": "Other- than- temporary impairment" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of contingent acquisition consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r84", "r87", "r108" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r82", "r85", "r149" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r86" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r86" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r88", "r222" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercises of awards under equity incentive plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r89", "r92", "r108" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities and sales of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Proceeds from sale of intangible assets" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product revenues", "verboseLabel": "Total net product revenues" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r174" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY, PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r172" ], "calculation": { "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r174", "r344" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r172" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r27" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfInventoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r15", "r329", "r341" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase commitments and other minimum contractual obligations" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r58" ], "calculation": { "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Less: gain (loss) reclassified from AOCI" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Amount Reclassified from AOCI Gain (Loss)" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Summary of Amounts Reclassified out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r228", "r363" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock units", "verboseLabel": "Unvested RSUs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r190", "r342" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r191", "r192" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net product revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r313", "r318" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r313", "r318" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesScheduleOfSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r7", "r34" ], "calculation": { "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales and Excise Tax Payable, Current", "terseLabel": "Value added taxes payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationScheduleOfAccountsPayableAndAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Marketed by Company" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Marketed by Genzyme" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalNetProductRevenuesBasedOnPatientLocationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Product Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationAdditionalInformationDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTotalNetProductRevenueConcentrationsAttributedToLargestCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r251", "r258", "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value Carrying Amount of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r204", "r218", "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfNetProductRevenuesByProductDetail", "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationDisaggregatesOfTotalRevenuesFromExternalCustomersAndCollaborativePartnersByGeographicRegionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Schedule of Net Product Revenues by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r165", "r167" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r165", "r167" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Summary of Derivatives Designated as Hedging Instruments Outstanding" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Minimum Lease Payments for Future Years" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r27", "r28", "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r174" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/PropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r205", "r221" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Stock Option Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r129", "r131", "r132", "r133", "r281", "r283" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedule of Net Product Revenue Concentrations Attributed to Largest Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/RevenueCreditConcentrationsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77", "r158" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r98" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award vesting service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per RSU granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Granted restricted stock units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationExpenseDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Shares, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per share granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r203", "r207" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r213", "r223" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationStockOptionValuationAssumptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Sell" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesDesignatedAsHedgingInstrumentsOutstandingDetail", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfDerivativesNotDesignatedAsHedgingInstrumentsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetail", "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "http://www.bmrn.com/role/DerivativeInstrumentsAndHedgingStrategiesSummaryOfImpactOfGainsAndLossesFromDerivativesDesignatedAsHedgingInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Common stock held by the NQDC" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails", "http://www.bmrn.com/role/NetLossPerCommonShareScheduleOfAntiDilutiveCommonStockExcludedFromComputationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r17", "r185", "r190" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r21", "r22", "r147" ], "calculation": { "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets", "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/SupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfChangesInAccumulatedBalancesOfAociIncludingCurrentPeriodOtherComprehensiveIncomeLossAndReclassificationsOutOfAociDetail", "http://www.bmrn.com/role/BasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r199", "r331" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/FinancialInstrumentsScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r123" ], "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "verboseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r116", "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares outstanding, basic", "verboseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bmrn.com/role/NetLossPerCommonShareNetLossPerCommonShareScheduleOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 14 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=75028277&loc=d3e19833-108362" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77913719&loc=d3e40879-112712" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r366": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r367": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r368": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r369": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" } }, "version": "2.1" } XML 90 R25.htm IDEA: XBRL DOCUMENT v3.19.3
BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019 or any other period.
On January 1, 2019, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 842, Leases (ASC Topic 842) using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC Topic 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC Topic 842 had a material impact on the Company’s Condensed Consolidated Balance Sheet but did not have a significant impact on the Company’s consolidated net loss. The Company elected to use the practical expedient allowing the use-of-hindsight and reassessed the lease term for all unexpired leases that commenced before the effective date of ASC Topic 842. For leases that commenced and expired before the effective date of ASC Topic 842, the Company elected not to reassess the expired leases. The Company also elected not to include leases with initial terms of twelve months or less in the recognized right-of-use (ROU) assets and lease liabilities.
As a result of the cumulative impact of adopting ASC Topic 842, the Company recorded lease ROU assets of $55.9 million and lease liabilities of $59.0 million as of January 1, 2019, primarily related to real estate and equipment, based on the present value of future lease payments on the date of adoption. The difference between the ROU assets and lease liabilities was recorded as an adjustment to Accumulated Deficit. Refer to Note 11 for additional disclosures required by ASC Topic 842.  
On January 1, 2019, the Company adopted Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (ASU 2017-12), using the modified retrospective method. This ASU provides new guidance about income statement classification and eliminates the requirement to separately measure and report hedge ineffectiveness. Results for reporting periods beginning January 1, 2019 are presented under ASU 2017-12, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the Company’s Condensed Consolidated Financial Statements. See Note 10 for additional disclosures required by ASU 2017-12.
U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.
Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.
Leases
Leases
The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, ROU assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. When an arrangement requires payments for lease and non-lease components, the Company has elected to account for lease and non-lease components separately. Lease expense for leases with a term of twelve months or less is recognized on a straight-line basis.
Derivatives and Hedging Activities
Derivatives and Hedging Activities
The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value, which is estimated using current exchange rates and interest rates and takes into consideration the current creditworthiness of the counterparties or the Company, as applicable. For derivatives designated as hedging instruments, the entire change in the fair value of qualifying derivative instruments is recorded in Accumulated Other Comprehensive Income (AOCI) and amounts deferred in AOCI will be reclassified to earnings in the same line item in which the earnings effect of the hedged item is reported. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in Operating Expenses in the Consolidated Statements of Comprehensive Income (Loss).
New Accounting Pronouncements
Accounting Pronouncements Not Yet Adopted
Effective January 1, 2020, the Company will adopt ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASU 2016-13), as amended, using a modified retrospective approach, with certain exceptions allowed. The standard amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary-impairment model. The Company is evaluating the impact of the adoption of ASU 2016-13 on its Condensed Consolidated Financial Statements.
XML 91 R21.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income (Loss) for all stock-based compensation arrangements was as follows: 
 
Three Months Ended September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Cost of sales
$
4,093

 
$
3,974

 
$
12,629

 
$
10,360

Research and development
14,261

 
14,257

 
43,037

 
43,099

Selling, general and administrative
20,819

 
18,815

 
66,097

 
58,802

Total stock-based compensation expense
$
39,173

 
$
37,046

 
$
121,763

 
$
112,261


Stock-based compensation of $5.1 million and $13.2 million was capitalized into inventory for the three and nine months ended September 30, 2019, respectively, compared to $5.3 million and $14.3 million for the three and nine months ended September 30, 2018, respectively. Capitalized stock-based compensation is recognized as cost of sales when the related product is sold.
Equity Awards with Service-Based Vesting Conditions
During the nine months ended September 30, 2019, the Company granted 1,844,308 RSUs with service-based vesting conditions with a weighted-average fair value of $91.23 per share. 
The Company did not grant any options to purchase shares of common stock during the three months ended September 30, 2019. During the nine months ended September 30, 2019, the Company granted 610,250 options to purchase shares of common stock with a weighted-average fair value of $36.84 per share.
The assumptions used to estimate the per share fair value of stock options granted during the periods presented were as follows: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Expected volatility
N/A
 
36.8%
 
37.1 – 37.4%
 
36.8 – 38.4%
Dividend yield
N/A
 
0.0%
 
0.0%
 
0.0%
Expected life (in years)
N/A
 
5.7
 
4.6 – 5.8
 
4.6 – 5.7
Risk-free interest rate
N/A
 
2.8%
 
2.2 – 3.0%
 
2.3 – 2.8%
 
The Company did not issue any new stock purchase rights under the Employee Stock Purchase Plan during the three months ended September 30, 2019. The Company issued 107,473 new stock purchase rights under the Employee Stock Purchase Plan during the nine months ended September 30, 2019.
Restricted Stock Unit Awards with Performance Conditions
In August 2019, the Compensation Committee of the Board of Directors (Board) approved the grant of 44,260 RSUs with performance-based vesting conditions and a grant date fair value of $81.00 per RSU. This award is contingent upon obtaining regulatory approval for valoctocogene roxaparvovec by January 2022 and the awarded RSUs, if any, vest ratably from the time regulatory approval is obtained through January 2022. The Company evaluated the current timeline and plans for submitting the regulatory applications and determined that for accounting purposes attainment of the performance measure is not probable as of September 30, 2019 as the regulatory approval is outside of the Company's control. Therefore, the Company did not record any expense associated with these awards.
In March 2019, the Compensation Committee and Board approved the grant of 99,010 RSUs with performance-based vesting conditions (base RSUs) and a grant date fair value of $94.53 per RSU. This award is contingent upon the achievement of a 2019 revenue target and the awarded RSUs, if any, vest ratably over a three-year service period. The Company evaluated the 2019 revenue target in the context of its current 2019 revenue forecast, and related confidence level in the forecast, and determined that attainment of the revenue target was probable for accounting purposes commencing in the first quarter of 2019. The number of shares that may be earned range between 0% and 200% of the base RSUs, depending on the percentage of 2019 “managed revenues” (defined as the Company’s net product revenues, excluding net revenues attributable to Aldurazyme, and determined using fixed foreign currency exchange rates) achieved against the target managed revenues, with a threshold achievement level of 75% of target and a ceiling achievement level of 125% of target.
Restricted Stock Unit Awards with Market Conditions
In March 2019, the Compensation Committee and Board approved the grant of 99,010 RSUs with market-based vesting conditions (base TSR-RSUs) to certain executives. These base TSR-RSUs, vest, if at all, in full following a three-year service period only if certain total shareholder return (TSR) results relative to the Nasdaq Biotechnology Index comparative companies are achieved. The number of shares that may be earned range between 0% and 200% of the base TSR-RSUs with a ceiling achievement level of 100% of the base TSR-RSUs in the event the Company’s absolute TSR multiplier is above the 50th percentile but the Company’s TSR multiplier is negative on an absolute basis. The Company utilized a Monte Carlo simulation model to determine the grant date fair value of $143.92 per base TSR-RSU. Compensation expense for awards with market conditions is recognized over the service period using the straight-line method and is not reversed if the market condition is not met.
XML 92 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Financial Instruments - Additional Information (Detail)
 9 Months Ended
Sep. 30, 2019
USD ($)
Investments, Debt and Equity Securities [Abstract]  
Other- than- temporary impairment $ 0
XML 93 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Inventory [Line Items]    
Raw materials $ 68,391 $ 74,616
Work-in-process 321,073 231,064
Finished goods 219,585 225,191
Total inventory 609,049 $ 530,871 [1]
Pre-Launch Valoctocogene Roxaparvovec    
Inventory [Line Items]    
Total inventory $ 7,100  
[1]
December 31, 2018 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 28, 2019.
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 95 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Derivative Instruments and Hedging Strategies - Summary of Derivatives Designated as Hedging Instruments Outstanding (Detail) - Derivatives Designated As Hedging Instruments - Foreign exchange contracts
€ in Millions, kr in Millions, $ in Millions, $ in Millions, $ in Millions
 9 Months Ended
Sep. 30, 2019
NOK (kr)
Derivative
Sep. 30, 2019
EUR (€)
Derivative
Sep. 30, 2019
COP ($)
Derivative
Sep. 30, 2019
AUD ($)
Derivative
Sep. 30, 2019
CAD ($)
Derivative
Derivative [Line Items]          
Number of Contracts 648 648 648 648 648
Australian Dollars | Sell          
Derivative [Line Items]          
Number of Contracts 6 6 6 6 6
Aggregate Notional Amount in Foreign Currency | $       $ 2.8  
Australian Dollars | Minimum | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Australian Dollars | Maximum | Sell          
Derivative [Line Items]          
Maturity Dec. 31, 2019        
Canadian Dollars | Sell          
Derivative [Line Items]          
Number of Contracts 24 24 24 24 24
Aggregate Notional Amount in Foreign Currency | $         $ 28.1
Canadian Dollars | Minimum | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Canadian Dollars | Maximum | Sell          
Derivative [Line Items]          
Maturity Sep. 30, 2020        
Colombian Pesos | Sell          
Derivative [Line Items]          
Number of Contracts 12 12 12 12 12
Aggregate Notional Amount in Foreign Currency | $     $ 89,400.0    
Colombian Pesos | Minimum | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Colombian Pesos | Maximum | Sell          
Derivative [Line Items]          
Maturity Sep. 30, 2020        
Euros | Sell          
Derivative [Line Items]          
Number of Contracts 453 453 453 453 453
Aggregate Notional Amount in Foreign Currency | €   € 624.2      
Euros | Purchase          
Derivative [Line Items]          
Number of Contracts 150 150 150 150 150
Aggregate Notional Amount in Foreign Currency | €   € 189.4      
Euros | Minimum | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Euros | Minimum | Purchase          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Euros | Maximum | Sell          
Derivative [Line Items]          
Maturity Sep. 30, 2022        
Euros | Maximum | Purchase          
Derivative [Line Items]          
Maturity Sep. 30, 2022        
Norwegian Krone | Sell          
Derivative [Line Items]          
Number of Contracts 3 3 3 3 3
Aggregate Notional Amount in Foreign Currency | kr kr 11.7        
Norwegian Krone | Minimum | Sell          
Derivative [Line Items]          
Maturity Oct. 31, 2019        
Norwegian Krone | Maximum | Sell          
Derivative [Line Items]          
Maturity Dec. 31, 2019        

XML 96 R67.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue from External Customer [Line Items]        
Net product revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
Aldurazyme        
Revenue from External Customer [Line Items]        
Net product revenues 22,852 27,593 73,945 117,652
Brineura        
Revenue from External Customer [Line Items]        
Net product revenues 19,840 9,936 46,815 27,743
Firdapse        
Revenue from External Customer [Line Items]        
Net product revenues 5,668 4,977 16,262 15,080
Kuvan        
Revenue from External Customer [Line Items]        
Net product revenues 120,524 113,254 340,771 321,414
Naglazyme        
Revenue from External Customer [Line Items]        
Net product revenues 94,408 103,089 279,462 269,171
Palynziq        
Revenue from External Customer [Line Items]        
Net product revenues 24,142 4,129 55,250 4,129
Vimizim        
Revenue from External Customer [Line Items]        
Net product revenues 163,466 123,342 411,953 368,016
Total net product revenues        
Revenue from External Customer [Line Items]        
Net product revenues $ 450,900 $ 386,320 $ 1,224,458 $ 1,123,205
XML 97 R63.htm IDEA: XBRL DOCUMENT v3.19.3
Accumulated Other Comprehensive Income - Amounts Reclassified out of Accumulated Other Comprehensive Income (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues $ 461,097 $ 391,706 $ 1,249,605 $ 1,137,998
Total gain (loss) on cash flow hedges 4,010 (15,741) (91,295) (85,376)
Net product revenues        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues 450,900 386,320 1,224,458 1,123,205
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Total gain (loss) on cash flow hedges 4,808 5,523 9,286 (2,921)
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Operating expenses (1,388) 498 (1,885) 3,762
Amount Reclassified from AOCI Gain (Loss) | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Net product revenues | Forward contracts        
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]        
Net product revenues $ 6,196 $ 5,025 $ 11,171 $ (6,683)